Enrichment analysis report,,,,,,,,,,,,,
Enrichment by Pathway Maps,,,,,down_genes_int_061520_genelist,,,,down_genes_rna_061620_genelist,,,,
#,Maps,Total,min(pValue),Min FDR,p-value,FDR,In Data,"Network Objects from
Active Data",p-value,FDR,In Data,"Network Objects from
Active Data",
1,Protein folding and maturation_POMC processing,30,2.188E-16,1.886E-13,4.055E-16,1.886E-13,19,"PAM, proACTH, POMC, N-POMC, beta-MSH, beta-Endorphin extracellular region, N-POC, gamma-LPH, ACTH 1-17, gamma3-MSH, ACTH, alpha-MSH, Joining peptide (JP), DA-alphaMSH, CLIP, PC1, gamma-MSH, beta-LPH, gamma2-MSH",2.188E-16,2.981E-13,19,"PAM, proACTH, POMC, N-POMC, beta-MSH, beta-Endorphin extracellular region, N-POC, gamma-LPH, ACTH 1-17, gamma3-MSH, ACTH, alpha-MSH, Joining peptide (JP), DA-alphaMSH, CLIP, PC1, gamma-MSH, beta-LPH, gamma2-MSH",
2,Development_Regulation of epithelial-to-mesenchymal transition (EMT),64,2.706E-16,1.886E-13,2.706E-16,1.886E-13,27,"HGF, IL-1 beta, N-cadherin, TGF-beta 2, NOTCH4, Caldesmon, ACTA2, FGF2, SNAIL1, PDGF-R-alpha, HGF receptor (Met), Fibronectin, Jagged1, Vimentin, TCF8, Claudin-1, WNT, TGF-beta receptor type II, SLUG, EGFR, MMP-9, Frizzled, EDNRA, ACTB, SIP1 (ZFHX1B), PDGF-R-beta, MMP-2",1.401E-14,6.361E-12,25,"HGF, IL-1 beta, N-cadherin, TGF-beta 2, NOTCH4, ACTA2, Caldesmon, FGF2, PDGF-R-alpha, HGF receptor (Met), Fibronectin, Jagged1, Vimentin, TCF8, Claudin-1, WNT, TGF-beta receptor type II, SLUG, EGFR, MMP-9, Frizzled, EDNRA, SIP1 (ZFHX1B), PDGF-R-beta, MMP-2",
3,Cell adhesion_ECM remodeling,55,4.000E-16,1.886E-13,4.000E-16,1.886E-13,25,"Matrilysin (MMP-7), Laminin 5, PLAUR (uPAR), alpha-5/beta-1 integrin, Actin cytoskeletal, alpha-1/beta-1 integrin, MMP-13, Collagen IV, CD44, SERPINE2, Caveolin-2, PLAT (TPA), MSN (moesin), Fibronectin, Nidogen, Osteonectin, IL-8, EGFR, LAMA4, MMP-9, PLAU (UPA), MMP-14, MMP-2, Versican, Collagen III",2.340E-15,1.593E-12,24,"Matrilysin (MMP-7), Laminin 5, PLAUR (uPAR), alpha-5/beta-1 integrin, alpha-1/beta-1 integrin, MMP-13, Collagen IV, CD44, SERPINE2, Caveolin-2, PLAT (TPA), MSN (moesin), Fibronectin, Nidogen, Osteonectin, IL-8, EGFR, LAMA4, MMP-9, PLAU (UPA), MMP-14, MMP-2, Versican, Collagen III",
4,Role of stellate cells in progression of pancreatic cancer,60,4.962E-15,1.730E-12,4.962E-15,1.730E-12,25,"GRO-2, IL-6, Galectin-1, NGF, ACTA2, alpha-5/beta-1 integrin, PI3K cat class IA, RECK, FGF2, MMP-13, SMAD3, CTGF, PDGF-R-alpha, AKT(PKB), PDGF receptor, OSF-2, CCL2, Fibronectin, IL-8, TGF-beta receptor type II, EGFR, ERK1/2, PDGF-R-beta, MMP-2, Collagen III",2.595E-13,8.834E-11,23,"GRO-2, IL-6, Galectin-1, NGF, ACTA2, alpha-5/beta-1 integrin, PI3K cat class IA, RECK, FGF2, MMP-13, CTGF, PDGF-R-alpha, AKT(PKB), PDGF receptor, OSF-2, CCL2, Fibronectin, IL-8, TGF-beta receptor type II, EGFR, PDGF-R-beta, MMP-2, Collagen III",
5,TGF-beta signaling via SMADs in breast cancer,47,1.700E-12,4.742E-10,1.700E-12,4.742E-10,20,"TGF-beta 2, PTHrP, HMGA2, SNAIL1, MMP-13, SMAD3, CTGF, RUNX2, CD44, p53, IL-8, ETS1, FOXQ1 (HFH1), TGF-beta receptor type II, SLUG, MMP-9, CD44 soluble, Fascin, GLI-2, MMP-14",1.008E-09,1.526E-07,17,"TGF-beta 2, PTHrP, HMGA2, MMP-13, CTGF, RUNX2, CD44, IL-8, ETS1, FOXQ1 (HFH1), TGF-beta receptor type II, SLUG, MMP-9, CD44 soluble, Fascin, GLI-2, MMP-14",
6,Putative roles of SETDB1 and PLU-1 in melanoma,23,4.696E-12,1.279E-09,7.375E-12,1.715E-09,14,"HOXA6, HOXA4, HOXA9, p14ARF, HOXA10, HOXA7, HOXA3, HOXA2, HOXA5, p16INK4, Jagged1, HOXA11, LMO2, CDK6",4.696E-12,1.279E-09,14,"HOXA6, HOXA4, HOXA9, p14ARF, HOXA10, HOXA7, HOXA3, HOXA2, HOXA5, p16INK4, Jagged1, HOXA11, LMO2, CDK6",
7,Stromal-epithelial interaction in Prostate Cancer,42,1.927E-11,3.793E-09,1.927E-11,3.793E-09,18,"HGF, Keratin 17, IL-6, TGF-beta 2, ACTA2, FGF2, SNAIL1, SMAD3, PDGF-R-alpha, HIC5, HGF receptor (Met), Fibronectin, Vimentin, TGF-beta receptor type II, MMP-9, PDGF-R-beta, MMP-2, Versican",1.290E-09,1.757E-07,16,"HGF, Keratin 17, IL-6, TGF-beta 2, ACTA2, FGF2, PDGF-R-alpha, HIC5, HGF receptor (Met), Fibronectin, Vimentin, TGF-beta receptor type II, MMP-9, PDGF-R-beta, MMP-2, Versican",
8,Stellate cells activation and liver fibrosis,70,2.175E-11,3.793E-09,2.175E-11,3.793E-09,23,"GRO-2, IL-1 beta, Biglycan, Beta-catenin, ACTA2, TNF-R2, PI3K cat class IA, GLI-1, SMAD3, PDGF-R-alpha, ERK2 (MAPK1), AKT(PKB), PTCH1, PDGF receptor, ICAM1, CCL2, Tcf(Lef), Dsh, TGF-beta receptor type II, Frizzled, TLR2, PDGF-R-beta, MMP-2",2.454E-08,1.990E-06,19,"GRO-2, IL-1 beta, Biglycan, ACTA2, TNF-R2, PI3K cat class IA, GLI-1, PDGF-R-alpha, AKT(PKB), PTCH1, PDGF receptor, ICAM1, CCL2, Tcf(Lef), TGF-beta receptor type II, Frizzled, TLR2, PDGF-R-beta, MMP-2",
9,Stimulation of TGF-beta signaling in lung cancer,48,2.877E-11,4.460E-09,2.877E-11,4.460E-09,19,"COX-2 (PTGS2), IL-1 beta, N-cadherin, TGF-beta 2, ITGB1, ACTA2, TGF-beta, Fyn, SNAIL1, SMAD3, AKT(PKB), Fibronectin, Vimentin, TGF-beta receptor type II, SLUG, MMP-9, IRAKM, Tropomyosin-2, MMP-2",1.473E-09,1.824E-07,17,"COX-2 (PTGS2), IL-1 beta, N-cadherin, TGF-beta 2, ITGB1, ACTA2, TGF-beta, Fyn, AKT(PKB), Fibronectin, Vimentin, TGF-beta receptor type II, SLUG, MMP-9, IRAKM, Tropomyosin-2, MMP-2",
10,TGF-beta 1-mediated induction of EMT in normal and asthmatic airway epithelium,44,4.971E-11,6.935E-09,4.971E-11,6.935E-09,18,"IL-1 beta, N-cadherin, ACTA2, HMGA2, SNAIL1, SMAD3, CTGF, CD44, Fibronectin, Jagged1, Vimentin, ITGB3, ETS1, TGF-beta receptor type II, BMP4, SLUG, MMP-9, MMP-2",2.874E-09,3.262E-07,16,"IL-1 beta, N-cadherin, ACTA2, HMGA2, CTGF, CD44, Fibronectin, Jagged1, Vimentin, ITGB3, ETS1, TGF-beta receptor type II, BMP4, SLUG, MMP-9, MMP-2",
11,Development_TGF-beta-dependent induction of EMT via SMADs ,35,7.776E-11,9.861E-09,7.776E-11,9.861E-09,16,"N-cadherin, TGF-beta 2, TGF-beta, HMGA2, SNAIL1, SMAD3, Fibronectin, Jagged1, Vimentin, TCF8, ETS1, Claudin-1, TGF-beta receptor type II, SLUG, SIP1 (ZFHX1B), MMP-2",6.665E-09,6.484E-07,14,"N-cadherin, TGF-beta 2, TGF-beta, HMGA2, Fibronectin, Jagged1, Vimentin, TCF8, ETS1, Claudin-1, TGF-beta receptor type II, SLUG, SIP1 (ZFHX1B), MMP-2",
12,Beta-catenin-dependent transcription regulation in colorectal cancer,36,1.318E-10,1.532E-08,1.318E-10,1.532E-08,16,"COX-2 (PTGS2), Beta-catenin, PLAUR (uPAR), LAMC2, LAMC2 (80kDa), LAMC2 (100kDa), CD44, IL-8, Claudin-1, CDX2, CD44 soluble, PLAU (UPA), MDR1, Fascin, MMP-14, CD44 (EXT)",9.608E-10,1.526E-07,15,"COX-2 (PTGS2), PLAUR (uPAR), LAMC2, LAMC2 (80kDa), LAMC2 (100kDa), CD44, IL-8, Claudin-1, CDX2, CD44 soluble, PLAU (UPA), MDR1, Fascin, MMP-14, CD44 (EXT)",
13,Inhibition of remyelination in multiple sclerosis: role of cell-cell and ECM-cell interactions,47,1.840E-10,1.975E-08,1.840E-10,1.975E-08,18,"Connexin 30, NGF, ITGB1, Myelin basic protein, Claudin-11, NGFR(TNFRSF16), Actin cytoskeletal, Fyn, Caspr1, Tetraspanin-2, NCAM1, PKC, Connexin 45, CD44, Fibronectin, Connexin 26, MMP-9, TLR2",1.008E-09,1.526E-07,17,"Connexin 30, NGF, ITGB1, Myelin basic protein, Claudin-11, NGFR(TNFRSF16), Fyn, Caspr1, Tetraspanin-2, NCAM1, PKC, Connexin 45, CD44, Fibronectin, Connexin 26, MMP-9, TLR2",
14,Immune response_CCL2 signaling,54,3.184E-10,3.173E-08,3.184E-10,3.173E-08,19,"IL-1 beta, IL-6, alpha-5/beta-1 integrin, Actin cytoskeletal, iNOS, Caveolin-1, alpha-4/beta-1 integrin, ICAM1, CCL2, PKC-alpha, p53, ITGB3, ETS1, CDH19, G-protein alpha-i family, PI3K cat class IA (p110-delta), ERK1/2, MMP-14, MMP-2",8.147E-08,5.284E-06,16,"IL-1 beta, IL-6, alpha-5/beta-1 integrin, iNOS, Caveolin-1, alpha-4/beta-1 integrin, ICAM1, CCL2, PKC-alpha, ITGB3, ETS1, CDH19, G-protein alpha-i family, PI3K cat class IA (p110-delta), MMP-14, MMP-2",
15,Rheumatoid arthritis (general schema),50,3.538E-10,5.641E-08,6.066E-10,5.641E-08,18,"IL-15, IL-1 beta, IL-6, TNF-R2, HLA-DRB1, TGF-beta, MHC class II, FGF2, MMP-8, PTPN22, CSF1, alpha-4/beta-1 integrin, ICAM1, MHC class II beta chain, HLA-DRB, MMP-9, TLR4, TLR2",3.538E-10,8.032E-08,18,"IL-15, IL-1 beta, IL-6, TNF-R2, HLA-DRB1, TGF-beta, MHC class II, FGF2, MMP-8, PTPN22, CSF1, alpha-4/beta-1 integrin, ICAM1, MHC class II beta chain, HLA-DRB, MMP-9, TLR4, TLR2",
16,Inflammatory mechanisms of pancreatic cancerogenesis,67,3.002E-09,2.617E-07,3.002E-09,2.617E-07,20,"STAT3, COX-2 (PTGS2), IL-32 (NK4), IL-1 beta, IL-6, TNF-R2, CCL20, TGF-alpha, GRO-1, iNOS, ICAM1, CCL2, IL-8, EGFR, MMP-9, G-protein alpha-i family, TLR4, PLAU (UPA), ENA-78, MMP-2",1.112E-08,1.010E-06,19,"COX-2 (PTGS2), IL-32 (NK4), IL-1 beta, IL-6, TNF-R2, CCL20, TGF-alpha, GRO-1, iNOS, ICAM1, CCL2, IL-8, EGFR, MMP-9, G-protein alpha-i family, TLR4, PLAU (UPA), ENA-78, MMP-2",
17,Cell adhesion_Tight junctions,38,3.753E-09,3.080E-07,3.753E-09,3.080E-07,15,"Claudin-16, Myosin II, ITGB1, Claudin-18, Claudin-11, Actomyosin, SNAIL1, F-Actin, Caveolin-1, Claudin-8, Tcf(Lef), Claudin-1, CDX2, Actin, CDX1",1.134E-05,2.117E-04,11,"Claudin-16, ITGB1, Claudin-18, Claudin-11, Caveolin-1, Claudin-8, Tcf(Lef), Claudin-1, CDX2, Actin, CDX1",
18,Hedgehog signaling in gastric cancer,29,4.325E-09,4.515E-07,6.474E-09,4.515E-07,13,"N-cadherin, GLI-1, SFRP1, PTCH1, CDX2, BMP4, SLUG, EDNRA, TWIST2, GLI-2, SIP1 (ZFHX1B), MEF2C, PDGF-R-beta",4.325E-09,4.531E-07,13,"N-cadherin, GLI-1, SFRP1, PTCH1, CDX2, BMP4, SLUG, EDNRA, TWIST2, GLI-2, SIP1 (ZFHX1B), MEF2C, PDGF-R-beta",
19,Airway smooth muscle contraction in asthma,56,4.966E-09,3.695E-07,4.966E-09,3.695E-07,18,"PGF2aR, PGE2R2, Histamine H1 receptor, Myosin II, Beta-2 adrenergic receptor, TRPC6, CPI-17, TRPC3, G-protein alpha-q/11, MELC, PKC-alpha, MyHC, G-protein alpha-i family, Adenylate cyclase, MLCK, MRLC, ACM3, Telokin",1.433E-07,8.343E-06,16,"PGF2aR, PGE2R2, Histamine H1 receptor, Beta-2 adrenergic receptor, TRPC6, CPI-17, TRPC3, G-protein alpha-q/11, MELC, PKC-alpha, G-protein alpha-i family, Adenylate cyclase, MLCK, MRLC, ACM3, Telokin",
20,TGF-beta 1-induced transactivation of membrane receptors signaling in HCC,50,5.032E-09,3.695E-07,5.032E-09,3.695E-07,17,"Beta-catenin, ITGB1, Laminin 5, alpha-5/beta-1 integrin, TGF-beta, PI3K cat class IA, SNAIL1, PDGF-R-alpha, AKT(PKB), PDGF receptor, ITGA5, Fibronectin, Cyclin E, Actin, TGF-beta receptor type II, SLUG, PDGF-R-beta",1.728E-07,9.415E-06,15,"ITGB1, Laminin 5, alpha-5/beta-1 integrin, TGF-beta, PI3K cat class IA, PDGF-R-alpha, AKT(PKB), PDGF receptor, ITGA5, Fibronectin, Cyclin E, Actin, TGF-beta receptor type II, SLUG, PDGF-R-beta",
21,WNT signaling in HCC,40,8.655E-09,5.683E-07,8.655E-09,5.683E-07,15,"WNT3, Beta-catenin, Prickle-1, p14ARF, LGR5, DVL-3, SFRP1, p53, Tcf(Lef), FZD7, Dsh, WNT, EGFR, Frizzled, DACT1",1.947E-05,3.156E-04,11,"WNT3, Prickle-1, p14ARF, LGR5, SFRP1, Tcf(Lef), FZD7, WNT, EGFR, Frizzled, DACT1",
22,Glomerular injury in Lupus Nephritis,92,8.963E-09,5.683E-07,8.963E-09,5.683E-07,23,"GRO-2, IL-1 beta, IL-6, TGF-beta, GRO-1, iNOS, AKT(PKB), CSF1, ICAM1, CCL2, PKC-alpha, TLR3, Fibronectin, C3a, IL-8, NGAL, GRO-3, A20, IFN-beta, MMP-9, IFI56, ERK1/2, PDGF-R-beta",2.484E-08,1.990E-06,22,"GRO-2, IL-1 beta, IL-6, TGF-beta, GRO-1, iNOS, AKT(PKB), CSF1, ICAM1, CCL2, PKC-alpha, TLR3, Fibronectin, C3a, IL-8, NGAL, GRO-3, A20, IFN-beta, MMP-9, IFI56, PDGF-R-beta",
23,"Development_TGF-beta-dependent induction of EMT via RhoA,  PI3K and ILK",46,9.799E-09,5.944E-07,9.799E-09,5.944E-07,16,"TGF-beta 2, Beta-catenin, Caldesmon, ACTA2, PI3K cat class IA, SNAIL1, SMAD3, AKT(PKB), HIC5, Fibronectin, Vimentin, Claudin-1, Actin, TGF-beta receptor type II, SLUG, ACTB",1.477E-05,2.646E-04,12,"TGF-beta 2, ACTA2, Caldesmon, PI3K cat class IA, AKT(PKB), HIC5, Fibronectin, Vimentin, Claudin-1, Actin, TGF-beta receptor type II, SLUG",
24,TNF-alpha and IL-1 beta-mediated regulation of contraction and secretion of inflammatory factors in normal and asthmatic airway smooth muscle,65,1.098E-08,6.384E-07,1.098E-08,6.384E-07,19,"COX-2 (PTGS2), GRO-2, IL-1 beta, IL-6, PA24A, GRO-1, TRPC3, AKT(PKB), PLA2, CCL2, PKC-alpha, CD38, IL-8, GRO-3, EGFR, MMP-9, ERK1/2, PDGF-R-beta, CCL7",4.073E-08,3.082E-06,18,"COX-2 (PTGS2), GRO-2, IL-1 beta, IL-6, PA24A, GRO-1, TRPC3, AKT(PKB), PLA2, CCL2, PKC-alpha, CD38, IL-8, GRO-3, EGFR, MMP-9, PDGF-R-beta, CCL7",
25,SHH signaling in colorectal cancer,31,1.747E-08,9.731E-07,1.747E-08,9.731E-07,13,"FOXC2, Beta-catenin, SNAIL1, GLI-1, PDGF-R-alpha, PTCH1, p53, Vimentin, WNT, IMP1(ZBP1), Frizzled, GLI-2, SIP1 (ZFHX1B)",9.777E-06,1.902E-04,10,"FOXC2, GLI-1, PDGF-R-alpha, PTCH1, Vimentin, WNT, IMP1(ZBP1), Frizzled, GLI-2, SIP1 (ZFHX1B)",
26,IL-1 signaling in melanoma,42,1.883E-08,9.731E-07,1.883E-08,9.731E-07,15,"COX-2 (PTGS2), GRO-2, IL-1 beta, IL-6, PD-L2, GRO-1, iNOS, alpha-4/beta-1 integrin, ICAM1, CCL2, p53, IL-8, GRO-3, MMP-9, PD-L1",1.014E-07,6.280E-06,14,"COX-2 (PTGS2), GRO-2, IL-1 beta, IL-6, PD-L2, GRO-1, iNOS, alpha-4/beta-1 integrin, ICAM1, CCL2, IL-8, GRO-3, MMP-9, PD-L1",
27,Signal transduction_WNT/Beta-catenin signaling in tissue homeostasis,42,1.883E-08,9.731E-07,1.883E-08,9.731E-07,15,"COX-2 (PTGS2), Beta-catenin, SNAIL1, iNOS, Tcf(Lef), IL-8, WNT, SLUG, ACADL, MMP-9, TCF7 (TCF1), CDX1, Frizzled, MMP-2, Versican",7.712E-07,2.452E-05,13,"COX-2 (PTGS2), iNOS, Tcf(Lef), IL-8, WNT, SLUG, ACADL, MMP-9, TCF7 (TCF1), CDX1, Frizzled, MMP-2, Versican",
28,Main genetic and epigenetic alterations in lung cancer,48,1.976E-08,9.846E-07,1.976E-08,9.846E-07,16,"GSTP1, HGF, Neuropilin-2, p14ARF, RECK, TGF-alpha, Caspase-8, p53, HGF receptor (Met), p16INK4, TGF-beta receptor type II, EGFR, IBP, Neuropilin-1, IBP3, MMP-2",6.553E-07,2.262E-05,14,"GSTP1, HGF, Neuropilin-2, p14ARF, RECK, TGF-alpha, HGF receptor (Met), p16INK4, TGF-beta receptor type II, EGFR, IBP, Neuropilin-1, IBP3, MMP-2",
29,Immune response_IL-1 signaling pathway,82,2.506E-08,1.206E-06,2.506E-08,1.206E-06,21,"COX-2 (PTGS2), IL-1 beta, IL-6, c-IAP2, PI3K cat class IA, FGF2, GRO-1, MMP-13, iNOS, RUNX2, AKT(PKB), ICAM1, CD44, CCL2, MYLK1, IL-8, IFN-beta, MMP-9, PLAU (UPA), ERK1/2, CCL7",7.526E-08,5.125E-06,20,"COX-2 (PTGS2), IL-1 beta, IL-6, c-IAP2, PI3K cat class IA, FGF2, GRO-1, MMP-13, iNOS, RUNX2, AKT(PKB), ICAM1, CD44, CCL2, MYLK1, IL-8, IFN-beta, MMP-9, PLAU (UPA), CCL7",
30,Development_WNT/Beta-catenin signaling in embryogenesis,43,2.724E-08,1.267E-06,2.724E-08,1.267E-06,15,"LBH, p15, Mixl1, Beta-catenin, p14ARF, SNAIL1, Oct-3/4, p16INK4, Tcf(Lef), En1, WNT, CDX2, TCF7 (TCF1), CDX1, Frizzled",1.044E-06,3.001E-05,13,"LBH, p15, Mixl1, p14ARF, Oct-3/4, p16INK4, Tcf(Lef), En1, WNT, CDX2, TCF7 (TCF1), CDX1, Frizzled",
31,Vascular endothelial cell damage in SLE,63,3.969E-08,1.786E-06,3.969E-08,1.786E-06,18,"HGF, IL-1 beta, IL-6, alpha-5/beta-1 integrin, PD-L2, iNOS, CSF1, alpha-4/beta-1 integrin, Tissue factor, ICAM1, CCL2, Caspase-1, Fibronectin, C3a, MSR1, IL-8, ERK1/2, PD-L1",1.470E-07,8.343E-06,17,"HGF, IL-1 beta, IL-6, alpha-5/beta-1 integrin, PD-L2, iNOS, CSF1, alpha-4/beta-1 integrin, Tissue factor, ICAM1, CCL2, Caspase-1, Fibronectin, C3a, MSR1, IL-8, PD-L1",
32,Signal transduction_PDGF signaling via PI3K/AKT and NFkB pathways,70,4.183E-08,1.824E-06,4.183E-08,1.824E-06,19,"PDGF-C, Transgelin, Beta-catenin, YB-1, ACTA2, SGK1, PDGFR-ab, PDGF-R-alpha, AKT(PKB), MYH11, PDGF receptor, CCL2, p53, ETS1, MMP-9, Phox1 (PRRX1), ERK1/2, PDGF-R-beta, MMP-2",7.439E-05,9.046E-04,14,"PDGF-C, Transgelin, ACTA2, SGK1, PDGFR-ab, PDGF-R-alpha, AKT(PKB), PDGF receptor, CCL2, ETS1, MMP-9, Phox1 (PRRX1), PDGF-R-beta, MMP-2",
33,TGF-beta-induced fibroblast/ myofibroblast migration and extracellular matrix production in asthmatic airways,64,5.199E-08,2.133E-06,5.199E-08,2.133E-06,18,"ITGA1, Biglycan, TGF-beta 2, ITGB1, PI3K cat class IA, COL4A1, MMP-13, SMAD3, AKT(PKB), COL5A1, Collagen IV, ITGA5, Fibronectin, TGF-beta receptor type II, MMP-9, ERK1/2, MMP-2, Collagen III",1.058E-06,3.001E-05,16,"ITGA1, Biglycan, TGF-beta 2, ITGB1, PI3K cat class IA, COL4A1, MMP-13, AKT(PKB), COL5A1, Collagen IV, ITGA5, Fibronectin, TGF-beta receptor type II, MMP-9, MMP-2, Collagen III",
34,Development_Positive regulation of WNT/Beta-catenin signaling at the receptor level,64,5.199E-08,2.133E-06,5.199E-08,2.133E-06,18,"R-spondins, WLS, Biglycan, RECK, LGR5, SFRP1, Caveolin-1, CD44, LGR6, GPR124, Tcf(Lef), WNT7A, WNT5B, Dsh, WNT, EGFR, Frizzled, ERK1/2",1.058E-06,3.001E-05,16,"R-spondins, WLS, Biglycan, RECK, LGR5, SFRP1, Caveolin-1, CD44, LGR6, GPR124, Tcf(Lef), WNT7A, WNT5B, WNT, EGFR, Frizzled",
35,Role of IL-8 in colorectal cancer,19,5.496E-08,2.190E-06,5.496E-08,2.190E-06,10,"HGF, IL-1 beta, PI3K cat class IA, ICAM1, CD44, HGF receptor (Met), IL-8, EGFR, ERK1/2, MMP-2",6.265E-07,2.262E-05,9,"HGF, IL-1 beta, PI3K cat class IA, ICAM1, CD44, HGF receptor (Met), IL-8, EGFR, MMP-2",
36,Disruption of epithelial layer restitution in asthma,34,6.575E-08,2.548E-06,6.575E-08,2.548E-06,13,"HGF, IL-1 beta, TGF-beta 2, ITGB1, PLAUR (uPAR), alpha-5/beta-1 integrin, SMAD3, HGF receptor (Met), Fibronectin, EGFR, MMP-9, PLAU (UPA), EDNRA",4.121E-07,1.701E-05,12,"HGF, IL-1 beta, TGF-beta 2, ITGB1, PLAUR (uPAR), alpha-5/beta-1 integrin, HGF receptor (Met), Fibronectin, EGFR, MMP-9, PLAU (UPA), EDNRA",
37,Role of adhesion of SCLC cells in tumor progression,35,6.665E-08,3.437E-06,9.856E-08,3.437E-06,13,"N-cadherin, ITGB1, alpha-5/beta-1 integrin, PTHrP, NCAM1, Caveolin-1, Collagen IV, alpha-4/beta-1 integrin, ICAM1, Fibronectin, ACM3, MMP-14, MMP-2",6.665E-08,4.778E-06,13,"N-cadherin, ITGB1, alpha-5/beta-1 integrin, PTHrP, NCAM1, Caveolin-1, Collagen IV, alpha-4/beta-1 integrin, ICAM1, Fibronectin, ACM3, MMP-14, MMP-2",
38,Role of Tissue factor-induced Thrombin signaling in cancerogenesis,65,6.770E-08,2.552E-06,6.770E-08,2.552E-06,18,"Angiopoietin 1, PAR3, Actin cytoskeletal, GRO-1, MMP-13, ERK2 (MAPK1), AKT(PKB), G-protein alpha-q/11, Tissue factor, MELC, PKC-alpha, IL-8, EGFR, G-protein alpha-i family, MLCK, MRLC, ERK1/2, MMP-2",6.705E-06,1.379E-04,15,"Angiopoietin 1, PAR3, GRO-1, MMP-13, AKT(PKB), G-protein alpha-q/11, Tissue factor, MELC, PKC-alpha, IL-8, EGFR, G-protein alpha-i family, MLCK, MRLC, MMP-2",
39,Transcription_HIF-1 targets,95,8.361E-08,3.069E-06,8.361E-08,3.069E-06,22,"Galectin-1, TGF-beta 2, NOXA, PLAUR (uPAR), 5'-NTD, FGF2, Ceruloplasmin, iNOS, CTGF, Lysyl oxidase, Transferrin, Alpha-1B adrenergic receptor, PLGF, Oct-3/4, p53, HGF receptor (Met), MMP-9, Carbonic anhydrase IX, MDR1, LOXL2, IBP3, MMP-2",2.187E-07,1.103E-05,21,"Galectin-1, TGF-beta 2, NOXA, PLAUR (uPAR), 5'-NTD, FGF2, Ceruloplasmin, iNOS, CTGF, Lysyl oxidase, Transferrin, Alpha-1B adrenergic receptor, PLGF, Oct-3/4, HGF receptor (Met), MMP-9, Carbonic anhydrase IX, MDR1, LOXL2, IBP3, MMP-2",
40,Role of growth factor receptors transactivation by Hyaluronic acid / CD44 signaling in tumor progression,35,9.856E-08,3.437E-06,9.856E-08,3.437E-06,13,"HGF, Ankyrin 1, PI3K cat class IA, PTHrP, SMAD3, CD44, PKC-alpha, HGF receptor (Met), EGFR, MMP-9, MDR1, ERK1/2, MMP-2",4.661E-06,1.024E-04,11,"HGF, Ankyrin 1, PI3K cat class IA, PTHrP, CD44, PKC-alpha, HGF receptor (Met), EGFR, MMP-9, MDR1, MMP-2",
41,Immune response_IL-17 signaling pathways,60,1.084E-07,3.688E-06,1.084E-07,3.688E-06,17,"COX-2 (PTGS2), IL-1 beta, IL-6, PI3K cat class IA, CCL20, GRO-1, iNOS, AKT(PKB), GCP2, ICAM1, CCL2, IL-8, NGAL, MMP-9, ERK1/2, ENA-78, CCL7",4.082E-07,1.701E-05,16,"COX-2 (PTGS2), IL-1 beta, IL-6, PI3K cat class IA, CCL20, GRO-1, iNOS, AKT(PKB), GCP2, ICAM1, CCL2, IL-8, NGAL, MMP-9, ENA-78, CCL7",
42,Development_WNT/Beta-catenin signaling in organogenesis,30,1.177E-07,3.820E-06,1.177E-07,3.820E-06,12,"FOXC2, LBH, Beta-catenin, PLA2G7, Oct-3/4, Tcf(Lef), IL-8, En1, WNT, BMP2, Frizzled, Neuropilin-1",8.101E-07,2.452E-05,11,"FOXC2, LBH, PLA2G7, Oct-3/4, Tcf(Lef), IL-8, En1, WNT, BMP2, Frizzled, Neuropilin-1",
43,Regulation of IGF family activity in colorectal cancer,30,1.177E-07,3.820E-06,1.177E-07,3.820E-06,12,"COX-2 (PTGS2), IL-1 beta, IL-6, Matrilysin (MMP-7), PLAUR (uPAR), PCSK5, IBP6, p53, MMP-9, IBP, PLAU (UPA), IBP3",8.101E-07,2.452E-05,11,"COX-2 (PTGS2), IL-1 beta, IL-6, Matrilysin (MMP-7), PLAUR (uPAR), PCSK5, IBP6, MMP-9, IBP, PLAU (UPA), IBP3",
44,E-cadherin signaling and its regulation in gastric cancer,36,1.454E-07,4.609E-06,1.454E-07,4.609E-06,13,"HGF, Beta-catenin, SNAIL1, HGF receptor (Met), TCF8, Dsh, WNT, Actin, SLUG, EGFR, BMP2, Frizzled, SIP1 (ZFHX1B)",4.233E-05,5.709E-04,10,"HGF, HGF receptor (Met), TCF8, WNT, Actin, SLUG, EGFR, BMP2, Frizzled, SIP1 (ZFHX1B)",
45,Muscle contraction_GPCRs in the regulation of smooth muscle tone,83,1.609E-07,4.988E-06,1.609E-07,4.988E-06,20,"PGE2R2, Histamine H1 receptor, Myosin II, TRPC4, Beta-2 adrenergic receptor, TRPC6, TRPC3, Adenosine A2b receptor, G-protein alpha-q/11, MELC, PKC-alpha, MyHC, NCX1, G-protein alpha-i family, Adenylate cyclase, MLCK, MRLC, EDNRA, ACM3, Telokin",2.146E-06,5.620E-05,18,"PGE2R2, Histamine H1 receptor, TRPC4, Beta-2 adrenergic receptor, TRPC6, TRPC3, Adenosine A2b receptor, G-protein alpha-q/11, MELC, PKC-alpha, NCX1, G-protein alpha-i family, Adenylate cyclase, MLCK, MRLC, EDNRA, ACM3, Telokin",
46,Glucocorticoid-induced elevation of intraocular pressure as glaucoma risk factor,62,1.836E-07,5.425E-06,1.836E-07,5.425E-06,17,"COX-2 (PTGS2), ITGB1, Laminin 5, Actin cytoskeletal, PI3K cat class IA, COL4A1, LAMB3, Collagen IV, PLAT (TPA), HGF receptor (Met), Fibronectin, ITGB3, Elastin, EGFR, LAMA1, MLCK, MMP-2",6.643E-07,2.262E-05,16,"COX-2 (PTGS2), ITGB1, Laminin 5, PI3K cat class IA, COL4A1, LAMB3, Collagen IV, PLAT (TPA), HGF receptor (Met), Fibronectin, ITGB3, Elastin, EGFR, LAMA1, MLCK, MMP-2",
47,Immune response_TLR2 and TLR4 signaling pathways,69,1.840E-07,5.425E-06,1.840E-07,5.425E-06,18,"COX-2 (PTGS2), IL-1 beta, IL-6, TLR1, PI3K cat class IA, Pellino 1, iNOS, CD14, AKT(PKB), Pellino 2, TLR10, IL-8, TLR6, Lyn, TLR4, TLR2, ERK1/2, MD-2",6.112E-07,2.262E-05,17,"COX-2 (PTGS2), IL-1 beta, IL-6, TLR1, PI3K cat class IA, Pellino 1, iNOS, CD14, AKT(PKB), Pellino 2, TLR10, IL-8, TLR6, Lyn, TLR4, TLR2, MD-2",
48,Probable BMP4-mediated induction of EMT in airway epithelium,21,1.867E-07,5.425E-06,1.867E-07,5.425E-06,10,"N-cadherin, Beta-catenin, SNAIL1, COL5A1, TCF8, BMP4, SLUG, MMP-9, SIP1 (ZFHX1B), MMP-2",1.937E-05,3.156E-04,8,"N-cadherin, COL5A1, TCF8, BMP4, SLUG, MMP-9, SIP1 (ZFHX1B), MMP-2",
49,Development_Neural stem cell lineage commitment (schema),38,2.058E-07,7.843E-06,3.025E-07,7.843E-06,13,"Myelin basic protein, Nestin, MCT1 (SLC16A1), MAP-1B, PDGF-R-alpha, PTCH1, Vimentin, WNT7A, BMP4, MAP2, GLAST1/EAAT1, BMP2, LIF",2.058E-07,1.078E-05,13,"Myelin basic protein, Nestin, MCT1 (SLC16A1), MAP-1B, PDGF-R-alpha, PTCH1, Vimentin, WNT7A, BMP4, MAP2, GLAST1/EAAT1, BMP2, LIF",
50,Development_Early embryonal hypaxial myogenesis,37,2.112E-07,6.013E-06,2.112E-07,6.013E-06,13,"Beta-catenin, GLI-1, SMAD3, PKC, PTCH1, WNT7A, FZD7, Dsh, BMP4, Adenylate cyclase, Frizzled, GLI-2, WNT6",5.485E-05,7.092E-04,10,"GLI-1, PKC, PTCH1, WNT7A, FZD7, BMP4, Adenylate cyclase, Frizzled, GLI-2, WNT6",
51,Macrophage and dendritic cell phenotype shift in cancer,100,2.202E-07,6.144E-06,2.202E-07,6.144E-06,22,"STAT3, COX-2 (PTGS2), PGE2R2, MFGE8, IL-1 beta, IL-6, HPRG, PGE2R4, IDO1, MHC class II, CD137 ligand(TNFSF9), TLR7, iNOS, CSF1, Activin A, OSF-2, PLGF, Jagged1, MSR1, IFN-beta, TLR4, TLR2",5.457E-07,2.186E-05,21,"COX-2 (PTGS2), PGE2R2, MFGE8, IL-1 beta, IL-6, HPRG, PGE2R4, IDO1, MHC class II, CD137 ligand(TNFSF9), TLR7, iNOS, CSF1, Activin A, OSF-2, PLGF, Jagged1, MSR1, IFN-beta, TLR4, TLR2",
52,Development_YAP/TAZ-mediated co-regulation of transcription,56,2.259E-07,6.178E-06,2.259E-07,6.178E-06,16,"Beta-catenin, HBP17, TAZ, SNAIL1, SMAD3, CTGF, RUNX2, ITGB2, Oct-3/4, UFO, Neurotractin, CDX2, SLUG, UCA1, SIP1 (ZFHX1B), CDK6",2.566E-05,3.973E-04,13,"HBP17, TAZ, CTGF, RUNX2, ITGB2, Oct-3/4, UFO, Neurotractin, CDX2, SLUG, UCA1, SIP1 (ZFHX1B), CDK6",
53,Expression targets of Tissue factor signaling in cancer,22,2.366E-07,8.042E-06,3.228E-07,8.042E-06,10,"PTX3, ITGB1, PLAUR (uPAR), GRO-1, CTGF, CSF1, Tissue factor, GFPT2, IL-8, PLAU (UPA)",2.366E-07,1.111E-05,10,"PTX3, ITGB1, PLAUR (uPAR), GRO-1, CTGF, CSF1, Tissue factor, GFPT2, IL-8, PLAU (UPA)",
54,Role of fibroblasts in the sensitization phase of allergic contact dermatitis,22,2.366E-07,8.042E-06,3.228E-07,8.042E-06,10,"IL-1 beta, IL-6, Laminin 5, Collagen IV, Fibronectin, Elastin, IL-8, MMP-9, MMP-2, Collagen III",2.366E-07,1.111E-05,10,"IL-1 beta, IL-6, Laminin 5, Collagen IV, Fibronectin, Elastin, IL-8, MMP-9, MMP-2, Collagen III",
55,HGF signaling in colorectal cancer,64,3.036E-07,7.843E-06,3.036E-07,7.843E-06,17,"HGF, COX-2 (PTGS2), Beta-catenin, Laminin 5, PLAUR (uPAR), Actin cytoskeletal, PI3K cat class IA, LAMC2, AKT(PKB), LAMB3, CD44, HGF receptor (Met), EGFR, MMP-9, LAMA3 (Epiligrin), ERK1/2, MMP-2",2.596E-05,3.973E-04,14,"HGF, COX-2 (PTGS2), Laminin 5, PLAUR (uPAR), PI3K cat class IA, LAMC2, AKT(PKB), LAMB3, CD44, HGF receptor (Met), EGFR, MMP-9, LAMA3 (Epiligrin), MMP-2",
56,Immune response_IFN-alpha/beta signaling via JAK/STAT,64,3.036E-07,7.843E-06,3.036E-07,7.843E-06,17,"STAT3, IFI17, TAP1 (PSF1), RSAD2, IFI27, ISG15, STAT4, CCL2, Caspase-8, p53, IFI6, I-TAC, ERAP140, IFN-beta, ISG54, XAF1, RIG-G",2.596E-05,3.973E-04,14,"IFI17, TAP1 (PSF1), RSAD2, IFI27, ISG15, STAT4, CCL2, IFI6, I-TAC, ERAP140, IFN-beta, ISG54, XAF1, RIG-G",
57,"Development_Hedgehog, BMP and Parathyroid hormone in osteogenesis",51,3.552E-07,8.543E-06,3.552E-07,8.543E-06,15,"ALPL, EGR2 (Krox20), TAZ, PTHrP, GLI-1, RUNX2, Osteoprotegerin, G-protein alpha-q/11, PTCH1, BMP6, DLX5, Adenylate cyclase, BMP2, ERK1/2, GLI-2",1.478E-06,4.109E-05,14,"ALPL, EGR2 (Krox20), TAZ, PTHrP, GLI-1, RUNX2, Osteoprotegerin, G-protein alpha-q/11, PTCH1, BMP6, DLX5, Adenylate cyclase, BMP2, GLI-2",
58,Development_Endothelial differentiation during embryonic development,51,3.552E-07,8.543E-06,3.552E-07,8.543E-06,15,"Angiopoietin 1, FOXC2, Beta-catenin, TIE2, PI3K cat class IA, PKC, AKT(PKB), ETS1, WNT, BMP4, SOX18, FOXC1, Neuropilin-1, ERK1/2, GLI-2",8.601E-06,1.698E-04,13,"Angiopoietin 1, FOXC2, TIE2, PI3K cat class IA, PKC, AKT(PKB), ETS1, WNT, BMP4, SOX18, FOXC1, Neuropilin-1, GLI-2",
59,Release of pro-inflammatory mediators and elastolytic enzymes by alveolar macrophages in COPD,28,3.567E-07,1.140E-05,4.984E-07,1.140E-05,11,"CHI3L1, IL-1 beta, IL-6, Matrilysin (MMP-7), CCL2, Cathepsin S, IL-8, MMP-9, TLR4, TLR2, MMP-2",3.567E-07,1.620E-05,11,"CHI3L1, IL-1 beta, IL-6, Matrilysin (MMP-7), CCL2, Cathepsin S, IL-8, MMP-9, TLR4, TLR2, MMP-2",
60,Immune response_Classical complement pathway,53,4.036E-07,1.368E-05,6.178E-07,1.368E-05,15,"C1r, C7, C4a, iC3b, C3dg, C1 inhibitor, C6, C3a, C3, Factor I, C3b, C4, C1s, C3c, C4b",4.036E-07,1.701E-05,15,"C1r, C7, C4a, iC3b, C3dg, C1 inhibitor, C6, C3a, C3, Factor I, C3b, C4, C1s, C3c, C4b",
61,LKB1 signaling pathway in lung cancer cells,45,4.046E-07,9.566E-06,4.046E-07,9.566E-06,14,"STAT3, COX-2 (PTGS2), N-cadherin, TGF-beta 2, Beta-catenin, ITGB1, Lysyl oxidase, Collagen IV, p53, p16INK4, Fibronectin, Vimentin, TCF8, ERK1/2",3.213E-04,2.860E-03,10,"COX-2 (PTGS2), N-cadherin, TGF-beta 2, ITGB1, Lysyl oxidase, Collagen IV, p16INK4, Fibronectin, Vimentin, TCF8",
62,Canonical WNT signaling pathway in colorectal cancer,66,4.911E-07,1.140E-05,4.911E-07,1.140E-05,17,"Beta-catenin, Matrilysin (MMP-7), PI3K cat class IA, iNOS, DVL-3, SFRP1, CD44, HGF receptor (Met), FZD7, Dsh, WNT, BMP4, SLUG, DACT3, TCF7 (TCF1), Frizzled, WNT6",3.745E-05,5.259E-04,14,"Matrilysin (MMP-7), PI3K cat class IA, iNOS, SFRP1, CD44, HGF receptor (Met), FZD7, WNT, BMP4, SLUG, DACT3, TCF7 (TCF1), Frizzled, WNT6",
63,Langerhans cell migration to lymph nodes in allergic contact dermatitis,35,5.923E-07,1.709E-05,8.454E-07,1.709E-05,12,"IL-1 beta, Laminin 5, TNF-R2, CCL20, Collagen IV, alpha-4/beta-1 integrin, ICAM1, CD44, Fibronectin, MMP-9, GITRL, MDR1",5.923E-07,2.262E-05,12,"IL-1 beta, Laminin 5, TNF-R2, CCL20, Collagen IV, alpha-4/beta-1 integrin, ICAM1, CD44, Fibronectin, MMP-9, GITRL, MDR1",
64,Chemotaxis_Inhibitory action of lipoxins on IL-8- and Leukotriene B4-induced neutrophil migration,53,6.178E-07,1.368E-05,6.178E-07,1.368E-05,15,"Myosin II, Actin cytoskeletal, Actomyosin, Rac2, AKT(PKB), ITGB2, ICAM1, MELC, MYLK1, IL-8, Actin, G-protein alpha-i family, MLCK, MRLC, ERK1/2",3.087E-04,2.798E-03,11,"Rac2, AKT(PKB), ITGB2, ICAM1, MELC, MYLK1, IL-8, Actin, G-protein alpha-i family, MLCK, MRLC",
65,"Chemokines in inflammation in adipose tissue and liver in obesity, type 2 diabetes and metabolic syndrome X",48,6.553E-07,1.949E-05,9.781E-07,1.949E-05,14,"IL-1 beta, IL-6, PLAUR (uPAR), MHC class II, CD14, ITGA4, EMR1, ICAM1, CD44, CCL2, CMKLR1, IL-8, TLR4, TLR2",6.553E-07,2.262E-05,14,"IL-1 beta, IL-6, PLAUR (uPAR), MHC class II, CD14, ITGA4, EMR1, ICAM1, CD44, CCL2, CMKLR1, IL-8, TLR4, TLR2",
66,"Signal transduction_Angiotensin II/ AGTR1 signaling via p38, ERK and PI3K",98,6.598E-07,1.438E-05,6.598E-07,1.438E-05,21,"Syk, COX-2 (PTGS2), PDGF-C, IL-6, PPARGC1 (PGC1-alpha), Fyn, PI3K cat class IA, RECK, AKT(PKB), OSF-2, CCL2, ETS1, cPLA2, EGFR, TLR4, ERK1/2, MEF2C, PDGF-R-beta, MMP-14, MMP-2, CMYA3",1.631E-06,4.444E-05,20,"Syk, COX-2 (PTGS2), PDGF-C, IL-6, PPARGC1 (PGC1-alpha), Fyn, PI3K cat class IA, RECK, AKT(PKB), OSF-2, CCL2, ETS1, cPLA2, EGFR, TLR4, MEF2C, PDGF-R-beta, MMP-14, MMP-2, CMYA3",
67,"Immune response_T cell co-signaling receptors, schema",55,6.846E-07,2.051E-05,1.044E-06,2.051E-05,15,"MHC class II, CD137 ligand(TNFSF9), PD-L2, DPP4, Collagen V, CD137(TNFRSF9), LIGHT(TNFSF14), Collagen VI, Galectin-9, CD30(TNFRSF8), CD70(TNFSF7), GITRL, PD-L1, Nectin-3, Collagen III",6.846E-07,2.274E-05,15,"MHC class II, CD137 ligand(TNFSF9), PD-L2, DPP4, Collagen V, CD137(TNFRSF9), LIGHT(TNFSF14), Collagen VI, Galectin-9, CD30(TNFRSF8), CD70(TNFSF7), GITRL, PD-L1, Nectin-3, Collagen III",
68,ERBB family and HGF signaling in gastric cancer,54,8.058E-07,1.709E-05,8.058E-07,1.709E-05,15,"BAD, STAT3, HGF, COX-2 (PTGS2), Beta-catenin, PI3K cat class IA, TGF-alpha, ERK2 (MAPK1), AKT(PKB), HGF receptor (Met), IL-8, Epiregulin, EGFR, Neuropilin-1, ERK1/2",1.462E-03,8.968E-03,10,"HGF, COX-2 (PTGS2), PI3K cat class IA, TGF-alpha, AKT(PKB), HGF receptor (Met), IL-8, Epiregulin, EGFR, Neuropilin-1",
69,Inter-cellular relations in COPD (general schema),30,8.101E-07,2.154E-05,1.127E-06,2.154E-05,11,"IL-1 beta, IL-6, TGF-beta, TGF-alpha, GRO-1, CTGF, CCL2, I-TAC, IL-8, EGFR, MMP-9",8.101E-07,2.452E-05,11,"IL-1 beta, IL-6, TGF-beta, TGF-alpha, GRO-1, CTGF, CCL2, I-TAC, IL-8, EGFR, MMP-9",
70,Maturation and migration of dendritic cells in skin sensitization,41,8.238E-07,1.709E-05,8.238E-07,1.709E-05,13,"MHC class II alpha chain, IL-1 beta, IL-6, TNF-R2, HLA-DRB1, MHC class II, CD83, HLA-DRA1, ICAM1, MHC class II beta chain, HLA-DRB, IL-8, ERK1/2",3.983E-06,9.353E-05,12,"MHC class II alpha chain, IL-1 beta, IL-6, TNF-R2, HLA-DRB1, MHC class II, CD83, HLA-DRA1, ICAM1, MHC class II beta chain, HLA-DRB, IL-8",
71,Plasminogen activators signaling in pancreatic cancer,35,8.454E-07,1.709E-05,8.454E-07,1.709E-05,12,"HGF, Galectin-1, PLAUR (uPAR), Fra-1, PLAT (TPA), HGF receptor (Met), EGFR, MMP-9, PLAU (UPA), ERK1/2, MMP-14, MMP-2",4.661E-06,1.024E-04,11,"HGF, Galectin-1, PLAUR (uPAR), Fra-1, PLAT (TPA), HGF receptor (Met), EGFR, MMP-9, PLAU (UPA), MMP-14, MMP-2",
72,Extracellular matrix-regulated proliferation of airway smooth muscle cells in asthma,35,8.454E-07,1.709E-05,8.454E-07,1.709E-05,12,"alpha-5/beta-1 integrin, PI3K cat class IA, SMAD3, CTGF, Collagen IV, alpha-4/beta-1 integrin, Fibronectin, TGF-beta receptor type II, EGFR, LAMA1, ERK1/2, Collagen III",3.233E-05,4.685E-04,10,"alpha-5/beta-1 integrin, PI3K cat class IA, CTGF, Collagen IV, alpha-4/beta-1 integrin, Fibronectin, TGF-beta receptor type II, EGFR, LAMA1, Collagen III",
73,Colorectal cancer (general schema),30,1.127E-06,2.154E-05,1.127E-06,2.154E-05,11,"HGF, IL-6, Beta-catenin, PTCH1, HGF receptor (Met), IL-8, WNT, TGF-beta receptor type II, EGFR, Ephrin-B receptors, Frizzled",7.006E-06,1.403E-04,10,"HGF, IL-6, PTCH1, HGF receptor (Met), IL-8, WNT, TGF-beta receptor type II, EGFR, Ephrin-B receptors, Frizzled",
74,Role of IL-8 in melanoma,36,1.195E-06,2.249E-05,1.195E-06,2.249E-05,12,"IL-1 beta, IL-6, Beta-catenin, SNAIL1, Beta-2 adrenergic receptor, AKT(PKB), ITGB2, ICAM1, IL-8, G-protein alpha-i family, ERK1/2, MMP-2",2.481E-04,2.346E-03,9,"IL-1 beta, IL-6, Beta-2 adrenergic receptor, AKT(PKB), ITGB2, ICAM1, IL-8, G-protein alpha-i family, MMP-2",
75,Hypertrophy of  asthmatic airway smooth muscle cells ,70,1.209E-06,2.249E-05,1.209E-06,2.249E-05,17,"STAT3, Smooth muscle myosin, IL-1 beta, Transgelin, TGF-beta 2, ACTA2, SMAD3, PDGF-R-alpha, AKT(PKB), MYH11, TGF-beta receptor type II, EGFR, IFN-beta, MLCK, EDNRA, Actin muscle, PDGF-R-beta",2.907E-04,2.675E-03,13,"IL-1 beta, Transgelin, TGF-beta 2, ACTA2, PDGF-R-alpha, AKT(PKB), TGF-beta receptor type II, EGFR, IFN-beta, MLCK, EDNRA, Actin muscle, PDGF-R-beta",
76,Resolution of inflammation in healing myocardial infarction,25,1.370E-06,2.514E-05,1.370E-06,2.514E-05,10,"Angiopoietin 1, STAT3, HGF, TIE2, FGF2, AKT(PKB), HGF receptor (Met), MMP-9, ERK1/2, MMP-2",8.263E-05,9.793E-04,8,"Angiopoietin 1, HGF, TIE2, FGF2, AKT(PKB), HGF receptor (Met), MMP-9, MMP-2",
77,Fibroblast differentiation to myofibroblasts in asthmatic airways,31,1.648E-06,2.985E-05,1.648E-06,2.985E-05,11,"ITGB1, ACTA2, alpha-5/beta-1 integrin, PI3K cat class IA, SMAD3, AKT(PKB), ITGA5, Fibronectin, TGF-beta receptor type II, EDNRA, ERK1/2",7.007E-05,8.598E-04,9,"ITGB1, ACTA2, alpha-5/beta-1 integrin, PI3K cat class IA, AKT(PKB), ITGA5, Fibronectin, TGF-beta receptor type II, EDNRA",
78,VEGF signaling in multiple myeloma,50,1.688E-06,3.020E-05,1.688E-06,3.020E-05,14,"STAT3, IL-6, ITGB1, alpha-5/beta-1 integrin, PI3K cat class IA, ERK2 (MAPK1), Caveolin-1, alpha-4/beta-1 integrin, ICAM1, PKC-alpha, Fibronectin, Semaphorin 3A, Neuropilin-1, MDR1",3.671E-05,5.208E-04,12,"IL-6, ITGB1, alpha-5/beta-1 integrin, PI3K cat class IA, Caveolin-1, alpha-4/beta-1 integrin, ICAM1, PKC-alpha, Fibronectin, Semaphorin 3A, Neuropilin-1, MDR1",
79,Development_Role of HGF in hematopoietic stem cell mobilization,21,1.783E-06,4.002E-05,2.353E-06,4.002E-05,9,"HGF, SGK1, PI3K cat class IA, RECK, AKT(PKB), HGF receptor (Met), MMP-9, MMP-14, MMP-2",1.783E-06,4.761E-05,9,"HGF, SGK1, PI3K cat class IA, RECK, AKT(PKB), HGF receptor (Met), MMP-9, MMP-14, MMP-2",
80,Transition of HCC cells to invasive and migratory phenotype,44,2.032E-06,3.574E-05,2.032E-06,3.574E-05,13,"N-cadherin, Beta-catenin, Matrilysin (MMP-7), PI3K cat class IA, SNAIL1, AKT(PKB), Caspase-8, p53, Vimentin, MMP-9, SIP1 (ZFHX1B), MMP-14, MMP-2",1.202E-03,8.062E-03,9,"N-cadherin, Matrilysin (MMP-7), PI3K cat class IA, AKT(PKB), Vimentin, MMP-9, SIP1 (ZFHX1B), MMP-14, MMP-2",
81,Signal transduction_PDGF signaling via MAPK cascades,65,2.050E-06,3.574E-05,2.050E-06,3.574E-05,16,"COX-2 (PTGS2), PDGF-C, IL-6, PDGFR-ab, MMP-13, TRPC6, PDGF-R-alpha, ERK2 (MAPK1), PDGF receptor, Tissue factor, Fra-1, MMP-9, Phox1 (PRRX1), ERK1/2, PDGF-R-beta, MMP-2",3.125E-05,4.677E-04,14,"COX-2 (PTGS2), PDGF-C, IL-6, PDGFR-ab, MMP-13, TRPC6, PDGF-R-alpha, PDGF receptor, Tissue factor, Fra-1, MMP-9, Phox1 (PRRX1), PDGF-R-beta, MMP-2",
82,Neutrophil chemotaxis in asthma,38,2.298E-06,3.957E-05,2.298E-06,3.957E-05,12,"GRO-2, GRO-1, CCL2, PLGF, IL-8, GRO-3, G-protein alpha-i family, Tissue kallikreins, TLR2, ERK1/2, ENA-78, CCL7",1.134E-05,2.117E-04,11,"GRO-2, GRO-1, CCL2, PLGF, IL-8, GRO-3, G-protein alpha-i family, Tissue kallikreins, TLR2, ENA-78, CCL7",
83,Immune response_Induction of the antigen presentation machinery by IFN-gamma,53,2.450E-06,5.740E-05,3.621E-06,5.740E-05,14,"CIITA, PSMB9, TAP1 (PSF1), HLA-DRB1, MHC class II, HLA-F, HLA-DRA1, PSMB8(LMP7), HLA-B, NLRC5, HLA-A, HLA-DMB, Cathepsin S, TAP2 (PSF2)",2.450E-06,6.297E-05,14,"CIITA, PSMB9, TAP1 (PSF1), HLA-DRB1, MHC class II, HLA-F, HLA-DRA1, PSMB8(LMP7), HLA-B, NLRC5, HLA-A, HLA-DMB, Cathepsin S, TAP2 (PSF2)",
84,HGF signaling in melanoma,39,3.129E-06,5.237E-05,3.129E-06,5.237E-05,12,"HGF, N-cadherin, Beta-catenin, PI3K cat class IA, AKT(PKB), CD44, alpha-MSH, PKC-alpha, HGF receptor (Met), Fibronectin, SLUG, ERK1/2",8.951E-05,1.042E-03,10,"HGF, N-cadherin, PI3K cat class IA, AKT(PKB), CD44, alpha-MSH, PKC-alpha, HGF receptor (Met), Fibronectin, SLUG",
85,ErbB2-induced breast cancer cell invasion,67,3.154E-06,5.237E-05,3.154E-06,5.237E-05,16,"PLAUR (uPAR), Actin cytoskeletal, PI3K cat class IA, MMP-13, AKT(PKB), ITGA4, PKC-alpha, ER81, ETS1, NGAL, EGFR, MMP-9, PLAU (UPA), ERK1/2, MMP-14, MMP-2",4.472E-05,5.913E-04,14,"PLAUR (uPAR), PI3K cat class IA, MMP-13, AKT(PKB), ITGA4, PKC-alpha, ER81, ETS1, NGAL, EGFR, MMP-9, PLAU (UPA), MMP-14, MMP-2",
86,Development_Role of cell-cell and ECM-cell interactions in oligodendrocyte differentiation and myelination,34,3.382E-06,6.929E-05,4.669E-06,6.929E-05,11,"Connexin 30, ITGB1, Myelin basic protein, Claudin-11, NGFR(TNFRSF16), Fyn, Caspr1, Tetraspanin-2, NCAM1, Connexin 45, Connexin 26",3.382E-06,8.328E-05,11,"Connexin 30, ITGB1, Myelin basic protein, Claudin-11, NGFR(TNFRSF16), Fyn, Caspr1, Tetraspanin-2, NCAM1, Connexin 45, Connexin 26",
87,Tumor-stroma interactions in pancreatic cancer,28,3.424E-06,6.926E-05,4.618E-06,6.926E-05,10,"HGF, alpha-5/beta-1 integrin, FGF2, GLI-1, PTCH1, OSF-2, HGF receptor (Met), Fibronectin, PDGF-R-beta, MMP-2",3.424E-06,8.328E-05,10,"HGF, alpha-5/beta-1 integrin, FGF2, GLI-1, PTCH1, OSF-2, HGF receptor (Met), Fibronectin, PDGF-R-beta, MMP-2",
88,Putative pathways of activation of classical complement system in major depressive disorder,28,3.424E-06,6.926E-05,4.618E-06,6.926E-05,10,"IL-1 beta, IL-6, C7, C4A protein, C6, C3, C4B protein, C3b, C4, C4b",3.424E-06,8.328E-05,10,"IL-1 beta, IL-6, C7, C4A protein, C6, C3, C4B protein, C3b, C4, C4b",
89,Signal transduction_MIF signaling pathway,60,3.462E-06,5.682E-05,3.462E-06,5.682E-05,15,"BAD, Syk, COX-2 (PTGS2), PI3K cat class IA, AKT(PKB), ICAM1, CD44, p53, SFK, IL-8, cPLA2, Lyn, G-protein alpha-i family, TLR4, ERK1/2",2.403E-04,2.346E-03,12,"Syk, COX-2 (PTGS2), PI3K cat class IA, AKT(PKB), ICAM1, CD44, SFK, IL-8, cPLA2, Lyn, G-protein alpha-i family, TLR4",
90,Transcription_Androgen Receptor nuclear signaling,46,3.538E-06,5.739E-05,3.538E-06,5.739E-05,13,"STAT3, IL-6, Beta-catenin, SMAD3, ERK2 (MAPK1), AKT(PKB), HIC5, Dsh, WNT, TGF-beta receptor type II, EGFR, Frizzled, MMP-2",6.358E-03,2.673E-02,8,"IL-6, AKT(PKB), HIC5, WNT, TGF-beta receptor type II, EGFR, Frizzled, MMP-2",
91,Immune response_HMGB1/RAGE signaling pathway,53,3.621E-06,5.740E-05,3.621E-06,5.740E-05,14,"IL-1 beta, IL-6, PI3K cat class IA, iNOS, AKT(PKB), Tissue factor, ICAM1, PLAT (TPA), IL-8, Secretogranin II, TLR4, TLR2, ERK1/2, MEF2C",1.356E-05,2.462E-04,13,"IL-1 beta, IL-6, PI3K cat class IA, iNOS, AKT(PKB), Tissue factor, ICAM1, PLAT (TPA), IL-8, Secretogranin II, TLR4, TLR2, MEF2C",
92,Basophil migration in asthma,55,3.956E-06,8.211E-05,5.822E-06,8.211E-05,14,"ST2(L), Secretoneurin, PLAUR (uPAR), Eotaxin-2, alpha-4/beta-1 integrin, ICAM1, CCL2, Fibronectin, IL-8, MMP-9, G-protein alpha-i family, IL-33, PLAU (UPA), CCL7",3.956E-06,9.353E-05,14,"ST2(L), Secretoneurin, PLAUR (uPAR), Eotaxin-2, alpha-4/beta-1 integrin, ICAM1, CCL2, Fibronectin, IL-8, MMP-9, G-protein alpha-i family, IL-33, PLAU (UPA), CCL7",
93,IL-1 beta- and Endothelin-1-induced fibroblast/ myofibroblast migration and extracellular matrix production in asthmatic airways,40,4.214E-06,6.606E-05,4.214E-06,6.606E-05,12,"IL-1 beta, COL4A1, CTGF, PDGF-R-alpha, CCL2, Fibronectin, EDNRA, ERK1/2, PDGF-R-beta, MMP-2, Versican, Collagen III",1.947E-05,3.156E-04,11,"IL-1 beta, COL4A1, CTGF, PDGF-R-alpha, CCL2, Fibronectin, EDNRA, PDGF-R-beta, MMP-2, Versican, Collagen III",
94,Th17 cells in CF,54,4.606E-06,6.926E-05,4.606E-06,6.926E-05,14,"STAT3, IL-1 beta, IL-6, MHC class II, CCL20, GRO-1, CD14, GCP2, ICAM1, IL-8, TGF-beta receptor type II, TLR4, ERK1/2, MD-2",8.269E-05,9.793E-04,12,"IL-1 beta, IL-6, MHC class II, CCL20, GRO-1, CD14, GCP2, ICAM1, IL-8, TGF-beta receptor type II, TLR4, MD-2",
95,Role of Th17 cells in asthma,28,4.618E-06,6.926E-05,4.618E-06,6.926E-05,10,"GRO-2, Myosin II, GRO-1, ICAM1, IL-8, GRO-3, EGFR, MRLC, ALOX5, ERK1/2",2.014E-04,2.032E-03,8,"GRO-2, GRO-1, ICAM1, IL-8, GRO-3, EGFR, MRLC, ALOX5",
96,Development_Extraembryonic differentiation of embryonic stem cells,35,4.661E-06,8.451E-05,6.422E-06,8.451E-05,11,"Nestin, NCAM1, HNF4, Transferrin, ID4, Gremlin, CGB3, BMP4, MAP2, BMP2, PAX6",4.661E-06,1.024E-04,11,"Nestin, NCAM1, HNF4, Transferrin, ID4, Gremlin, CGB3, BMP4, MAP2, BMP2, PAX6",
97,Cell adhesion_Plasmin signaling,35,4.661E-06,8.451E-05,6.422E-06,8.451E-05,11,"TGF-beta 2, PI3K cat class IA, FGF2, MMP-13, Collagen IV, TFPI-2, PLAT (TPA), C1 inhibitor, Fibronectin, TGF-beta receptor type II, PLAU (UPA)",4.661E-06,1.024E-04,11,"TGF-beta 2, PI3K cat class IA, FGF2, MMP-13, Collagen IV, TFPI-2, PLAT (TPA), C1 inhibitor, Fibronectin, TGF-beta receptor type II, PLAU (UPA)",
98,Development_Role of proteases in hematopoietic stem cell mobilization,18,4.914E-06,8.451E-05,6.298E-06,8.451E-05,8,"alpha-5/beta-1 integrin, DPP4, alpha-4/beta-1 integrin, CD44, Fibronectin, MMP-9, MMP-14, MMP-2",4.914E-06,1.051E-04,8,"alpha-5/beta-1 integrin, DPP4, alpha-4/beta-1 integrin, CD44, Fibronectin, MMP-9, MMP-14, MMP-2",
99,Bone metastases in Prostate Cancer,29,4.941E-06,8.589E-05,6.649E-06,8.589E-05,10,"PTHrP, RUNX2, Osteoprotegerin, CCL2, WNT, MMP-9, G-protein alpha-i family, Frizzled, EDNRA, IBP3",4.941E-06,1.051E-04,10,"PTHrP, RUNX2, Osteoprotegerin, CCL2, WNT, MMP-9, G-protein alpha-i family, Frizzled, EDNRA, IBP3",
100,Hypoxia-induced EMT in cancer and fibrosis,13,4.958E-06,7.280E-05,4.958E-06,7.280E-05,7,"SNAIL1, Lysyl oxidase, TCF8, ETS1, SLUG, LOXL2, SIP1 (ZFHX1B)",6.216E-05,7.767E-04,6,"Lysyl oxidase, TCF8, ETS1, SLUG, LOXL2, SIP1 (ZFHX1B)",
101,Immune response_IL-10 signaling pathway,62,5.375E-06,7.811E-05,5.375E-06,7.811E-05,15,"STAT3, COX-2 (PTGS2), CRP2, IL-1 beta, IL-6, MHC class II, PI3K cat class IA, iNOS, CD14, AKT(PKB), Fc gamma RII alpha, ICAM1, IRS-2, IL-8, MMP-9",1.769E-05,3.129E-04,14,"COX-2 (PTGS2), CRP2, IL-1 beta, IL-6, MHC class II, PI3K cat class IA, iNOS, CD14, AKT(PKB), Fc gamma RII alpha, ICAM1, IRS-2, IL-8, MMP-9",
102,Fibroblast/ myofibroblast proliferation in asthmatic airways,41,5.617E-06,8.078E-05,5.617E-06,8.078E-05,12,"Histamine H1 receptor, IL-1 beta, PI3K cat class IA, SMAD3, CTGF, PKC, PDGF-R-alpha, Tissue factor, ITGB3, TGF-beta receptor type II, EDNRA, ERK1/2",1.412E-04,1.526E-03,10,"Histamine H1 receptor, IL-1 beta, PI3K cat class IA, CTGF, PKC, PDGF-R-alpha, Tissue factor, ITGB3, TGF-beta receptor type II, EDNRA",
103,Role of alpha-V/ beta-6 integrin in colorectal cancer,23,5.827E-06,8.211E-05,5.827E-06,8.211E-05,9,"PKC, ERK2 (MAPK1), Collagen IV, Fibronectin, ETS1, MMP-9, PLAU (UPA), ERK1/2, MMP-2",3.297E-04,2.916E-03,7,"PKC, Collagen IV, Fibronectin, ETS1, MMP-9, PLAU (UPA), MMP-2",
104,Cell adhesion_Integrin-mediated cell adhesion and migration,48,5.958E-06,8.312E-05,5.958E-06,8.312E-05,13,"alpha-11/beta-1 integrin, alpha-5/beta-1 integrin, Actin cytoskeletal, alpha-1/beta-1 integrin, ERK2 (MAPK1), Collagen IV, MELC, Fibronectin, MyHC, MYLK1, MLCK, MRLC, ERK1/2",2.282E-03,1.238E-02,9,"alpha-11/beta-1 integrin, alpha-5/beta-1 integrin, alpha-1/beta-1 integrin, Collagen IV, MELC, Fibronectin, MYLK1, MLCK, MRLC",
105,Interleukins-induced inflammatory response in asthmatic airway fibroblasts,35,6.422E-06,8.451E-05,6.422E-06,8.451E-05,11,"COX-2 (PTGS2), GRO-2, IL-1 beta, IL-6, NGF, GRO-1, ICAM1, CCL2, IL-8, IL-33, ERK1/2",3.233E-05,4.685E-04,10,"COX-2 (PTGS2), GRO-2, IL-1 beta, IL-6, NGF, GRO-1, ICAM1, CCL2, IL-8, IL-33",
106,Role of osteoblasts in bone lesions formation in multiple myeloma,35,6.422E-06,8.451E-05,6.422E-06,8.451E-05,11,"HGF, ALPL, Beta-catenin, TAZ, RUNX2, Osteoprotegerin, alpha-4/beta-1 integrin, WNT, TCF7 (TCF1), BMP2, Frizzled",3.233E-05,4.685E-04,10,"HGF, ALPL, TAZ, RUNX2, Osteoprotegerin, alpha-4/beta-1 integrin, WNT, TCF7 (TCF1), BMP2, Frizzled",
107,Mechanisms of CAM-DR in multiple myeloma,35,6.422E-06,8.451E-05,6.422E-06,8.451E-05,11,"STAT3, WNT3, ITGB1, c-IAP2, alpha-5/beta-1 integrin, alpha-4/beta-1 integrin, ICAM1, Fibronectin, Cyclin E, Dsh, Frizzled",1.966E-04,2.029E-03,9,"WNT3, ITGB1, c-IAP2, alpha-5/beta-1 integrin, alpha-4/beta-1 integrin, ICAM1, Fibronectin, Cyclin E, Frizzled",
108,Prostate Cancer: candidate susceptibility genes in inflammatory pathways,29,6.649E-06,8.589E-05,6.649E-06,8.589E-05,10,"IL-1 beta, IL-6, TLR1, TNF-R2, p53, TLR10, MSR1, IL-8, TLR6, TLR4",3.890E-05,5.352E-04,9,"IL-1 beta, IL-6, TLR1, TNF-R2, TLR10, MSR1, IL-8, TLR6, TLR4",
109,Renal tubulointerstitial injury in Lupus Nephritis ,65,6.705E-06,1.155E-04,1.002E-05,1.155E-04,15,"IL-1 beta, IL-6, TNF-R2, MHC class II, CSF1, alpha-4/beta-1 integrin, ICAM1, CD44, CCL2, CMKLR1, Fibronectin, Vimentin, IL-8, PLAU (UPA), Collagen III",6.705E-06,1.379E-04,15,"IL-1 beta, IL-6, TNF-R2, MHC class II, CSF1, alpha-4/beta-1 integrin, ICAM1, CD44, CCL2, CMKLR1, Fibronectin, Vimentin, IL-8, PLAU (UPA), Collagen III",
110,Immune response_Lectin induced complement pathway,50,6.786E-06,1.141E-04,9.737E-06,1.141E-04,13,"C7, C4a, iC3b, C3dg, C1 inhibitor, C6, C3a, C3, Factor I, C3b, C4, C3c, C4b",6.786E-06,1.379E-04,13,"C7, C4a, iC3b, C3dg, C1 inhibitor, C6, C3a, C3, Factor I, C3b, C4, C3c, C4b",
111,FAK1 signaling in melanoma,42,7.414E-06,9.489E-05,7.414E-06,9.489E-05,12,"ITGB1, alpha-5/beta-1 integrin, Actin cytoskeletal, Caveolin-1, PKC-alpha, ITGA5, Fibronectin, ITGB3, PLAU (UPA), ERK1/2, MMP-14, MMP-2",1.752E-04,1.850E-03,10,"ITGB1, alpha-5/beta-1 integrin, Caveolin-1, PKC-alpha, ITGA5, Fibronectin, ITGB3, PLAU (UPA), MMP-14, MMP-2",
112,Role and regulation of Prostaglandin E2 in gastric cancer,49,7.644E-06,9.694E-05,7.644E-06,9.694E-05,13,"COX-2 (PTGS2), PGE2R2, IL-1 beta, PGE2R4, PLAUR (uPAR), CCL2, Jagged1, IL-8, EGFR, Adenylate cyclase, PLAU (UPA), TLR2, ERK1/2",2.953E-05,4.469E-04,12,"COX-2 (PTGS2), PGE2R2, IL-1 beta, PGE2R4, PLAUR (uPAR), CCL2, Jagged1, IL-8, EGFR, Adenylate cyclase, PLAU (UPA), TLR2",
113,MAPK-independent proliferation of normal and asthmatic smooth muscle cells,64,8.180E-06,1.028E-04,8.180E-06,1.028E-04,15,"STAT3, PDGF-C, Histamine H1 receptor, PI3K cat class IA, FGF2, PDGF-R-alpha, AKT(PKB), G-protein alpha-q/11, PDGF receptor, PLAT (TPA), EGFR, G-protein alpha-i family, EDNRA, PDGF-R-beta, IBP3",2.596E-05,3.973E-04,14,"PDGF-C, Histamine H1 receptor, PI3K cat class IA, FGF2, PDGF-R-alpha, AKT(PKB), G-protein alpha-q/11, PDGF receptor, PLAT (TPA), EGFR, G-protein alpha-i family, EDNRA, PDGF-R-beta, IBP3",
114,Cigarette smoke-induced inflammatory signaling in airway epithelial cells,36,8.721E-06,1.067E-04,8.721E-06,1.067E-04,11,"COX-2 (PTGS2), IL-1 beta, IL-6, TGF-alpha, ICAM1, PKC-alpha, MSR1, IL-8, EGFR, ERK1/2, sICAM1",4.233E-05,5.709E-04,10,"COX-2 (PTGS2), IL-1 beta, IL-6, TGF-alpha, ICAM1, PKC-alpha, MSR1, IL-8, EGFR, sICAM1",
115,WNT signaling in gastric cancer,36,8.721E-06,1.067E-04,8.721E-06,1.067E-04,11,"WNT3, Beta-catenin, Matrilysin (MMP-7), SFRP1, CD44, DKK3, Tcf(Lef), WNT7A, Dsh, WNT, Frizzled",2.481E-04,2.346E-03,9,"WNT3, Matrilysin (MMP-7), SFRP1, CD44, DKK3, Tcf(Lef), WNT7A, WNT, Frizzled",
116,CHDI_Correlations from Discovery data_Causal network (positive),36,8.721E-06,1.067E-04,8.721E-06,1.067E-04,11,"STAT3, alpha-5/beta-1 integrin, Actin cytoskeletal, TIE2, GABA-A receptor, Collagen IV, Actin, Ephrin-B receptors, LAMA3 (Epiligrin), MMP-2, Collagen III",2.481E-04,2.346E-03,9,"alpha-5/beta-1 integrin, TIE2, GABA-A receptor, Collagen IV, Actin, Ephrin-B receptors, LAMA3 (Epiligrin), MMP-2, Collagen III",
117,Hedgehog signaling in breast cancer,24,8.801E-06,1.068E-04,8.801E-06,1.068E-04,9,"PTHrP, GLI-1, PTCH1, p53, Cyclin E, MMP-9, MDR1, GLI-2, MMP-2",5.936E-05,7.486E-04,8,"PTHrP, GLI-1, PTCH1, Cyclin E, MMP-9, MDR1, GLI-2, MMP-2",
118,Macrophage-induced immunosuppression in the tumor microenvironment,97,9.039E-06,1.087E-04,9.039E-06,1.087E-04,19,"STAT3, COX-2 (PTGS2), IL-6, S1P1 receptor, IDO1, 5'-NTD, CD94, TIE2, CCL20, PD-L2, HLA-G, Adenosine A2b receptor, CSF1, CD44, CCL2, MSR1, IL-34, ERK1/2, PD-L1",7.668E-05,9.243E-04,17,"COX-2 (PTGS2), IL-6, S1P1 receptor, IDO1, 5'-NTD, CD94, TIE2, CCL20, PD-L2, HLA-G, Adenosine A2b receptor, CSF1, CD44, CCL2, MSR1, IL-34, PD-L1",
119,Angiogenesis in HCC,50,9.737E-06,1.141E-04,9.737E-06,1.141E-04,13,"Angiopoietin 1, STAT3, COX-2 (PTGS2), TIE2, FGF2, Heparanase 1, CCL2, IL-8, TGF-beta receptor type II, EGFR, Ephrin-B receptors, MMP-9, MMP-2",3.671E-05,5.208E-04,12,"Angiopoietin 1, COX-2 (PTGS2), TIE2, FGF2, Heparanase 1, CCL2, IL-8, TGF-beta receptor type II, EGFR, Ephrin-B receptors, MMP-9, MMP-2",
120,The role of PTEN and PI3K signaling in melanoma,50,9.737E-06,1.141E-04,9.737E-06,1.141E-04,13,"BAD, STAT3, p15, N-cadherin, Beta-catenin, alpha-5/beta-1 integrin, MCAM, PI3K cat class IA, SNAIL1, AKT(PKB), Caspase-8, Fibronectin, AKT3",1.055E-02,3.822E-02,8,"p15, N-cadherin, alpha-5/beta-1 integrin, MCAM, PI3K cat class IA, AKT(PKB), Fibronectin, AKT3",
121,Ovarian cancer (main signaling cascades),65,1.002E-05,1.155E-04,1.002E-05,1.155E-04,15,"HGF, IL-6, Beta-catenin, PI3K cat class IA, SNAIL1, AKT(PKB), HGF receptor (Met), Tcf(Lef), EGFR, MMP-9, G-protein alpha-i family, PLAU (UPA), EDNRA, ERK1/2, MMP-2",5.216E-04,4.179E-03,12,"HGF, IL-6, PI3K cat class IA, AKT(PKB), HGF receptor (Met), Tcf(Lef), EGFR, MMP-9, G-protein alpha-i family, PLAU (UPA), EDNRA, MMP-2",
122,DKK1 signaling in multiple myeloma,19,1.027E-05,1.175E-04,1.027E-05,1.175E-04,8,"ALPL, IL-6, Beta-catenin, Osteoprotegerin, Tcf(Lef), Dsh, BMP2, Frizzled",7.148E-04,5.234E-03,6,"ALPL, IL-6, Osteoprotegerin, Tcf(Lef), BMP2, Frizzled",
123,Influence of bone marrow cell environment on progression of multiple myeloma,52,1.083E-05,1.674E-04,1.548E-05,1.674E-04,13,"HGF, IL-1 beta, IL-6, ITGB1, alpha-5/beta-1 integrin, PI3K cat class IA, FGF2, alpha-4/beta-1 integrin, PTCH1, CD44, PKC-alpha, HGF receptor (Met), Fibronectin",1.083E-05,2.078E-04,13,"HGF, IL-1 beta, IL-6, ITGB1, alpha-5/beta-1 integrin, PI3K cat class IA, FGF2, alpha-4/beta-1 integrin, PTCH1, CD44, PKC-alpha, HGF receptor (Met), Fibronectin",
124,TGF-beta signaling via kinase cascades in breast cancer,58,1.135E-05,1.277E-04,1.135E-05,1.277E-04,14,"COX-2 (PTGS2), TGF-beta 2, ITGB1, TGF-alpha, MMP-13, AKT(PKB), ADAM12, ITGB3, IL-8, TGF-beta receptor type II, EGFR, MMP-9, ERK1/2, MMP-2",3.823E-05,5.313E-04,13,"COX-2 (PTGS2), TGF-beta 2, ITGB1, TGF-alpha, MMP-13, AKT(PKB), ADAM12, ITGB3, IL-8, TGF-beta receptor type II, EGFR, MMP-9, MMP-2",
125,Cytoskeleton remodeling_Regulation of actin cytoskeleton organization by the kinase effectors of Rho GTPases,58,1.135E-05,1.277E-04,1.135E-05,1.277E-04,14,"Myosin II, Caldesmon, Actin cytoskeletal, Actomyosin, Rac2, PAK, CPI-17, Rac1-related, MSN (moesin), ERM proteins, MyHC, F-Actin cytoskeleton, MLCK, MRLC",8.394E-03,3.276E-02,9,"Caldesmon, Rac2, PAK, CPI-17, Rac1-related, MSN (moesin), ERM proteins, MLCK, MRLC",
126,Endothelin-1- and TNF-alpha-induced inflammatory response in asthmatic airway fibroblasts,20,1.267E-05,1.696E-04,1.617E-05,1.696E-04,8,"COX-2 (PTGS2), IL-1 beta, IL-6, NGF, TGF-beta 2, ICAM1, IL-33, EDNRA",1.267E-05,2.332E-04,8,"COX-2 (PTGS2), IL-1 beta, IL-6, NGF, TGF-beta 2, ICAM1, IL-33, EDNRA",
127,Eosinophil survival in asthma,67,1.483E-05,1.655E-04,1.483E-05,1.655E-04,15,"TRUNDD(TNFRSF10D), Syk, IL-15, PGE2R2, NGF, ST2(L), c-IAP2, iNOS, Eotaxin-2, ICAM1, PGD2R, Fibronectin, Lyn, IL-33, ERK1/2",4.472E-05,5.913E-04,14,"TRUNDD(TNFRSF10D), Syk, IL-15, PGE2R2, NGF, ST2(L), c-IAP2, iNOS, Eotaxin-2, ICAM1, PGD2R, Fibronectin, Lyn, IL-33",
128,Th2 cytokine- and TNF-alpha-induced profibrotic response in asthmatic airway fibroblasts/ myofibroblasts,52,1.548E-05,1.674E-04,1.548E-05,1.674E-04,13,"COX-2 (PTGS2), IL-1 beta, NGF, Biglycan, ACTA2, SMAD3, PDGF-R-alpha, AKT(PKB), ETS1, MMP-9, ERK1/2, MMP-2, Collagen III",2.588E-04,2.431E-03,11,"COX-2 (PTGS2), IL-1 beta, NGF, Biglycan, ACTA2, PDGF-R-alpha, AKT(PKB), ETS1, MMP-9, MMP-2, Collagen III",
129,Immune response_Lysophosphatidic acid signaling via NF-kB,52,1.548E-05,1.674E-04,1.548E-05,1.674E-04,13,"COX-2 (PTGS2), IL-6, PKD, CCL20, PKC, ICAM1, CCL2, IL-8, GRO-3, A20, MMP-9, ERK1/2, MMP-2",5.572E-05,7.092E-04,12,"COX-2 (PTGS2), IL-6, PKD, CCL20, PKC, ICAM1, CCL2, IL-8, GRO-3, A20, MMP-9, MMP-2",
130,IGF signaling in HCC,52,1.548E-05,1.674E-04,1.548E-05,1.674E-04,13,"HGF, PI3K cat class IA, TGF-alpha, PKC, AKT(PKB), IRS-2, HGF receptor (Met), Jagged1, EGFR, MMP-9, ERK1/2, IBP3, MMP-2",5.572E-05,7.092E-04,12,"HGF, PI3K cat class IA, TGF-alpha, PKC, AKT(PKB), IRS-2, HGF receptor (Met), Jagged1, EGFR, MMP-9, IBP3, MMP-2",
131,Mechanisms of resistance to EGFR inhibitors in lung cancer,45,1.616E-05,1.696E-04,1.616E-05,1.696E-04,12,"CIN85, HGF, Beta-catenin, PI3K cat class IA, SNAIL1, ERK2 (MAPK1), AKT(PKB), HGF receptor (Met), Fibronectin, Vimentin, TCF8, EGFR",1.422E-03,8.864E-03,9,"CIN85, HGF, PI3K cat class IA, AKT(PKB), HGF receptor (Met), Fibronectin, Vimentin, TCF8, EGFR",
132,Role of cell adhesion molecules in progression of pancreatic cancer,45,1.616E-05,1.696E-04,1.616E-05,1.696E-04,12,"IL-1 beta, Beta-catenin, ITGB1, alpha-5/beta-1 integrin, iNOS, NCAM1, Collagen IV, ITGA5, Fibronectin, Tcf(Lef), SIAT8B, ERK1/2",3.213E-04,2.860E-03,10,"IL-1 beta, ITGB1, alpha-5/beta-1 integrin, iNOS, NCAM1, Collagen IV, ITGA5, Fibronectin, Tcf(Lef), SIAT8B",
133,Role of DNA methylation in progression of multiple myeloma,45,1.616E-05,1.696E-04,1.616E-05,1.696E-04,12,"STAT3, p15, IL-6, Beta-catenin, p14ARF, SFRP1, p53, DKK3, p16INK4, WNT, Frizzled, CDK6",1.422E-03,8.864E-03,9,"p15, IL-6, p14ARF, SFRP1, DKK3, p16INK4, WNT, Frizzled, CDK6",
134,"Signal transduction_Angiotensin II/AGTR1 signaling via Notch, Beta-catenin and NF-kB pathways",76,1.775E-05,1.845E-04,1.775E-05,1.845E-04,16,"IL-6, Beta-catenin, ACTA2, SNAIL1, TRPC6, CTGF, PKC, ERK2 (MAPK1), HES5, AKT(PKB), CCL2, Fibronectin, IL-8, MMP-9, ERK1/2, MMP-2",2.165E-03,1.204E-02,12,"IL-6, ACTA2, TRPC6, CTGF, PKC, HES5, AKT(PKB), CCL2, Fibronectin, IL-8, MMP-9, MMP-2",
135,"Stem cells_Cooperation between Hedgehog, IGF-2 and HGF signaling pathways in medulloblastoma stem cells",32,1.799E-05,1.845E-04,1.799E-05,1.845E-04,10,"BAD, HGF, Beta-catenin, PI3K cat class IA, GLI-1, AKT(PKB), PTCH1, HGF receptor (Met), Tcf(Lef), GLI-2",5.477E-04,4.363E-03,8,"HGF, PI3K cat class IA, GLI-1, AKT(PKB), PTCH1, HGF receptor (Met), Tcf(Lef), GLI-2",
136,"Development_Role of Ceramide 1-phosphate, Sphingosine 1-phosphate and Complement cascade in hematopoietic stem cell homing",32,1.799E-05,1.845E-04,1.799E-05,1.845E-04,10,"COX-2 (PTGS2), PGE2R2, PGE2R4, S1P1 receptor, iC3b, AKT(PKB), alpha-4/beta-1 integrin, C3a, MMP-9, ERK1/2",9.223E-05,1.065E-03,9,"COX-2 (PTGS2), PGE2R2, PGE2R4, S1P1 receptor, iC3b, AKT(PKB), alpha-4/beta-1 integrin, C3a, MMP-9",
137,Role of metalloproteases and heparanase in progression of pancreatic cancer,33,1.824E-05,2.343E-04,2.435E-05,2.343E-04,10,"Matrilysin (MMP-7), Heparanase 1, Collagen IV, CD44, EGFR, MMP-9, CD44 soluble, MMP-14, MMP-2, CD44 (EXT)",1.824E-05,3.144E-04,10,"Matrilysin (MMP-7), Heparanase 1, Collagen IV, CD44, EGFR, MMP-9, CD44 soluble, MMP-14, MMP-2, CD44 (EXT)",
138,Interaction of deficient alpha-MSH signaling with TNF-alpha in melanoma,33,1.824E-05,2.343E-04,2.435E-05,2.343E-04,10,"COX-2 (PTGS2), N-cadherin, ITGB1, ICAM1, alpha-MSH, Fibronectin, Vimentin, SLUG, MMP-9, SIP1 (ZFHX1B)",1.824E-05,3.144E-04,10,"COX-2 (PTGS2), N-cadherin, ITGB1, ICAM1, alpha-MSH, Fibronectin, Vimentin, SLUG, MMP-9, SIP1 (ZFHX1B)",
139,Development_Schema: FGF signaling in embryonic stem cell self-renewal and differentiation,47,1.873E-05,2.444E-04,2.611E-05,2.444E-04,12,"Mixl1, WNT3, Nestin, FGF2, NCAM1, PTCH1, SPRY2, Activin A, Gremlin, BMP4, BMP2, PAX6",1.873E-05,3.156E-04,12,"Mixl1, WNT3, Nestin, FGF2, NCAM1, PTCH1, SPRY2, Activin A, Gremlin, BMP4, BMP2, PAX6",
140,Immune response_Inhibitory PD-1 signaling in T cells,53,1.934E-05,1.969E-04,1.934E-05,1.969E-04,13,"Syk, p15, MHC class II, PI3K cat class IA, PD-L2, Lck, PKC-theta, SMAD3, AKT(PKB), ICAM1, Cyclin E, ERK1/2, PD-L1",1.259E-03,8.141E-03,10,"Syk, p15, MHC class II, PI3K cat class IA, PD-L2, PKC-theta, AKT(PKB), ICAM1, Cyclin E, PD-L1",
141,Inflammatory response in ischemia-reperfusion injury during myocardial infarction,21,1.937E-05,2.358E-04,2.468E-05,2.358E-04,8,"IL-1 beta, IL-6, ICAM1, CCL2, C3a, IL-8, TLR4, TLR2",1.937E-05,3.156E-04,8,"IL-1 beta, IL-6, ICAM1, CCL2, C3a, IL-8, TLR4, TLR2",
142,Cell adhesion_PLAU signaling,39,2.041E-05,2.049E-04,2.041E-05,2.049E-04,11,"HGF, PAI2, PLAUR (uPAR), PI3K cat class IA, AKT(PKB), SERPINE2, PLAT (TPA), HGF receptor (Met), EGFR, PLAU (UPA), ERK1/2",8.951E-05,1.042E-03,10,"HGF, PAI2, PLAUR (uPAR), PI3K cat class IA, AKT(PKB), SERPINE2, PLAT (TPA), HGF receptor (Met), EGFR, PLAU (UPA)",
143,FGF2 signaling in melanoma,39,2.041E-05,2.049E-04,2.041E-05,2.049E-04,11,"STAT3, PI3K cat class IA, FGF2, Heparanase 1, Caveolin-1, Collagen IV, SPRY2, Fra-1, Fibronectin, ERK1/2, MMP-2",4.731E-04,3.858E-03,9,"PI3K cat class IA, FGF2, Heparanase 1, Caveolin-1, Collagen IV, SPRY2, Fra-1, Fibronectin, MMP-2",
144,Neurophysiological process_Receptor-mediated axon growth repulsion,46,2.062E-05,2.054E-04,2.062E-05,2.054E-04,12,"Actin cytoskeletal, Fyn, Ephrin-A receptors, CRMP2, c-Fes, Plexin A2, Semaphorin 3A, EGFR, Pleiotrophin (OSF1), Ephrin-A receptor 2, F-Actin cytoskeleton, Neuropilin-1",3.883E-04,3.265E-03,10,"Fyn, Ephrin-A receptors, CRMP2, c-Fes, Plexin A2, Semaphorin 3A, EGFR, Pleiotrophin (OSF1), Ephrin-A receptor 2, Neuropilin-1",
145,"IGF family, invasion and metastasis in colorectal cancer",33,2.435E-05,2.343E-04,2.435E-05,2.343E-04,10,"Beta-catenin, ITGB1, PLAUR (uPAR), PI3K cat class IA, alpha-1/beta-1 integrin, Collagen IV, IBP6, PLAT (TPA), Fibronectin, PLAU (UPA)",1.200E-04,1.318E-03,9,"ITGB1, PLAUR (uPAR), PI3K cat class IA, alpha-1/beta-1 integrin, Collagen IV, IBP6, PLAT (TPA), Fibronectin, PLAU (UPA)",
146,Development_EGF-induced proliferation of Type C cells in SVZ of adult brain,33,2.435E-05,2.343E-04,2.435E-05,2.343E-04,10,"Fyn, PI3K cat class IA, TGF-alpha, DLX2, GLI-1, AKT(PKB), PTCH1, EGFR, ERK1/2, GLI-2",1.200E-04,1.318E-03,9,"Fyn, PI3K cat class IA, TGF-alpha, DLX2, GLI-1, AKT(PKB), PTCH1, EGFR, GLI-2",
147,SHH signaling in melanoma,33,2.435E-05,2.343E-04,2.435E-05,2.343E-04,10,"N-cadherin, GLI-1, SMAD3, PDGF-R-alpha, PTCH1, Vimentin, SLUG, MMP-9, GLI-2, MMP-2",1.200E-04,1.318E-03,9,"N-cadherin, GLI-1, PDGF-R-alpha, PTCH1, Vimentin, SLUG, MMP-9, GLI-2, MMP-2",
148,Pro-tumoral TNF-alpha signaling in melanoma,41,2.514E-05,3.101E-04,3.424E-05,3.101E-04,11,"ITGB1, TNF-R2, alpha-5/beta-1 integrin, PI3K cat class IA, AKT(PKB), ITGA4, alpha-4/beta-1 integrin, Fibronectin, IL-8, MMP-9, MMP-2",2.514E-05,3.973E-04,11,"ITGB1, TNF-R2, alpha-5/beta-1 integrin, PI3K cat class IA, AKT(PKB), ITGA4, alpha-4/beta-1 integrin, Fibronectin, IL-8, MMP-9, MMP-2",
149,Signal transduction_Adenosine A1 receptor signaling pathway,62,2.567E-05,2.436E-04,2.567E-05,2.436E-04,14,"BAD, STAT3, G-protein alpha-15, PKC, AKT(PKB), G-protein alpha-q/11, PKC-alpha, SFK, EGFR, G-protein alpha-i family, Adenylate cyclase, ERK1/2, MMP-2, ADA",1.244E-03,8.141E-03,11,"G-protein alpha-15, PKC, AKT(PKB), G-protein alpha-q/11, PKC-alpha, SFK, EGFR, G-protein alpha-i family, Adenylate cyclase, MMP-2, ADA",
150,Immune response_Histamine H1 receptor signaling in immune response,47,2.611E-05,2.444E-04,2.611E-05,2.444E-04,12,"Histamine H1 receptor, IL-6, MMP-13, iNOS, ERK2 (MAPK1), G-protein alpha-q/11, Tissue factor, ICAM1, PKC-alpha, IL-8, cPLA2, MMP-9",9.884E-05,1.122E-03,11,"Histamine H1 receptor, IL-6, MMP-13, iNOS, G-protein alpha-q/11, Tissue factor, ICAM1, PKC-alpha, IL-8, cPLA2, MMP-9",
151,CHDI_Correlations from Replication data_Causal network (negative correlations),40,2.656E-05,2.470E-04,2.656E-05,2.470E-04,11,"Beta-catenin, PLAUR (uPAR), PKC, AKT(PKB), Collagen IV, Fibronectin, Dsh, WNT, PLAU (UPA), Frizzled, ACM3",5.777E-04,4.467E-03,9,"PLAUR (uPAR), PKC, AKT(PKB), Collagen IV, Fibronectin, WNT, PLAU (UPA), Frizzled, ACM3",
152,Immune response_IL-18 signaling,63,3.111E-05,2.874E-04,3.111E-05,2.874E-04,14,"COX-2 (PTGS2), IL-1 beta, IL-6, IL-18R1, PI3K cat class IA, iNOS, AKT(PKB), ICAM1, CCL2, Fibronectin, IL-8, MMP-9, IL18RAP, ERK1/2",9.540E-05,1.092E-03,13,"COX-2 (PTGS2), IL-1 beta, IL-6, IL-18R1, PI3K cat class IA, iNOS, AKT(PKB), ICAM1, CCL2, Fibronectin, IL-8, MMP-9, IL18RAP",
153,Neuroendocrine transdifferentiation in Prostate Cancer,48,3.282E-05,2.993E-04,3.282E-05,2.993E-04,12,"STAT3, IL-6, Beta-catenin, BMX, PTHrP, ERK2 (MAPK1), AKT(PKB), Oct-3/4, Tcf(Lef), IL-8, EGFR, NT",2.282E-03,1.238E-02,9,"IL-6, BMX, PTHrP, AKT(PKB), Oct-3/4, Tcf(Lef), IL-8, EGFR, NT",
154,K-RAS signaling in lung cancer,48,3.282E-05,2.993E-04,3.282E-05,2.993E-04,12,"COX-2 (PTGS2), GRO-2, Beta-catenin, PA24A, GRO-1, AKT(PKB), SPRY2, CCL2, EGFR, MMP-9, ERK1/2, ENA-78",5.575E-04,4.389E-03,10,"COX-2 (PTGS2), GRO-2, PA24A, GRO-1, AKT(PKB), SPRY2, CCL2, EGFR, MMP-9, ENA-78",
155,Impaired inhibitory action of lipoxins on neutrophil migration in CF,56,3.638E-05,3.219E-04,3.638E-05,3.219E-04,13,"Myosin II, Actin cytoskeletal, Rac2, AKT(PKB), ITGB2, ICAM1, MELC, MYLK1, IL-8, G-protein alpha-i family, MLCK, MRLC, ERK1/2",1.947E-03,1.098E-02,10,"Rac2, AKT(PKB), ITGB2, ICAM1, MELC, MYLK1, IL-8, G-protein alpha-i family, MLCK, MRLC",
156,TLR and EGFR-induced inflammatory signaling in normal and asthmatic airway epithelium,22,3.663E-05,3.219E-04,3.663E-05,3.219E-04,8,"TGF-alpha, TLR3, IL-8, TLR6, EGFR, MMP-9, TLR2, ERK1/2",2.421E-04,2.346E-03,7,"TGF-alpha, TLR3, IL-8, TLR6, EGFR, MMP-9, TLR2",
157,Origin of Langerhans cells in the steady-state and under inflammatory conditions,22,3.663E-05,3.219E-04,3.663E-05,3.219E-04,8,"IL-1 beta, CCL20, SMAD3, CSF1, RUNX3, CCL2, IL-34, TGF-beta receptor type II",2.421E-04,2.346E-03,7,"IL-1 beta, CCL20, CSF1, RUNX3, CCL2, IL-34, TGF-beta receptor type II",
158,Rho-dependent regulation of normal and asthmatic smooth muscle contraction,28,3.692E-05,3.219E-04,3.692E-05,3.219E-04,9,"Histamine H1 receptor, Myosin II, CPI-17, PKC, G-protein alpha-q/11, G-protein alpha-i family, MRLC, EDNRA, ACM3",2.014E-04,2.032E-03,8,"Histamine H1 receptor, CPI-17, PKC, G-protein alpha-q/11, G-protein alpha-i family, MRLC, EDNRA, ACM3",
159,HGF signaling in pancreatic cancer,28,3.692E-05,3.219E-04,3.692E-05,3.219E-04,9,"HGF, PI3K cat class IA, p53, HGF receptor (Met), MMP-9, PLAU (UPA), Neuropilin-1, ERK1/2, MMP-2",1.217E-03,8.084E-03,7,"HGF, PI3K cat class IA, HGF receptor (Met), MMP-9, PLAU (UPA), Neuropilin-1, MMP-2",
160,Development_Astrocyte differentiation (general schema),28,3.692E-05,3.219E-04,3.692E-05,3.219E-04,9,"STAT3, Nestin, MCT1 (SLC16A1), CD44, Vimentin, BMP4, GLAST1/EAAT1, BMP2, LIF",2.014E-04,2.032E-03,8,"Nestin, MCT1 (SLC16A1), CD44, Vimentin, BMP4, GLAST1/EAAT1, BMP2, LIF",
161,CHDI_Correlations from Replication data_Cytoskeleton and adhesion module,64,3.752E-05,3.251E-04,3.752E-05,3.251E-04,14,"PLAUR (uPAR), Actin cytoskeletal, Fyn, MHC class II, AKT(PKB), Collagen IV, ITGB2, ICAM1, MELC, Fibronectin, MyHC, Ephrin-B receptors, PLAU (UPA), MRLC",4.500E-04,3.737E-03,12,"PLAUR (uPAR), Fyn, MHC class II, AKT(PKB), Collagen IV, ITGB2, ICAM1, MELC, Fibronectin, Ephrin-B receptors, PLAU (UPA), MRLC",
162,Immune response_M-CSF-receptor signaling pathway,81,4.086E-05,3.465E-04,4.086E-05,3.465E-04,16,"STAT3, Syk, Beta-catenin, Fyn, PI3K cat class IA, Rac2, PKC, AKT(PKB), CSF1, GRAP2, Tcf(Lef), MSR1, ETS1, IL-34, PLAU (UPA), ERK1/2",1.234E-03,8.141E-03,13,"Syk, Fyn, PI3K cat class IA, Rac2, PKC, AKT(PKB), CSF1, GRAP2, Tcf(Lef), MSR1, ETS1, IL-34, PLAU (UPA)",
163,Activation of TNF-alpha-dependent pro-tumoral effect in colorectal cancer,49,4.099E-05,3.465E-04,4.099E-05,3.465E-04,12,"COX-2 (PTGS2), PGE2R2, ALDR, IL-6, Beta-catenin, c-IAP2, GRO-1, alpha-4/beta-1 integrin, ICAM1, CCL2, IL-8, ERK1/2",6.625E-04,4.982E-03,10,"COX-2 (PTGS2), PGE2R2, ALDR, IL-6, c-IAP2, GRO-1, alpha-4/beta-1 integrin, ICAM1, CCL2, IL-8",
164,Glucocorticoids-mediated inhibition of pro-constrictory and pro-inflammatory signaling in airway smooth muscle cells,49,4.099E-05,3.465E-04,4.099E-05,3.465E-04,12,"COX-2 (PTGS2), IL-1 beta, IL-6, Myosin II, PA24A, GRO-1, Beta-2 adrenergic receptor, CPI-17, PLA2, CD38, MRLC, ERK1/2",6.625E-04,4.982E-03,10,"COX-2 (PTGS2), IL-1 beta, IL-6, PA24A, GRO-1, Beta-2 adrenergic receptor, CPI-17, PLA2, CD38, MRLC",
165,Th17 cells in CF (mouse model),49,4.099E-05,3.465E-04,4.099E-05,3.465E-04,12,"STAT3, IL-1 beta, IL-6, MHC class II, GRO-1, SMAD3, CD14, GCP2, ICAM1, TGF-beta receptor type II, TLR4, MD-2",6.625E-04,4.982E-03,10,"IL-1 beta, IL-6, MHC class II, GRO-1, CD14, GCP2, ICAM1, TGF-beta receptor type II, TLR4, MD-2",
166,CHDI_Correlations from Discovery data_Causal network,73,4.365E-05,3.668E-04,4.365E-05,3.668E-04,15,"Syk, p15, Beta-catenin, PI3K cat class IA, MEF2, SMAD3, PDGF-R-alpha, AKT(PKB), CCL2, Kir3.4, Dsh, WNT, G-protein alpha-i family, Frizzled, ERK1/2",4.722E-03,2.108E-02,11,"Syk, p15, PI3K cat class IA, MEF2, PDGF-R-alpha, AKT(PKB), CCL2, Kir3.4, WNT, G-protein alpha-i family, Frizzled",
167,Regulation of angiogenesis in prostate cancer,51,4.536E-05,5.028E-04,6.272E-05,5.028E-04,12,"Angiopoietin 1, COX-2 (PTGS2), TIE2, PI3K cat class IA, AKT(PKB), Collagen IV, CCL2, IL-8, TGF-beta receptor type II, EGFR, MMP-9, PLAU (UPA)",4.536E-05,5.940E-04,12,"Angiopoietin 1, COX-2 (PTGS2), TIE2, PI3K cat class IA, AKT(PKB), Collagen IV, CCL2, IL-8, TGF-beta receptor type II, EGFR, MMP-9, PLAU (UPA)",
168,Epigenetic alterations in ovarian cancer,82,4.783E-05,3.972E-04,4.783E-05,3.972E-04,16,"GSTP1, p15, N-cadherin, Maspin, HOXA10, SNAIL1, GLI-1, p16INK4, DACT3, Ephrin-A receptor 2, MMP-9, GLI-2, AL1A1, MMP-2, CYP11A1, CDK6",1.214E-04,1.323E-03,15,"GSTP1, p15, N-cadherin, Maspin, HOXA10, GLI-1, p16INK4, DACT3, Ephrin-A receptor 2, MMP-9, GLI-2, AL1A1, MMP-2, CYP11A1, CDK6",
169,Development_Negative regulation of WNT/Beta-catenin signaling in the cytoplasm,82,4.783E-05,3.972E-04,4.783E-05,3.972E-04,16,"Beta-catenin, Prickle-1, TAZ, Nucleoredoxin, PKC-alpha, p53, Tcf(Lef), Dsh, WNT, A20, DACT3, RIPK4, Frizzled, YAP1/TAZ, DACT1, CDK6",1.385E-03,8.777E-03,13,"Prickle-1, TAZ, Nucleoredoxin, PKC-alpha, Tcf(Lef), WNT, A20, DACT3, RIPK4, Frizzled, YAP1/TAZ, DACT1, CDK6",
170,Role of integrins in eosinophil degranulation in asthma,58,5.399E-05,4.456E-04,5.399E-05,4.456E-04,13,"PI3K cat class IA, PKC, ERK2 (MAPK1), Eotaxin-2, Fc gamma RII alpha, alpha-4/beta-1 integrin, ICAM1, PRG2, Fibronectin, C3b, G-protein alpha-i family, ERK1/2, CCL7",6.969E-04,5.159E-03,11,"PI3K cat class IA, PKC, Eotaxin-2, Fc gamma RII alpha, alpha-4/beta-1 integrin, ICAM1, PRG2, Fibronectin, C3b, G-protein alpha-i family, CCL7",
171,Cytoskeleton remodeling_Hyaluronic acid/ CD44 signaling pathways,43,5.546E-05,4.524E-04,5.546E-05,4.524E-04,11,"HGF, Ankyrin 1, Actin cytoskeletal, Fyn, Lck, CD44, HGF receptor (Met), MSN (moesin), Actin, MLCK, ERK1/2",4.154E-03,1.905E-02,8,"HGF, Ankyrin 1, Fyn, CD44, HGF receptor (Met), MSN (moesin), Actin, MLCK",
172,"NF-kB-, AP-1- and MAPKs-mediated proinflammatory cytokine production by eosinophils in asthma",43,5.546E-05,4.524E-04,5.546E-05,4.524E-04,11,"IL-1 beta, IL-6, ST2(L), GRO-1, ERK2 (MAPK1), PRG2, CCL2, IL-8, IL-33, ERK1/2, ENA-78",1.010E-03,6.912E-03,9,"IL-1 beta, IL-6, ST2(L), GRO-1, PRG2, CCL2, IL-8, IL-33, ENA-78",
173,Cytoskeleton remodeling_Keratin filaments,36,5.620E-05,4.558E-04,5.620E-05,4.558E-04,10,"Tubulin beta, Keratin 17, Keratin 16, Keratin 5/14, Keratin 6C, Actin cytoskeletal, Keratin 6A, Keratin 14, Vimentin, Keratin 5",2.481E-04,2.346E-03,9,"Tubulin beta, Keratin 17, Keratin 16, Keratin 5/14, Keratin 6C, Keratin 6A, Keratin 14, Vimentin, Keratin 5",
174,PI3K signaling in gastric cancer,51,6.272E-05,5.028E-04,6.272E-05,5.028E-04,12,"BAD, HGF, Beta-catenin, PI3K cat class IA, PRNP, AKT(PKB), G-protein alpha-q/11, HGF receptor (Met), IL-8, EGFR, BMP2, MDR1",9.218E-04,6.406E-03,10,"HGF, PI3K cat class IA, PRNP, AKT(PKB), G-protein alpha-q/11, HGF receptor (Met), IL-8, EGFR, BMP2, MDR1",
175,Development_Growth factors in regulation of oligodendrocyte progenitor cell proliferation,67,6.425E-05,5.122E-04,6.425E-05,5.122E-04,14,"HGF, NGF, Myelin basic protein, Fyn, PI3K cat class IA, FGF2, PKC, PDGF-R-alpha, AKT(PKB), HGF receptor (Met), Fibronectin, Lyn, EGFR, ERK1/2",1.842E-04,1.930E-03,13,"HGF, NGF, Myelin basic protein, Fyn, PI3K cat class IA, FGF2, PKC, PDGF-R-alpha, AKT(PKB), HGF receptor (Met), Fibronectin, Lyn, EGFR",
176,Role of free fatty acids in obesity and type 2 diabetes,45,6.447E-05,6.463E-04,8.709E-05,6.463E-04,11,"COX-2 (PTGS2), IL-1 beta, IL-6, PI3K cat class IA, PKC-theta, iNOS, AKT(PKB), CCL2, IFN-beta, TLR4, TLR2",6.447E-05,7.983E-04,11,"COX-2 (PTGS2), IL-1 beta, IL-6, PI3K cat class IA, PKC-theta, iNOS, AKT(PKB), CCL2, IFN-beta, TLR4, TLR2",
177,Inhibition of apoptosis in pancreatic cancer,59,6.528E-05,5.174E-04,6.528E-05,5.174E-04,13,"BAD, STAT3, COX-2 (PTGS2), IL-6, PI3K cat class IA, PKR2, AKT(PKB), p53, EGFR, G-protein alpha-i family, Neuropilin-1, ALOX5, ERK1/2",9.381E-03,3.559E-02,9,"COX-2 (PTGS2), IL-6, PI3K cat class IA, PKR2, AKT(PKB), EGFR, G-protein alpha-i family, Neuropilin-1, ALOX5",
178,Inhibition of Ephrin receptors in colorectal cancer,30,6.818E-05,5.284E-04,6.818E-05,5.284E-04,9,"Beta-catenin, Ephrin-A receptors, SMAD3, Ephrin-B receptor 1, WNT, Ephrin-B receptors, Ephrin-A receptor 2, Ephrin-B receptor 2, Frizzled",1.879E-03,1.071E-02,7,"Ephrin-A receptors, Ephrin-B receptor 1, WNT, Ephrin-B receptors, Ephrin-A receptor 2, Ephrin-B receptor 2, Frizzled",
179,Development_Transcription factors in segregation of hepatocytic lineage,30,6.818E-05,5.284E-04,6.818E-05,5.284E-04,9,"Follistatin, Beta-catenin, p14ARF, Activin A, HGF receptor (Met), p16INK4, A2M, TGF-beta receptor type II, Activin",3.400E-04,2.931E-03,8,"Follistatin, p14ARF, Activin A, HGF receptor (Met), p16INK4, A2M, TGF-beta receptor type II, Activin",
180,Development_WNT/Beta-catenin signaling in cell differentiation,30,6.818E-05,5.284E-04,6.818E-05,5.284E-04,9,"Follistatin, Beta-catenin, Tcf(Lef), WNT, SLUG, TCF7 (TCF1), CDX1, BMP2, Frizzled",3.400E-04,2.931E-03,8,"Follistatin, Tcf(Lef), WNT, SLUG, TCF7 (TCF1), CDX1, BMP2, Frizzled",
181,Activation of TGF-beta signaling in advanced colorectal cancer,30,6.818E-05,5.284E-04,6.818E-05,5.284E-04,9,"TGF-beta 2, PI3K cat class IA, SNAIL1, SMAD3, AKT(PKB), IL-8, TGF-beta receptor type II, MMP-9, IBP3",1.879E-03,1.071E-02,7,"TGF-beta 2, PI3K cat class IA, AKT(PKB), IL-8, TGF-beta receptor type II, MMP-9, IBP3",
182,Inhibition of remyelination in multiple sclerosis: regulation of cytoskeleton proteins,44,6.975E-05,5.376E-04,6.975E-05,5.376E-04,11,"Tubulin beta, Myosin II, Myelin basic protein, NGFR(TNFRSF16), TGF-beta, Actin cytoskeletal, Fyn, MELC, PKC-alpha, Fibronectin, MRLC",1.202E-03,8.062E-03,9,"Tubulin beta, Myelin basic protein, NGFR(TNFRSF16), TGF-beta, Fyn, MELC, PKC-alpha, Fibronectin, MRLC",
183,G protein-coupled receptors signaling in lung cancer,76,7.135E-05,5.469E-04,7.135E-05,5.469E-04,15,"STAT3, PGE2R4, Galpha(i)-specific peptide GPCRs, TGF-alpha, Galpha(q)-specific peptide GPCRs, AKT(PKB), G-protein alpha-q/11, CD44, IL-8, EGFR, NT, G-protein alpha-i family, EDNRA, ERK1/2, MMP-2",6.657E-04,4.982E-03,13,"PGE2R4, Galpha(i)-specific peptide GPCRs, TGF-alpha, Galpha(q)-specific peptide GPCRs, AKT(PKB), G-protein alpha-q/11, CD44, IL-8, EGFR, NT, G-protein alpha-i family, EDNRA, MMP-2",
184,Role of alveolar cell senescence in COPD,37,7.268E-05,5.540E-04,7.268E-05,5.540E-04,10,"IL-6, IGFBP7, CTGF, AKT(PKB), Caveolin-1, p53, p16INK4, IL-8, ERK1/2, IBP3",1.531E-03,9.107E-03,8,"IL-6, IGFBP7, CTGF, AKT(PKB), Caveolin-1, p16INK4, IL-8, IBP3",
185,Eosinophil adhesion and transendothelial migration in asthma,68,7.626E-05,5.782E-04,7.626E-05,5.782E-04,14,"PLAUR (uPAR), alpha-1/beta-1 integrin, PKC, Eotaxin-2, Collagen IV, alpha-4/beta-1 integrin, ICAM1, CD44, Fibronectin, C3a, MMP-9, PLAU (UPA), ERK1/2, CCL7",2.152E-04,2.146E-03,13,"PLAUR (uPAR), alpha-1/beta-1 integrin, PKC, Eotaxin-2, Collagen IV, alpha-4/beta-1 integrin, ICAM1, CD44, Fibronectin, C3a, MMP-9, PLAU (UPA), CCL7",
186,Immune response_IFN-alpha/beta signaling via PI3K and NF-kB pathways,94,7.684E-05,5.794E-04,7.684E-05,5.794E-04,17,"STAT3, PCNA, p15, IFI17, PI3K cat class IA, RSAD2, AKT(PKB), ISG15, IRS-2, PKC-alpha, p16INK4, I-TAC, Cyclin E, IFN-beta, ISG54, NMI, ERK1/2",1.713E-03,9.969E-03,14,"p15, IFI17, PI3K cat class IA, RSAD2, AKT(PKB), ISG15, IRS-2, PKC-alpha, p16INK4, I-TAC, Cyclin E, IFN-beta, ISG54, NMI",
187,Pro-oncogenic action of Estradiol/ Estrogen receptors in ovarian cancer,60,7.857E-05,5.893E-04,7.857E-05,5.893E-04,13,"STAT3, BETA-IG-H3, PI3K cat class IA, ERK2 (MAPK1), AKT(PKB), CD44, Fra-1, Fibronectin, Cyclin E, EGFR, MMP-9, PLAU (UPA), IBP3",9.379E-04,6.484E-03,11,"BETA-IG-H3, PI3K cat class IA, AKT(PKB), CD44, Fra-1, Fibronectin, Cyclin E, EGFR, MMP-9, PLAU (UPA), IBP3",
188,Immune response_IFN-alpha/beta signaling via MAPKs,77,8.351E-05,6.229E-04,8.351E-05,6.229E-04,15,"TAP1 (PSF1), Beta-catenin, Matrilysin (MMP-7), RSAD2, Lck, PKC-theta, SMAD3, AKT(PKB), ISG15, FZD7, IFN-beta, ISG54, RIG-G, ERK1/2, PL scramblase 1",7.104E-03,2.932E-02,11,"TAP1 (PSF1), Matrilysin (MMP-7), RSAD2, PKC-theta, AKT(PKB), ISG15, FZD7, IFN-beta, ISG54, RIG-G, PL scramblase 1",
189,Role of TGF-beta 1 in fibrosis development after myocardial infarction,38,9.308E-05,6.810E-04,9.308E-05,6.810E-04,10,"Biglycan, ACTA2, SMAD3, CTGF, Fibronectin, TGF-beta receptor type II, MMP-9, EDNRA, MMP-2, Collagen III",3.846E-04,3.253E-03,9,"Biglycan, ACTA2, CTGF, Fibronectin, TGF-beta receptor type II, MMP-9, EDNRA, MMP-2, Collagen III",
190,WNT signaling in invasive-type melanoma cells,38,9.308E-05,6.810E-04,9.308E-05,6.810E-04,10,"STAT3, Beta-catenin, cPKC (conventional), SFRP3 (FRZB1), SNAIL1, PKC, CD44, TLR3, Vimentin, MMP-2",7.604E-03,3.019E-02,7,"cPKC (conventional), SFRP3 (FRZB1), PKC, CD44, TLR3, Vimentin, MMP-2",
191,IL-6 signaling in breast cancer cells,53,9.373E-05,6.810E-04,9.373E-05,6.810E-04,12,"STAT3, IL-6, N-cadherin, PI3K cat class IA, SNAIL1, AKT(PKB), Jagged1, Vimentin, Carbonic anhydrase IX, MDR1, Fascin, ERK1/2",4.587E-03,2.076E-02,9,"IL-6, N-cadherin, PI3K cat class IA, AKT(PKB), Jagged1, Vimentin, Carbonic anhydrase IX, MDR1, Fascin",
192,EGFR signaling pathway in lung cancer,53,9.373E-05,6.810E-04,9.373E-05,6.810E-04,12,"STAT3, HGF, COX-2 (PTGS2), IL-6, PI3K cat class IA, TGF-alpha, AKT(PKB), HGF receptor (Met), EGFR, MMP-9, Carbonic anhydrase IX, ERK1/2",1.259E-03,8.141E-03,10,"HGF, COX-2 (PTGS2), IL-6, PI3K cat class IA, TGF-alpha, AKT(PKB), HGF receptor (Met), EGFR, MMP-9, Carbonic anhydrase IX",
193,FGF signaling in pancreatic cancer,46,1.080E-04,7.805E-04,1.080E-04,7.805E-04,11,"Beta-catenin, HBP17, PI3K cat class IA, FGF2, Heparanase 1, AKT(PKB), PLAT (TPA), MMP-9, PLAU (UPA), ERK1/2, MMP-14",1.673E-03,9.850E-03,9,"HBP17, PI3K cat class IA, FGF2, Heparanase 1, AKT(PKB), PLAT (TPA), MMP-9, PLAU (UPA), MMP-14",
194,Immune response_HSP60 and HSP70/ TLR signaling pathway,54,1.137E-04,8.089E-04,1.137E-04,8.089E-04,12,"IL-1 beta, IL-6, MHC class II, CD83, iNOS, CD14, ICAM1, IL-8, TLR4, TLR2, ERK1/2, MD-2",3.666E-04,3.140E-03,11,"IL-1 beta, IL-6, MHC class II, CD83, iNOS, CD14, ICAM1, IL-8, TLR4, TLR2, MD-2",
195,"Disruption of apoptosis, proliferation and shedding of epithelial cells in asthma",54,1.137E-04,8.089E-04,1.137E-04,8.089E-04,12,"p15, IL-1 beta, TGF-beta 2, TNF-R2, TGF-alpha, Desmocollin 3, SMAD3, ICAM1, p53, EGFR, MMP-9, ERK1/2",5.212E-03,2.275E-02,9,"p15, IL-1 beta, TGF-beta 2, TNF-R2, TGF-alpha, Desmocollin 3, ICAM1, EGFR, MMP-9",
196,Role of IL-23/ T17 pathogenic axis in psoriasis,54,1.137E-04,8.089E-04,1.137E-04,8.089E-04,12,"STAT3, IL-15, IL-1 beta, IL-6, sIL-15RA, MHC class II, IL-15RA, CCL20, AKT(PKB), IL-8, IL22RA1, ERK1/2",1.462E-03,8.968E-03,10,"IL-15, IL-1 beta, IL-6, sIL-15RA, MHC class II, IL-15RA, CCL20, AKT(PKB), IL-8, IL22RA1",
197,Role of tumor microenvironment in plexiform neurofibroma formation in neurofibromatosis type 1,39,1.181E-04,8.366E-04,1.181E-04,8.366E-04,10,"NGF, PI3K cat class IA, FGF2, Rac2, AKT(PKB), alpha-4/beta-1 integrin, Fibronectin, ERK1/2, PDGF-R-beta, MMP-2",4.731E-04,3.858E-03,9,"NGF, PI3K cat class IA, FGF2, Rac2, AKT(PKB), alpha-4/beta-1 integrin, Fibronectin, PDGF-R-beta, MMP-2",
198,Upregulation of IL-8 expression in colorectal cancer,32,1.192E-04,8.395E-04,1.192E-04,8.395E-04,9,"IL-1 beta, Beta-catenin, SNAIL1, IL-8, WNT, TGF-beta receptor type II, NT, Frizzled, WNT6",2.792E-03,1.451E-02,7,"IL-1 beta, IL-8, WNT, TGF-beta receptor type II, NT, Frizzled, WNT6",
199,The innate immune response to contact allergens,33,1.200E-04,1.043E-03,1.547E-04,1.043E-03,9,"IL-1 beta, IL-6, Biglycan, CD14, CCL2, Caspase-1, IL-8, TLR4, TLR2",1.200E-04,1.318E-03,9,"IL-1 beta, IL-6, Biglycan, CD14, CCL2, Caspase-1, IL-8, TLR4, TLR2",
200,Inhibition of neutrophil migration by proresolving lipid mediators in COPD,71,1.247E-04,8.745E-04,1.247E-04,8.745E-04,14,"IL-1 beta, TNF-R2, Actin cytoskeletal, cPKC (conventional), Rac2, PKC, ITGB2, ICAM1, MSN (moesin), ICAM2, IL-8, G-protein alpha-i family, TLR4, TLR2",3.362E-04,2.931E-03,13,"IL-1 beta, TNF-R2, cPKC (conventional), Rac2, PKC, ITGB2, ICAM1, MSN (moesin), ICAM2, IL-8, G-protein alpha-i family, TLR4, TLR2",
201,Development_TGF-beta-dependent induction of EMT via MAPK ,47,1.330E-04,9.277E-04,1.330E-04,9.277E-04,11,"TGF-beta 2, ITGB1, TGF-beta, SNAIL1, Fibronectin, Vimentin, ITGB3, Claudin-1, TGF-beta receptor type II, ERK1/2, MMP-2",1.959E-03,1.098E-02,9,"TGF-beta 2, ITGB1, TGF-beta, Fibronectin, Vimentin, ITGB3, Claudin-1, TGF-beta receptor type II, MMP-2",
202,Immune response_Role of DAP12 receptors in NK cells,55,1.371E-04,9.515E-04,1.371E-04,9.515E-04,12,"Syk, NKG2C, Actin cytoskeletal, Fyn, CD94, PI3K cat class IA, KLRC3, Lck, HLA-G, PKC-theta, HLA-B, ERK1/2",5.901E-03,2.512E-02,9,"Syk, NKG2C, Fyn, CD94, PI3K cat class IA, KLRC3, HLA-G, PKC-theta, HLA-B",
203,Hypothetical role of microRNAs in fibrosis development after myocardial infarction,26,1.426E-04,9.846E-04,1.426E-04,9.846E-04,8,"Fibrillin 1, PI3K cat class IA, SMAD3, CTGF, AKT(PKB), TGF-beta receptor type II, MMP-2, Collagen III",7.527E-04,5.453E-03,7,"Fibrillin 1, PI3K cat class IA, CTGF, AKT(PKB), TGF-beta receptor type II, MMP-2, Collagen III",
204,Development_H3K27 demethylases in differentiation of stem cells,40,1.487E-04,1.017E-03,1.487E-04,1.017E-03,10,"Nestin, HOXA1, HOXA7, HOXA3, SMAD3, DLX5, BMP4, HOXA11, BMP2, PAX6",5.777E-04,4.467E-03,9,"Nestin, HOXA1, HOXA7, HOXA3, DLX5, BMP4, HOXA11, BMP2, PAX6",
205,Cell adhesion_IL-8 family-dependent cell migration and adhesion,40,1.487E-04,1.017E-03,1.487E-04,1.017E-03,10,"GRO-2, GRO-1, GCP2, ITGB2, ICAM1, IL-8, GRO-3, G-protein alpha-i family, ERK1/2, ENA-78",5.777E-04,4.467E-03,9,"GRO-2, GRO-1, GCP2, ITGB2, ICAM1, IL-8, GRO-3, G-protein alpha-i family, ENA-78",
206,Role of IFN-beta in the improvement of blood-brain barrier integrity in multiple sclerosis,27,1.520E-04,1.248E-03,1.914E-04,1.248E-03,8,"TNF-R2, 5'-NTD, ITGA4, alpha-4/beta-1 integrin, ICAM1, IFN-beta, MMP-9, sICAM1",1.520E-04,1.630E-03,8,"TNF-R2, 5'-NTD, ITGA4, alpha-4/beta-1 integrin, ICAM1, IFN-beta, MMP-9, sICAM1",
207,Normal and pathological TGF-beta-mediated regulation of cell proliferation,33,1.547E-04,1.043E-03,1.547E-04,1.043E-03,9,"Beta-catenin, FGF2, SMAD3, PDGF-R-alpha, PDGF receptor, p53, ITGB3, TGF-beta receptor type II, PDGF-R-beta",1.402E-02,4.809E-02,6,"FGF2, PDGF-R-alpha, PDGF receptor, ITGB3, TGF-beta receptor type II, PDGF-R-beta",
208,Development_Role of PKR1 and ILK in cardiac progenitor cells,33,1.547E-04,1.043E-03,1.547E-04,1.043E-03,9,"Beta-catenin, ITGB1, PI3K cat class IA, AKT(PKB), G-protein alpha-q/11, alpha-4/beta-1 integrin, Fibronectin, Tcf(Lef), ERK1/2",3.359E-03,1.634E-02,7,"ITGB1, PI3K cat class IA, AKT(PKB), G-protein alpha-q/11, alpha-4/beta-1 integrin, Fibronectin, Tcf(Lef)",
209,Immune response_C3a signaling,48,1.628E-04,1.087E-03,1.628E-04,1.087E-03,11,"IL-1 beta, IL-6, NGF, MHC class II, AKT(PKB), CCL2, C3a, IL-8, G-protein alpha-i family, Adenylate cyclase, ERK1/2",5.575E-04,4.389E-03,10,"IL-1 beta, IL-6, NGF, MHC class II, AKT(PKB), CCL2, C3a, IL-8, G-protein alpha-i family, Adenylate cyclase",
210,Signal transduction_Adenosine A3 receptor signaling pathway,48,1.628E-04,1.087E-03,1.628E-04,1.087E-03,11,"BAD, STAT3, IL-1 beta, Rho GTPase, PI3K cat class IA, PKC, AKT(PKB), G-protein alpha-q/11, G-protein alpha-i family, Adenylate cyclase, ERK1/2",8.256E-03,3.250E-02,8,"IL-1 beta, Rho GTPase, PI3K cat class IA, PKC, AKT(PKB), G-protein alpha-q/11, G-protein alpha-i family, Adenylate cyclase",
211,Role of FSH and Lutropin in ovarian cancer,56,1.646E-04,1.093E-03,1.646E-04,1.093E-03,12,"COX-2 (PTGS2), IL-6, TRPC3, AKT(PKB), CD44, PKC-alpha, Cyclin E, EGFR, MMP-9, Adenylate cyclase, ERK1/2, MMP-2",5.097E-04,4.133E-03,11,"COX-2 (PTGS2), IL-6, TRPC3, AKT(PKB), CD44, PKC-alpha, Cyclin E, EGFR, MMP-9, Adenylate cyclase, MMP-2",
212,Regulation and signaling of HGF receptor (Met) and MSP receptor (RON) in lung cancer,73,1.703E-04,1.126E-03,1.703E-04,1.126E-03,14,"STAT3, HGF, COX-2 (PTGS2), IL-1 beta, IL-6, Beta-catenin, PI3K cat class IA, FGF2, AKT(PKB), PKC-alpha, HGF receptor (Met), MMP-9, ERK1/2, MMP-2",4.722E-03,2.108E-02,11,"HGF, COX-2 (PTGS2), IL-1 beta, IL-6, PI3K cat class IA, FGF2, AKT(PKB), PKC-alpha, HGF receptor (Met), MMP-9, MMP-2",
213,Multiple sclerosis (general schema),21,1.742E-04,1.365E-03,2.144E-04,1.365E-03,7,"NGF, FGF2, ICAM1, Fibronectin, Jagged1, IFN-beta, LIF",1.742E-04,1.850E-03,7,"NGF, FGF2, ICAM1, Fibronectin, Jagged1, IFN-beta, LIF",
214,Androgen receptor activation and downstream signaling in Prostate cancer,110,1.820E-04,1.197E-03,1.820E-04,1.197E-03,18,"STAT3, IL-6, N-cadherin, Matrilysin (MMP-7), SGK1, FGF2, ERK2 (MAPK1), AKT(PKB), Caveolin-1, SPRY2, p53, STEAP1, ER81, IL-8, EGFR, TLR2, IBP3, Versican",2.903E-03,1.496E-02,15,"IL-6, N-cadherin, Matrilysin (MMP-7), SGK1, FGF2, AKT(PKB), Caveolin-1, SPRY2, STEAP1, ER81, IL-8, EGFR, TLR2, IBP3, Versican",
215,Pancreatic cancer cell resistance to Tarceva (erlotinib),27,1.914E-04,1.248E-03,1.914E-04,1.248E-03,8,"Beta-catenin, PI3K cat class IA, TGF-alpha, SNAIL1, AKT(PKB), Vimentin, TCF8, EGFR",5.120E-03,2.250E-02,6,"PI3K cat class IA, TGF-alpha, AKT(PKB), Vimentin, TCF8, EGFR",
216,Immune response_TLR ligands,35,1.966E-04,1.549E-03,2.526E-04,1.549E-03,9,"TLR1, TLR7, CD14, TLR10, Fibronectin, TLR6, TLR4, TLR2, MD-2",1.966E-04,2.029E-03,9,"TLR1, TLR7, CD14, TLR10, Fibronectin, TLR6, TLR4, TLR2, MD-2",
217,Mechanisms of drug resistance in multiple myeloma,49,1.980E-04,1.283E-03,1.980E-04,1.283E-03,11,"BAD, STAT3, IL-6, Beta-catenin, NOXA, CD44, Jagged1, IL-8, Frizzled, MDR1, ERK1/2",2.898E-02,8.507E-02,7,"IL-6, NOXA, CD44, Jagged1, IL-8, Frizzled, MDR1",
218,Development_Epigenetic and transcriptional regulation of oligodendrocyte precursor cell differentiation and myelination,34,1.987E-04,1.283E-03,1.987E-04,1.283E-03,9,"Beta-catenin, SOX10, Myelin basic protein, C11orf9, HES5, SOX8, ID4, Jagged1, Frizzled",8.478E-04,5.983E-03,8,"SOX10, Myelin basic protein, C11orf9, HES5, SOX8, ID4, Jagged1, Frizzled",
219,Cytoskeleton remodeling_PDGF signaling via calcium and Rho GTPases,83,2.018E-04,1.297E-03,2.018E-04,1.297E-03,15,"PDGF-C, N-cadherin, Beta-catenin, Actin cytoskeletal, Fyn, PDGFR-ab, Schwannomin (NF2), TRPC6, Lysyl oxidase, PKC, PDGF-R-alpha, F-Actin, PDGF receptor, PKC-alpha, PDGF-R-beta",1.232E-02,4.303E-02,11,"PDGF-C, N-cadherin, Fyn, PDGFR-ab, TRPC6, Lysyl oxidase, PKC, PDGF-R-alpha, PDGF receptor, PKC-alpha, PDGF-R-beta",
220,Development_Role of G-CSF in hematopoietic stem cell mobilization,21,2.144E-04,1.365E-03,2.144E-04,1.365E-03,7,"STAT3, S1P1 receptor, DPP4, ICAM1, MMP-9, MMP-14, GFI-1",1.286E-03,8.187E-03,6,"S1P1 receptor, DPP4, ICAM1, MMP-9, MMP-14, GFI-1",
221,Role of cell adhesion in vaso-occlusion in Sickle cell disease,43,2.159E-04,1.693E-03,2.828E-04,1.693E-03,10,"IL-1 beta, iC3b, CD14, Fc gamma RII alpha, ITGB2, alpha-4/beta-1 integrin, ICAM1, CD44, Fibronectin, IL-8",2.159E-04,2.146E-03,10,"IL-1 beta, iC3b, CD14, Fc gamma RII alpha, ITGB2, alpha-4/beta-1 integrin, ICAM1, CD44, Fibronectin, IL-8",
222,Inhibition of apoptosis in gastric cancer,42,2.299E-04,1.445E-03,2.299E-04,1.445E-03,10,"BAD, HGF, c-IAP2, Caspase-10, AKT(PKB), RUNX3, Caspase-8, HGF receptor (Met), TGF-beta receptor type II, XAF1",3.569E-03,1.694E-02,8,"HGF, c-IAP2, Caspase-10, AKT(PKB), RUNX3, HGF receptor (Met), TGF-beta receptor type II, XAF1",
223,Development_TGF-beta family mediated differentiation of embryonic stem cells,42,2.299E-04,1.445E-03,2.299E-04,1.445E-03,10,"Mixl1, Nestin, TAZ, HOXA1, SMAD3, Activin A, Oct-3/4, TGF-beta receptor type II, BMP4, PAX6",8.437E-04,5.983E-03,9,"Mixl1, Nestin, TAZ, HOXA1, Activin A, Oct-3/4, TGF-beta receptor type II, BMP4, PAX6",
224,Chemoresistance pathways mediated by constitutive activation of PI3K pathway and BCL-2 in small cell lung cancer,42,2.299E-04,1.445E-03,2.299E-04,1.445E-03,10,"Laminin 5, alpha-5/beta-1 integrin, BMX, PI3K cat class IA, FGF2, LAMC2, AKT(PKB), Collagen IV, p53, Fibronectin",8.437E-04,5.983E-03,9,"Laminin 5, alpha-5/beta-1 integrin, BMX, PI3K cat class IA, FGF2, LAMC2, AKT(PKB), Collagen IV, Fibronectin",
225,Development_Thromboxane A2 signaling pathway,50,2.396E-04,1.492E-03,2.396E-04,1.492E-03,11,"IL-6, Beta-catenin, cPKC (conventional), PI3K cat class IA, PKC, AKT(PKB), Tcf(Lef), EGFR, G-protein alpha-i family, Adenylate cyclase, ERK1/2",3.056E-03,1.519E-02,9,"IL-6, cPKC (conventional), PI3K cat class IA, PKC, AKT(PKB), Tcf(Lef), EGFR, G-protein alpha-i family, Adenylate cyclase",
226,Survival pathways in Prostate Cancer,50,2.396E-04,1.492E-03,2.396E-04,1.492E-03,11,"BAD, STAT3, TRUNDD(TNFRSF10D), IL-6, PI3K cat class IA, Caspase-10, ERK2 (MAPK1), AKT(PKB), CCL2, Caspase-8, p53",8.431E-02,1.846E-01,6,"TRUNDD(TNFRSF10D), IL-6, PI3K cat class IA, Caspase-10, AKT(PKB), CCL2",
227,Th2 cytokine- and TNF-alpha-induced inflammatory response in asthmatic airway fibroblasts,35,2.526E-04,1.549E-03,2.526E-04,1.549E-03,9,"COX-2 (PTGS2), IL-6, ITGB1, alpha-5/beta-1 integrin, ICAM1, CCL2, ITGA5, IL-8, ERK1/2",1.041E-03,7.087E-03,8,"COX-2 (PTGS2), IL-6, ITGB1, alpha-5/beta-1 integrin, ICAM1, CCL2, ITGA5, IL-8",
228,Development_WNT and Notch signaling in early cardiac myogenesis,35,2.526E-04,1.549E-03,2.526E-04,1.549E-03,9,"Beta-catenin, Jagged1, FZD7, Dsh, WNT, TCF7 (TCF1), BMP2, Frizzled, MEF2C",4.752E-03,2.108E-02,7,"Jagged1, FZD7, WNT, TCF7 (TCF1), BMP2, Frizzled, MEF2C",
229,The role of aberrations in CDKN2 locus and CDK4 in familial melanoma,28,2.532E-04,1.549E-03,2.532E-04,1.549E-03,8,"p15, p14ARF, RUNX2, p53, p16INK4, FLRT3, EGFR, CDK6",1.217E-03,8.084E-03,7,"p15, p14ARF, RUNX2, p16INK4, FLRT3, EGFR, CDK6",
230,"Role of microRNAs in cell migration, survival and angiogenesis in colorectal cancer",67,2.556E-04,1.557E-03,2.556E-04,1.557E-03,13,"COX-2 (PTGS2), PGE2R4, CTGF, AKT(PKB), SPRY2, Fra-1, p53, HGF receptor (Met), UFO, TGF-beta receptor type II, MMP-9, Neuropilin-1, MMP-2",6.939E-04,5.159E-03,12,"COX-2 (PTGS2), PGE2R4, CTGF, AKT(PKB), SPRY2, Fra-1, HGF receptor (Met), UFO, TGF-beta receptor type II, MMP-9, Neuropilin-1, MMP-2",
231,Release of pro-inflammatory factors and proteases by alveolar macrophages in asthma,44,2.643E-04,1.979E-03,3.454E-04,1.979E-03,10,"GRO-2, IL-1 beta, IL-6, GRO-1, iNOS, CCL2, IL-8, MMP-9, TLR4, TLR2",2.643E-04,2.448E-03,10,"GRO-2, IL-1 beta, IL-6, GRO-1, iNOS, CCL2, IL-8, MMP-9, TLR4, TLR2",
232,Arachidonic acid metabolites production in eosinophils in asthma,44,2.643E-04,1.979E-03,3.454E-04,1.979E-03,10,"COX-2 (PTGS2), PA24A, PKC, alpha-4/beta-1 integrin, ICAM1, PGD2R, Fibronectin, cPLA2, G-protein alpha-i family, ALOX5",2.643E-04,2.448E-03,10,"COX-2 (PTGS2), PA24A, PKC, alpha-4/beta-1 integrin, ICAM1, PGD2R, Fibronectin, cPLA2, G-protein alpha-i family, ALOX5",
233,Development_Regulation of cytoskeleton proteins in oligodendrocyte differentiation and myelination,59,2.768E-04,1.679E-03,2.768E-04,1.679E-03,12,"Tubulin beta, Myosin II, Myelin basic protein, Actin cytoskeletal, Fyn, MAP-1B, NCAM1, PDGF-R-alpha, PDGF receptor, MELC, MAP2, MRLC",2.911E-03,1.496E-02,10,"Tubulin beta, Myelin basic protein, Fyn, MAP-1B, NCAM1, PDGF-R-alpha, PDGF receptor, MELC, MAP2, MRLC",
234,Effect of H. pylori infection on gastric epithelial cells motility,43,2.828E-04,1.693E-03,2.828E-04,1.693E-03,10,"Beta-catenin, ITGB1, alpha-5/beta-1 integrin, Actin cytoskeletal, PKC-alpha, Claudin-1, Lyn, Actin, PTPR-zeta, ERK1/2",1.490E-02,4.987E-02,7,"ITGB1, alpha-5/beta-1 integrin, PKC-alpha, Claudin-1, Lyn, Actin, PTPR-zeta",
235,Immune response_Substance P-stimulated expression of proinflammatory cytokines via MAPKs,43,2.828E-04,1.693E-03,2.828E-04,1.693E-03,10,"COX-2 (PTGS2), GRO-2, IL-6, PKC-theta, AKT(PKB), CCL2, PKC-alpha, IL-8, GRO-3, ERK1/2",1.010E-03,6.912E-03,9,"COX-2 (PTGS2), GRO-2, IL-6, PKC-theta, AKT(PKB), CCL2, PKC-alpha, IL-8, GRO-3",
236,Role of activation of WNT signaling in the progression of lung cancer,77,3.055E-04,1.813E-03,3.055E-04,1.813E-03,14,"WNT3, Beta-catenin, Matrilysin (MMP-7), iNOS, DVL-3, SFRP1, RUNX3, Oct-3/4, DKK3, Tcf(Lef), FZD7, Dsh, WNT, Frizzled",7.104E-03,2.932E-02,11,"WNT3, Matrilysin (MMP-7), iNOS, SFRP1, RUNX3, Oct-3/4, DKK3, Tcf(Lef), FZD7, WNT, Frizzled",
237,Immune response _CCR3 signaling in eosinophils,77,3.055E-04,1.813E-03,3.055E-04,1.813E-03,14,"Myosin II, Actin cytoskeletal, Rac2, iNOS, ERK2 (MAPK1), Eotaxin-2, MELC, PKC-alpha, MyHC, cPLA2, G-protein alpha-i family, MLCK, MRLC, CCL7",1.893E-02,6.011E-02,10,"Rac2, iNOS, Eotaxin-2, MELC, PKC-alpha, cPLA2, G-protein alpha-i family, MLCK, MRLC, CCL7",
238,Immune response_Alternative complement pathway,53,3.087E-04,2.273E-03,4.107E-04,2.273E-03,11,"C7, PTX3, iC3b, C3dg, FHR-1, C6, C3a, C3, Factor I, C3b, C3c",3.087E-04,2.798E-03,11,"C7, PTX3, iC3b, C3dg, FHR-1, C6, C3a, C3, Factor I, C3b, C3c",
239,Gamma-secretase regulation of osteogenesis,37,3.102E-04,2.215E-03,3.969E-04,2.215E-03,9,"ALPL, CD44 (ICD), RUNX2, Osteoprotegerin, CSF1, CD44, Jagged1, CD44 soluble, CD44 (EXT)",3.102E-04,2.798E-03,9,"ALPL, CD44 (ICD), RUNX2, Osteoprotegerin, CSF1, CD44, Jagged1, CD44 soluble, CD44 (EXT)",
240,IGF-1 signaling in pancreatic cancer,36,3.180E-04,1.864E-03,3.180E-04,1.864E-03,9,"STAT3, COX-2 (PTGS2), PI3K cat class IA, NUAK1, IRS-2, MMP-9, ERK1/2, MMP-14, MMP-2",5.594E-03,2.403E-02,7,"COX-2 (PTGS2), PI3K cat class IA, NUAK1, IRS-2, MMP-9, MMP-14, MMP-2",
241,Th17 cytokines in COPD,36,3.180E-04,1.864E-03,3.180E-04,1.864E-03,9,"STAT3, IL-1 beta, IL-6, MHC class II, CCL20, GRO-1, CCL2, IL-8, MMP-9",1.267E-03,8.141E-03,8,"IL-1 beta, IL-6, MHC class II, CCL20, GRO-1, CCL2, IL-8, MMP-9",
242,Development_Thrombospondin 1 signaling,36,3.180E-04,1.864E-03,3.180E-04,1.864E-03,9,"Fyn, FGF2, alpha-4/beta-1 integrin, Caspase-8, alpha-9/beta-1 integrin, VLDLR, ITGB3, G-protein alpha-i family, Adenylate cyclase",1.267E-03,8.141E-03,8,"Fyn, FGF2, alpha-4/beta-1 integrin, alpha-9/beta-1 integrin, VLDLR, ITGB3, G-protein alpha-i family, Adenylate cyclase",
243,Suppression of TGF-beta signaling in pancreatic cancer,29,3.304E-04,1.929E-03,3.304E-04,1.929E-03,8,"p15, Biglycan, SMAD3, ERK2 (MAPK1), ETS1, TGF-beta receptor type II, MMP-9, PLAU (UPA)",7.402E-03,2.991E-02,6,"p15, Biglycan, ETS1, TGF-beta receptor type II, MMP-9, PLAU (UPA)",
244,Role of adipose tissue hypoxia in obesity and type 2 diabetes,30,3.400E-04,2.329E-03,4.258E-04,2.329E-03,8,"Angiopoietin 1, IL-1 beta, IL-6, MCT1 (SLC16A1), Lysyl oxidase, CCL2, MMP-9, IBP3",3.400E-04,2.931E-03,8,"Angiopoietin 1, IL-1 beta, IL-6, MCT1 (SLC16A1), Lysyl oxidase, CCL2, MMP-9, IBP3",
245,IGF signaling in lung cancer,44,3.454E-04,1.979E-03,3.454E-04,1.979E-03,10,"BAD, PI3K cat class IA, AKT(PKB), IRS-2, MMP-9, IBP, PLAU (UPA), ERK1/2, IBP3, MMP-2",4.811E-03,2.127E-02,8,"PI3K cat class IA, AKT(PKB), IRS-2, MMP-9, IBP, PLAU (UPA), IBP3, MMP-2",
246,Mucin expression in CF airways,69,3.462E-04,1.979E-03,3.462E-04,1.979E-03,13,"PGF2aR, COX-2 (PTGS2), PGE2R2, IL-1 beta, PGE2R4, PI3K cat class IA, TGF-alpha, PKC-theta, AKT(PKB), G-protein alpha-q/11, PKC-alpha, EGFR, ERK1/2",9.114E-04,6.366E-03,12,"PGF2aR, COX-2 (PTGS2), PGE2R2, IL-1 beta, PGE2R4, PI3K cat class IA, TGF-alpha, PKC-theta, AKT(PKB), G-protein alpha-q/11, PKC-alpha, EGFR",
247,Calcium-dependent regulation of normal and asthmatic smooth muscle contraction,69,3.462E-04,1.979E-03,3.462E-04,1.979E-03,13,"Histamine H1 receptor, Myosin II, TRPC4, TRPC6, TRPC3, CD38, MYLK1, NCX1, G-protein alpha-i family, MLCK, MRLC, EDNRA, ACM3",9.114E-04,6.366E-03,12,"Histamine H1 receptor, TRPC4, TRPC6, TRPC3, CD38, MYLK1, NCX1, G-protein alpha-i family, MLCK, MRLC, EDNRA, ACM3",
248,Development_c-Kit ligand signaling pathway during hemopoiesis,61,3.833E-04,2.182E-03,3.833E-04,2.182E-03,12,"BAD, STAT3, Fyn, PI3K cat class IA, AKT(PKB), PLGF, PKC-alpha, GRAP2, Lyn, SLUG, MMP-9, ERK1/2",1.162E-02,4.099E-02,9,"Fyn, PI3K cat class IA, AKT(PKB), PLGF, PKC-alpha, GRAP2, Lyn, SLUG, MMP-9",
249,Development_Oligodendrocyte differentiation (general schema),38,3.846E-04,2.625E-03,4.912E-04,2.625E-03,9,"SOX10, Myelin basic protein, FGF2, TGF-alpha, PDGF-R-alpha, BMP4, EGFR, BMP2, EDNRA",3.846E-04,3.253E-03,9,"SOX10, Myelin basic protein, FGF2, TGF-alpha, PDGF-R-alpha, BMP4, EGFR, BMP2, EDNRA",
250,Development_MAG-dependent inhibition of neurite outgrowth,37,3.969E-04,2.215E-03,3.969E-04,2.215E-03,9,"NGF, Myosin II, NGFR (ICD), NGFR(TNFRSF16), Actin cytoskeletal, NGFR (CTF), MELC, MyHC, MRLC",2.393E-02,7.323E-02,6,"NGF, NGFR (ICD), NGFR(TNFRSF16), NGFR (CTF), MELC, MRLC",
251,Development_Beta-adrenergic receptors transactivation of EGFR,37,3.969E-04,2.215E-03,3.969E-04,2.215E-03,9,"PI3K cat class IA, Beta-2 adrenergic receptor, ERK2 (MAPK1), ADAM12, CD44, MYLK1, EGFR, G-protein alpha-i family, ERK1/2",6.542E-03,2.716E-02,7,"PI3K cat class IA, Beta-2 adrenergic receptor, ADAM12, CD44, MYLK1, EGFR, G-protein alpha-i family",
252,Development_Retinoic acid and retinoic acid receptors in regulation of oligodendrocyte differentiation,37,3.969E-04,2.215E-03,3.969E-04,2.215E-03,9,"p15, Myelin basic protein, STRA6, p14ARF, DHA2, PDGF-R-alpha, p53, BMP4, BMP2",1.531E-03,9.107E-03,8,"p15, Myelin basic protein, STRA6, p14ARF, DHA2, PDGF-R-alpha, BMP4, BMP2",
253,Attenuation of IFN type I signaling in melanoma cells,37,3.969E-04,2.215E-03,3.969E-04,2.215E-03,9,"STAT3, PSMB9, TAP1 (PSF1), PSMB8(LMP7), HLA-A, I-TAC, TAP, IFN-beta, TAP2 (PSF2)",1.531E-03,9.107E-03,8,"PSMB9, TAP1 (PSF1), PSMB8(LMP7), HLA-A, I-TAC, TAP, IFN-beta, TAP2 (PSF2)",
254,Stem cells_Aberrant Wnt signaling in medulloblastoma stem cells,23,4.042E-04,2.246E-03,4.042E-04,2.246E-03,7,"Beta-catenin, Matrilysin (MMP-7), AKT(PKB), CD44, Dsh, WNT, Frizzled",1.149E-02,4.077E-02,5,"Matrilysin (MMP-7), AKT(PKB), CD44, WNT, Frizzled",
255,Cell adhesion_Histamine H1 receptor signaling in the interruption of cell barrier integrity,45,4.192E-04,2.302E-03,4.192E-04,2.302E-03,10,"Histamine H1 receptor, Myosin II, Beta-catenin, Actin cytoskeletal, CPI-17, G-protein alpha-q/11, MELC, PKC-alpha, MLCK, MRLC",1.889E-02,6.011E-02,7,"Histamine H1 receptor, CPI-17, G-protein alpha-q/11, MELC, PKC-alpha, MLCK, MRLC",
256,Proinflammatory mediators production and activation of basophils in asthma,45,4.192E-04,2.302E-03,4.192E-04,2.302E-03,10,"NGF, ST2(L), MHC class II, PI3K cat class IA, DHA2, AKT(PKB), ITGA4, IL-8, IL-33, ERK1/2",1.422E-03,8.864E-03,9,"NGF, ST2(L), MHC class II, PI3K cat class IA, DHA2, AKT(PKB), ITGA4, IL-8, IL-33",
257,Arachidonic acid metabolites production in alveolar macrophages in asthma,31,4.339E-04,2.782E-03,5.424E-04,2.782E-03,8,"COX-2 (PTGS2), IL-1 beta, CCL2, IL-8, cPLA2, TLR4, TLR2, ALOX5",4.339E-04,3.625E-03,8,"COX-2 (PTGS2), IL-1 beta, CCL2, IL-8, cPLA2, TLR4, TLR2, ALOX5",
258,Immune response_Antigen presentation by MHC class II,118,4.437E-04,2.418E-03,4.437E-04,2.418E-03,18,"MHC class II alpha chain, Syk, Dectin-1, LY75, MHC class II, PI3K cat class IA, Langerin, PKC, MHC class II beta chain, ARL14, PKC-alpha, Dynein 1, cytoplasmic, intermediate chains, Cathepsin S, Cathepsin V, TAP, TLR4, TLR2, ERK1/2",8.477E-04,5.983E-03,17,"MHC class II alpha chain, Syk, Dectin-1, LY75, MHC class II, PI3K cat class IA, Langerin, PKC, MHC class II beta chain, ARL14, PKC-alpha, Dynein 1, cytoplasmic, intermediate chains, Cathepsin S, Cathepsin V, TAP, TLR4, TLR2",
259,"Immune response_IL-4-induced regulators of cell growth, survival, differentiation and metabolism",62,4.483E-04,2.434E-03,4.483E-04,2.434E-03,12,"STAT3, EGR2 (Krox20), MMP-13, ATP6V0D2, DHA2, Osteoprotegerin, AKT(PKB), Cyclin E, Cathepsin V, ACADL, GFI-1, CDK6",1.244E-03,8.141E-03,11,"EGR2 (Krox20), MMP-13, ATP6V0D2, DHA2, Osteoprotegerin, AKT(PKB), Cyclin E, Cathepsin V, ACADL, GFI-1, CDK6",
260,Complement pathway disruption in thrombotic microangiopathy,39,4.731E-04,3.033E-03,6.031E-04,3.033E-03,9,"IL-1 beta, cPKC (conventional), PKC, MYLK1, C3a, C3, IL-8, Factor I, C3b",4.731E-04,3.858E-03,9,"IL-1 beta, cPKC (conventional), PKC, MYLK1, C3a, C3, IL-8, Factor I, C3b",
261,Growth factors in regulation of oligodendrocyte precursor cells proliferation in multiple sclerosis,54,4.866E-04,2.625E-03,4.866E-04,2.625E-03,11,"HGF, NGF, Myelin basic protein, PI3K cat class IA, FGF2, PKC, PDGF-R-alpha, AKT(PKB), HGF receptor (Met), Fibronectin, ERK1/2",1.462E-03,8.968E-03,10,"HGF, NGF, Myelin basic protein, PI3K cat class IA, FGF2, PKC, PDGF-R-alpha, AKT(PKB), HGF receptor (Met), Fibronectin",
262,Insulin-like growth factor family signaling in melanoma,38,4.912E-04,2.625E-03,4.912E-04,2.625E-03,9,"Beta-catenin, PI3K cat class IA, PKC, AKT(PKB), p53, IL-8, Cyclin E, ERK1/2, IBP3",2.699E-02,7.973E-02,6,"PI3K cat class IA, PKC, AKT(PKB), IL-8, Cyclin E, IBP3",
263,WNT signaling in proliferative-type melanoma cells,38,4.912E-04,2.625E-03,4.912E-04,2.625E-03,9,"Beta-catenin, DVL-3, DKK3, Fibronectin, Dsh, WNT, Frizzled, ERK1/2, DACT1",8.105E-02,1.792E-01,5,"DKK3, Fibronectin, WNT, Frizzled, DACT1",
264,Signal transduction_PTEN pathway,46,5.057E-04,2.693E-03,5.057E-04,2.693E-03,10,"BAD, PCNA, Beta-catenin, alpha-5/beta-1 integrin, PI3K cat class IA, AKT(PKB), p53, Tcf(Lef), EGFR, ERK1/2",1.499E-01,2.774E-01,5,"alpha-5/beta-1 integrin, PI3K cat class IA, AKT(PKB), Tcf(Lef), EGFR",
265,Populations of skin dendritic cells involved in contact hypersensitivity,18,5.156E-04,3.048E-03,6.161E-04,3.048E-03,6,"LY75, MHC class II, CD83, Langerin, EMR1, CD1d",5.156E-04,4.156E-03,6,"LY75, MHC class II, CD83, Langerin, EMR1, CD1d",
266,Transport_Macropinocytosis regulation by growth factors,63,5.224E-04,2.771E-03,5.224E-04,2.771E-03,12,"HGF, AMPK gamma subunit, NGF, Actin cytoskeletal, PDGF-R-alpha, AKT(PKB), CSF1, PDGF receptor, IRS-2, HGF receptor (Met), EGFR, PDGF-R-beta",1.425E-03,8.864E-03,11,"HGF, AMPK gamma subunit, NGF, PDGF-R-alpha, AKT(PKB), CSF1, PDGF receptor, IRS-2, HGF receptor (Met), EGFR, PDGF-R-beta",
267,Blood coagulation_Platelet microparticle generation,72,5.327E-04,2.782E-03,5.327E-04,2.782E-03,13,"IL-1 beta, ITGB1, Actin cytoskeletal, cPKC (conventional), PLA2G7, TRPC6, PKC, Tissue factor, MSN (moesin), Fibronectin, MyHC, MYLK1, cPLA2",4.239E-03,1.931E-02,11,"IL-1 beta, ITGB1, cPKC (conventional), PLA2G7, TRPC6, PKC, Tissue factor, MSN (moesin), Fibronectin, MYLK1, cPLA2",
268,Cell adhesion_Endothelial cell contacts by non-junctional mechanisms,24,5.396E-04,2.782E-03,5.396E-04,2.782E-03,7,"N-cadherin, Beta-catenin, alpha-5/beta-1 integrin, alpha-1/beta-1 integrin, Collagen IV, Fibronectin, F-Actin cytoskeleton",1.380E-02,4.747E-02,5,"N-cadherin, alpha-5/beta-1 integrin, alpha-1/beta-1 integrin, Collagen IV, Fibronectin",
269,Development_Schema: SMAD-dependent TGF-beta family signaling in embryonic stem cells,24,5.396E-04,2.782E-03,5.396E-04,2.782E-03,7,"FGF2, SMAD3, Activin A, Oct-3/4, Gremlin, BMP4, BMP2",2.725E-03,1.433E-02,6,"FGF2, Activin A, Oct-3/4, Gremlin, BMP4, BMP2",
270,Deregulation of canonical WNT signaling in major depressive disorder,31,5.424E-04,2.782E-03,5.424E-04,2.782E-03,8,"Beta-catenin, MAP-1B, Tcf(Lef), WNT7A, Dsh, WNT, TCF7 (TCF1), Frizzled",1.034E-02,3.816E-02,6,"MAP-1B, Tcf(Lef), WNT7A, WNT, TCF7 (TCF1), Frizzled",
271,Autocrine production of eosinophil pro-survival cytokines in asthma,31,5.424E-04,2.782E-03,5.424E-04,2.782E-03,8,"IL-15, YB-1, PI3K cat class IA, alpha-4/beta-1 integrin, ICAM1, CD44, Fibronectin, ERK1/2",1.034E-02,3.816E-02,6,"IL-15, PI3K cat class IA, alpha-4/beta-1 integrin, ICAM1, CD44, Fibronectin",
272,Role of inhibition of WNT signaling in the progression of lung cancer,31,5.424E-04,2.782E-03,5.424E-04,2.782E-03,8,"N-cadherin, Beta-catenin, p53, Vimentin, WNT7A, Dsh, MMP-9, Frizzled",3.881E-02,1.066E-01,5,"N-cadherin, Vimentin, WNT7A, MMP-9, Frizzled",
273,Mechanisms of K-RAS addiction in lung cancer cells,31,5.424E-04,2.782E-03,5.424E-04,2.782E-03,8,"BAD, Syk, AKT(PKB), Stk33, Vimentin, TCF8, IL-8, ERK1/2",1.034E-02,3.816E-02,6,"Syk, AKT(PKB), Stk33, Vimentin, TCF8, IL-8",
274,Development_Embryonal epaxial myogenesis,31,5.424E-04,2.782E-03,5.424E-04,2.782E-03,8,"Beta-catenin, GLI-1, SMAD3, PTCH1, WNT, BMP4, Frizzled, WNT6",1.034E-02,3.816E-02,6,"GLI-1, PTCH1, WNT, BMP4, Frizzled, WNT6",
275,PGE2 pathways in cancer,55,5.740E-04,2.933E-03,5.740E-04,2.933E-03,11,"COX-2 (PTGS2), PGE2R2, PGE2R4, Beta-catenin, TGF-alpha, ERK2 (MAPK1), AKT(PKB), Tcf(Lef), EGFR, G-protein alpha-i family, Adenylate cyclase",5.901E-03,2.512E-02,9,"COX-2 (PTGS2), PGE2R2, PGE2R4, TGF-alpha, AKT(PKB), Tcf(Lef), EGFR, G-protein alpha-i family, Adenylate cyclase",
276,Immune escape mechanisms in Prostate Cancer,25,5.805E-04,3.445E-03,7.088E-04,3.445E-03,7,"IL-6, TAP1 (PSF1), TGF-beta, CCL2, TAP, TLR4, TAP2 (PSF2)",5.805E-04,4.467E-03,7,"IL-6, TAP1 (PSF1), TGF-beta, CCL2, TAP, TLR4, TAP2 (PSF2)",
277,SLE genetic marker-specific pathways in T cells,101,5.925E-04,3.017E-03,5.925E-04,3.017E-03,16,"STAT3, HLA-DRB1, MHC class II, Lck, PTPN22, PKC-theta, TCR beta subunit, CalDAG-GEFIII, RUNX3, MHC class II beta chain, STAT4, HLA-DRB, ETS1, A20, IFN-beta, ERK1/2",8.718E-03,3.381E-02,13,"HLA-DRB1, MHC class II, PTPN22, PKC-theta, TCR beta subunit, CalDAG-GEFIII, RUNX3, MHC class II beta chain, STAT4, HLA-DRB, ETS1, A20, IFN-beta",
278,MicroRNAs in melanoma,57,5.972E-04,3.766E-03,7.883E-04,3.766E-03,11,"FGF2, Calponin-1, Cadherin 11, RUNX3, HGF receptor (Met), microRNA 221, ITGB3, ETS1, TGF-beta receptor type II, BMP4, miR-221-3p",5.972E-04,4.570E-03,11,"FGF2, Calponin-1, Cadherin 11, RUNX3, HGF receptor (Met), microRNA 221, ITGB3, ETS1, TGF-beta receptor type II, BMP4, miR-221-3p",
279,Cell cycle progression in Prostate Cancer,39,6.031E-04,3.033E-03,6.031E-04,3.033E-03,9,"STAT3, IL-6, Beta-catenin, AKT(PKB), Tcf(Lef), WNT, Frizzled, ERK1/2, CDK6",3.030E-02,8.742E-02,6,"IL-6, AKT(PKB), Tcf(Lef), WNT, Frizzled, CDK6",
280,Immune response_TSLP signalling,39,6.031E-04,3.033E-03,6.031E-04,3.033E-03,9,"STAT3, IL-6, PI3K cat class IA, IL7RA, AKT(PKB), STAT4, CCL2, IL-8, ERK1/2",8.789E-03,3.381E-02,7,"IL-6, PI3K cat class IA, IL7RA, AKT(PKB), STAT4, CCL2, IL-8",
281,Development_HGF signaling pathway,47,6.064E-04,3.033E-03,6.064E-04,3.033E-03,10,"STAT3, HGF, COX-2 (PTGS2), Beta-catenin, PI3K cat class IA, SNAIL1, AKT(PKB), HGF receptor (Met), PLAU (UPA), ERK1/2",6.629E-02,1.557E-01,6,"HGF, COX-2 (PTGS2), PI3K cat class IA, AKT(PKB), HGF receptor (Met), PLAU (UPA)",
282,Myeloid-derived suppressor cells and M2 macrophages in cancer,64,6.066E-04,3.033E-03,6.066E-04,3.033E-03,12,"STAT3, COX-2 (PTGS2), PGE2R2, IL-1 beta, IL-6, PGE2R4, IDO1, iNOS, CSF1, TLR4, SLC7A11, PD-L1",1.628E-03,9.639E-03,11,"COX-2 (PTGS2), PGE2R2, IL-1 beta, IL-6, PGE2R4, IDO1, iNOS, CSF1, TLR4, SLC7A11, PD-L1",
283,Mast cell migration in asthma,73,6.112E-04,3.045E-03,6.112E-04,3.045E-03,13,"TGF-beta 2, alpha-5/beta-1 integrin, FGF2, PDGF receptor, CD44, CCL2, Fibronectin, I-TAC, C3a, IL-8, TGF-beta receptor type II, G-protein alpha-i family, ERK1/2",1.518E-03,9.107E-03,12,"TGF-beta 2, alpha-5/beta-1 integrin, FGF2, PDGF receptor, CD44, CCL2, Fibronectin, I-TAC, C3a, IL-8, TGF-beta receptor type II, G-protein alpha-i family",
284,FGF2 in multiple myeloma,18,6.161E-04,3.048E-03,6.161E-04,3.048E-03,6,"IL-6, PI3K cat class IA, FGF2, Heparanase 1, ERK2 (MAPK1), AKT(PKB)",3.775E-03,1.779E-02,5,"IL-6, PI3K cat class IA, FGF2, Heparanase 1, AKT(PKB)",
285,MAPK-mediated proliferation of normal and asthmatic smooth muscle cells,56,6.741E-04,3.323E-03,6.741E-04,3.323E-03,11,"PDGF-C, FGF2, PDGF-R-alpha, PDGF receptor, PKC-alpha, PLAT (TPA), EGFR, G-protein alpha-i family, EDNRA, ERK1/2, PDGF-R-beta",1.947E-03,1.098E-02,10,"PDGF-C, FGF2, PDGF-R-alpha, PDGF receptor, PKC-alpha, PLAT (TPA), EGFR, G-protein alpha-i family, EDNRA, PDGF-R-beta",
286,Hedgehog signaling in pancreatic cancer,32,6.835E-04,3.357E-03,6.835E-04,3.357E-03,8,"IL-1 beta, SNAIL1, GLI-1, SMAD3, PTCH1, MMP-9, ERK1/2, GLI-2",4.376E-02,1.157E-01,5,"IL-1 beta, GLI-1, PTCH1, MMP-9, GLI-2",
287,Activation of pro-oncogenic TGF-beta potential in gastric cancer,25,7.088E-04,3.445E-03,7.088E-04,3.445E-03,7,"GSTP1, TGF-beta 2, SMAD3, Fibronectin, TGF-beta receptor type II, MMP-9, MMP-2",3.402E-03,1.637E-02,6,"GSTP1, TGF-beta 2, Fibronectin, TGF-beta receptor type II, MMP-9, MMP-2",
288,Inhibition of oligodendrocyte precursor cells differentiation by Wnt signaling in multiple sclerosis,25,7.088E-04,3.445E-03,7.088E-04,3.445E-03,7,"Beta-catenin, GLI-1, FZD7, Dsh, WNT, Frizzled, GLI-2",1.640E-02,5.383E-02,5,"GLI-1, FZD7, WNT, Frizzled, GLI-2",
289,Development_Schema: Adult neurogenesis in the Subventricular Zone,19,7.148E-04,4.016E-03,8.525E-04,4.016E-03,6,"Nestin, DLX2, NCAM1, Vimentin, MAP2, GLAST1/EAAT1",7.148E-04,5.234E-03,6,"Nestin, DLX2, NCAM1, Vimentin, MAP2, GLAST1/EAAT1",
290,Development_VEGF signaling via VEGFR2 - generic cascades,93,7.172E-04,3.474E-03,7.172E-04,3.474E-03,15,"COX-2 (PTGS2), Beta-catenin, PLAUR (uPAR), Actin cytoskeletal, Fyn, PI3K cat class IA, iNOS, PKC, ERK2 (MAPK1), AKT(PKB), CCL2, PKC-alpha, PLAU (UPA), MLCK, ERK1/2",2.688E-02,7.973E-02,11,"COX-2 (PTGS2), PLAUR (uPAR), Fyn, PI3K cat class IA, iNOS, PKC, AKT(PKB), CCL2, PKC-alpha, PLAU (UPA), MLCK",
291,SHH signaling in oligodendrocyte precursor cells differentiation in multiple sclerosis,13,7.332E-04,4.016E-03,8.538E-04,4.016E-03,5,"SOX10, Myelin basic protein, GLI-1, PTCH1, GLI-2",7.332E-04,5.340E-03,5,"SOX10, Myelin basic protein, GLI-1, PTCH1, GLI-2",
292,Development_WNT/Beta-catenin and NOTCH in induction of osteogenesis,40,7.350E-04,3.536E-03,7.350E-04,3.536E-03,9,"ALPL, Beta-catenin, RUNX2, Osteoprotegerin, Jagged1, Dsh, WNT, TCF7 (TCF1), Frizzled",1.010E-02,3.780E-02,7,"ALPL, RUNX2, Osteoprotegerin, Jagged1, WNT, TCF7 (TCF1), Frizzled",
293,Development_Astrocyte differentiation from adult stem cells,40,7.350E-04,3.536E-03,7.350E-04,3.536E-03,9,"STAT3, Nestin, CD44, ID4, Vimentin, BMP4, BMP2, ERK1/2, LIF",1.010E-02,3.780E-02,7,"Nestin, CD44, ID4, Vimentin, BMP4, BMP2, LIF",
294,Apoptotic pathways and resistance to apoptosis in lung cancer cells,57,7.883E-04,3.766E-03,7.883E-04,3.766E-03,11,"BAD, c-IAP2, FGF2, Caspase-10, Caspase-1, PKC-alpha, Caspase-8, p53, microRNA 221, miR-221-3p, ERK1/2",5.882E-02,1.428E-01,7,"c-IAP2, FGF2, Caspase-10, Caspase-1, PKC-alpha, microRNA 221, miR-221-3p",
295,Reactive oxygen and nitrogen species production in eosinophils in asthma,59,8.100E-04,4.703E-03,1.065E-03,4.703E-03,11,"Histamine H1 receptor, ST2(L), ITGB1, PI3K cat class IA, iNOS, Eotaxin-2, ITGA4, ITGB2, ICAM1, C3a, IL-33",8.100E-04,5.837E-03,11,"Histamine H1 receptor, ST2(L), ITGB1, PI3K cat class IA, iNOS, Eotaxin-2, ITGA4, ITGB2, ICAM1, C3a, IL-33",
296,Development_NOTCH-induced EMT,19,8.525E-04,4.016E-03,8.525E-04,4.016E-03,6,"NOTCH4, SNAIL1, SMAD3, Fibronectin, Jagged1, SLUG",2.611E-02,7.852E-02,4,"NOTCH4, Fibronectin, Jagged1, SLUG",
297,Development_Self-renewal and pluripotency maintenance of human embryonic stem cells,33,8.527E-04,4.016E-03,8.527E-04,4.016E-03,8,"p14ARF, FGF2, Oct-3/4, p53, CGB3, CDX2, BMP4, PAX6",3.359E-03,1.634E-02,7,"p14ARF, FGF2, Oct-3/4, CGB3, CDX2, BMP4, PAX6",
298,Neutrophil-derived granule proteins and cytokines in asthma,49,8.578E-04,4.016E-03,8.578E-04,4.016E-03,10,"CHI3L1, Syk, TGF-beta 2, Rac2, MMP-8, PKC, PRG2, IL-8, MMP-9, ERK1/2",2.647E-03,1.408E-02,9,"CHI3L1, Syk, TGF-beta 2, Rac2, MMP-8, PKC, PRG2, IL-8, MMP-9",
299,PDE4 regulation of cyto/chemokine expression in arthritis,49,8.578E-04,4.016E-03,8.578E-04,4.016E-03,10,"PGE2R2, IL-1 beta, IL-6, PGE2R4, PI3K cat class IA, Lck, AKT(PKB), CCL2, IL-8, ENA-78",2.647E-03,1.408E-02,9,"PGE2R2, IL-1 beta, IL-6, PGE2R4, PI3K cat class IA, AKT(PKB), CCL2, IL-8, ENA-78",
300,Regulation of beta-adrenergic receptors signaling in pancreatic cancer,41,8.895E-04,4.136E-03,8.895E-04,4.136E-03,9,"COX-2 (PTGS2), IL-6, nAChR alpha-7, Beta-2 adrenergic receptor, cPLA2, EGFR, G-protein alpha-i family, Adenylate cyclase, ERK1/2",3.050E-03,1.519E-02,8,"COX-2 (PTGS2), IL-6, nAChR alpha-7, Beta-2 adrenergic receptor, cPLA2, EGFR, G-protein alpha-i family, Adenylate cyclase",
301,Development_VEGF-family signaling,41,8.895E-04,4.136E-03,8.895E-04,4.136E-03,9,"Neuropilin-2, alpha-5/beta-1 integrin, PI3K cat class IA, AKT(PKB), PLGF, PKC-alpha, Fibronectin, Neuropilin-1, ERK1/2",3.050E-03,1.519E-02,8,"Neuropilin-2, alpha-5/beta-1 integrin, PI3K cat class IA, AKT(PKB), PLGF, PKC-alpha, Fibronectin, Neuropilin-1",
302,Development_Positive regulation of WNT/Beta-catenin signaling in the cytoplasm,76,9.076E-04,4.193E-03,9.076E-04,4.193E-03,13,"COX-2 (PTGS2), Beta-catenin, ITGB1, SMAD3, ERK2 (MAPK1), AKT(PKB), IRS-2, Tcf(Lef), Dsh, WNT, RIPK4, Frizzled, DACT1",4.256E-02,1.139E-01,9,"COX-2 (PTGS2), ITGB1, AKT(PKB), IRS-2, Tcf(Lef), WNT, RIPK4, Frizzled, DACT1",
303,"Immune response_IL-5 signaling via PI3K, MAPK and NF-kB",76,9.076E-04,4.193E-03,9.076E-04,4.193E-03,13,"Syk, Beta-catenin, Fyn, PI3K cat class IA, AKT(PKB), Fc gamma RII alpha, ITGB2, ICAM1, cPLA2, Lyn, MMP-9, ERK1/2, MMP-2",6.435E-03,2.697E-02,11,"Syk, Fyn, PI3K cat class IA, AKT(PKB), Fc gamma RII alpha, ITGB2, ICAM1, cPLA2, Lyn, MMP-9, MMP-2",
304,Cell adhesion_Integrin inside-out signaling,58,9.181E-04,4.213E-03,9.181E-04,4.213E-03,11,"ITGB1, alpha-5/beta-1 integrin, Actin cytoskeletal, alpha-1/beta-1 integrin, ERK2 (MAPK1), G-protein alpha-q/11, ITGB2, Fibronectin, ITGB3, G-protein alpha-i family, ERK1/2",2.456E-02,7.484E-02,8,"ITGB1, alpha-5/beta-1 integrin, alpha-1/beta-1 integrin, G-protein alpha-q/11, ITGB2, Fibronectin, ITGB3, G-protein alpha-i family",
305,Immune response_IL-15 signaling,58,9.181E-04,4.213E-03,9.181E-04,4.213E-03,11,"IL-15, IL-6, sIL-15RA, PI3K cat class IA, IL-15RA, Lck, AKT(PKB), UFO, IL-8, ETS1, ERK1/2",8.394E-03,3.276E-02,9,"IL-15, IL-6, sIL-15RA, PI3K cat class IA, IL-15RA, AKT(PKB), UFO, IL-8, ETS1",
306,Immune response_IL-11 signaling pathway via MEK/ERK and PI3K/AKT cascades,67,9.300E-04,4.253E-03,9.300E-04,4.253E-03,12,"ALPL, IL-1 beta, IL-6, Fyn, SNAIL1, RUNX2, AKT(PKB), ICAM1, SFK, IL-8, Cyclin E, ERK1/2",7.395E-03,2.991E-02,10,"ALPL, IL-1 beta, IL-6, Fyn, RUNX2, AKT(PKB), ICAM1, SFK, IL-8, Cyclin E",
307,"Cigarette smoke-induced proliferation, metaplasia and survival of airway epithelial cells ",50,1.012E-03,4.570E-03,1.012E-03,4.570E-03,10,"PCNA, nAChR alpha-7, PI3K cat class IA, Keratin 14, Fra-1, EGFR, MMP-9, ERK1/2, MMP-2, Keratin 5",1.055E-02,3.822E-02,8,"nAChR alpha-7, PI3K cat class IA, Keratin 14, Fra-1, EGFR, MMP-9, MMP-2, Keratin 5",
308,IgE- and MGF-induced Lyn-mediated production of cytokines and arachidonic acid metabolites in lung mast cells in asthma,50,1.012E-03,4.570E-03,1.012E-03,4.570E-03,10,"Syk, Fyn, AKT(PKB), CCL2, PKC-alpha, GRAP2, IL-8, cPLA2, Lyn, ERK1/2",3.056E-03,1.519E-02,9,"Syk, Fyn, AKT(PKB), CCL2, PKC-alpha, GRAP2, IL-8, cPLA2, Lyn",
309,HBV-dependent NF-kB and PI3K/AKT pathways leading to HCC,50,1.012E-03,4.570E-03,1.012E-03,4.570E-03,10,"BAD, PI3K cat class IA, iNOS, AKT(PKB), PKC-alpha, p53, A2M, Cyclin E, MMP-9, PLAU (UPA)",1.055E-02,3.822E-02,8,"PI3K cat class IA, iNOS, AKT(PKB), PKC-alpha, A2M, Cyclin E, MMP-9, PLAU (UPA)",
310,PDE4 regulation of cyto/chemokine expression in inflammatory skin diseases,50,1.012E-03,4.570E-03,1.012E-03,4.570E-03,10,"IL-1 beta, IL-6, G-protein alpha-i1, MxA, iNOS, CCL2, IL-8, G-protein alpha-i family, Adenylate cyclase, ERK1/2",3.056E-03,1.519E-02,9,"IL-1 beta, IL-6, G-protein alpha-i1, MxA, iNOS, CCL2, IL-8, G-protein alpha-i family, Adenylate cyclase",
311,Development_FGF2 signaling during embryonic stem cell differentiation,34,1.054E-03,4.703E-03,1.054E-03,4.703E-03,8,"Nestin, FGF2, NCAM1, PTCH1, SPRY2, Activin A, ERK1/2, PAX6",4.010E-03,1.864E-02,7,"Nestin, FGF2, NCAM1, PTCH1, SPRY2, Activin A, PAX6",
312,Nicotine / Beta-adrenergic signaling in lung cancer,34,1.054E-03,4.703E-03,1.054E-03,4.703E-03,8,"BAD, Beta-2 adrenergic receptor, AKT(PKB), PKC-alpha, Beta-adrenergic receptor, G-protein alpha-i family, Adenylate cyclase, ERK1/2",1.616E-02,5.369E-02,6,"Beta-2 adrenergic receptor, AKT(PKB), PKC-alpha, Beta-adrenergic receptor, G-protein alpha-i family, Adenylate cyclase",
313,Development_Role of CDK5 in neuronal development,34,1.054E-03,4.703E-03,1.054E-03,4.703E-03,8,"Beta-catenin, Actin cytoskeletal, Fyn, PI3K cat class IA, AKT(PKB), Dynein 1, cytoplasmic, intermediate chains, VLDLR, Reelin",1.616E-02,5.369E-02,6,"Fyn, PI3K cat class IA, AKT(PKB), Dynein 1, cytoplasmic, intermediate chains, VLDLR, Reelin",
314,Immune response_Sublytic effects of membrane attack complex,68,1.065E-03,4.703E-03,1.065E-03,4.703E-03,12,"BAD, IL-6, Actin cytoskeletal, PKC, AKT(PKB), Caspase-8, RGC32, cPLA2, EGFR, G-protein alpha-i family, XAF1, ERK1/2",5.581E-02,1.365E-01,8,"IL-6, PKC, AKT(PKB), RGC32, cPLA2, EGFR, G-protein alpha-i family, XAF1",
315,Immune response_Gastrin in inflammatory response,68,1.065E-03,4.703E-03,1.065E-03,4.703E-03,12,"COX-2 (PTGS2), GRO-2, PAI2, PI3K cat class IA, MEF2, ERK2 (MAPK1), AKT(PKB), G-protein alpha-q/11, PKC-alpha, IL-8, EGFR, MEF2C",2.685E-03,1.423E-02,11,"COX-2 (PTGS2), GRO-2, PAI2, PI3K cat class IA, MEF2, AKT(PKB), G-protein alpha-q/11, PKC-alpha, IL-8, EGFR, MEF2C",
316,Signal transduction_mTORC2 downstream signaling,68,1.065E-03,4.703E-03,1.065E-03,4.703E-03,12,"BAD, Beta-catenin, SGK1, cPKC (conventional), IL7RA, PKC, AKT(PKB), PKC-alpha, p53, IMP1(ZBP1), TLR4, F-Actin cytoskeleton",5.581E-02,1.365E-01,8,"SGK1, cPKC (conventional), IL7RA, PKC, AKT(PKB), PKC-alpha, IMP1(ZBP1), TLR4",
317,Growth factors in regulation of oligodendrocyte precursor cells survival in multiple sclerosis,42,1.069E-03,4.706E-03,1.069E-03,4.706E-03,9,"BAD, NGF, NGFR(TNFRSF16), Fyn, PI3K cat class IA, PDGF-R-alpha, AKT(PKB), Lyn, IBP",3.569E-03,1.694E-02,8,"NGF, NGFR(TNFRSF16), Fyn, PI3K cat class IA, PDGF-R-alpha, AKT(PKB), Lyn, IBP",
318,Development_Self-renewal of adult neural stem cells,52,1.080E-03,5.805E-03,1.390E-03,5.805E-03,10,"TLX, Nestin, p14ARF, GLI-1, HES5, PTCH1, FKHL1, p16INK4, WNT7A, GLI-2",1.080E-03,7.316E-03,10,"TLX, Nestin, p14ARF, GLI-1, HES5, PTCH1, FKHL1, p16INK4, WNT7A, GLI-2",
319,Inhibition of TGF-beta 1 signaling in early colorectal cancer,27,1.172E-03,5.139E-03,1.172E-03,5.139E-03,7,"PI3K cat class IA, SMAD3, AKT(PKB), TGF-beta receptor type II, MMP-9, MAP2, MMP-2",5.120E-03,2.250E-02,6,"PI3K cat class IA, AKT(PKB), TGF-beta receptor type II, MMP-9, MAP2, MMP-2",
320,Immune response_Histamine signaling in dendritic cells,51,1.189E-03,5.167E-03,1.189E-03,5.167E-03,10,"Histamine H1 receptor, IL-1 beta, IL-6, ERK2 (MAPK1), G-protein alpha-q/11, CCL2, PKC-alpha, IL-8, G-protein alpha-i family, Adenylate cyclase",3.513E-03,1.685E-02,9,"Histamine H1 receptor, IL-1 beta, IL-6, G-protein alpha-q/11, CCL2, PKC-alpha, IL-8, G-protein alpha-i family, Adenylate cyclase",
321,IL-6 signaling in multiple myeloma,51,1.189E-03,5.167E-03,1.189E-03,5.167E-03,10,"BAD, STAT3, IL-6, PI3K cat class IA, FGF2, AKT(PKB), p53, Lyn, ERK1/2, CDK6",9.086E-02,1.937E-01,6,"IL-6, PI3K cat class IA, FGF2, AKT(PKB), Lyn, CDK6",
322,Some pathways of EMT in cancer cells,51,1.189E-03,5.167E-03,1.189E-03,5.167E-03,10,"STAT3, Beta-catenin, PI3K cat class IA, SNAIL1, PDGF-R-alpha, AKT(PKB), PDGF receptor, EGFR, EDNRA, PDGF-R-beta",3.518E-02,9.860E-02,7,"PI3K cat class IA, PDGF-R-alpha, AKT(PKB), PDGF receptor, EGFR, EDNRA, PDGF-R-beta",
323,EGFR signaling pathway in colorectal cancer,60,1.231E-03,5.299E-03,1.231E-03,5.299E-03,11,"BAD, COX-2 (PTGS2), PGE2R4, Matrilysin (MMP-7), TGF-alpha, Trypsin I, Epiregulin, EGFR, NT, ERK1/2, ACM3",1.045E-02,3.822E-02,9,"COX-2 (PTGS2), PGE2R4, Matrilysin (MMP-7), TGF-alpha, Trypsin I, Epiregulin, EGFR, NT, ACM3",
324,Immune response_LTBR1 signaling,60,1.231E-03,5.299E-03,1.231E-03,5.299E-03,11,"Syk, COX-2 (PTGS2), PI3K cat class IA, G-protein alpha-15, iNOS, PKC, AKT(PKB), G-protein alpha-q/11, G-protein alpha-i family, Adenylate cyclase, ERK1/2",3.305E-03,1.634E-02,10,"Syk, COX-2 (PTGS2), PI3K cat class IA, G-protein alpha-15, iNOS, PKC, AKT(PKB), G-protein alpha-q/11, G-protein alpha-i family, Adenylate cyclase",
325,Immune response_TREM1 signaling pathway,60,1.231E-03,5.299E-03,1.231E-03,5.299E-03,11,"BAD, Syk, IL-1 beta, IL-6, PI3K cat class IA, AKT(PKB), CCL2, IL-8, TLR4, TLR2, ERK1/2",1.045E-02,3.822E-02,9,"Syk, IL-1 beta, IL-6, PI3K cat class IA, AKT(PKB), CCL2, IL-8, TLR4, TLR2",
326,Translation_Non-genomic (rapid) action of Androgen Receptor,43,1.278E-03,5.417E-03,1.278E-03,5.417E-03,9,"Beta-catenin, ERK2 (MAPK1), AKT(PKB), Caveolin-1, Tcf(Lef), Dsh, WNT, EGFR, Frizzled",4.613E-02,1.188E-01,6,"AKT(PKB), Caveolin-1, Tcf(Lef), WNT, EGFR, Frizzled",
327,Prostaglandins and leukotrienes-mediated induction of expression of mucins in normal and asthmatic epithelium ,43,1.278E-03,5.417E-03,1.278E-03,5.417E-03,9,"PGF2aR, PGE2R2, PGE2R4, G-protein alpha-q/11, PKC-alpha, EGFR, G-protein alpha-i family, Adenylate cyclase, ERK1/2",4.154E-03,1.905E-02,8,"PGF2aR, PGE2R2, PGE2R4, G-protein alpha-q/11, PKC-alpha, EGFR, G-protein alpha-i family, Adenylate cyclase",
328,"POMC, alpha-MSH and AGRP in regulation of food intake and energy expenditure in obesity in hypothalamus",43,1.278E-03,5.417E-03,1.278E-03,5.417E-03,9,"proACTH, POMC, Beta-MSH / Beta-Endorphin, ERK2 (MAPK1), alpha-MSH, PKC-alpha, G-protein alpha-i family, PC1, beta-LPH",4.154E-03,1.905E-02,8,"proACTH, POMC, Beta-MSH / Beta-Endorphin, alpha-MSH, PKC-alpha, G-protein alpha-i family, PC1, beta-LPH",
329,FGF signaling in Prostate Cancer,43,1.278E-03,5.417E-03,1.278E-03,5.417E-03,9,"STAT3, Matrilysin (MMP-7), HBP17, PI3K cat class IA, FGF2, ERK2 (MAPK1), AKT(PKB), SPRY2, FGF9",1.490E-02,4.987E-02,7,"Matrilysin (MMP-7), HBP17, PI3K cat class IA, FGF2, AKT(PKB), SPRY2, FGF9",
330,Regulation of immune cell differentiation by Notch signaling,43,1.278E-03,5.417E-03,1.278E-03,5.417E-03,9,"NOTCH4 (ICD4), NOTCH4, PI3K cat class IA, Lck, SMAD3, AKT(PKB), IFI16, Jagged1, ADAM19",1.490E-02,4.987E-02,7,"NOTCH4 (ICD4), NOTCH4, PI3K cat class IA, AKT(PKB), IFI16, Jagged1, ADAM19",
331,Putative pathways of MHC class I-dependent postsynaptic long-term depression in major depressive disorder,21,1.286E-03,6.272E-03,1.529E-03,6.272E-03,6,"MHC Class I alpha chain, TAP1 (PSF1), HLA-B, HLA-A, TAP, TAP2 (PSF2)",1.286E-03,8.187E-03,6,"MHC Class I alpha chain, TAP1 (PSF1), HLA-B, HLA-A, TAP, TAP2 (PSF2)",
332,Role of Tissue factor in cancer independent of coagulation protease signaling,35,1.291E-03,5.459E-03,1.291E-03,5.459E-03,8,"Laminin 5, Actin cytoskeletal, ERK2 (MAPK1), AKT(PKB), Tissue factor, PKC-alpha, Lyn, ERK1/2",6.078E-02,1.461E-01,5,"Laminin 5, AKT(PKB), Tissue factor, PKC-alpha, Lyn",
333,Chemotaxis_SDF-1/ CXCR4-induced chemotaxis of immune cells,79,1.316E-03,5.530E-03,1.316E-03,5.530E-03,13,"ITGB1, Fyn, PI3K cat class IA, PAK, Lck, AKT(PKB), ITGB2, alpha-4/beta-1 integrin, ICAM1, SFK, G-protein alpha-i family, F-Actin cytoskeleton, ERK1/2",2.230E-02,6.919E-02,10,"ITGB1, Fyn, PI3K cat class IA, PAK, AKT(PKB), ITGB2, alpha-4/beta-1 integrin, ICAM1, SFK, G-protein alpha-i family",
334,CHDI_Correlations from Replication data_Causal network (positive correlations),79,1.316E-03,5.530E-03,1.316E-03,5.530E-03,13,"MHC class II, PI3K cat class IA, CD83, Lck, MEF2, PKC-theta, AKT(PKB), ICAM1, CD44, PKC-alpha, NR2A, NR2, TLR2",3.022E-03,1.519E-02,12,"MHC class II, PI3K cat class IA, CD83, MEF2, PKC-theta, AKT(PKB), ICAM1, CD44, PKC-alpha, NR2A, NR2, TLR2",
335,Mechanisms of drug resistance in SCLC,70,1.386E-03,5.805E-03,1.386E-03,5.805E-03,12,"BAD, ITGB1, alpha-5/beta-1 integrin, PI3K cat class IA, FGF2, AKT(PKB), Collagen IV, alpha-4/beta-1 integrin, Caspase-8, Fibronectin, MDR1, ERK1/2",2.679E-02,7.973E-02,9,"ITGB1, alpha-5/beta-1 integrin, PI3K cat class IA, FGF2, AKT(PKB), Collagen IV, alpha-4/beta-1 integrin, Fibronectin, MDR1",
336,Regulation of Beta-catenin activity  in melanoma,28,1.478E-03,6.135E-03,1.478E-03,6.135E-03,7,"Beta-catenin, AKT(PKB), alpha-MSH, p16INK4, IMP1(ZBP1), MMP-9, MMP-2",6.185E-03,2.616E-02,6,"AKT(PKB), alpha-MSH, p16INK4, IMP1(ZBP1), MMP-9, MMP-2",
337,IL-17 and IL-17F-induced inflammatory signaling in normal and asthmatic airway epithelium,28,1.478E-03,6.135E-03,1.478E-03,6.135E-03,7,"IL-6, GRO-1, GCP2, ICAM1, IL-8, ERK1/2, ENA-78",6.185E-03,2.616E-02,6,"IL-6, GRO-1, GCP2, ICAM1, IL-8, ENA-78",
338,Main pathways of Schwann cells transformation in neurofibromatosis type 1 ,80,1.482E-03,6.136E-03,1.482E-03,6.136E-03,13,"BAD, IL-6, Beta-catenin, ITGB1, Myelin basic protein, PI3K cat class IA, Rac2, TGF-alpha, AKT(PKB), PDGF receptor, EGFR, ERK1/2, PDGF-R-beta",2.414E-02,7.371E-02,10,"IL-6, ITGB1, Myelin basic protein, PI3K cat class IA, Rac2, TGF-alpha, AKT(PKB), PDGF receptor, EGFR, PDGF-R-beta",
339,Leptin signaling in colorectal cancer,44,1.517E-03,6.263E-03,1.517E-03,6.263E-03,9,"STAT3, IL-6, Beta-catenin, Matrilysin (MMP-7), PI3K cat class IA, AKT(PKB), IL-8, Cyclin E, ERK1/2",5.076E-02,1.264E-01,6,"IL-6, Matrilysin (MMP-7), PI3K cat class IA, AKT(PKB), IL-8, Cyclin E",
340,Role of Neuregulin 1 and Thymosin beta-4 in myocardium regeneration after infarction,29,1.520E-03,7.344E-03,1.843E-03,7.344E-03,7,"Angiopoietin 1, ITGB1, alpha-5/beta-1 integrin, PI3K cat class IA, AKT(PKB), ITGA5, Fibronectin",1.520E-03,9.107E-03,7,"Angiopoietin 1, ITGB1, alpha-5/beta-1 integrin, PI3K cat class IA, AKT(PKB), ITGA5, Fibronectin",
341,Cigarette smoke-mediated attenuation of antibacterial and antivirus immune response,29,1.520E-03,7.344E-03,1.843E-03,7.344E-03,7,"IL-1 beta, IL-6, ICAM1, IL-8, IFN-beta, TLR4, sICAM1",1.520E-03,9.107E-03,7,"IL-1 beta, IL-6, ICAM1, IL-8, IFN-beta, TLR4, sICAM1",
342,Inhibition of tumor suppressive pathways in pancreatic cancer,21,1.529E-03,6.272E-03,1.529E-03,6.272E-03,6,"p15, p14ARF, SNAIL1, p53, p16INK4, CDK6",3.661E-02,1.024E-01,4,"p15, p14ARF, p16INK4, CDK6",
343,A shift in alveolar macrophage phenotype in COPD,37,1.531E-03,7.417E-03,1.893E-03,7.417E-03,8,"Matrilysin (MMP-7), MHC class II, iNOS, CD14, AKT(PKB), CD44, MARCO, MMP-2",1.531E-03,9.107E-03,8,"Matrilysin (MMP-7), MHC class II, iNOS, CD14, AKT(PKB), CD44, MARCO, MMP-2",
344,Immune response_IL-6 signaling pathway via JAK/STAT,71,1.573E-03,6.417E-03,1.573E-03,6.417E-03,12,"STAT3, ALPL, COX-2 (PTGS2), IL-6, Rac2, iNOS, RUNX2, AKT(PKB), ICAM1, CCL2, Mucin 13, CDK6",3.796E-03,1.783E-02,11,"ALPL, COX-2 (PTGS2), IL-6, Rac2, iNOS, RUNX2, AKT(PKB), ICAM1, CCL2, Mucin 13, CDK6",
345,Development_EGFR signaling pathway,71,1.573E-03,6.417E-03,1.573E-03,6.417E-03,12,"STAT3, PI3K cat class IA, TGF-alpha, PKC-theta, ERK2 (MAPK1), AKT(PKB), PKC-alpha, Epiregulin, EGFR, MMP-9, ERK1/2, MMP-2",2.908E-02,8.517E-02,9,"PI3K cat class IA, TGF-alpha, PKC-theta, AKT(PKB), PKC-alpha, Epiregulin, EGFR, MMP-9, MMP-2",
346,Chemotaxis_CCR1 signaling,53,1.618E-03,6.541E-03,1.618E-03,6.541E-03,10,"STAT3, IL-6, G-protein alpha-15, IL-8, cPLA2, MMP-9, G-protein alpha-i family, Adenylate cyclase, ERK1/2, CCL7",1.483E-02,4.987E-02,8,"IL-6, G-protein alpha-15, IL-8, cPLA2, MMP-9, G-protein alpha-i family, Adenylate cyclase, CCL7",
347,Notch signaling in breast cancer,53,1.618E-03,6.541E-03,1.618E-03,6.541E-03,10,"NOTCH4 (ICD4), Beta-catenin, NOTCH4, NOXA, HES5, CD44, Jagged1, SLUG, EGFR, PLAU (UPA)",4.587E-03,2.076E-02,9,"NOTCH4 (ICD4), NOTCH4, NOXA, HES5, CD44, Jagged1, SLUG, EGFR, PLAU (UPA)",
348,Non-genomic signaling of ESR2 (membrane) in lung cancer cells,53,1.618E-03,6.541E-03,1.618E-03,6.541E-03,10,"nAChR alpha-7, PI3K cat class IA, TGF-alpha, ERK2 (MAPK1), AKT(PKB), Caveolin-1, EGFR, G-protein alpha-i family, Adenylate cyclase, ERK1/2",1.483E-02,4.987E-02,8,"nAChR alpha-7, PI3K cat class IA, TGF-alpha, AKT(PKB), Caveolin-1, EGFR, G-protein alpha-i family, Adenylate cyclase",
349,Transition of Monoclonal gammopathy of undetermined significance to active multiple myeloma (schema),22,1.678E-03,7.777E-03,1.990E-03,7.777E-03,6,"p15, NCAM1, Osteoprotegerin, p16INK4, MMP-9, MMP-2",1.678E-03,9.850E-03,6,"p15, NCAM1, Osteoprotegerin, p16INK4, MMP-9, MMP-2",
350,Immune response_Immunological synapse formation,55,1.690E-03,8.316E-03,2.164E-03,8.316E-03,10,"ITGB1, Fyn, MHC class II, PI3K cat class IA, PKC-theta, ITGB2, alpha-4/beta-1 integrin, ICAM1, PKC-alpha, GRAP2",1.690E-03,9.881E-03,10,"ITGB1, Fyn, MHC class II, PI3K cat class IA, PKC-theta, ITGB2, alpha-4/beta-1 integrin, ICAM1, PKC-alpha, GRAP2",
351,Role of alpha-6/beta-4 integrins in carcinoma progression,45,1.792E-03,7.225E-03,1.792E-03,7.225E-03,9,"HGF, Laminin 5, Actin cytoskeletal, PI3K cat class IA, AKT(PKB), IRS-2, PKC-alpha, HGF receptor (Met), EGFR",5.543E-03,2.397E-02,8,"HGF, Laminin 5, PI3K cat class IA, AKT(PKB), IRS-2, PKC-alpha, HGF receptor (Met), EGFR",
352,Pro-oncogenic action of PTHrP in breast cancer,29,1.843E-03,7.344E-03,1.843E-03,7.344E-03,7,"ITGB1, PTHrP, MMP-13, G-protein alpha-q/11, PKC-alpha, ITGA5, ERK1/2",7.402E-03,2.991E-02,6,"ITGB1, PTHrP, MMP-13, G-protein alpha-q/11, PKC-alpha, ITGA5",
353,Abnormalities in cell cycle in SCLC,29,1.843E-03,7.344E-03,1.843E-03,7.344E-03,7,"PCNA, p15, p14ARF, p53, p16INK4, Cyclin E, CDK6",2.998E-02,8.724E-02,5,"p15, p14ARF, p16INK4, Cyclin E, CDK6",
354,NF-AT signaling in cardiac hypertrophy,65,1.853E-03,9.033E-03,2.409E-03,9.033E-03,11,"IL-6, HDAC9, PI3K cat class IA, AKT(PKB), G-protein alpha-q/11, HAND2, PKC-alpha, NCX1, G-protein alpha-i family, MEF2C, LIF",1.853E-03,1.071E-02,11,"IL-6, HDAC9, PI3K cat class IA, AKT(PKB), G-protein alpha-q/11, HAND2, PKC-alpha, NCX1, G-protein alpha-i family, MEF2C, LIF",
355,Membrane-bound ESR1: interaction with G-proteins signaling,54,1.875E-03,7.417E-03,1.875E-03,7.417E-03,10,"Caveolin-1, ADAM12, PKC-alpha, EGFR, MMP-9, G-protein alpha-i family, Adenylate cyclase, ERK1/2, MMP-14, MMP-2",5.212E-03,2.275E-02,9,"Caveolin-1, ADAM12, PKC-alpha, EGFR, MMP-9, G-protein alpha-i family, Adenylate cyclase, MMP-14, MMP-2",
356,NRF2 regulation of oxidative stress response,54,1.875E-03,7.417E-03,1.875E-03,7.417E-03,10,"GSTP1, Actin cytoskeletal, Fyn, PI3K cat class IA, UGT1A1, PKC, ERK2 (MAPK1), AKT(PKB), p53, SLC7A11",4.603E-02,1.188E-01,7,"GSTP1, Fyn, PI3K cat class IA, UGT1A1, PKC, AKT(PKB), SLC7A11",
357,Cell adhesion_Gap junctions,30,1.879E-03,8.573E-03,2.274E-03,8.573E-03,7,"Tubulin beta, PKC, Connexin 45, Caveolin-1, Connexin 26, Actin, Connexin 31",1.879E-03,1.071E-02,7,"Tubulin beta, PKC, Connexin 45, Caveolin-1, Connexin 26, Actin, Connexin 31",
358,Role of SHH and Notch in SCLC,30,1.879E-03,8.573E-03,2.274E-03,8.573E-03,7,"Nestin, GLI-1, PTCH1, Jagged1, BMP4, GLI-2, AL1A1",1.879E-03,1.071E-02,7,"Nestin, GLI-1, PTCH1, Jagged1, BMP4, GLI-2, AL1A1",
359,Cell adhesion_Role of tetraspanins in the integrin-mediated cell adhesion,37,1.893E-03,7.417E-03,1.893E-03,7.417E-03,8,"ITGB1, Laminin 5, alpha-5/beta-1 integrin, Actin cytoskeletal, alpha-4/beta-1 integrin, PKC-alpha, Fibronectin, Actin",6.542E-03,2.716E-02,7,"ITGB1, Laminin 5, alpha-5/beta-1 integrin, alpha-4/beta-1 integrin, PKC-alpha, Fibronectin, Actin",
360,Development_Delta-type opioid receptor mediated cardioprotection,37,1.893E-03,7.417E-03,1.893E-03,7.417E-03,8,"STAT3, PI3K cat class IA, Metenkefalin, ERK2 (MAPK1), AKT(PKB), ADAM12, EGFR, G-protein alpha-i family",2.393E-02,7.323E-02,6,"PI3K cat class IA, Metenkefalin, AKT(PKB), ADAM12, EGFR, G-protein alpha-i family",
361,Role of red blood cell adhesion to endothelium in vaso-occlusion in Sickle cell disease,37,1.893E-03,7.417E-03,1.893E-03,7.417E-03,8,"Beta-2 adrenergic receptor, ITGA4, alpha-4/beta-1 integrin, CD44, Fibronectin, IL-8, G-protein alpha-i family, ERK1/2",6.542E-03,2.716E-02,7,"Beta-2 adrenergic receptor, ITGA4, alpha-4/beta-1 integrin, CD44, Fibronectin, IL-8, G-protein alpha-i family",
362,Immune response_PGE2 in immune and neuroendocrine system interactions,47,1.959E-03,9.150E-03,2.460E-03,9.150E-03,9,"PGF2aR, COX-2 (PTGS2), IL-1 beta, PGE2R4, GABA-A receptor, ACTH, cPLA2, G-protein alpha-i family, TLR4",1.959E-03,1.098E-02,9,"PGF2aR, COX-2 (PTGS2), IL-1 beta, PGE2R4, GABA-A receptor, ACTH, cPLA2, G-protein alpha-i family, TLR4",
363,"Immune response_IL-2 signaling via ERK, PI3K, and PLC-gamma",73,2.012E-03,7.839E-03,2.012E-03,7.839E-03,12,"STAT3, Syk, Fyn, PI3K cat class IA, Lck, PKC-theta, ERK2 (MAPK1), AKT(PKB), IRS-2, Cyclin E, Lyn, ERK1/2",7.810E-02,1.764E-01,8,"Syk, Fyn, PI3K cat class IA, PKC-theta, AKT(PKB), IRS-2, Cyclin E, Lyn",
364,Regulation of GSK3 beta in bipolar disorder,46,2.105E-03,8.139E-03,2.105E-03,8.139E-03,9,"IL-1 beta, NGF, FGF2, AKT(PKB), Nucleoredoxin, Dsh, WNT, Frizzled, ERK1/2",2.114E-02,6.572E-02,7,"IL-1 beta, NGF, FGF2, AKT(PKB), Nucleoredoxin, WNT, Frizzled",
365,High shear stress-induced platelet activation,46,2.105E-03,8.139E-03,2.105E-03,8.139E-03,9,"Actin cytoskeletal, Ephrin-B receptor 1, AKT(PKB), Fibronectin, Collagen VI, UFO, ITGB3, G-protein alpha-i family, Collagen III",6.358E-03,2.673E-02,8,"Ephrin-B receptor 1, AKT(PKB), Fibronectin, Collagen VI, UFO, ITGB3, G-protein alpha-i family, Collagen III",
366,"Immune response_IL-3 signaling via JAK/STAT, p38, JNK and NF-kB",93,2.106E-03,8.139E-03,2.106E-03,8.139E-03,14,"BAD, STAT3, IL-6, NOTCH4, ITGB1, MHC class II, PI3K cat class IA, DHA2, AKT(PKB), ICAM1, Fibronectin, Lyn, Pim-1, BMP2",1.127E-02,4.049E-02,12,"IL-6, NOTCH4, ITGB1, MHC class II, PI3K cat class IA, DHA2, AKT(PKB), ICAM1, Fibronectin, Lyn, Pim-1, BMP2",
367,Immune response_T regulatory cell-mediated modulation of effector T cell and NK cell functions,55,2.164E-03,8.316E-03,2.164E-03,8.316E-03,10,"COX-2 (PTGS2), PGE2R2, Galectin-1, PGE2R4, 5'-NTD, SMAD3, STAT4, Jagged1, TGF-beta receptor type II, Adenylate cyclase type VII",5.901E-03,2.512E-02,9,"COX-2 (PTGS2), PGE2R2, Galectin-1, PGE2R4, 5'-NTD, STAT4, Jagged1, TGF-beta receptor type II, Adenylate cyclase type VII",
368,Gamma-secretase proteolytic targets,76,2.165E-03,1.031E-02,2.852E-03,1.031E-02,12,"NOTCH4 (ICD4), N-cadherin, NOTCH4, NGFR (ICD), N-cadherin (CTF1), N-cadherin (CTF2), NGFR(TNFRSF16), CD44 (ICD), NGFR (CTF), CD44, CD44 soluble, CD44 (EXT)",2.165E-03,1.204E-02,12,"NOTCH4 (ICD4), N-cadherin, NOTCH4, NGFR (ICD), N-cadherin (CTF1), N-cadherin (CTF2), NGFR(TNFRSF16), CD44 (ICD), NGFR (CTF), CD44, CD44 soluble, CD44 (EXT)",
369,Blood coagulation_Blood coagulation,39,2.189E-03,9.897E-03,2.696E-03,9.897E-03,8,"PAI2, Tissue factor, SERPINE2, PLAT (TPA), A2M, Protein S, Protein C, PLAU (UPA)",2.189E-03,1.207E-02,8,"PAI2, Tissue factor, SERPINE2, PLAT (TPA), A2M, Protein S, Protein C, PLAU (UPA)",
370,Cooperative action of IFN-gamma and TNF-alpha on astrocytes in multiple sclerosis,39,2.189E-03,9.897E-03,2.696E-03,9.897E-03,8,"CIITA, MHC class II, HLA-DRA1, Beta-2 adrenergic receptor, iNOS, ICAM1, CCL2, Adenylate cyclase",2.189E-03,1.207E-02,8,"CIITA, MHC class II, HLA-DRA1, Beta-2 adrenergic receptor, iNOS, ICAM1, CCL2, Adenylate cyclase",
371,Ca(2+)-dependent NF-AT signaling in cardiac hypertrophy,57,2.234E-03,1.031E-02,2.849E-03,1.031E-02,10,"MEF2, TRPC6, TRPC3, G-protein alpha-q/11, HAND2, Alpha-1B adrenergic receptor, PKC-alpha, NCX1, G-protein alpha-i family, MEF2C",2.234E-03,1.227E-02,10,"MEF2, TRPC6, TRPC3, G-protein alpha-q/11, HAND2, Alpha-1B adrenergic receptor, PKC-alpha, NCX1, G-protein alpha-i family, MEF2C",
372,Signal transduction_HTR2A signaling outside the nervous system,74,2.266E-03,8.573E-03,2.266E-03,8.573E-03,12,"STAT3, COX-2 (PTGS2), cPKC (conventional), PI3K cat class IA, PKC, AKT(PKB), G-protein alpha-q/11, Caveolin-1, EGFR, G-protein alpha-i family, Adenylate cyclase, ERK1/2",1.460E-02,4.987E-02,10,"COX-2 (PTGS2), cPKC (conventional), PI3K cat class IA, PKC, AKT(PKB), G-protein alpha-q/11, Caveolin-1, EGFR, G-protein alpha-i family, Adenylate cyclase",
373,Role of Endothelin-1 in inflammation and vasoconstriction in Sickle cell disease,38,2.267E-03,8.573E-03,2.267E-03,8.573E-03,8,"PI3K cat class IA, AKT(PKB), CCL2, PLGF, PKC-alpha, IL-8, EDNRA, ERK1/2",7.604E-03,3.019E-02,7,"PI3K cat class IA, AKT(PKB), CCL2, PLGF, PKC-alpha, IL-8, EDNRA",
374,Immune response_Role of integrins in NK cells cytotoxicity,38,2.267E-03,8.573E-03,2.267E-03,8.573E-03,8,"CD94, ERK2 (MAPK1), alpha-4/beta-1 integrin, ICAM1, Fibronectin, ICAM2, IL-8, Lyn",7.604E-03,3.019E-02,7,"CD94, alpha-4/beta-1 integrin, ICAM1, Fibronectin, ICAM2, IL-8, Lyn",
375,Eosinophil-derived cytokines in airway remodeling in asthma,38,2.267E-03,8.573E-03,2.267E-03,8.573E-03,8,"NGF, TGF-beta 2, FGF2, TGF-alpha, CD44, PKC-alpha, MMP-9, ERK1/2",7.604E-03,3.019E-02,7,"NGF, TGF-beta 2, FGF2, TGF-alpha, CD44, PKC-alpha, MMP-9",
376,Development_Role of BMP signaling in embryonic stem cell neural differentiation,30,2.274E-03,8.573E-03,2.274E-03,8.573E-03,7,"Follistatin, Tubulin beta 2B, NCAM1, IRX1, BMP4, BMP2, ERK1/2",8.782E-03,3.381E-02,6,"Follistatin, Tubulin beta 2B, NCAM1, IRX1, BMP4, BMP2",
377,Neurophysiological process_ACM regulation of nerve impulse,48,2.282E-03,1.031E-02,2.860E-03,1.031E-02,9,"ACM4, cPKC (conventional), TRPC6, TRPC3, PKC, G-protein alpha-q/11, PKC-alpha, G-protein alpha-i family, ACM3",2.282E-03,1.238E-02,9,"ACM4, cPKC (conventional), TRPC6, TRPC3, PKC, G-protein alpha-q/11, PKC-alpha, G-protein alpha-i family, ACM3",
378,Immune response_CD40 signaling,65,2.409E-03,9.033E-03,2.409E-03,9.033E-03,11,"STAT3, COX-2 (PTGS2), IL-6, PI3K cat class IA, AKT(PKB), ICAM1, CCL2, p53, IL-8, Lyn, A20",1.724E-02,5.605E-02,9,"COX-2 (PTGS2), IL-6, PI3K cat class IA, AKT(PKB), ICAM1, CCL2, IL-8, Lyn, A20",
379,Immune response_Induction of apoptosis and inhibition of proliferation mediated by IFN-gamma,47,2.460E-03,9.150E-03,2.460E-03,9.150E-03,9,"IL-15, IFI17, IDO1, CTGF, Caspase-1, Caspase-8, p53, Cyclin E, IFN-beta",2.356E-02,7.245E-02,7,"IL-15, IFI17, IDO1, CTGF, Caspase-1, Cyclin E, IFN-beta",
380,Regulation of mast cell survival in asthma,47,2.460E-03,9.150E-03,2.460E-03,9.150E-03,9,"BAD, Syk, IL-6, NGF, TNF-R2, alpha-5/beta-1 integrin, AKT(PKB), Fibronectin, ERK1/2",2.356E-02,7.245E-02,7,"Syk, IL-6, NGF, TNF-R2, alpha-5/beta-1 integrin, AKT(PKB), Fibronectin",
381,Immune response_IFN-gamma signaling via PI3K and NF-kB,56,2.488E-03,9.230E-03,2.488E-03,9.230E-03,10,"Beta-catenin, Fyn, PI3K cat class IA, iNOS, AKT(PKB), RUNX3, TLR3, HLA-B7, ERK1/2, PD-L1",2.025E-02,6.369E-02,8,"Fyn, PI3K cat class IA, iNOS, AKT(PKB), RUNX3, TLR3, HLA-B7, PD-L1",
382,EGFR family signaling in pancreatic cancer,75,2.545E-03,9.418E-03,2.545E-03,9.418E-03,12,"STAT3, COX-2 (PTGS2), PI3K cat class IA, TGF-alpha, AKT(PKB), Cyclin E, EGFR, MMP-9, PLAU (UPA), Neuropilin-1, ERK1/2, MMP-2",1.595E-02,5.326E-02,10,"COX-2 (PTGS2), PI3K cat class IA, TGF-alpha, AKT(PKB), Cyclin E, EGFR, MMP-9, PLAU (UPA), Neuropilin-1, MMP-2",
383,Apoptosis and survival_NGF activation of NF-kB,40,2.592E-03,1.125E-02,3.186E-03,1.125E-02,8,"GSTP1, Synapsin II, NGF, NGFR(TNFRSF16), PI3K cat class IA, iNOS, HES5, AKT(PKB)",2.592E-03,1.401E-02,8,"GSTP1, Synapsin II, NGF, NGFR(TNFRSF16), PI3K cat class IA, iNOS, HES5, AKT(PKB)",
384,Bacterial infections in CF airways,49,2.647E-03,1.131E-02,3.311E-03,1.131E-02,9,"TLR1, iNOS, CD14, Cathepsin S, IL-8, IFN-beta, TLR4, TLR2, MD-2",2.647E-03,1.408E-02,9,"TLR1, iNOS, CD14, Cathepsin S, IL-8, IFN-beta, TLR4, TLR2, MD-2",
385,Immune response_Bacterial infections in normal airways,49,2.647E-03,1.131E-02,3.311E-03,1.131E-02,9,"IL-1 beta, IL-6, TLR1, iNOS, CD14, IL-8, TLR4, TLR2, MD-2",2.647E-03,1.408E-02,9,"IL-1 beta, IL-6, TLR1, iNOS, CD14, IL-8, TLR4, TLR2, MD-2",
386,Immune response_Differentiation and clonal expansion of CD8+ T cells,39,2.696E-03,9.897E-03,2.696E-03,9.897E-03,8,"STAT3, MHC class II, CD137 ligand(TNFSF9), ICAM1, CD137(TNFRSF9), STAT4, IFN-beta, CD70(TNFSF7)",8.789E-03,3.381E-02,7,"MHC class II, CD137 ligand(TNFSF9), ICAM1, CD137(TNFRSF9), STAT4, IFN-beta, CD70(TNFSF7)",
387,Retinoic acid regulation of oligodendrocyte differentiation in multiple sclerosis,24,2.725E-03,1.129E-02,3.220E-03,1.129E-02,6,"Myelin basic protein, STRA6, DHA2, PDGF-R-alpha, BMP4, BMP2",2.725E-03,1.433E-02,6,"Myelin basic protein, STRA6, DHA2, PDGF-R-alpha, BMP4, BMP2",
388,Signal transduction_PDGF signaling via JAK-STAT and reactive oxygen species (ROS),66,2.729E-03,9.991E-03,2.729E-03,9.991E-03,11,"STAT3, PDGF-C, PDGFR-ab, PDGF-R-alpha, PDGF receptor, CCL2, I-TAC, cPLA2, ERK1/2, PDGF-R-beta, CCL7",1.892E-02,6.011E-02,9,"PDGF-C, PDGFR-ab, PDGF-R-alpha, PDGF receptor, CCL2, I-TAC, cPLA2, PDGF-R-beta, CCL7",
389,Putative glucocorticoid- and LABA-mediated inhibition of pro-fibrotic signaling in airway fibroblasts/myofibroblasts,31,2.779E-03,1.012E-02,2.779E-03,1.012E-02,7,"ACTA2, Beta-2 adrenergic receptor, SMAD3, Fibronectin, MMP-9, ERK1/2, Collagen III",3.881E-02,1.066E-01,5,"ACTA2, Beta-2 adrenergic receptor, Fibronectin, MMP-9, Collagen III",
390,Development_Dopamine-induced transactivation of EGFR in SVZ neural stem cells,31,2.779E-03,1.012E-02,2.779E-03,1.012E-02,7,"TGF-alpha, PKC, ADAM12, EGFR, G-protein alpha-i family, ERK1/2, PAX6",1.034E-02,3.816E-02,6,"TGF-alpha, PKC, ADAM12, EGFR, G-protein alpha-i family, PAX6",
391,Development_H3K4 demethylases in stem cell maintenance,32,2.792E-03,1.131E-02,3.366E-03,1.131E-02,7,"ACM4, TLX, HOXA1, SCN2A, HOXA7, SCN3A, HOXA5",2.792E-03,1.451E-02,7,"ACM4, TLX, HOXA1, SCN2A, HOXA7, SCN3A, HOXA5",
392,Development_Schema: Histone H3 demethylases in stem cells,32,2.792E-03,1.131E-02,3.366E-03,1.131E-02,7,"p15, p14ARF, HOXA1, SCN2A, HOXA7, p16INK4, HOXA11",2.792E-03,1.451E-02,7,"p15, p14ARF, HOXA1, SCN2A, HOXA7, p16INK4, HOXA11",
393,Immune response_Antigen presentation by MHC class I: cross-presentation,99,2.814E-03,1.255E-02,3.799E-03,1.255E-02,14,"Syk, Dectin-1, LY75, Rac2, TLR7, Fc gamma RII alpha, TLR3, UFO, Cathepsin S, MSR1, cPLA2, TAP, TLR4, TLR2",2.814E-03,1.458E-02,14,"Syk, Dectin-1, LY75, Rac2, TLR7, Fc gamma RII alpha, TLR3, UFO, Cathepsin S, MSR1, cPLA2, TAP, TLR4, TLR2",
394,Gamma-Secretase regulation of neuronal cell development and function,57,2.849E-03,1.031E-02,2.849E-03,1.031E-02,10,"Transgelin, N-cadherin, NGF, Beta-catenin, ACTA2, NGFR (ICD), N-cadherin (CTF1), N-cadherin (CTF2), NGFR(TNFRSF16), NGFR (CTF)",7.488E-03,3.017E-02,9,"Transgelin, N-cadherin, NGF, ACTA2, NGFR (ICD), N-cadherin (CTF1), N-cadherin (CTF2), NGFR(TNFRSF16), NGFR (CTF)",
395,Breast cancer (general schema),41,3.050E-03,1.246E-02,3.743E-03,1.246E-02,8,"IL-6, NOTCH4, TGF-beta, PTHrP, PTCH1, Jagged1, TGF-beta receptor type II, EGFR",3.050E-03,1.519E-02,8,"IL-6, NOTCH4, TGF-beta, PTHrP, PTCH1, Jagged1, TGF-beta receptor type II, EGFR",
396,Immune response_IFN-gamma in macrophages activation,50,3.056E-03,1.255E-02,3.816E-03,1.255E-02,9,"COX-2 (PTGS2), IL-6, PAI2, iNOS, CCL2, Caspase-1, CLIC5, Pleiotrophin (OSF1), TLR4",3.056E-03,1.519E-02,9,"COX-2 (PTGS2), IL-6, PAI2, iNOS, CCL2, Caspase-1, CLIC5, Pleiotrophin (OSF1), TLR4",
397,Protein folding and maturation_Posttranslational processing of neuroendocrine peptides,50,3.056E-03,1.255E-02,3.816E-03,1.255E-02,9,"PAM, Trypsin, PCSK5, LargeNT, LargeNN, NN, NT/NN, NT, PC1",3.056E-03,1.519E-02,9,"PAM, Trypsin, PCSK5, LargeNT, LargeNN, NN, NT/NN, NT, PC1",
398,Role of neuropeptides in pathogenesis of SCLC,67,3.082E-03,1.105E-02,3.082E-03,1.105E-02,11,"cPKC (conventional), Fyn, PKC, AKT(PKB), G-protein alpha-q/11, Neprilysin, Neuromedin B, PKC-alpha, EGFR, NT, ERK1/2",7.395E-03,2.991E-02,10,"cPKC (conventional), Fyn, PKC, AKT(PKB), G-protein alpha-q/11, Neprilysin, Neuromedin B, PKC-alpha, EGFR, NT",
399,B-regulatory cells and tumor cells intercellular interaction,67,3.082E-03,1.105E-02,3.082E-03,1.105E-02,11,"STAT3, IL-1 beta, IL-6, ST2(L), TNF-R2, MCAM, TLR7, CCL2, TLR4, IL-33, PD-L1",7.395E-03,2.991E-02,10,"IL-1 beta, IL-6, ST2(L), TNF-R2, MCAM, TLR7, CCL2, TLR4, IL-33, PD-L1",
400,Stem cells_NOTCH1-induced self-renewal of glioblastoma stem cells,40,3.186E-03,1.125E-02,3.186E-03,1.125E-02,8,"STAT3, Nestin, HES5, p53, Jagged1, BMP4, EGFR, BMP2",3.386E-02,9.588E-02,6,"Nestin, HES5, Jagged1, BMP4, EGFR, BMP2",
401,The role of UV radiation in melanoma development,40,3.186E-03,1.125E-02,3.186E-03,1.125E-02,8,"POMC, TGF-alpha, ERK2 (MAPK1), AKT(PKB), alpha-MSH, p16INK4, EGFR, ERK1/2",3.386E-02,9.588E-02,6,"POMC, TGF-alpha, AKT(PKB), alpha-MSH, p16INK4, EGFR",
402,IFN-gamma and Th2 cytokines-induced inflammatory signaling in normal and asthmatic airway epithelium,40,3.186E-03,1.125E-02,3.186E-03,1.125E-02,8,"IL-6, ST2(L), ICAM1, CCL2, Fibronectin, I-TAC, IL-8, ERK1/2",1.010E-02,3.780E-02,7,"IL-6, ST2(L), ICAM1, CCL2, Fibronectin, I-TAC, IL-8",
403,Stem cells_Pancreatic cancer stem cells in tumor metastasis,40,3.186E-03,1.125E-02,3.186E-03,1.125E-02,8,"Myosin II, Fyn, MELC, MyHC, G-protein alpha-i family, F-Actin cytoskeleton, MLCK, MRLC",9.633E-02,2.023E-01,5,"Fyn, MELC, G-protein alpha-i family, MLCK, MRLC",
404,Inhibition of Vitamin D pathway in Prostate Cancer,40,3.186E-03,1.125E-02,3.186E-03,1.125E-02,8,"IL-6, CYP27A1, SMAD3, RUNX2, CYP24A1, GFI-1, IBP3, CDK6",1.010E-02,3.780E-02,7,"IL-6, CYP27A1, RUNX2, CYP24A1, GFI-1, IBP3, CDK6",
405,Proteolysis_Role of Parkin in the Ubiquitin-Proteasomal Pathway,24,3.220E-03,1.129E-02,3.220E-03,1.129E-02,6,"Tubulin beta, Alpha-synuclein, Caspase-1, Caspase-8, Cyclin E, Synphilin 1",1.380E-02,4.747E-02,5,"Tubulin beta, Alpha-synuclein, Caspase-1, Cyclin E, Synphilin 1",
406,Development_Dopamine D2 receptor transactivation of EGFR,24,3.220E-03,1.129E-02,3.220E-03,1.129E-02,6,"PI3K cat class IA, ERK2 (MAPK1), AKT(PKB), ADAM12, EGFR, G-protein alpha-i family",1.380E-02,4.747E-02,5,"PI3K cat class IA, AKT(PKB), ADAM12, EGFR, G-protein alpha-i family",
407,Chemotaxis_Lysophosphatidic acid signaling via GPCRs,129,3.232E-03,1.130E-02,3.232E-03,1.130E-02,17,"Beta-catenin, Rho GTPase, Actin cytoskeletal, cPKC (conventional), TAZ, PAK, CTGF, PKC, AKT(PKB), G-protein alpha-q/11, p53, Tcf(Lef), IL-8, EGFR, G-protein alpha-i family, F-Actin cytoskeleton, ERK1/2",9.843E-02,2.050E-01,12,"Rho GTPase, cPKC (conventional), TAZ, PAK, CTGF, PKC, AKT(PKB), G-protein alpha-q/11, Tcf(Lef), IL-8, EGFR, G-protein alpha-i family",
408,Immune response_IL-33 signaling pathway,58,3.252E-03,1.131E-02,3.252E-03,1.131E-02,10,"IL-6, ST2(L), PI3K cat class IA, GRO-1, AKT(PKB), ICAM1, CCL2, IL-8, IL-33, ERK1/2",8.394E-03,3.276E-02,9,"IL-6, ST2(L), PI3K cat class IA, GRO-1, AKT(PKB), ICAM1, CCL2, IL-8, IL-33",
409,Signal transduction_IP3 signaling,49,3.311E-03,1.131E-02,3.311E-03,1.131E-02,9,"Syk, Galpha(q)-specific nucleotide-like GPCRs, PI3K cat class IA, MEF2, AKT(PKB), G-protein alpha-q/11, PDGF receptor, HGF receptor (Met), ERK1/2",9.351E-03,3.559E-02,8,"Syk, Galpha(q)-specific nucleotide-like GPCRs, PI3K cat class IA, MEF2, AKT(PKB), G-protein alpha-q/11, PDGF receptor, HGF receptor (Met)",
410,Cytoskeleton remodeling_Integrin outside-in signaling,49,3.311E-03,1.131E-02,3.311E-03,1.131E-02,9,"alpha-11/beta-1 integrin, Beta-catenin, alpha-5/beta-1 integrin, Actin cytoskeletal, AKT(PKB), Collagen IV, Fibronectin, Tcf(Lef), ERK1/2",7.803E-02,1.764E-01,6,"alpha-11/beta-1 integrin, alpha-5/beta-1 integrin, AKT(PKB), Collagen IV, Fibronectin, Tcf(Lef)",
411,Tissue Factor signaling in cancer via PAR1 and PAR2,49,3.311E-03,1.131E-02,3.311E-03,1.131E-02,9,"PI3K cat class IA, TGF-alpha, AKT(PKB), G-protein alpha-q/11, Tissue factor, PKC-alpha, IL-8, EGFR, ERK1/2",9.351E-03,3.559E-02,8,"PI3K cat class IA, TGF-alpha, AKT(PKB), G-protein alpha-q/11, Tissue factor, PKC-alpha, IL-8, EGFR",
412,Neurophysiological process_HTR2A signaling in the nervous system,49,3.311E-03,1.131E-02,3.311E-03,1.131E-02,9,"cPKC (conventional), iNOS, PKC, GABA-A receptor, AKT(PKB), G-protein alpha-q/11, Caveolin-1, SFK, ERK1/2",9.351E-03,3.559E-02,8,"cPKC (conventional), iNOS, PKC, GABA-A receptor, AKT(PKB), G-protein alpha-q/11, Caveolin-1, SFK",
413,Signal transduction_Soluble CXCL16 signaling,49,3.311E-03,1.131E-02,3.311E-03,1.131E-02,9,"STAT3, AKT(PKB), CD44, IL-8, MMP-9, G-protein alpha-i family, F-Actin cytoskeleton, ERK1/2, MMP-2",7.803E-02,1.764E-01,6,"AKT(PKB), CD44, IL-8, MMP-9, G-protein alpha-i family, MMP-2",
414,Transition of Smoldering multiple myeloma to active multiple myeloma (schema),17,3.319E-03,1.131E-02,3.319E-03,1.131E-02,5,"IL-1 beta, IL-6, CCL2, p53, IL-8",1.767E-02,5.731E-02,4,"IL-1 beta, IL-6, CCL2, IL-8",
415,Influence of multiple myeloma cells on bone marrow stromal cells,33,3.359E-03,1.305E-02,4.042E-03,1.305E-02,7,"COX-2 (PTGS2), IL-1 beta, IL-6, FGF2, Osteoprotegerin, ITGA4, ICAM1",3.359E-03,1.634E-02,7,"COX-2 (PTGS2), IL-1 beta, IL-6, FGF2, Osteoprotegerin, ITGA4, ICAM1",
416,Role of GSK3 beta in cardioprotection against myocardial infarction,33,3.359E-03,1.305E-02,4.042E-03,1.305E-02,7,"PI3K cat class IA, CRLR, MMP-8, Metenkefalin, AKT(PKB), EGFR, Enkephalin A",3.359E-03,1.634E-02,7,"PI3K cat class IA, CRLR, MMP-8, Metenkefalin, AKT(PKB), EGFR, Enkephalin A",
417,Immune response_TLR3 and TLR4 induced TICAM1-specific signaling pathway,33,3.359E-03,1.305E-02,4.042E-03,1.305E-02,7,"PI3K cat class IA, CD14, AKT(PKB), TLR3, IFN-beta, TLR4, MD-2",3.359E-03,1.634E-02,7,"PI3K cat class IA, CD14, AKT(PKB), TLR3, IFN-beta, TLR4, MD-2",
418,Cytoskeleton remodeling_Fibronectin-binding integrins in cell motility,32,3.366E-03,1.131E-02,3.366E-03,1.131E-02,7,"alpha-5/beta-1 integrin, Actin cytoskeletal, Fyn, PI3K cat class IA, Caveolin-1, ITGA5, Fibronectin",1.208E-02,4.229E-02,6,"alpha-5/beta-1 integrin, Fyn, PI3K cat class IA, Caveolin-1, ITGA5, Fibronectin",
419,EML4/ALK fusion protein in nonsmoking-related lung cancer ,32,3.366E-03,1.131E-02,3.366E-03,1.131E-02,7,"STAT3, PI3K cat class IA, AKT(PKB), IRS-2, p53, EGFR, ERK1/2",1.305E-01,2.510E-01,4,"PI3K cat class IA, AKT(PKB), IRS-2, EGFR",
420,Immunological synapse between dendritic and CD8+ T cells in allergic contact dermatitis,32,3.366E-03,1.131E-02,3.366E-03,1.131E-02,7,"CD137 ligand(TNFSF9), PD-L2, Lck, ICAM1, CD137(TNFRSF9), CD70(TNFSF7), PD-L1",1.208E-02,4.229E-02,6,"CD137 ligand(TNFSF9), PD-L2, ICAM1, CD137(TNFRSF9), CD70(TNFSF7), PD-L1",
421,The role of KEAP1/NRF2 pathway in skin sensitization,32,3.366E-03,1.131E-02,3.366E-03,1.131E-02,7,"IL-1 beta, TNF-R2, ERK2 (MAPK1), Caspase-1, IL-8, TLR4, ERK1/2",4.376E-02,1.157E-01,5,"IL-1 beta, TNF-R2, Caspase-1, IL-8, TLR4",
422,Interleukins-induced inflammatory signaling in normal and asthmatic airway epithelium,32,3.366E-03,1.131E-02,3.366E-03,1.131E-02,7,"IL-1 beta, IL-6, ST2(L), Fibronectin, IL-8, IL-33, ERK1/2",1.208E-02,4.229E-02,6,"IL-1 beta, IL-6, ST2(L), Fibronectin, IL-8, IL-33",
423,Immune response_LPS-induced platelet activation,25,3.402E-03,1.305E-02,4.013E-03,1.305E-02,6,"COX-2 (PTGS2), IL-1 beta, CD14, TLR4, TLR2, MD-2",3.402E-03,1.637E-02,6,"COX-2 (PTGS2), IL-1 beta, CD14, TLR4, TLR2, MD-2",
424,T cell generation in COPD,25,3.402E-03,1.305E-02,4.013E-03,1.305E-02,6,"MHC class II, CCL20, Langerin, ICAM1, CCL2, CCL7",3.402E-03,1.637E-02,6,"MHC class II, CCL20, Langerin, ICAM1, CCL2, CCL7",
425,Transcription targets of Androgen receptor involved in Prostate Cancer,42,3.569E-03,1.388E-02,4.372E-03,1.388E-02,8,"IL-6, N-cadherin, Matrilysin (MMP-7), ER81, IL-8, TLR2, IBP3, Versican",3.569E-03,1.694E-02,8,"IL-6, N-cadherin, Matrilysin (MMP-7), ER81, IL-8, TLR2, IBP3, Versican",
426,Transcription_Role of VDR in regulation of genes involved in osteoporosis,59,3.698E-03,1.240E-02,3.698E-03,1.240E-02,10,"IL-1 beta, IL-6, SMAD3, TRPC3, RUNX2, Osteoprotegerin, Fra-1, CDX2, CYP24A1, CALB1",9.381E-03,3.559E-02,9,"IL-1 beta, IL-6, TRPC3, RUNX2, Osteoprotegerin, Fra-1, CDX2, CYP24A1, CALB1",
427,Development_Regulation of lung epithelial progenitor cell differentiation,41,3.743E-03,1.246E-02,3.743E-03,1.246E-02,8,"STAT3, Beta-catenin, Jagged1, Tcf(Lef), WNT, BMP4, Frizzled, ERM",3.768E-02,1.050E-01,6,"Jagged1, Tcf(Lef), WNT, BMP4, Frizzled, ERM",
428,Immune response_TLR2-induced platelet activation,41,3.743E-03,1.246E-02,3.743E-03,1.246E-02,8,"IL-1 beta, TLR1, PI3K cat class IA, AKT(PKB), PKC-alpha, cPLA2, TLR2, ERK1/2",1.156E-02,4.088E-02,7,"IL-1 beta, TLR1, PI3K cat class IA, AKT(PKB), PKC-alpha, cPLA2, TLR2",
429,Rb proteins signaling in multiple myeloma,18,3.775E-03,1.388E-02,4.358E-03,1.388E-02,5,"p15, IL-6, p16INK4, Cyclin E, CDK6",3.775E-03,1.779E-02,5,"p15, IL-6, p16INK4, Cyclin E, CDK6",
430,Pro-inflammatory action of Gastrin in gastric cancer,50,3.816E-03,1.255E-02,3.816E-03,1.255E-02,9,"COX-2 (PTGS2), GRO-2, PAI2, PI3K cat class IA, AKT(PKB), G-protein alpha-q/11, IL-8, EGFR, ERK1/2",1.055E-02,3.822E-02,8,"COX-2 (PTGS2), GRO-2, PAI2, PI3K cat class IA, AKT(PKB), G-protein alpha-q/11, IL-8, EGFR",
431,IGF-1 signaling in multiple myeloma,50,3.816E-03,1.255E-02,3.816E-03,1.255E-02,9,"BAD, ITGB1, c-IAP2, PI3K cat class IA, ERK2 (MAPK1), AKT(PKB), IRS-2, Fibronectin, ERK1/2",8.431E-02,1.846E-01,6,"ITGB1, c-IAP2, PI3K cat class IA, AKT(PKB), IRS-2, Fibronectin",
432,Immune response_B cell antigen receptor (BCR) pathway,110,3.970E-03,1.303E-02,3.970E-03,1.303E-02,15,"BAD, CIN85, Syk, Actin cytoskeletal, AKT(PKB), CalDAG-GEFIII, alpha-4/beta-1 integrin, CKLFSF7, ICAM1, Fibronectin, ETS1, Lyn, PI3K cat class IA (p110-delta), ERK1/2, CDK6",3.723E-02,1.039E-01,12,"CIN85, Syk, AKT(PKB), CalDAG-GEFIII, alpha-4/beta-1 integrin, CKLFSF7, ICAM1, Fibronectin, ETS1, Lyn, PI3K cat class IA (p110-delta), CDK6",
433,NK cells in allergic contact dermatitis,34,4.010E-03,1.517E-02,4.817E-03,1.517E-02,7,"CIITA, MHC class II, CCL20, HLA-DRA1, NCAM1, ICAM1, CCL2",4.010E-03,1.864E-02,7,"CIITA, MHC class II, CCL20, HLA-DRA1, NCAM1, ICAM1, CCL2",
434,Role of IFN-beta in inhibition of Th1 cell differentiation in multiple sclerosis,34,4.010E-03,1.517E-02,4.817E-03,1.517E-02,7,"IL-18R1, MHC class II, PI3K cat class IA, AKT(PKB), IFN-beta, TLR4, PD-L1",4.010E-03,1.864E-02,7,"IL-18R1, MHC class II, PI3K cat class IA, AKT(PKB), IFN-beta, TLR4, PD-L1",
435,"Development_ROBO2, ROBO3 and ROBO4 signaling pathways",25,4.013E-03,1.305E-02,4.013E-03,1.305E-02,6,"ROBO3, Myosin II, alpha-5/beta-1 integrin, P-cadherin, HIC5, ROBO4",1.640E-02,5.383E-02,5,"ROBO3, alpha-5/beta-1 integrin, P-cadherin, HIC5, ROBO4",
436,Dual role of BMP signaling in gastric cancer,25,4.013E-03,1.305E-02,4.013E-03,1.305E-02,6,"PI3K cat class IA, SNAIL1, AKT(PKB), CDX2, BMP4, BMP2",1.640E-02,5.383E-02,5,"PI3K cat class IA, AKT(PKB), CDX2, BMP4, BMP2",
437,"Chemotaxis_CCL16-, CCL20-, CXCL16- and CCL25-mediated cell migration",43,4.154E-03,1.561E-02,5.079E-03,1.561E-02,8,"CCL20, MMP-8, MMP-13, AKT(PKB), MMP-9, G-protein alpha-i family, MLCK, MMP-2",4.154E-03,1.905E-02,8,"CCL20, MMP-8, MMP-13, AKT(PKB), MMP-9, G-protein alpha-i family, MLCK, MMP-2",
438,Role of fibroblasts and keratinocytes in the elicitation phase of allergic contact dermatitis,26,4.196E-03,1.542E-02,4.942E-03,1.542E-02,6,"GRO-2, IL-1 beta, CCL20, GRO-1, CCL2, IL-8",4.196E-03,1.918E-02,6,"GRO-2, IL-1 beta, CCL20, GRO-1, CCL2, IL-8",
439,Apoptosis and survival_Apoptotic TNF-family pathways,42,4.372E-03,1.388E-02,4.372E-03,1.388E-02,8,"NGF, TNF-R2, NGFR(TNFRSF16), Caspase-10, LIGHT(TNFSF14), Caspase-8, CD70(TNFSF7), GITRL",1.315E-02,4.558E-02,7,"NGF, TNF-R2, NGFR(TNFRSF16), Caspase-10, LIGHT(TNFSF14), CD70(TNFSF7), GITRL",
440,Development_NOTCH in inhibition of WNT/Beta-catenin-induced osteogenesis,42,4.372E-03,1.388E-02,4.372E-03,1.388E-02,8,"ALPL, Beta-catenin, RUNX2, Jagged1, Dsh, WNT, TCF7 (TCF1), Frizzled",4.177E-02,1.133E-01,6,"ALPL, RUNX2, Jagged1, WNT, TCF7 (TCF1), Frizzled",
441,Signal transduction_Angiotensin II/ AGTR1 signaling via TGF-beta 1 and SMADs,42,4.372E-03,1.388E-02,4.372E-03,1.388E-02,8,"IL-1 beta, SMAD3, CTGF, AKT(PKB), OSF-2, Caspase-1, TGF-beta receptor type II, ERK1/2",4.177E-02,1.133E-01,6,"IL-1 beta, CTGF, AKT(PKB), OSF-2, Caspase-1, TGF-beta receptor type II",
442,"TNF-alpha, IL-1 beta induce dyslipidemia and inflammation in obesity and type 2 diabetes in adipocytes ",42,4.372E-03,1.388E-02,4.372E-03,1.388E-02,8,"COX-2 (PTGS2), IL-1 beta, IL-6, PTX3, TNF-R2, iNOS, CCL2, ERK1/2",1.315E-02,4.558E-02,7,"COX-2 (PTGS2), IL-1 beta, IL-6, PTX3, TNF-R2, iNOS, CCL2",
443,Development_Signaling pathways in embryonic hepatocyte maturation,51,4.378E-03,1.388E-02,4.378E-03,1.388E-02,9,"STAT3, HGF, Beta-catenin, PI3K cat class IA, OSMR, AKT(PKB), Transferrin, Caspase-8, HGF receptor (Met)",9.086E-02,1.937E-01,6,"HGF, PI3K cat class IA, OSMR, AKT(PKB), Transferrin, HGF receptor (Met)",
444,Epithelial cell anoikis in COPD,51,4.378E-03,1.388E-02,4.378E-03,1.388E-02,9,"BAD, Laminin 5, Actin cytoskeletal, PI3K cat class IA, MMP-8, AKT(PKB), IRS-2, MMP-9, ERK1/2",9.086E-02,1.937E-01,6,"Laminin 5, PI3K cat class IA, MMP-8, AKT(PKB), IRS-2, MMP-9",
445,Development_Schema: Embryonal myogenesis,12,4.696E-03,1.623E-02,5.292E-03,1.623E-02,4,"HGF, HGF receptor (Met), WNT7A, BMP4",4.696E-03,2.108E-02,4,"HGF, HGF receptor (Met), WNT7A, BMP4",
446,Development_Transcriptional regulation of megakaryopoiesis,35,4.752E-03,1.706E-02,5.698E-03,1.706E-02,7,"NF-E2 (45 kDa), Fc gamma RII alpha, CD38, Jagged1, ETS, ETS1, LMO2",4.752E-03,2.108E-02,7,"NF-E2 (45 kDa), Fc gamma RII alpha, CD38, Jagged1, ETS, ETS1, LMO2",
447,Development_Schema: Adult neuron differentiation in the Subventricular and Subgranular Zones,35,4.752E-03,1.706E-02,5.698E-03,1.706E-02,7,"Nestin, DLX2, NCAM1, GAD1, Vimentin, Chordin-like 1, MAP2",4.752E-03,2.108E-02,7,"Nestin, DLX2, NCAM1, GAD1, Vimentin, Chordin-like 1, MAP2",
448,Apoptosis and survival_Role of CDK5 in neuronal death and survival,34,4.817E-03,1.517E-02,4.817E-03,1.517E-02,7,"BAD, NGF, NGFR(TNFRSF16), PI3K cat class IA, AKT(PKB), p53, ERK1/2",1.533E-01,2.806E-01,4,"NGF, NGFR(TNFRSF16), PI3K cat class IA, AKT(PKB)",
449,Hedgehog signaling in prostate cancer,26,4.942E-03,1.542E-02,4.942E-03,1.542E-02,6,"Nestin, SNAIL1, GLI-1, PTCH1, IBP6, GLI-2",1.931E-02,6.087E-02,5,"Nestin, GLI-1, PTCH1, IBP6, GLI-2",
450,Muscle contraction_Delta-type opioid receptor in smooth muscle contraction,26,4.942E-03,1.542E-02,4.942E-03,1.542E-02,6,"Myosin II, Metenkefalin, CPI-17, Leu-enkephalin, G-protein alpha-i family, MRLC",1.931E-02,6.087E-02,5,"Metenkefalin, CPI-17, Leu-enkephalin, G-protein alpha-i family, MRLC",
451,Immune response_Role of HMGB1 in dendritic cell maturation and migration,26,4.942E-03,1.542E-02,4.942E-03,1.542E-02,6,"IL-15, IL-1 beta, IL-6, MHC class II, IL-8, ERK1/2",1.931E-02,6.087E-02,5,"IL-15, IL-1 beta, IL-6, MHC class II, IL-8",
452,Immune response_IL-3 signaling via ERK and PI3K,102,4.989E-03,1.554E-02,4.989E-03,1.554E-02,14,"BAD, Syk, ITGB1, alpha-5/beta-1 integrin, cPKC (conventional), PI3K cat class IA, AKT(PKB), alpha-4/beta-1 integrin, p53, NGAL, cPLA2, Lyn, PI3K cat class IA (p110-delta), ERK1/2",4.810E-02,1.236E-01,11,"Syk, ITGB1, alpha-5/beta-1 integrin, cPKC (conventional), PI3K cat class IA, AKT(PKB), alpha-4/beta-1 integrin, NGAL, cPLA2, Lyn, PI3K cat class IA (p110-delta)",
453,Signal transduction_Additional pathways of NF-kB activation (in the cytoplasm),52,5.004E-03,1.555E-02,5.004E-03,1.555E-02,9,"PI3K cat class IA, Lck, PKC-theta, AKT(PKB), PKC-alpha, Pim-1, Adenylate cyclase, ERK1/2, CDK6",3.859E-02,1.066E-01,7,"PI3K cat class IA, PKC-theta, AKT(PKB), PKC-alpha, Pim-1, Adenylate cyclase, CDK6",
454,Immune response_IL-7 signaling in B lymphocytes,43,5.079E-03,1.561E-02,5.079E-03,1.561E-02,8,"STAT3, Fyn, IL7RA, EBF, AKT(PKB), Lyn, Pim-1, ERK1/2",4.613E-02,1.188E-01,6,"Fyn, IL7RA, EBF, AKT(PKB), Lyn, Pim-1",
455,Th2-cytokines-induced expression of mucins in asthma ,43,5.079E-03,1.561E-02,5.079E-03,1.561E-02,8,"STAT3, GRO-2, IL-6, TGF-beta 2, GRO-1, IL-8, TGF-beta receptor type II, ERK1/2",4.613E-02,1.188E-01,6,"GRO-2, IL-6, TGF-beta 2, GRO-1, IL-8, TGF-beta receptor type II",
456,Environmental factors-induced inflammatory signaling in normal and asthmatic airway epithelium,43,5.079E-03,1.561E-02,5.079E-03,1.561E-02,8,"IL-1 beta, IL-6, iNOS, PKC, ICAM1, IL-8, ERK1/2, sICAM1",1.490E-02,4.987E-02,7,"IL-1 beta, IL-6, iNOS, PKC, ICAM1, IL-8, sICAM1",
457,Regulation of Tissue factor signaling in cancer,43,5.079E-03,1.561E-02,5.079E-03,1.561E-02,8,"TNF-R2, Heparanase 1, ERK2 (MAPK1), AKT(PKB), Tissue factor, p53, EGFR, ERK1/2",1.217E-01,2.379E-01,5,"TNF-R2, Heparanase 1, AKT(PKB), Tissue factor, EGFR",
458,Eosinophil chemotaxis in asthma,64,5.327E-03,1.973E-02,6.705E-03,1.973E-02,10,"NGF, Secretoneurin, S1P1 receptor, NGFR(TNFRSF16), CCL20, Eotaxin-2, C3a, IL-8, G-protein alpha-i family, CCL7",5.327E-03,2.318E-02,10,"NGF, Secretoneurin, S1P1 receptor, NGFR(TNFRSF16), CCL20, Eotaxin-2, C3a, IL-8, G-protein alpha-i family, CCL7",
459,Muscle contraction_Oxytocin signaling in uterus and mammary gland,62,5.333E-03,1.632E-02,5.333E-03,1.632E-02,10,"PGF2aR, COX-2 (PTGS2), cPKC (conventional), AKR1C3, PKC, G-protein alpha-q/11, PKC-alpha, cPLA2, EGFR, ERK1/2",1.287E-02,4.484E-02,9,"PGF2aR, COX-2 (PTGS2), cPKC (conventional), AKR1C3, PKC, G-protein alpha-q/11, PKC-alpha, cPLA2, EGFR",
460,G-protein signaling_Regulation of Cyclic AMP levels by ACM,45,5.543E-03,1.979E-02,6.753E-03,1.979E-02,8,"ACM4, PDE1A, PDE1C, G-protein alpha-q/11, PKC-alpha, G-protein alpha-i family, ACM3, Adenylate cyclase type VII",5.543E-03,2.397E-02,8,"ACM4, PDE1A, PDE1C, G-protein alpha-q/11, PKC-alpha, G-protein alpha-i family, ACM3, Adenylate cyclase type VII",
461,Development_Hedgehog and PTH signaling pathways in bone and cartilage development,36,5.594E-03,1.973E-02,6.695E-03,1.973E-02,7,"PTHrP, MMP-13, GLI-1, RUNX2, G-protein alpha-q/11, PTCH1, GLI-2",5.594E-03,2.403E-02,7,"PTHrP, MMP-13, GLI-1, RUNX2, G-protein alpha-q/11, PTCH1, GLI-2",
462,Cytoskeleton remodeling_Alpha-1A adrenergic receptor-dependent inhibition of PI3K,19,5.610E-03,1.706E-02,5.610E-03,1.706E-02,5,"Myosin II, AKT(PKB), MELC, MLCK, MRLC",2.611E-02,7.852E-02,4,"AKT(PKB), MELC, MLCK, MRLC",
463,Development_Role of growth factors in the maintenance of embryonic stem cell pluripotency,53,5.696E-03,1.706E-02,5.696E-03,1.706E-02,9,"Myosin II, PI3K cat class IA, FGF2, SMAD3, AKT(PKB), Activin A, Oct-3/4, TGF-beta receptor type II, ERK1/2",1.048E-01,2.146E-01,6,"PI3K cat class IA, FGF2, AKT(PKB), Activin A, Oct-3/4, TGF-beta receptor type II",
464,Proinflammatory cytokine production by Th17 cells in asthma,53,5.696E-03,1.706E-02,5.696E-03,1.706E-02,9,"STAT3, COX-2 (PTGS2), IL-1 beta, IL-6, MHC class II, CCL20, C3a, C3, IL-8",1.483E-02,4.987E-02,8,"COX-2 (PTGS2), IL-1 beta, IL-6, MHC class II, CCL20, C3a, C3, IL-8",
465,Cell cycle_Influence of Ras and Rho proteins on G1/S Transition,53,5.696E-03,1.706E-02,5.696E-03,1.706E-02,9,"STAT3, alpha-5/beta-1 integrin, PI3K cat class IA, AKT(PKB), Cyclin E, MLCK, MRLC, ERK1/2, CDK6",4.220E-02,1.139E-01,7,"alpha-5/beta-1 integrin, PI3K cat class IA, AKT(PKB), Cyclin E, MLCK, MRLC, CDK6",
466,Production and activation of TGF-beta in airway smooth muscle cells,35,5.698E-03,1.706E-02,5.698E-03,1.706E-02,7,"TGF-beta 2, TGF-beta, TGF-beta receptor type II, G-protein alpha-i family, TLR4, PLAU (UPA), ERK1/2",1.852E-02,5.964E-02,6,"TGF-beta 2, TGF-beta, TGF-beta receptor type II, G-protein alpha-i family, TLR4, PLAU (UPA)",
467,IL-6 signaling pathway in lung cancer,35,5.698E-03,1.706E-02,5.698E-03,1.706E-02,7,"STAT3, COX-2 (PTGS2), IL-6, PI3K cat class IA, AKT(PKB), EGFR, ERK1/2",6.078E-02,1.461E-01,5,"COX-2 (PTGS2), IL-6, PI3K cat class IA, AKT(PKB), EGFR",
468,Cell adhesion_Alpha-4 integrins in cell migration and adhesion,35,5.698E-03,1.706E-02,5.698E-03,1.706E-02,7,"ITGB1, Actin cytoskeletal, PI3K cat class IA, ITGA4, alpha-4/beta-1 integrin, Fibronectin, F-Actin cytoskeleton",6.078E-02,1.461E-01,5,"ITGB1, PI3K cat class IA, ITGA4, alpha-4/beta-1 integrin, Fibronectin",
469,NALP3 inflammasome activation in age-related macular degeneration (AMD),35,5.698E-03,1.706E-02,5.698E-03,1.706E-02,7,"IL-1 beta, IL-6, IL-18R1, CCL20, Caspase-1, Caspase-8, TLR2",1.852E-02,5.964E-02,6,"IL-1 beta, IL-6, IL-18R1, CCL20, Caspase-1, TLR2",
470,Influence of smoking on activation of EGFR signaling in lung cancer cells,44,5.871E-03,1.754E-02,5.871E-03,1.754E-02,8,"ERK2 (MAPK1), Fra-1, Epiregulin, EGFR, MMP-9, Adenylate cyclase, ERK1/2, MMP-2",5.076E-02,1.264E-01,6,"Fra-1, Epiregulin, EGFR, MMP-9, Adenylate cyclase, MMP-2",
471,Activation of TGF-beta signaling in pancreatic cancer,27,6.020E-03,1.794E-02,6.020E-03,1.794E-02,6,"SMAD3, ERK2 (MAPK1), ICAM1, TGF-beta receptor type II, SLUG, GLI-2",8.058E-02,1.792E-01,4,"ICAM1, TGF-beta receptor type II, SLUG, GLI-2",
472,Eosinophil granule protein release in asthma,54,6.461E-03,1.922E-02,6.461E-03,1.922E-02,9,"NGF, ST2(L), cPKC (conventional), PKC, PRG2, PKC-alpha, C3a, IL-33, ERK1/2",1.650E-02,5.403E-02,8,"NGF, ST2(L), cPKC (conventional), PKC, PRG2, PKC-alpha, C3a, IL-33",
473,Cigarette smoke components TCDD and Benzo[a]pyrene and receptor AHR signaling in lung epithelial cells,36,6.695E-03,1.973E-02,6.695E-03,1.973E-02,7,"COX-2 (PTGS2), IL-1 beta, TGF-alpha, SMAD3, CYP1A1, CCL2, TGF-beta receptor type II",2.111E-02,6.572E-02,6,"COX-2 (PTGS2), IL-1 beta, TGF-alpha, CYP1A1, CCL2, TGF-beta receptor type II",
474,HBV signaling via protein kinases leading to HCC,36,6.695E-03,1.973E-02,6.695E-03,1.973E-02,7,"cPKC (conventional), SMAD3, PKC, ERK2 (MAPK1), PKC-alpha, MMP-9, ERK1/2",1.775E-01,3.127E-01,4,"cPKC (conventional), PKC, PKC-alpha, MMP-9",
475,Upregulation of MITF in melanoma,36,6.695E-03,1.973E-02,6.695E-03,1.973E-02,7,"SOX10, ERK2 (MAPK1), alpha-MSH, HGF receptor (Met), p16INK4, IMP1(ZBP1), ERK1/2",6.718E-02,1.567E-01,5,"SOX10, alpha-MSH, HGF receptor (Met), p16INK4, IMP1(ZBP1)",
476,Signal transduction_Angiotensin II/ AGTR1 signaling via JAK/STAT,45,6.753E-03,1.979E-02,6.753E-03,1.979E-02,8,"STAT3, IL-6, IL-18R1, Fyn, PKC, RGS2, p53, ERK1/2",1.402E-01,2.664E-01,5,"IL-6, IL-18R1, Fyn, PKC, RGS2",
477,Development_H3K36 demethylation in stem cell maintenance,20,7.096E-03,2.075E-02,7.096E-03,2.075E-02,5,"p15, p14ARF, p53, p16INK4, CDK6",3.110E-02,8.937E-02,4,"p15, p14ARF, p16INK4, CDK6",
478,Immune response_Innate immune response to RNA viral infection,28,7.258E-03,2.118E-02,7.258E-03,2.118E-02,6,"Caspase-10, TLR7, Caspase-8, TLR3, IL-8, IFN-beta",2.609E-02,7.852E-02,5,"Caspase-10, TLR7, TLR3, IL-8, IFN-beta",
479,Immune response_Platelet activating factor/ PTAFR pathway signaling,55,7.301E-03,2.122E-02,7.301E-03,2.122E-02,9,"STAT3, IL-1 beta, PI3K cat class IA, AKT(PKB), CCL2, MMP-9, G-protein alpha-i family, Adenylate cyclase, F-Actin cytoskeleton",5.008E-02,1.263E-01,7,"IL-1 beta, PI3K cat class IA, AKT(PKB), CCL2, MMP-9, G-protein alpha-i family, Adenylate cyclase",
480,Aberrant B-Raf signaling in melanoma progression,55,7.301E-03,2.122E-02,7.301E-03,2.122E-02,9,"BAD, ITGB1, ERK2 (MAPK1), AKT(PKB), SPRY2, ITGB3, MAP2, AKT3, ERK1/2",1.197E-01,2.373E-01,6,"ITGB1, AKT(PKB), SPRY2, ITGB3, MAP2, AKT3",
481,Stem cells_Notch signaling in medulloblastoma stem cells,29,7.402E-03,2.464E-02,8.671E-03,2.464E-02,6,"GLI-1, HES5, PTCH1, FKHL1, Jagged1, GLI-2",7.402E-03,2.991E-02,6,"GLI-1, HES5, PTCH1, FKHL1, Jagged1, GLI-2",
482,EZH2 in Prostate Cancer,29,7.402E-03,2.464E-02,8.671E-03,2.464E-02,6,"Follistatin, Keratin 17, Alpha-synuclein, ITGB2, RUNX3, Ephrin-B receptor 6",7.402E-03,2.991E-02,6,"Follistatin, Keratin 17, Alpha-synuclein, ITGB2, RUNX3, Ephrin-B receptor 6",
483,Noise-induced hair cell death and spiral ganglion neuron degeneration,96,7.486E-03,2.167E-02,7.486E-03,2.167E-02,13,"BAD, STAT3, COX-2 (PTGS2), IL-1 beta, IL-6, AMPK gamma subunit, iNOS, CCL2, Caspase-8, p53, ERM proteins, Actin, F-Actin cytoskeleton",2.364E-01,3.874E-01,8,"COX-2 (PTGS2), IL-1 beta, IL-6, AMPK gamma subunit, iNOS, CCL2, ERM proteins, Actin",
484,Dysregulation of germinal center response in SLE,65,7.486E-03,2.167E-02,7.486E-03,2.167E-02,10,"STAT3, IL-15, MFGE8, IL-15RA, TLR7, C3dg, alpha-4/beta-1 integrin, ICAM1, BOB1, PI3K cat class IA (p110-delta)",1.724E-02,5.605E-02,9,"IL-15, MFGE8, IL-15RA, TLR7, C3dg, alpha-4/beta-1 integrin, ICAM1, BOB1, PI3K cat class IA (p110-delta)",
485,Substance P-mediated inflammation and pain in Sickle cell disease,38,7.604E-03,2.540E-02,9.068E-03,2.540E-02,7,"IL-1 beta, IL-6, CD14, alpha-4/beta-1 integrin, Tissue factor, ICAM1, IL-8",7.604E-03,3.019E-02,7,"IL-1 beta, IL-6, CD14, alpha-4/beta-1 integrin, Tissue factor, ICAM1, IL-8",
486,Development_Schema: Osteogenic and adipogenic differentiation of mesenchymal stem cells,21,7.694E-03,2.490E-02,8.835E-03,2.490E-02,5,"RUNX2, BMP6, Beta-adrenergic receptor, BMP4, BMP2",7.694E-03,3.046E-02,5,"RUNX2, BMP6, Beta-adrenergic receptor, BMP4, BMP2",
487,Immune response_Inhibitory action of Lipoxins on pro-inflammatory TNF-alpha signaling,46,7.731E-03,2.224E-02,7.731E-03,2.224E-02,8,"STAT3, IL-1 beta, IL-6, TNF-R2, PI3K cat class IA, AKT(PKB), IL-8, Cyclin E",2.114E-02,6.572E-02,7,"IL-1 beta, IL-6, TNF-R2, PI3K cat class IA, AKT(PKB), IL-8, Cyclin E",
488,EGFR signaling in Prostate Cancer,46,7.731E-03,2.224E-02,7.731E-03,2.224E-02,8,"STAT3, PI3K cat class IA, TGF-alpha, ERK2 (MAPK1), AKT(PKB), Caveolin-1, EGFR, ERK1/2",1.499E-01,2.774E-01,5,"PI3K cat class IA, TGF-alpha, AKT(PKB), Caveolin-1, EGFR",
489,Dual function of Treg cells in cancer development,46,7.731E-03,2.224E-02,7.731E-03,2.224E-02,8,"STAT3, COX-2 (PTGS2), IL-6, Beta-catenin, 5'-NTD, ETS1, WNT, Neuropilin-1",6.084E-02,1.461E-01,6,"COX-2 (PTGS2), IL-6, 5'-NTD, ETS1, WNT, Neuropilin-1",
490,IL-6 signaling in colorectal cancer,37,7.815E-03,2.243E-02,7.815E-03,2.243E-02,7,"STAT3, IL-6, TNF-R2, ICAM1, p53, Cyclin E, TGF-beta receptor type II",7.394E-02,1.684E-01,5,"IL-6, TNF-R2, ICAM1, Cyclin E, TGF-beta receptor type II",
491,Nociception_Nociceptin receptor signaling,76,8.194E-03,2.347E-02,8.194E-03,2.347E-02,11,"STAT3, cPKC (conventional), G-protein alpha-15, PKC, PKC-alpha, Kir3.4, cPLA2, Actin, G-protein alpha-i family, Adenylate cyclase, ERK1/2",4.256E-02,1.139E-01,9,"cPKC (conventional), G-protein alpha-15, PKC, PKC-alpha, Kir3.4, cPLA2, Actin, G-protein alpha-i family, Adenylate cyclase",
492,Regulation of Beta-catenin activity in colorectal cancer,56,8.223E-03,2.351E-02,8.223E-03,2.351E-02,9,"PGE2R2, PGE2R4, Beta-catenin, PI3K cat class IA, SNAIL1, DVL-3, AKT(PKB), Adenylate cyclase, ERK1/2",2.595E-01,4.157E-01,5,"PGE2R2, PGE2R4, PI3K cat class IA, AKT(PKB), Adenylate cyclase",
493,Common mechanisms of Th17 cell migration,48,8.256E-03,2.747E-02,1.000E-02,2.747E-02,8,"MCAM, CCL20, alpha-4/beta-1 integrin, ICAM1, CCL2, I-TAC, G-protein alpha-i family, CCL7",8.256E-03,3.250E-02,8,"MCAM, CCL20, alpha-4/beta-1 integrin, ICAM1, CCL2, I-TAC, G-protein alpha-i family, CCL7",
494,Oxidative stress_ROS-induced cellular signaling,108,8.267E-03,2.359E-02,8.267E-03,2.359E-02,14,"GSTP1, Syk, COX-2 (PTGS2), IL-1 beta, IL-6, NOXA, iNOS, PKC, HES5, AKT(PKB), p53, IL-8, Carbonic anhydrase IX, ERK1/2",3.295E-02,9.407E-02,12,"GSTP1, Syk, COX-2 (PTGS2), IL-1 beta, IL-6, NOXA, iNOS, PKC, HES5, AKT(PKB), IL-8, Carbonic anhydrase IX",
495,Type 2 diabetes (general schema),14,8.606E-03,2.676E-02,9.667E-03,2.676E-02,4,"IL-1 beta, IL-6, POMC, CCL2",8.606E-03,3.349E-02,4,"IL-1 beta, IL-6, POMC, CCL2",
496,Immune response_Fc gamma R-mediated phagocytosis in macrophages,47,8.812E-03,2.489E-02,8.812E-03,2.489E-02,8,"Syk, Myosin II, Actin cytoskeletal, PI3K cat class IA, Fc gamma RII alpha, PKC-alpha, Lyn, F-Actin cytoskeleton",1.599E-01,2.907E-01,5,"Syk, PI3K cat class IA, Fc gamma RII alpha, PKC-alpha, Lyn",
497,Mitogenic action of ESR1 (membrane) in breast cancer,47,8.812E-03,2.489E-02,8.812E-03,2.489E-02,8,"SGK1, ERK2 (MAPK1), AKT(PKB), Cyclin E, EGFR, MMP-9, ERK1/2, MMP-2",6.629E-02,1.557E-01,6,"SGK1, AKT(PKB), Cyclin E, EGFR, MMP-9, MMP-2",
498,Canonical Leptin pathways in breast cancer,47,8.812E-03,2.489E-02,8.812E-03,2.489E-02,8,"STAT3, IL-1 beta, Beta-catenin, PI3K cat class IA, AKT(PKB), IRS-2, Tcf(Lef), ERK1/2",1.599E-01,2.907E-01,5,"IL-1 beta, PI3K cat class IA, AKT(PKB), IRS-2, Tcf(Lef)",
499,Apoptosis and survival_NGF/ TrkA PI3K-mediated signaling,77,9.028E-03,2.539E-02,9.028E-03,2.539E-02,11,"BAD, NGF, Myosin II, Actin cytoskeletal, PI3K cat class IA, AKT(PKB), MSN (moesin), ARAP3, CLCN4, MRLC, ERK1/2",1.932E-01,3.339E-01,7,"NGF, PI3K cat class IA, AKT(PKB), MSN (moesin), ARAP3, CLCN4, MRLC",
500,Cell cycle_Regulation of G1/S transition (part 1),38,9.068E-03,2.540E-02,9.068E-03,2.540E-02,7,"p15, TGF-beta 2, SMAD3, p16INK4, Cyclin E, TGF-beta receptor type II, CDK6",2.699E-02,7.973E-02,6,"p15, TGF-beta 2, p16INK4, Cyclin E, TGF-beta receptor type II, CDK6",
501,Immune response_Role of PKR in stress-induced antiviral cell response,57,9.231E-03,2.570E-02,9.231E-03,2.570E-02,9,"IL-1 beta, IL-6, Caspase-8, TLR3, IL-8, IFN-beta, TLR4, TLR2, ERK1/2",5.882E-02,1.428E-01,7,"IL-1 beta, IL-6, TLR3, IL-8, IFN-beta, TLR4, TLR2",
502,CCR7 signaling pathways in dendritic cells in allergic contact dermatitis,57,9.231E-03,2.570E-02,9.231E-03,2.570E-02,9,"Myosin II, Actin cytoskeletal, Rac2, AKT(PKB), alpha-4/beta-1 integrin, ICAM1, Fibronectin, G-protein alpha-i family, ERK1/2",1.356E-01,2.587E-01,6,"Rac2, AKT(PKB), alpha-4/beta-1 integrin, ICAM1, Fibronectin, G-protein alpha-i family",
503,Signal transduction_Angiotensin II signaling via Beta-arrestin,57,9.231E-03,2.570E-02,9.231E-03,2.570E-02,9,"BAD, DGK, TRPC3, AKT(PKB), MYLK1, EGFR, MLCK, MRLC, ERK1/2",5.882E-02,1.428E-01,7,"DGK, TRPC3, AKT(PKB), MYLK1, EGFR, MLCK, MRLC",
504,Ligand-independent activation of Androgen receptor in Prostate Cancer,67,9.257E-03,2.572E-02,9.257E-03,2.572E-02,10,"STAT3, Beta-catenin, PI3K cat class IA, FGF2, ERK2 (MAPK1), AKT(PKB), Tcf(Lef), EGFR, Frizzled, IBP3",1.158E-01,2.322E-01,7,"PI3K cat class IA, FGF2, AKT(PKB), Tcf(Lef), EGFR, Frizzled, IBP3",
505,Development_H3K9 demethylases in pluripotency maintenance of stem cells,22,9.463E-03,2.927E-02,1.085E-02,2.927E-02,5,"ZFP57, AKT(PKB), Oct-3/4, CDX2, LBP9",9.463E-03,3.580E-02,5,"ZFP57, AKT(PKB), Oct-3/4, CDX2, LBP9",
506,IL-6 signaling in tumor-associated monocytes/macrophages in breast cancer,14,9.667E-03,2.676E-02,9.667E-03,2.676E-02,4,"STAT3, IL-6, Fra-1, MMP-9",5.054E-02,1.264E-01,3,"IL-6, Fra-1, MMP-9",
507,Signal transduction_Angiotensin II/ AGTR1 signaling via RhoA and JNK,78,9.927E-03,2.742E-02,9.927E-03,2.742E-02,11,"RECK, CTGF, G-protein alpha-q/11, CCL2, MMP-9, TLR4, MLCK, MRLC, ERK1/2, MMP-2, Collagen III",2.057E-02,6.454E-02,10,"RECK, CTGF, G-protein alpha-q/11, CCL2, MMP-9, TLR4, MLCK, MRLC, MMP-2, Collagen III",
508,Immune response_IL-12 signaling pathway,48,1.000E-02,2.747E-02,1.000E-02,2.747E-02,8,"STAT3, PI3K cat class IA, Lck, iNOS, AKT(PKB), RUNX3, STAT4, ERM",7.202E-02,1.654E-01,6,"PI3K cat class IA, iNOS, AKT(PKB), RUNX3, STAT4, ERM",
509,Development_Role of Thyroid hormone in regulation of oligodendrocyte differentiation,48,1.000E-02,2.747E-02,1.000E-02,2.747E-02,8,"p15, NGF, Myelin basic protein, p14ARF, PDGF-R-alpha, AKT(PKB), ID4, p53",2.618E-02,7.853E-02,7,"p15, NGF, Myelin basic protein, p14ARF, PDGF-R-alpha, AKT(PKB), ID4",
510,"Immune response_Mast cell proliferation, differentiation and survival",30,1.027E-02,2.814E-02,1.027E-02,2.814E-02,6,"STAT3, Syk, Fyn, AKT(PKB), Lyn, ERK1/2",1.092E-01,2.213E-01,4,"Syk, Fyn, AKT(PKB), Lyn",
511,Development_Negative regulation of WNT/Beta-catenin signaling in the nucleus,89,1.031E-02,2.814E-02,1.031E-02,2.814E-02,12,"Beta-catenin, RUNX3, HIC5, Oct-3/4, Tcf(Lef), Dsh, WNT, CDX2, TCF7 (TCF1), CDX1, Frizzled, DACT1",4.581E-02,1.188E-01,10,"RUNX3, HIC5, Oct-3/4, Tcf(Lef), WNT, CDX2, TCF7 (TCF1), CDX1, Frizzled, DACT1",
512,"Immune response_TLR5, TLR7, TLR8 and TLR9 signaling pathways",58,1.033E-02,2.814E-02,1.033E-02,2.814E-02,9,"STAT3, IL-1 beta, IL-6, PI3K cat class IA, TLR7, AKT(PKB), IL-8, IFN-beta, ERK1/2",6.352E-02,1.510E-01,7,"IL-1 beta, IL-6, PI3K cat class IA, TLR7, AKT(PKB), IL-8, IFN-beta",
513,Hyaluronic acid/ CD44 signaling in cancer,58,1.033E-02,2.814E-02,1.033E-02,2.814E-02,9,"STAT3, Ankyrin 1, HOXD10, Actin cytoskeletal, ERK2 (MAPK1), Collagen IV, CD44, MMP-9, MDR1",1.439E-01,2.712E-01,6,"Ankyrin 1, HOXD10, Collagen IV, CD44, MMP-9, MDR1",
514,Development_Regulation of endothelial progenitor cell differentiation from adult stem cells,60,1.045E-02,3.361E-02,1.282E-02,3.361E-02,9,"Angiopoietin 1, TIE2, PI3K cat class IA, AKT(PKB), CSF1, alpha-4/beta-1 integrin, ICAM1, MMP-9, G-protein alpha-i family",1.045E-02,3.822E-02,9,"Angiopoietin 1, TIE2, PI3K cat class IA, AKT(PKB), CSF1, alpha-4/beta-1 integrin, ICAM1, MMP-9, G-protein alpha-i family",
515,Signal transduction_Leptin signaling via JAK/STAT and MAPK cascade,39,1.046E-02,2.845E-02,1.046E-02,2.845E-02,7,"STAT3, POMC, cPLA2, NT/NN, MMP-9, BMP2, ERK1/2",8.852E-02,1.926E-01,5,"POMC, cPLA2, NT/NN, MMP-9, BMP2",
516,EGF- and HGF-dependent stimulation of metastasis in gastric cancer,22,1.085E-02,2.927E-02,1.085E-02,2.927E-02,5,"HGF, HGF receptor (Met), EGFR, PLAU (UPA), ERK1/2",4.264E-02,1.139E-01,4,"HGF, HGF receptor (Met), EGFR, PLAU (UPA)",
517,Ubiquitin-proteasome system in Huntington's disease,22,1.085E-02,2.927E-02,1.085E-02,2.927E-02,5,"PSMB9, PKC-alpha, p53, NR2A, NR2",4.264E-02,1.139E-01,4,"PSMB9, PKC-alpha, NR2A, NR2",
518,Immune response_IL-15 signaling via JAK-STAT cascade,22,1.085E-02,2.927E-02,1.085E-02,2.927E-02,5,"STAT3, Syk, IL-15, sIL-15RA, IL-15RA",4.264E-02,1.139E-01,4,"Syk, IL-15, sIL-15RA, IL-15RA",
519,Immune response_Regulatory role of C1q in platelet activation,15,1.117E-02,3.330E-02,1.253E-02,3.330E-02,4,"PKC, Fc gamma RII alpha, C3b, Collagen III",1.117E-02,4.026E-02,4,"PKC, Fc gamma RII alpha, C3b, Collagen III",
520,Stem cells_Aberrant Hedgehog signaling in medulloblastoma stem cells,15,1.117E-02,3.330E-02,1.253E-02,3.330E-02,4,"GLI-1, SFRP1, PTCH1, GLI-2",1.117E-02,4.026E-02,4,"GLI-1, SFRP1, PTCH1, GLI-2",
521,Development_Melanocyte development and pigmentation,49,1.131E-02,3.028E-02,1.131E-02,3.028E-02,8,"Beta-catenin, SOX10, PI3K cat class IA, AKT(PKB), ACTH, alpha-MSH, Frizzled, ERK1/2",7.803E-02,1.764E-01,6,"SOX10, PI3K cat class IA, AKT(PKB), ACTH, alpha-MSH, Frizzled",
522,Transcription_CREB signaling pathway,49,1.131E-02,3.028E-02,1.131E-02,3.028E-02,8,"CDO1, cPKC (conventional), PI3K cat class IA, Galpha(s)-specific amine GPCRs, AKT(PKB), PKC-alpha, DREAM, ERK1/2",2.898E-02,8.507E-02,7,"CDO1, cPKC (conventional), PI3K cat class IA, Galpha(s)-specific amine GPCRs, AKT(PKB), PKC-alpha, DREAM",
523,Development_PEDF signaling,49,1.131E-02,3.028E-02,1.131E-02,3.028E-02,8,"IL-1 beta, IL-6, NGF, c-IAP2, PI3K cat class IA, AKT(PKB), Fra-1, ERK1/2",2.898E-02,8.507E-02,7,"IL-1 beta, IL-6, NGF, c-IAP2, PI3K cat class IA, AKT(PKB), Fra-1",
524,Development_G-CSF signaling,49,1.131E-02,3.028E-02,1.131E-02,3.028E-02,8,"STAT3, ITGA9, c-IAP2, PI3K cat class IA, AKT(PKB), Lyn, ERK1/2, GFI-1",7.803E-02,1.764E-01,6,"ITGA9, c-IAP2, PI3K cat class IA, AKT(PKB), Lyn, GFI-1",
525,Stem cells_MMP-14-induced COX-2 expression in glioblastoma stem cells,23,1.149E-02,3.404E-02,1.315E-02,3.404E-02,5,"COX-2 (PTGS2), AKT(PKB), cPLA2, MMP-14, MMP-2",1.149E-02,4.077E-02,5,"COX-2 (PTGS2), AKT(PKB), cPLA2, MMP-14, MMP-2",
526,Translation_Opioid receptors in regulation of translation ,23,1.149E-02,3.404E-02,1.315E-02,3.404E-02,5,"Metenkefalin, AKT(PKB), Leu-enkephalin, G-protein alpha-i family, Kappa-type opioid receptor",1.149E-02,4.077E-02,5,"Metenkefalin, AKT(PKB), Leu-enkephalin, G-protein alpha-i family, Kappa-type opioid receptor",
527,Development_Delta- and kappa-type opioid receptors signaling via beta-arrestin,23,1.149E-02,3.404E-02,1.315E-02,3.404E-02,5,"Metenkefalin, PKC, Leu-enkephalin, G-protein alpha-i family, Kappa-type opioid receptor",1.149E-02,4.077E-02,5,"Metenkefalin, PKC, Leu-enkephalin, G-protein alpha-i family, Kappa-type opioid receptor",
528,Role of IL-17-producing T cells in allergic contact dermatitis,23,1.149E-02,3.404E-02,1.315E-02,3.404E-02,5,"IL-6, MHC class II, GRO-1, ICAM1, IL-8",1.149E-02,4.077E-02,5,"IL-6, MHC class II, GRO-1, ICAM1, IL-8",
529,IL-6 signaling in Prostate Cancer,40,1.201E-02,3.208E-02,1.201E-02,3.208E-02,7,"STAT3, IL-6, BMX, PI3K cat class IA, ERK2 (MAPK1), AKT(PKB), Pim-1",9.633E-02,2.023E-01,5,"IL-6, BMX, PI3K cat class IA, AKT(PKB), Pim-1",
530,Neutrophil adhesion and transendothelial migration in asthma,31,1.207E-02,3.219E-02,1.207E-02,3.219E-02,6,"alpha-4/beta-1 integrin, ICAM1, alpha-9/beta-1 integrin, IL-8, cPLA2, ERK1/2",3.881E-02,1.066E-01,5,"alpha-4/beta-1 integrin, ICAM1, alpha-9/beta-1 integrin, IL-8, cPLA2",
531,Modulation of tumor response to cytotoxic T cells by hypoxia in tumors,50,1.274E-02,3.352E-02,1.274E-02,3.352E-02,8,"STAT3, 5'-NTD, CD137 ligand(TNFSF9), HOXA1, AKT(PKB), CD137(TNFRSF9), ERK1/2, PD-L1",8.431E-02,1.846E-01,6,"5'-NTD, CD137 ligand(TNFSF9), HOXA1, AKT(PKB), CD137(TNFRSF9), PD-L1",
532,Development_GM-CSF signaling,50,1.274E-02,3.352E-02,1.274E-02,3.352E-02,8,"BAD, STAT3, PI3K cat class IA, AKT(PKB), CCL2, Lyn, Pim-1, ERK1/2",1.912E-01,3.310E-01,5,"PI3K cat class IA, AKT(PKB), CCL2, Lyn, Pim-1",
533,Proteases and EGFR-activated mucin production in airway epithelium in COPD,50,1.274E-02,3.352E-02,1.274E-02,3.352E-02,8,"PPARGC1 (PGC1-alpha), PI3K cat class IA, TGF-alpha, AKT(PKB), CD44, EGFR, MMP-9, ERK1/2",3.198E-02,9.151E-02,7,"PPARGC1 (PGC1-alpha), PI3K cat class IA, TGF-alpha, AKT(PKB), CD44, EGFR, MMP-9",
534,Immune response_C5a signaling,50,1.274E-02,3.352E-02,1.274E-02,3.352E-02,8,"BAD, IL-1 beta, Rac2, PKC, AKT(PKB), IL-8, G-protein alpha-i family, ERK1/2",8.431E-02,1.846E-01,6,"IL-1 beta, Rac2, PKC, AKT(PKB), IL-8, G-protein alpha-i family",
535,Signal transduction_CXCR4 signaling via second messengers and JAK/STAT,50,1.274E-02,3.352E-02,1.274E-02,3.352E-02,8,"STAT3, alpha-1 Adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1B adrenergic receptor, G-protein alpha-i family, Adenylate cyclase, MLCK, MRLC",3.198E-02,9.151E-02,7,"alpha-1 Adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1B adrenergic receptor, G-protein alpha-i family, Adenylate cyclase, MLCK, MRLC",
536,IGF family signaling in colorectal cancer,60,1.282E-02,3.361E-02,1.282E-02,3.361E-02,9,"COX-2 (PTGS2), Beta-catenin, ERK2 (MAPK1), AKT(PKB), IRS-2, IL-8, IBP, ERK1/2, IBP3",1.613E-01,2.921E-01,6,"COX-2 (PTGS2), AKT(PKB), IRS-2, IL-8, IBP, IBP3",
537,Cytoskeleton remodeling_ESR1 action on cytoskeleton remodeling and cell migration,23,1.315E-02,3.404E-02,1.315E-02,3.404E-02,5,"PI3K cat class IA, AKT(PKB), MSN (moesin), ERM proteins, F-Actin cytoskeleton",4.920E-02,1.246E-01,4,"PI3K cat class IA, AKT(PKB), MSN (moesin), ERM proteins",
538,FGF signaling in gastric cancer,23,1.315E-02,3.404E-02,1.315E-02,3.404E-02,5,"Beta-catenin, FGF2, ERK2 (MAPK1), MMP-9, PLAU (UPA)",1.647E-01,2.953E-01,3,"FGF2, MMP-9, PLAU (UPA)",
539,Role of Leptin in regulation of eating behavior in obesity,23,1.315E-02,3.404E-02,1.315E-02,3.404E-02,5,"NPY, STAT3, POMC, AKT(PKB), ERK1/2",1.647E-01,2.953E-01,3,"NPY, POMC, AKT(PKB)",
540,Role of Bregs in attenuation of T and NK cells mediated anti-tumor immune responses,41,1.371E-02,3.528E-02,1.371E-02,3.528E-02,7,"STAT3, 5'-NTD, Lck, SMAD3, CD1d, TGF-beta receptor type II, PD-L1",2.427E-01,3.945E-01,4,"5'-NTD, CD1d, TGF-beta receptor type II, PD-L1",
541,Main growth factor signaling cascades in multiple myeloma cells,41,1.371E-02,3.528E-02,1.371E-02,3.528E-02,7,"BAD, STAT3, PI3K cat class IA, FGF2, ERK2 (MAPK1), AKT(PKB), IRS-2",2.427E-01,3.945E-01,4,"PI3K cat class IA, FGF2, AKT(PKB), IRS-2",
542,Cytoskeleton remodeling_Role of PKA in cytoskeleton reorganisation,41,1.371E-02,3.528E-02,1.371E-02,3.528E-02,7,"Actin cytoskeletal, Beta adducin, alpha-4/beta-1 integrin, MELC, Adenylate cyclase, F-Actin cytoskeleton, MLCK",1.045E-01,2.146E-01,5,"Beta adducin, alpha-4/beta-1 integrin, MELC, Adenylate cyclase, MLCK",
543,Cytoskeleton remodeling_Reverse signaling by Ephrin-B,32,1.408E-02,3.610E-02,1.408E-02,3.610E-02,6,"Beta-catenin, Actin cytoskeletal, F-Actin, Ephrin-B receptors, G-protein alpha-i family, PINCH-2",3.135E-01,4.750E-01,3,"Ephrin-B receptors, G-protein alpha-i family, PINCH-2",
544,Activation of ACTH production in pituitary gland in major depressive disorder,32,1.408E-02,3.610E-02,1.408E-02,3.610E-02,6,"STAT3, IL-1 beta, IL-6, POMC, TNF-R2, ACTH",4.376E-02,1.157E-01,5,"IL-1 beta, IL-6, POMC, TNF-R2, ACTH",
545,Immune response_IL-9 signaling pathway,61,1.422E-02,3.638E-02,1.422E-02,3.638E-02,9,"STAT3, PI3K cat class IA, MC-CPA, AKT(PKB), IRS-2, CCL2, Pim-1, ERK1/2, CCL7",7.896E-02,1.775E-01,7,"PI3K cat class IA, MC-CPA, AKT(PKB), IRS-2, CCL2, Pim-1, CCL7",
546,Inflammatory factors-induced expression of mucins in normal and asthmatic epithelium,51,1.429E-02,3.638E-02,1.429E-02,3.638E-02,8,"COX-2 (PTGS2), Histamine H1 receptor, IL-1 beta, IL-6, C3a, IL-8, ALOX5, ERK1/2",3.518E-02,9.860E-02,7,"COX-2 (PTGS2), Histamine H1 receptor, IL-1 beta, IL-6, C3a, IL-8, ALOX5",
547,Development_Oligodendrocyte differentiation from adult stem cells,51,1.429E-02,3.638E-02,1.429E-02,3.638E-02,8,"Myelin basic protein, FGF2, PDGF-R-alpha, PTCH1, BMP4, BMP2, EDNRA, ERK1/2",3.518E-02,9.860E-02,7,"Myelin basic protein, FGF2, PDGF-R-alpha, PTCH1, BMP4, BMP2, EDNRA",
548,Inhibition of Calcitriol/ VDR signaling in colorectal cancer,51,1.429E-02,3.638E-02,1.429E-02,3.638E-02,8,"G0/G1switch 2, Beta-catenin, CYP27A1, Kallikrein 6 (Neurosin), SNAIL1, SLUG, CYP24A1, Kallikrein 10 (KLK10)",9.086E-02,1.937E-01,6,"G0/G1switch 2, CYP27A1, Kallikrein 6 (Neurosin), SLUG, CYP24A1, Kallikrein 10 (KLK10)",
549,Immune response_Antiviral actions of Interferons,53,1.483E-02,4.381E-02,1.781E-02,4.381E-02,8,"CIITA, IDO1, MxA, MHC class II, HLA-DRA1, iNOS, HLA-A, IFN-beta",1.483E-02,4.987E-02,8,"CIITA, IDO1, MxA, MHC class II, HLA-DRA1, iNOS, HLA-A, IFN-beta",
550,Role of Insulin in regulation of eating behavior in obesity,43,1.490E-02,4.365E-02,1.761E-02,4.365E-02,7,"NPY, POMC, PKC-theta, AKT(PKB), IRS-2, TLR4, Acyl-CoA synthetase",1.490E-02,4.987E-02,7,"NPY, POMC, PKC-theta, AKT(PKB), IRS-2, TLR4, Acyl-CoA synthetase",
551,"Oxidative stress_Activation of NOX1, NOX5, DUOX1 and DUOX2 NADPH Oxidases",42,1.557E-02,3.957E-02,1.557E-02,3.957E-02,7,"DUOX2, cPKC (conventional), Rac2, PKC, ERK2 (MAPK1), PKC-alpha, DUOXA1",4.177E-02,1.133E-01,6,"DUOX2, cPKC (conventional), Rac2, PKC, PKC-alpha, DUOXA1",
552,Development_WNT/Beta-catenin signaling in the nucleus,62,1.572E-02,3.981E-02,1.572E-02,3.981E-02,9,"Beta-catenin, SNAIL1, MEF2, Tcf(Lef), RUNX, Dsh, WNT, TCF7 (TCF1), Frizzled",1.794E-01,3.149E-01,6,"MEF2, Tcf(Lef), RUNX, WNT, TCF7 (TCF1), Frizzled",
553,Development_Alpha-2 adrenergic receptor activation of ERK,62,1.572E-02,3.981E-02,1.572E-02,3.981E-02,9,"G-protein alpha-i1, PI3K cat class IA, ERK2 (MAPK1), AKT(PKB), ADAM12, cPLA2, EGFR, G-protein alpha-i family, ERK1/2",8.454E-02,1.848E-01,7,"G-protein alpha-i1, PI3K cat class IA, AKT(PKB), ADAM12, cPLA2, EGFR, G-protein alpha-i family",
554,Development_Endothelin-1/EDNRA signaling,52,1.598E-02,4.031E-02,1.598E-02,4.031E-02,8,"Beta-catenin, PI3K cat class IA, AKT(PKB), G-protein alpha-q/11, G-protein alpha-i family, Adenylate cyclase, EDNRA, ERK1/2",9.768E-02,2.037E-01,6,"PI3K cat class IA, AKT(PKB), G-protein alpha-q/11, G-protein alpha-i family, Adenylate cyclase, EDNRA",
555,Signal transduction_Activation of PKC via G-Protein coupled receptor,52,1.598E-02,4.031E-02,1.598E-02,4.031E-02,8,"MEF2, PKC-theta, CPI-17, G-protein alpha-q/11, MELC, PKC-alpha, MLCK, ERK1/2",3.859E-02,1.066E-01,7,"MEF2, PKC-theta, CPI-17, G-protein alpha-q/11, MELC, PKC-alpha, MLCK",
556,p53 signaling in Prostate Cancer,33,1.631E-02,4.084E-02,1.631E-02,4.084E-02,6,"NOXA, PI3K cat class IA, AKT(PKB), p53 (mitochondrial), p53, IBP3",1.417E-01,2.681E-01,4,"NOXA, PI3K cat class IA, AKT(PKB), IBP3",
557,SDF-1 axis in endothelial progenitor cell recruitment in healing myocardial infarction,33,1.631E-02,4.084E-02,1.631E-02,4.084E-02,6,"Angiopoietin 1, TIE2, Rac2, ERK2 (MAPK1), AKT(PKB), ICAM1",4.907E-02,1.246E-01,5,"Angiopoietin 1, TIE2, Rac2, AKT(PKB), ICAM1",
558,Chemotaxis_CCL19- and CCL21-mediated chemotaxis,33,1.631E-02,4.084E-02,1.631E-02,4.084E-02,6,"PGE2R2, PGE2R4, MMP-9, G-protein alpha-i family, Adenylate cyclase, ERK1/2",4.907E-02,1.246E-01,5,"PGE2R2, PGE2R4, MMP-9, G-protein alpha-i family, Adenylate cyclase",
559,Signal transduction_Activin A signaling regulation,33,1.631E-02,4.084E-02,1.631E-02,4.084E-02,6,"Follistatin, MECOM, SMAD3, Activin A, FKHL1, DLX1",4.907E-02,1.246E-01,5,"Follistatin, MECOM, Activin A, FKHL1, DLX1",
560,Zinc deficiency in Prostate Cancer,25,1.640E-02,4.514E-02,1.871E-02,4.514E-02,5,"IL-6, c-IAP2, ICAM1, IL-8, MMP-9",1.640E-02,5.383E-02,5,"IL-6, c-IAP2, ICAM1, IL-8, MMP-9",
561,Role of keratinocytes and Langerhans cells in skin sensitization,25,1.640E-02,4.514E-02,1.871E-02,4.514E-02,5,"IL-1 beta, TNF-R2, IL-18R1, MHC class II, Caspase-1",1.640E-02,5.383E-02,5,"IL-1 beta, TNF-R2, IL-18R1, MHC class II, Caspase-1",
562,Neurophysiological process_Constitutive and regulated NMDA receptor trafficking,65,1.724E-02,5.005E-02,2.095E-02,5.005E-02,9,"cPKC (conventional), Fyn, KIF17, PKC, NR2A, NR2, PACAP, G-protein alpha-i family, Adenylate cyclase",1.724E-02,5.605E-02,9,"cPKC (conventional), Fyn, KIF17, PKC, NR2A, NR2, PACAP, G-protein alpha-i family, Adenylate cyclase",
563,Development_ACM2 and ACM4 activation of ERK,43,1.761E-02,4.365E-02,1.761E-02,4.365E-02,7,"ACM4, Caldesmon, Fyn, PKC-alpha, EGFR, G-protein alpha-i family, ERK1/2",4.613E-02,1.188E-01,6,"ACM4, Caldesmon, Fyn, PKC-alpha, EGFR, G-protein alpha-i family",
564,HGF receptor (Met) and MSP receptor (RON) signaling pathways in SCLC,43,1.761E-02,4.365E-02,1.761E-02,4.365E-02,7,"STAT3, HGF, PI3K cat class IA, FGF2, AKT(PKB), HGF receptor (Met), ERK1/2",1.217E-01,2.379E-01,5,"HGF, PI3K cat class IA, FGF2, AKT(PKB), HGF receptor (Met)",
565,ESR1 (membrane) 36 kDa isoform signaling in breast cancer,43,1.761E-02,4.365E-02,1.761E-02,4.365E-02,7,"PI3K cat class IA, SNAIL1, AKT(PKB), PKC-alpha, EGFR, ERK1/2, AL1A1",1.217E-01,2.379E-01,5,"PI3K cat class IA, AKT(PKB), PKC-alpha, EGFR, AL1A1",
566,Nicotine / nAChR alpha-7 signaling in NSCLC,43,1.761E-02,4.365E-02,1.761E-02,4.365E-02,7,"nAChR alpha-7, PI3K cat class IA, AKT(PKB), PKC-alpha, Fibronectin, Cyclin E, ERK1/2",4.613E-02,1.188E-01,6,"nAChR alpha-7, PI3K cat class IA, AKT(PKB), PKC-alpha, Fibronectin, Cyclin E",
567,Role of epigenetic alterations in survival and migration of SCLC cells,43,1.761E-02,4.365E-02,1.761E-02,4.365E-02,7,"Laminin 5, LAMC2, LAMB3, Caspase-8, HGF receptor (Met), Connexin 26, LAMA3 (Epiligrin)",4.613E-02,1.188E-01,6,"Laminin 5, LAMC2, LAMB3, HGF receptor (Met), Connexin 26, LAMA3 (Epiligrin)",
568,Regulation of VEGF expression in lung cancer,53,1.781E-02,4.381E-02,1.781E-02,4.381E-02,8,"STAT3, COX-2 (PTGS2), IL-1 beta, IL-6, PI3K cat class IA, AKT(PKB), ERK1/2, MMP-2",1.048E-01,2.146E-01,6,"COX-2 (PTGS2), IL-1 beta, IL-6, PI3K cat class IA, AKT(PKB), MMP-2",
569,Signal transduction_CXCR4 signaling via MAPKs cascades,53,1.781E-02,4.381E-02,1.781E-02,4.381E-02,8,"BAD, IL-6, PAK, SMAD3, CTGF, GAD1, G-protein alpha-i family, ERK1/2",2.246E-01,3.748E-01,5,"IL-6, PAK, CTGF, GAD1, G-protein alpha-i family",
570,Proliferative action of Gastrin in gastric cancer,53,1.781E-02,4.381E-02,1.781E-02,4.381E-02,8,"Beta-catenin, cPKC (conventional), PI3K cat class IA, PKC, G-protein alpha-q/11, PKC-alpha, EGFR, ERK1/2",1.048E-01,2.146E-01,6,"cPKC (conventional), PI3K cat class IA, PKC, G-protein alpha-q/11, PKC-alpha, EGFR",
571,Immune response_Inflammasome in inflammatory response,35,1.852E-02,5.103E-02,2.147E-02,5.103E-02,6,"CARD7, IL-1 beta, Caspase-5, Biglycan, Caspase-1, TLR4",1.852E-02,5.964E-02,6,"CARD7, IL-1 beta, Caspase-5, Biglycan, Caspase-1, TLR4",
572,Role of Nicotine-induced Leptin resistance in hypothalamus in development of obesity,25,1.871E-02,4.514E-02,1.871E-02,4.514E-02,5,"NPY, STAT3, POMC, AKT(PKB), ERK1/2",1.961E-01,3.359E-01,3,"NPY, POMC, AKT(PKB)",
573,IGF-1 receptor/EGFR cooperation in lung cancer,25,1.871E-02,4.514E-02,1.871E-02,4.514E-02,5,"BAD, PI3K cat class IA, AKT(PKB), IRS-2, EGFR",6.387E-02,1.510E-01,4,"PI3K cat class IA, AKT(PKB), IRS-2, EGFR",
574,Apoptosis and survival_Apoptotic Activin A signaling,25,1.871E-02,4.514E-02,1.871E-02,4.514E-02,5,"SMAD3, ERK2 (MAPK1), AKT(PKB), Activin A, p53",4.598E-01,6.237E-01,2,"AKT(PKB), Activin A",
575,Development_Trophectoderm differentiation,25,1.871E-02,4.514E-02,1.871E-02,4.514E-02,5,"P-cadherin, SMAD3, Oct-3/4, CDX2, BMP4",6.387E-02,1.510E-01,4,"P-cadherin, Oct-3/4, CDX2, BMP4",
576,A proinflammatory phenotype of senescent alveolar epithelial cells in COPD,25,1.871E-02,4.514E-02,1.871E-02,4.514E-02,5,"IL-6, p53, p16INK4, IL-8, PI3K cat class IA (p110-delta)",6.387E-02,1.510E-01,4,"IL-6, p16INK4, IL-8, PI3K cat class IA (p110-delta)",
577,HBV-dependent transcription regulation leading to HCC,25,1.871E-02,4.514E-02,1.871E-02,4.514E-02,5,"PCNA, EGR2 (Krox20), IL-8, MMP-14, MMP-2",6.387E-02,1.510E-01,4,"EGR2 (Krox20), IL-8, MMP-14, MMP-2",
578,Cytoskeleton remodeling_Neurofilaments,25,1.871E-02,4.514E-02,1.871E-02,4.514E-02,5,"Tubulin beta, Nestin, Actin cytoskeletal, Alpha-internexin, Vimentin",6.387E-02,1.510E-01,4,"Tubulin beta, Nestin, Alpha-internexin, Vimentin",
579,Signal transduction_Erk Interactions: Inhibition of Erk,34,1.877E-02,4.514E-02,1.877E-02,4.514E-02,6,"Lck, PKC, ERK2 (MAPK1), AKT(PKB), PTPRR, ERK1/2",3.479E-01,5.150E-01,3,"PKC, AKT(PKB), PTPRR",
580,Development_S1P1 receptor signaling via beta-arrestin,34,1.877E-02,4.514E-02,1.877E-02,4.514E-02,6,"G-protein alpha-i1, S1P1 receptor, ERK2 (MAPK1), G-protein alpha-i family, ERK1/2, PDGF-R-beta",1.533E-01,2.806E-01,4,"G-protein alpha-i1, S1P1 receptor, G-protein alpha-i family, PDGF-R-beta",
581,Th2 cell migration in asthma,34,1.877E-02,4.514E-02,1.877E-02,4.514E-02,6,"Lck, Beta-2 adrenergic receptor, alpha-4/beta-1 integrin, ICAM1, CD44, G-protein alpha-i family",5.474E-02,1.351E-01,5,"Beta-2 adrenergic receptor, alpha-4/beta-1 integrin, ICAM1, CD44, G-protein alpha-i family",
582,Proinflammatory cytokine release from eosinophils in asthma,34,1.877E-02,4.514E-02,1.877E-02,4.514E-02,6,"IL-1 beta, IL-6, NGF, IL-8, ERK1/2, LIF",5.474E-02,1.351E-01,5,"IL-1 beta, IL-6, NGF, IL-8, LIF",
583,Development_Negative regulation of WNT/Beta-catenin signaling at the receptor level,45,1.889E-02,5.155E-02,2.225E-02,5.155E-02,7,"TIKI, LRP4, SFRP, Tcf(Lef), WNT, SOSTDC1, Frizzled",1.889E-02,6.011E-02,7,"TIKI, LRP4, SFRP, Tcf(Lef), WNT, SOSTDC1, Frizzled",
584,Cell adhesion_Ephrin signaling,45,1.889E-02,5.155E-02,2.225E-02,5.155E-02,7,"HGK(MAP4K4), Fyn, Ephrin-A receptors, Ephrin-B receptor 1, Ephrin-B receptors, Ephrin-A receptor 2, G-protein alpha-i family",1.889E-02,6.011E-02,7,"HGK(MAP4K4), Fyn, Ephrin-A receptors, Ephrin-B receptor 1, Ephrin-B receptors, Ephrin-A receptor 2, G-protein alpha-i family",
585,Differentiation of Th2 cells in asthma,45,1.889E-02,5.155E-02,2.225E-02,5.155E-02,7,"Histamine H1 receptor, MHC class II, PI3K cat class IA, CCL20, AKT(PKB), CCL2, Jagged1",1.889E-02,6.011E-02,7,"Histamine H1 receptor, MHC class II, PI3K cat class IA, CCL20, AKT(PKB), CCL2, Jagged1",
586,Role of CD8+ Tc1 cells in COPD,44,1.984E-02,4.755E-02,1.984E-02,4.755E-02,7,"STAT3, IL-15, IL-18R1, STAT4, CCL2, Cathepsin S, MMP-9",5.076E-02,1.264E-01,6,"IL-15, IL-18R1, STAT4, CCL2, Cathepsin S, MMP-9",
587,Immune response_CRTH2 signaling in Th2 cells,44,1.984E-02,4.755E-02,1.984E-02,4.755E-02,7,"BAD, PKC, AKT(PKB), ITGB2, ICAM1, G-protein alpha-i family, Adenylate cyclase",5.076E-02,1.264E-01,6,"PKC, AKT(PKB), ITGB2, ICAM1, G-protein alpha-i family, Adenylate cyclase",
588,Development_Role of IL-8 in angiogenesis,65,2.095E-02,5.005E-02,2.095E-02,5.005E-02,9,"STAT3, PI3K cat class IA, AKT(PKB), Caveolin-1, IL-8, EGFR, G-protein alpha-i family, ERK1/2, MMP-14",1.026E-01,2.128E-01,7,"PI3K cat class IA, AKT(PKB), Caveolin-1, IL-8, EGFR, G-protein alpha-i family, MMP-14",
589,Immune response_HMGB1/TLR signaling pathway,36,2.111E-02,5.577E-02,2.443E-02,5.577E-02,6,"IL-1 beta, IL-6, IL-8, IFN-beta, TLR4, TLR2",2.111E-02,6.572E-02,6,"IL-1 beta, IL-6, IL-8, IFN-beta, TLR4, TLR2",
590,Immune response_Fc epsilon RI pathway: Lyn-mediated cytokine production,87,2.141E-02,5.103E-02,2.141E-02,5.103E-02,11,"Syk, IL-1 beta, IL-6, PKC, CCL2, PKC-alpha, GRAP2, Lyn, IL-33, ERK1/2, MEF2C",4.014E-02,1.100E-01,10,"Syk, IL-1 beta, IL-6, PKC, CCL2, PKC-alpha, GRAP2, Lyn, IL-33, MEF2C",
591,Pro-oncogenic action of Androgen receptor in breast cancer,35,2.147E-02,5.103E-02,2.147E-02,5.103E-02,6,"Beta-catenin, SGK1, AKR1C3, RUNX2, TCF8, ERK1/2",1.652E-01,2.953E-01,4,"SGK1, AKR1C3, RUNX2, TCF8",
592,Cell adhesion_Role of CDK5 in cell adhesion,10,2.186E-02,5.145E-02,2.186E-02,5.145E-02,3,"Beta-catenin, ITGB1, Tcf(Lef)",1.222E-01,2.385E-01,2,"ITGB1, Tcf(Lef)",
593,Chemotaxis_CCL2-induced chemotaxis,55,2.190E-02,5.145E-02,2.190E-02,5.145E-02,8,"Actin cytoskeletal, PI3K cat class IA, PA24A, CCL2, cPLA2, Lyn, G-protein alpha-i family, ERK1/2",1.197E-01,2.373E-01,6,"PI3K cat class IA, PA24A, CCL2, cPLA2, Lyn, G-protein alpha-i family",
594,Development_WNT/Beta-catenin signaling in the cytoplasm,55,2.190E-02,5.145E-02,2.190E-02,5.145E-02,8,"Beta-catenin, SNAIL1, AKT(PKB), Nucleoredoxin, Tcf(Lef), Dsh, WNT, Frizzled",2.477E-01,4.006E-01,5,"AKT(PKB), Nucleoredoxin, Tcf(Lef), WNT, Frizzled",
595,Role of Thyroid hormone in regulation of oligodendrocyte differentiation in multiple sclerosis,55,2.190E-02,5.145E-02,2.190E-02,5.145E-02,8,"p15, NGF, Myelin basic protein, p14ARF, PDGF-R-alpha, AKT(PKB), ID4, p53",5.008E-02,1.263E-01,7,"p15, NGF, Myelin basic protein, p14ARF, PDGF-R-alpha, AKT(PKB), ID4",
596,Downregulation of MITF in melanoma,26,2.198E-02,5.145E-02,2.198E-02,5.145E-02,5,"STAT3, IL-1 beta, IL-6, SOX10, GLI-2",7.198E-02,1.654E-01,4,"IL-1 beta, IL-6, SOX10, GLI-2",
597,Development_S1P2 and S1P3 receptors in cell proliferation and differentiation,26,2.198E-02,5.145E-02,2.198E-02,5.145E-02,5,"Transgelin, ACTA2, MYH11, Actin, ERK1/2",2.123E-01,3.599E-01,3,"Transgelin, ACTA2, Actin",
598,Cell adhesion_Endothelial cell contacts by junctional mechanisms,26,2.198E-02,5.145E-02,2.198E-02,5.145E-02,5,"N-cadherin, Beta-catenin, Actin cytoskeletal, Vimentin, Claudin-1",2.123E-01,3.599E-01,3,"N-cadherin, Vimentin, Claudin-1",
599,Cell adhesion_Classical cadherin-mediated cell adhesion,26,2.198E-02,5.145E-02,2.198E-02,5.145E-02,5,"N-cadherin, Beta-catenin, Actin cytoskeletal, F-Actin, F-Actin cytoskeleton",8.079E-01,9.057E-01,1,N-cadherin,
600,Signal transduction_HTR2A-dependent arachidonic acid production,26,2.198E-02,5.145E-02,2.198E-02,5.145E-02,5,"COX-2 (PTGS2), G-protein alpha-q/11, cPLA2, G-protein alpha-i family, ERK1/2",7.198E-02,1.654E-01,4,"COX-2 (PTGS2), G-protein alpha-q/11, cPLA2, G-protein alpha-i family",
601,Regulation of relaxation of airway smooth muscle cells,45,2.225E-02,5.155E-02,2.225E-02,5.155E-02,7,"PGE2R2, PGE2R4, Beta-2 adrenergic receptor, PGD2R, PACAP, F-Actin cytoskeleton, MLCK",5.566E-02,1.365E-01,6,"PGE2R2, PGE2R4, Beta-2 adrenergic receptor, PGD2R, PACAP, MLCK",
602,Retinal ganglion cell damage in glaucoma,45,2.225E-02,5.155E-02,2.225E-02,5.155E-02,7,"BAD, NGF, NGFR(TNFRSF16), iNOS, A2M, C3, EDNRA",5.566E-02,1.365E-01,6,"NGF, NGFR(TNFRSF16), iNOS, A2M, C3, EDNRA",
603,Immune response_PGE2 signaling in immune response,45,2.225E-02,5.155E-02,2.225E-02,5.155E-02,7,"HGF, COX-2 (PTGS2), PGE2R2, PGE2R4, ERK2 (MAPK1), IL-8, Adenylate cyclase",5.566E-02,1.365E-01,6,"HGF, COX-2 (PTGS2), PGE2R2, PGE2R4, IL-8, Adenylate cyclase",
604,Th2-cytokines and IFN-mediated regulation of airway smooth muscle contraction,27,2.253E-02,5.781E-02,2.561E-02,5.781E-02,5,"Histamine H1 receptor, IRS-2, CD38, IFN-beta, PI3K cat class IA (p110-delta)",2.253E-02,6.975E-02,5,"Histamine H1 receptor, IRS-2, CD38, IFN-beta, PI3K cat class IA (p110-delta)",
605,Cell adhesion_Integrin inside-out signaling in neutrophils,77,2.327E-02,5.384E-02,2.327E-02,5.384E-02,10,"Syk, GRO-1, iNOS, ERK2 (MAPK1), ITGB2, ICAM1, CD44, IL-8, Lyn, G-protein alpha-i family",4.568E-02,1.188E-01,9,"Syk, GRO-1, iNOS, ITGB2, ICAM1, CD44, IL-8, Lyn, G-protein alpha-i family",
606,Th9 cells in asthma,47,2.356E-02,6.115E-02,2.766E-02,6.115E-02,7,"ST2(L), TGF-beta, MHC class II, CRLR, Activin A, IL-33, CCL7",2.356E-02,7.245E-02,7,"ST2(L), TGF-beta, MHC class II, CRLR, Activin A, IL-33, CCL7",
607,Main chemotherapy drugs and their action in SCLC cells,100,2.429E-02,5.577E-02,2.429E-02,5.577E-02,12,"BAD, AKT(PKB), Caveolin-1, CCL2, PKC-alpha, p53, IL-8, Cyclin E, EGFR, PLAU (UPA), MDR1, ERK1/2",1.604E-01,2.913E-01,9,"AKT(PKB), Caveolin-1, CCL2, PKC-alpha, IL-8, Cyclin E, EGFR, PLAU (UPA), MDR1",
608,Immune response_IL-6-induced acute-phase response in hepatocytes,36,2.443E-02,5.577E-02,2.443E-02,5.577E-02,6,"STAT3, IL-6, GRO-1, SAA1, A2M, C3",6.718E-02,1.567E-01,5,"IL-6, GRO-1, SAA1, A2M, C3",
609,Immune response_IL-22 signaling pathway,36,2.443E-02,5.577E-02,2.443E-02,5.577E-02,6,"STAT3, MHC class II, STAT4, IL22RA1, IL-22RA2, ERK1/2",1.775E-01,3.127E-01,4,"MHC class II, STAT4, IL22RA1, IL-22RA2",
610,Development_EPO-induced Jak-STAT pathway,36,2.443E-02,5.577E-02,2.443E-02,5.577E-02,6,"STAT3, c-Fes, ERK2 (MAPK1), Lyn, Pim-1, ERK1/2",3.821E-01,5.472E-01,3,"c-Fes, Lyn, Pim-1",
611,PR action in breast cancer: stimulation of cell growth and proliferation,36,2.443E-02,5.577E-02,2.443E-02,5.577E-02,6,"STAT3, Cyclin E, EGFR, MMP-9, ERK1/2, MMP-2",1.775E-01,3.127E-01,4,"Cyclin E, EGFR, MMP-9, MMP-2",
612,Microsatellite instability in colorectal cancer,36,2.443E-02,5.577E-02,2.443E-02,5.577E-02,6,"PCNA, HLA-DRA1, p53, TGF-beta receptor type II, EGFR, Ephrin-B receptor 2",1.775E-01,3.127E-01,4,"HLA-DRA1, TGF-beta receptor type II, EGFR, Ephrin-B receptor 2",
613,Inhibition of apoptosis in multiple myeloma,36,2.443E-02,5.577E-02,2.443E-02,5.577E-02,6,"STAT3, IL-6, c-IAP2, p53, Jagged1, TLR4",1.775E-01,3.127E-01,4,"IL-6, c-IAP2, Jagged1, TLR4",
614,Signal transduction_CXCR4 signaling via PI3K cascade,46,2.485E-02,5.646E-02,2.485E-02,5.646E-02,7,"BAD, IL-6, Beta-catenin, SGK1, PI3K cat class IA, AKT(PKB), G-protein alpha-i family",1.499E-01,2.774E-01,5,"IL-6, SGK1, PI3K cat class IA, AKT(PKB), G-protein alpha-i family",
615,Transcription_Hypoxia- and receptor-mediated HIF-1 activation,46,2.485E-02,5.646E-02,2.485E-02,5.646E-02,7,"STAT3, HGF, IL-1 beta, PI3K cat class IA, AKT(PKB), EGFR, ERK1/2",1.499E-01,2.774E-01,5,"HGF, IL-1 beta, PI3K cat class IA, AKT(PKB), EGFR",
616,Nociception_Expression and role of Nociceptin in immune system,46,2.485E-02,5.646E-02,2.485E-02,5.646E-02,7,"STAT3, IL-1 beta, IL-6, CCL2, TLR4, ERK1/2, LIF",1.499E-01,2.774E-01,5,"IL-1 beta, IL-6, CCL2, TLR4, LIF",
617,HCV-dependent cytoplasmic signaling leading to HCC,27,2.561E-02,5.781E-02,2.561E-02,5.781E-02,5,"BAD, PKC, ERK2 (MAPK1), AKT(PKB), ERK1/2",5.005E-01,6.664E-01,2,"PKC, AKT(PKB)",
618,Regulation of VEGF signaling in pancreatic cancer,27,2.561E-02,5.781E-02,2.561E-02,5.781E-02,5,"STAT3, Neuropilin-2, IL-6, Neuropilin-1, ERK1/2",2.287E-01,3.780E-01,3,"Neuropilin-2, IL-6, Neuropilin-1",
619,HCV-dependent regulation of membrane receptors signaling in HCC,27,2.561E-02,5.781E-02,2.561E-02,5.781E-02,5,"IL-1 beta, TGF-alpha, ERK2 (MAPK1), EGFR, ERK1/2",2.287E-01,3.780E-01,3,"IL-1 beta, TGF-alpha, EGFR",
620,Glucocorticoid- and LABA-mediated inhibition of pro-inflammatory signaling in airway fibroblasts/myofibroblasts,28,2.609E-02,6.472E-02,2.960E-02,6.472E-02,5,"IL-1 beta, IL-6, Beta-2 adrenergic receptor, ICAM1, IL-8",2.609E-02,7.852E-02,5,"IL-1 beta, IL-6, Beta-2 adrenergic receptor, ICAM1, IL-8",
621,Possible influence of low doses of Arsenite on glucose uptake in muscle,28,2.609E-02,6.472E-02,2.960E-02,6.472E-02,5,"PI3K cat class IA, PTGIS, AKT(PKB), IRS-2, MEF2C",2.609E-02,7.852E-02,5,"PI3K cat class IA, PTGIS, AKT(PKB), IRS-2, MEF2C",
622,Th1 and Th17 cells in an autoimmune mechanism of emphysema formation in smokers,28,2.609E-02,6.472E-02,2.960E-02,6.472E-02,5,"MHC class II, CCL20, CD44, Elastin, MMP-9",2.609E-02,7.852E-02,5,"MHC class II, CCL20, CD44, Elastin, MMP-9",
623,Skeletal muscle atrophy in COPD,57,2.663E-02,5.981E-02,2.663E-02,5.981E-02,8,"PPARGC1 (PGC1-alpha), iNOS, SMAD3, ERK2 (MAPK1), AKT(PKB), Vimentin, MyHC, ERK1/2",4.672E-01,6.319E-01,4,"PPARGC1 (PGC1-alpha), iNOS, AKT(PKB), Vimentin",
624,Development_Cytokine-mediated regulation of megakaryopoiesis,57,2.663E-02,5.981E-02,2.663E-02,5.981E-02,8,"STAT3, IL-1 beta, IL-6, NF-E2 (45 kDa), PI3K cat class IA, AKT(PKB), ERK1/2, LIF",1.356E-01,2.587E-01,6,"IL-1 beta, IL-6, NF-E2 (45 kDa), PI3K cat class IA, AKT(PKB), LIF",
625,Lysophospholipid mediators-induced inflammatory signaling in normal and asthmatic airway epithelium,57,2.663E-02,5.981E-02,2.663E-02,5.981E-02,8,"COX-2 (PTGS2), CCL20, AKT(PKB), IL-8, Lyn, MMP-9, G-protein alpha-i family, ERK1/2",5.882E-02,1.428E-01,7,"COX-2 (PTGS2), CCL20, AKT(PKB), IL-8, Lyn, MMP-9, G-protein alpha-i family",
626,T follicular helper cell dysfunction in SLE,90,2.683E-02,6.017E-02,2.683E-02,6.017E-02,11,"STAT3, IL-6, Fyn, MHC class II, PI3K cat class IA, TLR7, PKC-theta, AKT(PKB), A20, IFN-beta, BLIMP1 (PRDI-BF1)",4.883E-02,1.246E-01,10,"IL-6, Fyn, MHC class II, PI3K cat class IA, TLR7, PKC-theta, AKT(PKB), A20, IFN-beta, BLIMP1 (PRDI-BF1)",
627,Signal transduction_Production and main functions of biologically active prostaglandins and Thromboxane A2,59,2.694E-02,6.881E-02,3.201E-02,6.881E-02,8,"PGF2aR, COX-2 (PTGS2), PGE2R2, PGE2R4, PTGIS, AKR1C3, PGD2R, cPLA2",2.694E-02,7.973E-02,8,"PGF2aR, COX-2 (PTGS2), PGE2R2, PGE2R4, PTGIS, AKR1C3, PGD2R, cPLA2",
628,Role of type 2 innate lymphoid cells in airway allergic inflammation and tissue repair,38,2.699E-02,6.711E-02,3.113E-02,6.711E-02,6,"ST2(L), IL7RA, ETS1, EGFR, IL-33, PI3K cat class IA (p110-delta)",2.699E-02,7.973E-02,6,"ST2(L), IL7RA, ETS1, EGFR, IL-33, PI3K cat class IA (p110-delta)",
629,Impaired macrophage phagocytic function in asthma,38,2.699E-02,6.711E-02,3.113E-02,6.711E-02,6,"GSTP1, TNF-R2, PA24A, iC3b, CD14, MMP-9",2.699E-02,7.973E-02,6,"GSTP1, TNF-R2, PA24A, iC3b, CD14, MMP-9",
630,Immune response_Fc epsilon RI pathway: calcium-dependent signaling,68,2.733E-02,6.115E-02,2.733E-02,6.115E-02,9,"Syk, Myosin II, Fyn, AKT(PKB), PKC-alpha, ERM proteins, cPLA2, Lyn, ERK1/2",1.226E-01,2.386E-01,7,"Syk, Fyn, AKT(PKB), PKC-alpha, ERM proteins, cPLA2, Lyn",
631,Development_Growth factors in regulation of oligodendrocyte precursor cell survival,37,2.764E-02,6.115E-02,2.764E-02,6.115E-02,6,"BAD, Fyn, PI3K cat class IA, PDGF-R-alpha, AKT(PKB), Lyn",7.394E-02,1.684E-01,5,"Fyn, PI3K cat class IA, PDGF-R-alpha, AKT(PKB), Lyn",
632,Down-regulation of mast cell functions through ITIM-containing inhibitory receptors in asthma,37,2.764E-02,6.115E-02,2.764E-02,6.115E-02,6,"Syk, SHPS-1, Fyn, CCL2, Lyn, ERK1/2",7.394E-02,1.684E-01,5,"Syk, SHPS-1, Fyn, CCL2, Lyn",
633,FGFR3 signaling in multiple myeloma,37,2.764E-02,6.115E-02,2.764E-02,6.115E-02,6,"STAT3, FGF2, ERK2 (MAPK1), AKT(PKB), FGF9, ERK1/2",3.990E-01,5.626E-01,3,"FGF2, AKT(PKB), FGF9",
634,Development_Negative feedback regulation of WNT/Beta-catenin signaling,37,2.764E-02,6.115E-02,2.764E-02,6.115E-02,6,"Beta-catenin, Tcf(Lef), Dsh, WNT, G-protein alpha-i family, Frizzled",1.900E-01,3.306E-01,4,"Tcf(Lef), WNT, G-protein alpha-i family, Frizzled",
635,G-protein signaling_H-RAS regulation pathway,37,2.764E-02,6.115E-02,2.764E-02,6.115E-02,6,"Angiopoietin 1, TIE2, PI3K cat class IA, Lck, CalDAG-GEFIII, PDGF-R-beta",7.394E-02,1.684E-01,5,"Angiopoietin 1, TIE2, PI3K cat class IA, CalDAG-GEFIII, PDGF-R-beta",
636,Immune response_PGE2 common pathways,47,2.766E-02,6.115E-02,2.766E-02,6.115E-02,7,"COX-2 (PTGS2), PGE2R2, PGE2R4, ERK2 (MAPK1), AKT(PKB), G-protein alpha-i family, Adenylate cyclase",6.629E-02,1.557E-01,6,"COX-2 (PTGS2), PGE2R2, PGE2R4, AKT(PKB), G-protein alpha-i family, Adenylate cyclase",
637,Immune response_Role of DPP4 (CD26) in immune regulation,47,2.766E-02,6.115E-02,2.766E-02,6.115E-02,7,"IL-6, Fyn, MHC class II, Lck, DPP4, Caveolin-1, ADA",6.629E-02,1.557E-01,6,"IL-6, Fyn, MHC class II, DPP4, Caveolin-1, ADA",
638,Aberrant production of IL-2 and IL-17 in SLE T cells,58,2.923E-02,6.453E-02,2.923E-02,6.453E-02,8,"Syk, IL-1 beta, IL-6, MHC class II, Lck, AKT(PKB), ETS1, ERK1/2",1.439E-01,2.712E-01,6,"Syk, IL-1 beta, IL-6, MHC class II, AKT(PKB), ETS1",
639,Impaired inhibition of Th17 cell differentiation by IFN-beta in multiple sclerosis,28,2.960E-02,6.472E-02,2.960E-02,6.472E-02,5,"STAT3, IL-1 beta, IL-6, TGF-beta receptor type II, IFN-beta",8.966E-02,1.935E-01,4,"IL-1 beta, IL-6, TGF-beta receptor type II, IFN-beta",
640,Development_Role of CNTF and LIF in regulation of oligodendrocyte development,28,2.960E-02,6.472E-02,2.960E-02,6.472E-02,5,"STAT3, c-IAP2, PI3K cat class IA, AKT(PKB), LIF",8.966E-02,1.935E-01,4,"c-IAP2, PI3K cat class IA, AKT(PKB), LIF",
641,Development_Mu-type opioid receptor regulation of proliferation,28,2.960E-02,6.472E-02,2.960E-02,6.472E-02,5,"beta-Endorphin extracellular region, ADAM12, EGFR, G-protein alpha-i family, ERK1/2",8.966E-02,1.935E-01,4,"beta-Endorphin extracellular region, ADAM12, EGFR, G-protein alpha-i family",
642,Immune response_CD16 signaling in NK cells,69,2.973E-02,6.479E-02,2.973E-02,6.479E-02,9,"Syk, Actin cytoskeletal, CD94, PI3K cat class IA, Lck, PKC-theta, ERK2 (MAPK1), PLA2, ERK1/2",4.191E-01,5.836E-01,5,"Syk, CD94, PI3K cat class IA, PKC-theta, PLA2",
643,Chemotaxis_CXCR3-A signaling,69,2.973E-02,6.479E-02,2.973E-02,6.479E-02,9,"Lck, AKT(PKB), STAT4, I-TAC, IL-8, MMP-9, PREX2, ERK1/2, MMP-2",1.297E-01,2.510E-01,7,"AKT(PKB), STAT4, I-TAC, IL-8, MMP-9, PREX2, MMP-2",
644,Apoptosis and survival_nAChR in apoptosis inhibition and cell cycle progression,29,2.998E-02,7.266E-02,3.396E-02,7.266E-02,5,"nAChR alpha-7, Fyn, PI3K cat class IA, nAChR alpha, AKT(PKB)",2.998E-02,8.724E-02,5,"nAChR alpha-7, Fyn, PI3K cat class IA, nAChR alpha, AKT(PKB)",
645,Development_Auditory hair cell differentiation in embryogenesis,29,2.998E-02,7.266E-02,3.396E-02,7.266E-02,5,"NGFR(TNFRSF16), HES5, Jagged1, BMP4, GFI-1",2.998E-02,8.724E-02,5,"NGFR(TNFRSF16), HES5, Jagged1, BMP4, GFI-1",
646,Development_BMP7 in brown adipocyte differentiation,39,3.030E-02,7.344E-02,3.488E-02,7.344E-02,6,"PPARGC1 (PGC1-alpha), COL5A1, Annexin I, PSAT, EDNRA, OTOP1",3.030E-02,8.742E-02,6,"PPARGC1 (PGC1-alpha), COL5A1, Annexin I, PSAT, EDNRA, OTOP1",
647,Immune response_HMGB1 release from the cell,39,3.030E-02,7.344E-02,3.488E-02,7.344E-02,6,"IL-1 beta, TNF-R2, PI3K cat class IA, PKC-alpha, TLR4, TLR2",3.030E-02,8.742E-02,6,"IL-1 beta, TNF-R2, PI3K cat class IA, PKC-alpha, TLR4, TLR2",
648,PXR-mediated direct regulation of xenobiotic metabolizing enzymes / Rodent version,39,3.030E-02,7.344E-02,3.488E-02,7.344E-02,6,"CYP27A1, UGT1A1, CYP24A1, MDR1, UGT1A6, CYP11A1",3.030E-02,8.742E-02,6,"CYP27A1, UGT1A1, CYP24A1, MDR1, UGT1A6, CYP11A1",
649,Neuropeptide signaling in pancreatic cancer,48,3.067E-02,6.665E-02,3.067E-02,6.665E-02,7,"HGF, G-protein alpha-q/11, CCL2, PKC-alpha, HGF receptor (Met), NT, ERK1/2",7.202E-02,1.654E-01,6,"HGF, G-protein alpha-q/11, CCL2, PKC-alpha, HGF receptor (Met), NT",
650,Muscle contraction_Relaxin signaling pathway,48,3.067E-02,6.665E-02,3.067E-02,6.665E-02,7,"LGR7, iNOS, AKT(PKB), MMP-9, G-protein alpha-i family, ERK1/2, MMP-2",7.202E-02,1.654E-01,6,"LGR7, iNOS, AKT(PKB), MMP-9, G-protein alpha-i family, MMP-2",
651,Development_FGF2-dependent induction of EMT,20,3.110E-02,7.344E-02,3.459E-02,7.344E-02,4,"IL-1 beta, PI3K cat class IA, FGF2, AKT(PKB)",3.110E-02,8.937E-02,4,"IL-1 beta, PI3K cat class IA, FGF2, AKT(PKB)",
652,Development_Gastrin in differentiation of the gastric mucosa,38,3.113E-02,6.711E-02,3.113E-02,6.711E-02,6,"cPKC (conventional), PKC-theta, PKC, G-protein alpha-q/11, PKC-alpha, ERK1/2",8.105E-02,1.792E-01,5,"cPKC (conventional), PKC-theta, PKC, G-protein alpha-q/11, PKC-alpha",
653,Transcription_Role of AP-1 in regulation of cellular metabolism,38,3.113E-02,6.711E-02,3.113E-02,6.711E-02,6,"PLAUR (uPAR), ITGA5, TSG-6, CGB3, IFN-beta, ERK1/2",8.105E-02,1.792E-01,5,"PLAUR (uPAR), ITGA5, TSG-6, CGB3, IFN-beta",
654,TNF-alpha-induced inflammatory signaling in normal and asthmatic airway epithelium,38,3.113E-02,6.711E-02,3.113E-02,6.711E-02,6,"IL-6, GRO-1, ICAM1, CCL2, IL-8, ERK1/2",8.105E-02,1.792E-01,5,"IL-6, GRO-1, ICAM1, CCL2, IL-8",
655,CHDI_DEGs from Replication data_Causal network,81,3.183E-02,6.853E-02,3.183E-02,6.853E-02,10,"Beta-catenin, PKC, AKT(PKB), p53, cPLA2, Dsh, WNT, Frizzled, ERK1/2, ACM3",3.794E-01,5.468E-01,6,"PKC, AKT(PKB), cPLA2, WNT, Frizzled, ACM3",
656,CAR-mediated direct regulation of xenobiotic metabolizing enzymes / Rodent version,40,3.386E-02,8.008E-02,3.892E-02,8.008E-02,6,"GSTP1, UGT1A1, CYP24A1, MDR1, AL1A1, UGT1A6",3.386E-02,9.588E-02,6,"GSTP1, UGT1A1, CYP24A1, MDR1, AL1A1, UGT1A6",
657,CAR-mediated direct regulation of xenobiotic metabolizing enzymes / Human version,40,3.386E-02,8.008E-02,3.892E-02,8.008E-02,6,"GSTP1, UGT1A1, CYP24A1, MDR1, AL1A1, UGT1A6",3.386E-02,9.588E-02,6,"GSTP1, UGT1A1, CYP24A1, MDR1, AL1A1, UGT1A6",
658,Immune response_PD-1-induced metabolic changes in T cells,49,3.390E-02,7.266E-02,3.390E-02,7.266E-02,7,"Fyn, PI3K cat class IA, PD-L2, Lck, AKT(PKB), ERK1/2, PD-L1",1.805E-01,3.149E-01,5,"Fyn, PI3K cat class IA, PD-L2, AKT(PKB), PD-L1",
659,PDGF activation of prostacyclin synthesis ,30,3.422E-02,8.008E-02,3.870E-02,8.008E-02,5,"COX-2 (PTGS2), PTGIS, PA24A, PKC-alpha, PDGF-R-beta",3.422E-02,9.649E-02,5,"COX-2 (PTGS2), PTGIS, PA24A, PKC-alpha, PDGF-R-beta",
660,Gamma-secretase regulation of angiogenesis,30,3.422E-02,8.008E-02,3.870E-02,8.008E-02,5,"Angiopoietin 1, NOTCH4 (ICD4), NOTCH4, TIE2, Ephrin-B receptor 2",3.422E-02,9.649E-02,5,"Angiopoietin 1, NOTCH4 (ICD4), NOTCH4, TIE2, Ephrin-B receptor 2",
661,Role of Langerin+ dermal dendritic cells in contact hypersensitivity,20,3.459E-02,7.344E-02,3.459E-02,7.344E-02,4,"STAT3, Langerin, ITGB2, CCL2",1.210E-01,2.379E-01,3,"Langerin, ITGB2, CCL2",
662,DNA damage_Inhibition of telomerase activity and cellular senescence,20,3.459E-02,7.344E-02,3.459E-02,7.344E-02,4,"AKT(PKB), p53, p16INK4, CDK6",1.210E-01,2.379E-01,3,"AKT(PKB), p16INK4, CDK6",
663,Cytoskeleton remodeling_Role of Activin A in cytoskeleton remodeling,20,3.459E-02,7.344E-02,3.459E-02,7.344E-02,4,"ACTA2, SMAD3, Activin A, Fibronectin",1.210E-01,2.379E-01,3,"ACTA2, Activin A, Fibronectin",
664,Resistance of melanoma cells to Apo-2L(TNFSF10)-induced apoptosis,39,3.488E-02,7.344E-02,3.488E-02,7.344E-02,6,"STAT3, TRUNDD(TNFRSF10D), PI3K cat class IA, Caspase-8, p53, ERK1/2",7.007E-01,8.364E-01,2,"TRUNDD(TNFRSF10D), PI3K cat class IA",
665,Development_ERBB-family signaling,39,3.488E-02,7.344E-02,3.488E-02,7.344E-02,6,"PI3K cat class IA, TGF-alpha, AKT(PKB), Epiregulin, EGFR, ERK1/2",8.852E-02,1.926E-01,5,"PI3K cat class IA, TGF-alpha, AKT(PKB), Epiregulin, EGFR",
666,Activation of Notch signaling in breast cancer,39,3.488E-02,7.344E-02,3.488E-02,7.344E-02,6,"STAT3, NOTCH4, SNAIL1, MAML2, Jagged1, TCF8",2.159E-01,3.622E-01,4,"NOTCH4, MAML2, Jagged1, TCF8",
667,Development_Stimulation of differentiation of mouse embryonic fibroblasts into adipocytes by extracellular factors,71,3.496E-02,7.344E-02,3.496E-02,7.344E-02,9,"EGR2 (Krox20), Lysyl oxidase, ERK2 (MAPK1), IRS-2, NGAL, Adenylate cyclase, BMP2, ERK1/2, LIF",1.445E-01,2.714E-01,7,"EGR2 (Krox20), Lysyl oxidase, IRS-2, NGAL, Adenylate cyclase, BMP2, LIF",
668,Development_Positive regulation of STK3/4 (Hippo) pathway and negative regulation of YAP/TAZ function,71,3.496E-02,7.344E-02,3.496E-02,7.344E-02,9,"AMPK gamma subunit, Beta-catenin, Actin cytoskeletal, TAZ, Schwannomin (NF2), Beta-2 adrenergic receptor, Angiomotin (AMOT), Adenylate cyclase, LIF",2.696E-01,4.284E-01,6,"AMPK gamma subunit, TAZ, Beta-2 adrenergic receptor, Angiomotin (AMOT), Adenylate cyclase, LIF",
669,Immune response_IL-4 signaling pathway,94,3.551E-02,7.450E-02,3.551E-02,7.450E-02,11,"BAD, STAT3, Syk, c-Fes, PKC, ERK2 (MAPK1), AKT(PKB), PDE3A, IRS-2, PI3K cat class IA (p110-delta), ERK1/2",3.559E-01,5.230E-01,7,"Syk, c-Fes, PKC, AKT(PKB), PDE3A, IRS-2, PI3K cat class IA (p110-delta)",
670,Transport_The role of AVP in regulation of Aquaporin 2 and renal water reabsorption,50,3.735E-02,7.823E-02,3.735E-02,7.823E-02,7,"Myosin II, Actin cytoskeletal, MyHC, MLCK, MRLC, ACTB, ERK1/2",8.210E-01,9.136E-01,2,"MLCK, MRLC",
671,Degranulation of lung mast cells,63,3.807E-02,9.067E-02,4.491E-02,9.067E-02,8,"Syk, PGE2R2, cPKC (conventional), Fyn, PI3K cat class IA, Beta-2 adrenergic receptor, Lyn, G-protein alpha-i family",3.807E-02,1.058E-01,8,"Syk, PGE2R2, cPKC (conventional), Fyn, PI3K cat class IA, Beta-2 adrenergic receptor, Lyn, G-protein alpha-i family",
672,Immune response_iC3b-induced phagocytosis via alpha-M/beta-2 integrin,61,3.810E-02,7.956E-02,3.810E-02,7.956E-02,8,"Syk, Myosin II, Actin cytoskeletal, PI3K cat class IA, Rac2, iC3b, PKC, ITGB2",1.702E-01,3.027E-01,6,"Syk, PI3K cat class IA, Rac2, iC3b, PKC, ITGB2",
673,Effect of H. pylori infection on inflammation in gastric epithelial cells,61,3.810E-02,7.956E-02,3.810E-02,7.956E-02,8,"COX-2 (PTGS2), IL-6, iNOS, PKC-alpha, IL-8, TLR4, TLR2, ERK1/2",7.896E-02,1.775E-01,7,"COX-2 (PTGS2), IL-6, iNOS, PKC-alpha, IL-8, TLR4, TLR2",
674,Development_G-CSF-induced myeloid differentiation,30,3.870E-02,8.008E-02,3.870E-02,8.008E-02,5,"STAT3, ITGB2, NGAL, ERK1/2, GFI-1",2.793E-01,4.382E-01,3,"ITGB2, NGAL, GFI-1",
675,Role of CNTF and LIF in regulation of oligodendrocyte development in multiple sclerosis,30,3.870E-02,8.008E-02,3.870E-02,8.008E-02,5,"STAT3, c-IAP2, PI3K cat class IA, AKT(PKB), LIF",1.092E-01,2.213E-01,4,"c-IAP2, PI3K cat class IA, AKT(PKB), LIF",
676,Alternative complement cascade disruption in age-related macular degeneration,31,3.881E-02,8.898E-02,4.382E-02,8.898E-02,5,"iC3b, C3a, C3, Factor I, C3b",3.881E-02,1.066E-01,5,"iC3b, C3a, C3, Factor I, C3b",
677,Development_Role of Activin A in cell differentiation and proliferation,40,3.892E-02,8.008E-02,3.892E-02,8.008E-02,6,"p15, SMAD3, Activin A, Oct-3/4, Adenylate cyclase, CYP11A1",9.633E-02,2.023E-01,5,"p15, Activin A, Oct-3/4, Adenylate cyclase, CYP11A1",
678,Development_FGF2-induced self-renewal of adult neural stem cells,40,3.892E-02,8.008E-02,3.892E-02,8.008E-02,6,"PI3K cat class IA, FGF2, PKC, AKT(PKB), Jagged1, ERK1/2",9.633E-02,2.023E-01,5,"PI3K cat class IA, FGF2, PKC, AKT(PKB), Jagged1",
679,Development_SLIT-ROBO1 signaling,40,3.892E-02,8.008E-02,3.892E-02,8.008E-02,6,"Myosin II, Fyn, PI3K cat class IA, AKT(PKB), F-Actin cytoskeleton, ACTB",4.490E-01,6.139E-01,3,"Fyn, PI3K cat class IA, AKT(PKB)",
680,Development_FGF signaling in pancreatic and hepatic differentiation of embryonic stem cells,40,3.892E-02,8.008E-02,3.892E-02,8.008E-02,6,"N-cadherin, FGF2, Activin A, BMP4, BMP2, ERK1/2",9.633E-02,2.023E-01,5,"N-cadherin, FGF2, Activin A, BMP4, BMP2",
681,Immune response_NF-AT in immune response,51,4.102E-02,8.427E-02,4.102E-02,8.427E-02,7,"Syk, MHC class II, PI3K cat class IA, Lck, PKC-theta, AKT(PKB), Lyn",9.086E-02,1.937E-01,6,"Syk, MHC class II, PI3K cat class IA, PKC-theta, AKT(PKB), Lyn",
682,Development_Negative regulation of STK3/4 (Hippo) pathway and positive regulation of YAP/TAZ function,62,4.141E-02,8.483E-02,4.141E-02,8.483E-02,8,"Actin cytoskeletal, TAZ, Schwannomin (NF2), G-protein alpha-q/11, CD44, Angiomotin (AMOT), EGFR, ERK1/2",3.323E-01,4.947E-01,5,"TAZ, G-protein alpha-q/11, CD44, Angiomotin (AMOT), EGFR",
683,Development_Gastrin in cell growth and proliferation,62,4.141E-02,8.483E-02,4.141E-02,8.483E-02,8,"STAT3, Beta-catenin, PI3K cat class IA, ERK2 (MAPK1), G-protein alpha-q/11, PKC-alpha, EGFR, ERK1/2",5.338E-01,7.004E-01,4,"PI3K cat class IA, G-protein alpha-q/11, PKC-alpha, EGFR",
684,Transport_ACM3 signaling in salivary glands,42,4.177E-02,9.564E-02,4.785E-02,9.564E-02,6,"G-protein alpha-i1, PKC, G-protein alpha-q/11, G-protein alpha-i family, MLCK, ACM3",4.177E-02,1.133E-01,6,"G-protein alpha-i1, PKC, G-protein alpha-q/11, G-protein alpha-i family, MLCK, ACM3",
685,PXR-mediated direct regulation of xenobiotic metabolizing enzymes / Human version,42,4.177E-02,9.564E-02,4.785E-02,9.564E-02,6,"CYP27A1, UGT1A1, CYP24A1, MDR1, UGT1A6, CYP11A1",4.177E-02,1.133E-01,6,"CYP27A1, UGT1A1, CYP24A1, MDR1, UGT1A6, CYP11A1",
686,Aryl hydrocarbon receptor signaling,53,4.220E-02,9.758E-02,4.903E-02,9.758E-02,7,"COX-2 (PTGS2), UGT1A1, CYP1A1, IL-8, Epiregulin, SLUG, UGT1A6",4.220E-02,1.139E-01,7,"COX-2 (PTGS2), UGT1A1, CYP1A1, IL-8, Epiregulin, SLUG, UGT1A6",
687,Development_Generation of pancreatic beta-cells from embryonic stem cells (late stages),22,4.264E-02,9.489E-02,4.728E-02,9.489E-02,4,"HGF, FGF2, BMP4, PAX6",4.264E-02,1.139E-01,4,"HGF, FGF2, BMP4, PAX6",
688,Development_Muscle progenitor cell migration in hypaxial myogenesis,41,4.324E-02,8.819E-02,4.324E-02,8.819E-02,6,"HGF, SNAIL1, HGF receptor (Met), G-protein alpha-i family, ERK1/2, MEF2C",2.427E-01,3.945E-01,4,"HGF, HGF receptor (Met), G-protein alpha-i family, MEF2C",
689,Development_Neurotrophin family signaling,41,4.324E-02,8.819E-02,4.324E-02,8.819E-02,6,"NGF, NGFR(TNFRSF16), PI3K cat class IA, AKT(PKB), p53, ERK1/2",2.427E-01,3.945E-01,4,"NGF, NGFR(TNFRSF16), PI3K cat class IA, AKT(PKB)",
690,Stem cells_Inhibition of Hedgehog signaling in medulloblastoma stem cells,41,4.324E-02,8.819E-02,4.324E-02,8.819E-02,6,"FGF2, GLI-1, PTCH1, PACAP, ERK1/2, GLI-2",1.045E-01,2.146E-01,5,"FGF2, GLI-1, PTCH1, PACAP, GLI-2",
691,Androstenedione and testosterone biosynthesis and metabolism p.2,32,4.376E-02,9.761E-02,4.933E-02,9.761E-02,5,"AKR1C1, AKR1C3, UGT1A1, AKR1C4, AKR1C2",4.376E-02,1.157E-01,5,"AKR1C1, AKR1C3, UGT1A1, AKR1C4, AKR1C2",
692,Protein folding and maturation_Bradykinin / Kallidin maturation,32,4.376E-02,9.761E-02,4.933E-02,9.761E-02,5,"MMP-8, Neprilysin, ACE2, Tissue kallikreins, CD13",4.376E-02,1.157E-01,5,"MMP-8, Neprilysin, ACE2, Tissue kallikreins, CD13",
693,NETosis in SLE,31,4.382E-02,8.898E-02,4.382E-02,8.898E-02,5,"IL-1 beta, TLR7, PKC, Fc gamma RII alpha, ERK1/2",1.196E-01,2.373E-01,4,"IL-1 beta, TLR7, PKC, Fc gamma RII alpha",
694,Development_Transactivation of PDGFR in non-neuronal cells by Dopamine D2 receptor,31,4.382E-02,8.898E-02,4.382E-02,8.898E-02,5,"PI3K cat class IA, ERK2 (MAPK1), PDGF receptor, G-protein alpha-i family, PDGF-R-beta",1.196E-01,2.373E-01,4,"PI3K cat class IA, PDGF receptor, G-protein alpha-i family, PDGF-R-beta",
695,Signal transduction_mTORC1 upstream signaling,74,4.394E-02,8.909E-02,4.394E-02,8.909E-02,9,"ERK2 (MAPK1), AKT(PKB), PDGF receptor, Dsh, WNT, EGFR, TLR4, Frizzled, ERK1/2",3.019E-01,4.657E-01,6,"AKT(PKB), PDGF receptor, WNT, EGFR, TLR4, Frizzled",
696,Cell adhesion_Integrin inside-out signaling in T cells,52,4.491E-02,9.067E-02,4.491E-02,9.067E-02,7,"ITGB1, CCL20, Lck, ITGB2, alpha-4/beta-1 integrin, ICAM1, G-protein alpha-i family",9.768E-02,2.037E-01,6,"ITGB1, CCL20, ITGB2, alpha-4/beta-1 integrin, ICAM1, G-protein alpha-i family",
697,Neurophysiological process_Synaptic vesicle fusion and recycling in nerve terminals,52,4.491E-02,9.067E-02,4.491E-02,9.067E-02,7,"CaMK I, Synapsin II, Alpha-synuclein, SV2A, AP180, Endophilin A1, F-Actin",9.768E-02,2.037E-01,6,"CaMK I, Synapsin II, Alpha-synuclein, SV2A, AP180, Endophilin A1",
698,"Immune response_Antigen presentation by MHC class I, classical pathway",54,4.603E-02,1.042E-01,5.339E-02,1.042E-01,7,"MHC Class I alpha chain, PSMB9, TAP1 (PSF1), ERAP2, PSMB8(LMP7), TAP, TAP2 (PSF2)",4.603E-02,1.188E-01,7,"MHC Class I alpha chain, PSMB9, TAP1 (PSF1), ERAP2, PSMB8(LMP7), TAP, TAP2 (PSF2)",
699,Development_EPO-induced PI3K/AKT pathway and Ca(2+) influx,43,4.613E-02,1.034E-01,5.276E-02,1.034E-01,6,"Syk, PI3K cat class IA, TRPC3, AKT(PKB), IRS-2, Lyn",4.613E-02,1.188E-01,6,"Syk, PI3K cat class IA, TRPC3, AKT(PKB), IRS-2, Lyn",
700,Role of platelets in the initiation of in-stent restenosis,43,4.613E-02,1.034E-01,5.276E-02,1.034E-01,6,"Tissue factor, ICAM1, CCL2, ICAM2, IL-8, Collagen III",4.613E-02,1.188E-01,6,"Tissue factor, ICAM1, CCL2, ICAM2, IL-8, Collagen III",
701,Development_S1P3 receptor signaling pathway,43,4.613E-02,1.034E-01,5.276E-02,1.034E-01,6,"PI3K cat class IA, AKT(PKB), PDGF receptor, CD44, G-protein alpha-i family, Adenylate cyclase",4.613E-02,1.188E-01,6,"PI3K cat class IA, AKT(PKB), PDGF receptor, CD44, G-protein alpha-i family, Adenylate cyclase",
702,Role of platelets in allograft rejection,43,4.613E-02,1.034E-01,5.276E-02,1.034E-01,6,"IL-1 beta, TGF-beta, Tissue factor, ICAM1, Kainate receptor, Collagen III",4.613E-02,1.188E-01,6,"IL-1 beta, TGF-beta, Tissue factor, ICAM1, Kainate receptor, Collagen III",
703,Immune response_Oncostatin M signaling via JAK-Stat,22,4.728E-02,9.489E-02,4.728E-02,9.489E-02,4,"STAT3, ACTA2, OSMR, CCL2",1.496E-01,2.774E-01,3,"ACTA2, OSMR, CCL2",
704,Development_Mu-type opioid receptor signaling via Beta-arrestin,22,4.728E-02,9.489E-02,4.728E-02,9.489E-02,4,"STAT3, ERK2 (MAPK1), G-protein alpha-i family, ERK1/2",7.524E-01,8.655E-01,1,G-protein alpha-i family,
705,Inhibition of RUNX3 signaling in gastric cancer,22,4.728E-02,9.489E-02,4.728E-02,9.489E-02,4,"RUNX3, Caspase-8, MMP-9, MDR1",1.496E-01,2.774E-01,3,"RUNX3, MMP-9, MDR1",
706,Development_VEGF signaling and activation,42,4.785E-02,9.564E-02,4.785E-02,9.564E-02,6,"PI3K cat class IA, PKC, AKT(PKB), ICAM1, PKC-alpha, ERK1/2",1.129E-01,2.269E-01,5,"PI3K cat class IA, PKC, AKT(PKB), ICAM1, PKC-alpha",
707,Effect of H. pylori infection on apoptosis in gastric epithelial cells,53,4.903E-02,9.758E-02,4.903E-02,9.758E-02,7,"COX-2 (PTGS2), NOXA, c-IAP2, MHC class II, Caspase-1, Caspase-8, PTPR-zeta",1.048E-01,2.146E-01,6,"COX-2 (PTGS2), NOXA, c-IAP2, MHC class II, Caspase-1, PTPR-zeta",
708,ENaC regulation in normal and CF airways ,53,4.903E-02,9.758E-02,4.903E-02,9.758E-02,7,"cPKC (conventional), PI3K cat class IA, Beta-2 adrenergic receptor, G-protein alpha-q/11, SERPINE2, Adenylate cyclase, ERK1/2",1.048E-01,2.146E-01,6,"cPKC (conventional), PI3K cat class IA, Beta-2 adrenergic receptor, G-protein alpha-q/11, SERPINE2, Adenylate cyclase",
709,Development_BMP signaling,33,4.907E-02,1.067E-01,5.523E-02,1.067E-01,5,"Follistatin, BMP6, Gremlin, BMP4, BMP2",4.907E-02,1.246E-01,5,"Follistatin, BMP6, Gremlin, BMP4, BMP2",
710,Apoptosis and survival_Beta-2 adrenergic receptor anti-apoptotic action,23,4.920E-02,1.057E-01,5.446E-02,1.057E-01,4,"Beta-2 adrenergic receptor, AKT(PKB), G-protein alpha-i family, Adenylate cyclase type VII",4.920E-02,1.246E-01,4,"Beta-2 adrenergic receptor, AKT(PKB), G-protein alpha-i family, Adenylate cyclase type VII",
711,Development_EGFR signaling via PIP3,23,4.920E-02,1.057E-01,5.446E-02,1.057E-01,4,"PI3K cat class IA, AKT(PKB), IRS-2, EGFR",4.920E-02,1.246E-01,4,"PI3K cat class IA, AKT(PKB), IRS-2, EGFR",
712,Inhibition of LKB1 / AMPK signaling in breast cancer,32,4.933E-02,9.761E-02,4.933E-02,9.761E-02,5,"IL-6, PPARGC1 (PGC1-alpha), SNAIL1, AKT(PKB), Vimentin",1.305E-01,2.510E-01,4,"IL-6, PPARGC1 (PGC1-alpha), AKT(PKB), Vimentin",
713,Role of IL-6 in obesity and type 2 diabetes in adipocytes,32,4.933E-02,9.761E-02,4.933E-02,9.761E-02,5,"STAT3, IL-6, PPARGC1 (PGC1-alpha), CCL2, ERK1/2",3.135E-01,4.750E-01,3,"IL-6, PPARGC1 (PGC1-alpha), CCL2",
714,Role of TLR signaling in skin sensitization,44,5.076E-02,1.105E-01,5.796E-02,1.105E-01,6,"IL-1 beta, IL-6, CD14, IFN-beta, TLR4, TLR2",5.076E-02,1.264E-01,6,"IL-1 beta, IL-6, CD14, IFN-beta, TLR4, TLR2",
715,Development_S1P1 signaling pathway,44,5.076E-02,1.105E-01,5.796E-02,1.105E-01,6,"G-protein alpha-i1, S1P1 receptor, AKT(PKB), CD44, G-protein alpha-i family, Adenylate cyclase",5.076E-02,1.264E-01,6,"G-protein alpha-i1, S1P1 receptor, AKT(PKB), CD44, G-protein alpha-i family, Adenylate cyclase",
716,Signal transduction_AKT signaling,43,5.276E-02,1.034E-01,5.276E-02,1.034E-01,6,"BAD, PCNA, PI3K cat class IA, AKT(PKB), p53, HGF receptor (Met)",4.971E-01,6.645E-01,3,"PI3K cat class IA, AKT(PKB), HGF receptor (Met)",
717,Apoptosis and survival_Anti-apoptotic action of Gastrin,43,5.276E-02,1.034E-01,5.276E-02,1.034E-01,6,"BAD, PI3K cat class IA, AKT(PKB), G-protein alpha-q/11, PKC-alpha, ERK1/2",2.702E-01,4.284E-01,4,"PI3K cat class IA, AKT(PKB), G-protein alpha-q/11, PKC-alpha",
718,Development_WNT/Beta-catenin signaling pathway. Signalosome,43,5.276E-02,1.034E-01,5.276E-02,1.034E-01,6,"Schwannomin (NF2), DAAM2, Dsh, WNT, G-protein alpha-i family, Frizzled",2.702E-01,4.284E-01,4,"DAAM2, WNT, G-protein alpha-i family, Frizzled",
719,Neurophysiological process_Dynein-dynactin motor complex in axonal transport in neurons,54,5.339E-02,1.042E-01,5.339E-02,1.042E-01,7,"NGF, PRNP, AKT(PKB), Dynein 1, cytoplasmic, intermediate chains, DYNC1I1, Vimentin, ERK1/2",1.121E-01,2.259E-01,6,"NGF, PRNP, AKT(PKB), Dynein 1, cytoplasmic, intermediate chains, DYNC1I1, Vimentin",
720,Immune response_IFN-gamma actions on extracellular matrix and cell differentiation,54,5.339E-02,1.042E-01,5.339E-02,1.042E-01,7,"CIITA, ACTA2, MYLPF, iNOS, MYH11, ICAM1, MMP-9",1.121E-01,2.259E-01,6,"CIITA, ACTA2, MYLPF, iNOS, ICAM1, MMP-9",
721,Blood coagulation_GPIb-IX-V-dependent platelet activation,77,5.435E-02,1.057E-01,5.435E-02,1.057E-01,9,"Syk, Fyn, ERK2 (MAPK1), Fc gamma RII alpha, PKC-alpha, ITGB3, cPLA2, Lyn, Actin",9.926E-02,2.061E-01,8,"Syk, Fyn, Fc gamma RII alpha, PKC-alpha, ITGB3, cPLA2, Lyn, Actin",
722,Action of GSK3 beta in bipolar disorder,23,5.446E-02,1.057E-01,5.446E-02,1.057E-01,4,"Beta-catenin, MAP-1B, p53, Tcf(Lef)",4.171E-01,5.821E-01,2,"MAP-1B, Tcf(Lef)",
723,Mechanism of action of CCR4 antagonists in asthma and atopic dermatitis (Variant 1),34,5.474E-02,1.164E-01,6.151E-02,1.164E-01,5,"ITGB1, ITGB2, alpha-4/beta-1 integrin, ICAM1, G-protein alpha-i family",5.474E-02,1.351E-01,5,"ITGB1, ITGB2, alpha-4/beta-1 integrin, ICAM1, G-protein alpha-i family",
724,CCR4-dependent immune cell chemotaxis in asthma and atopic dermatitis ,34,5.474E-02,1.164E-01,6.151E-02,1.164E-01,5,"ITGB1, ITGB2, alpha-4/beta-1 integrin, ICAM1, G-protein alpha-i family",5.474E-02,1.351E-01,5,"ITGB1, ITGB2, alpha-4/beta-1 integrin, ICAM1, G-protein alpha-i family",
725,Chemotaxis_CCR4-induced chemotaxis of immune cells,34,5.474E-02,1.164E-01,6.151E-02,1.164E-01,5,"ITGB1, ITGB2, alpha-4/beta-1 integrin, ICAM1, G-protein alpha-i family",5.474E-02,1.351E-01,5,"ITGB1, ITGB2, alpha-4/beta-1 integrin, ICAM1, G-protein alpha-i family",
726,Deficient alpha-MSH signaling in melanoma,33,5.523E-02,1.067E-01,5.523E-02,1.067E-01,5,"SOX10, PI3K cat class IA, AKT(PKB), alpha-MSH, ERK1/2",1.417E-01,2.681E-01,4,"SOX10, PI3K cat class IA, AKT(PKB), alpha-MSH",
727,LRRK2 in neurons in Parkinson's disease,33,5.523E-02,1.067E-01,5.523E-02,1.067E-01,5,"Alpha-synuclein, Actin cytoskeletal, MSN (moesin), ACTB, ERK1/2",6.103E-01,7.696E-01,2,"Alpha-synuclein, MSN (moesin)",
728,Immune response_IL-13 signaling via JAK-STAT,44,5.796E-02,1.105E-01,5.796E-02,1.105E-01,6,"STAT3, MMP-8, iNOS, SCCA-2, CCL2, SCCA-1",1.308E-01,2.510E-01,5,"MMP-8, iNOS, SCCA-2, CCL2, SCCA-1",
729,K-RAS signaling in pancreatic cancer,44,5.796E-02,1.105E-01,5.796E-02,1.105E-01,6,"SNAIL1, AKT(PKB), p53, IL-8, PLAU (UPA), ERK1/2",5.127E-01,6.787E-01,3,"AKT(PKB), IL-8, PLAU (UPA)",
730,"Development_Activation of Erk by ACM1, ACM3 and ACM5",44,5.796E-02,1.105E-01,5.796E-02,1.105E-01,6,"TGF-alpha, PKC-alpha, cPLA2, EGFR, ERK1/2, ACM3",1.308E-01,2.510E-01,5,"TGF-alpha, PKC-alpha, cPLA2, EGFR, ACM3",
731,Development_Ligand-independent activation of ESR1 and ESR2,44,5.796E-02,1.105E-01,5.796E-02,1.105E-01,6,"PI3K cat class IA, ERK2 (MAPK1), AKT(PKB), Caveolin-1, EGFR, ERK1/2",2.841E-01,4.432E-01,4,"PI3K cat class IA, AKT(PKB), Caveolin-1, EGFR",
732,Proteases and EGFR-induced mucin synthesis in normal and asthmatic epithelium,55,5.798E-02,1.105E-01,5.798E-02,1.105E-01,7,"TGF-alpha, G-protein alpha-q/11, ICAM1, CD44, PKC-alpha, EGFR, ERK1/2",1.197E-01,2.373E-01,6,"TGF-alpha, G-protein alpha-q/11, ICAM1, CD44, PKC-alpha, EGFR",
733,Apoptosis and survival_NO synthesis and signaling,55,5.798E-02,1.105E-01,5.798E-02,1.105E-01,7,"COX-2 (PTGS2), CaMK I, IL-1 beta, iNOS, AKT(PKB), PI3K cat class IA (p110-delta), ERK1/2",1.197E-01,2.373E-01,6,"COX-2 (PTGS2), CaMK I, IL-1 beta, iNOS, AKT(PKB), PI3K cat class IA (p110-delta)",
734,Immune response_IL-16 signaling pathway,55,5.798E-02,1.105E-01,5.798E-02,1.105E-01,7,"IL-15, IL-1 beta, IL-6, cPKC (conventional), Lck, PKC, AKT(PKB)",1.197E-01,2.373E-01,6,"IL-15, IL-1 beta, IL-6, cPKC (conventional), PKC, AKT(PKB)",
735,Immune response_CD28 signaling,55,5.798E-02,1.105E-01,5.798E-02,1.105E-01,7,"BAD, Fyn, PI3K cat class IA, Lck, PKC-theta, AKT(PKB), GRAP2",2.477E-01,4.006E-01,5,"Fyn, PI3K cat class IA, PKC-theta, AKT(PKB), GRAP2",
736,Role of GITR in skin sensitization,15,6.039E-02,1.228E-01,6.549E-02,1.228E-01,3,"IL-1 beta, TNF-R2, GITRL",6.039E-02,1.461E-01,3,"IL-1 beta, TNF-R2, GITRL",
737,Signal transduction_Calcium signaling,46,6.084E-02,1.281E-01,6.924E-02,1.281E-01,6,"CaMK I, cPKC (conventional), MEF2, AKAP6, CD44, NCX1",6.084E-02,1.461E-01,6,"CaMK I, cPKC (conventional), MEF2, AKAP6, CD44, NCX1",
738,Development_HGF-dependent inhibition of TGF-beta-induced EMT,34,6.151E-02,1.164E-01,6.151E-02,1.164E-01,5,"HGF, COX-2 (PTGS2), HGF receptor (Met), TGF-beta receptor type II, ERK1/2",1.533E-01,2.806E-01,4,"HGF, COX-2 (PTGS2), HGF receptor (Met), TGF-beta receptor type II",
739,Role of Apo-2L(TNFSF10) in Prostate Cancer cell apoptosis,34,6.151E-02,1.164E-01,6.151E-02,1.164E-01,5,"TRUNDD(TNFRSF10D), c-IAP2, Caspase-10, Osteoprotegerin, Caspase-8",1.533E-01,2.806E-01,4,"TRUNDD(TNFRSF10D), c-IAP2, Caspase-10, Osteoprotegerin",
740,Tissue factor signaling in lung cancer,24,6.220E-02,1.176E-01,6.220E-02,1.176E-01,4,"AKT(PKB), Tissue factor, p53, ERK1/2",4.387E-01,6.029E-01,2,"AKT(PKB), Tissue factor",
741,Role of tumor-infiltrating B cells in anti-tumor immunity,91,6.234E-02,1.177E-01,6.234E-02,1.177E-01,10,"STAT3, IL-18R1, MHC class II, ADAM-TS9, CXorf61, p53, CD38, I-TAC, G-protein alpha-i family, BLIMP1 (PRDI-BF1)",1.952E-01,3.359E-01,8,"IL-18R1, MHC class II, ADAM-TS9, CXorf61, CD38, I-TAC, G-protein alpha-i family, BLIMP1 (PRDI-BF1)",
742,Immune response_IL-5 signaling via JAK/STAT,56,6.281E-02,1.182E-01,6.281E-02,1.182E-01,7,"STAT3, IL-1 beta, c-IAP2, PRG2, IL-8, Pim-1, BLIMP1 (PRDI-BF1)",1.275E-01,2.474E-01,6,"IL-1 beta, c-IAP2, PRG2, IL-8, Pim-1, BLIMP1 (PRDI-BF1)",
743,Mitogenic action of ErbB2 in breast cancer,56,6.281E-02,1.182E-01,6.281E-02,1.182E-01,7,"Beta-catenin, PI3K cat class IA, AKT(PKB), ER81, Cyclin E, EGFR, ERK1/2",2.595E-01,4.157E-01,5,"PI3K cat class IA, AKT(PKB), ER81, Cyclin E, EGFR",
744,Immune response_TNF-R2 signaling pathways,45,6.345E-02,1.193E-01,6.345E-02,1.193E-01,6,"TNF-R2, c-IAP2, BMX, PI3K cat class IA, AKT(PKB), ERK1/2",1.402E-01,2.664E-01,5,"TNF-R2, c-IAP2, BMX, PI3K cat class IA, AKT(PKB)",
745,Role of B cells in SLE,58,6.352E-02,1.341E-01,7.318E-02,1.341E-01,7,"Syk, IL-6, MHC class II, PI3K cat class IA, AKT(PKB), ICAM1, Lyn",6.352E-02,1.510E-01,7,"Syk, IL-6, MHC class II, PI3K cat class IA, AKT(PKB), ICAM1, Lyn",
746,Development_Cross-talk between VEGF and Angiopoietin 1 signaling pathways,25,6.387E-02,1.297E-01,7.048E-02,1.297E-01,4,"Angiopoietin 1, TIE2, ICAM1, PKC-alpha",6.387E-02,1.510E-01,4,"Angiopoietin 1, TIE2, ICAM1, PKC-alpha",
747,Generation of cytotoxic CD8+ T cells in COPD,25,6.387E-02,1.297E-01,7.048E-02,1.297E-01,4,"MHC class II, CD137 ligand(TNFSF9), ICAM1, CD137(TNFRSF9)",6.387E-02,1.510E-01,4,"MHC class II, CD137 ligand(TNFSF9), ICAM1, CD137(TNFRSF9)",
748,Production of reactive oxygen species and arachidonic acid metabolites by neutrophils in asthma,68,6.529E-02,1.226E-01,6.529E-02,1.226E-01,8,"PI3K cat class IA, PA24A, PKC, PRG2, IL-8, G-protein alpha-i family, ALOX5, ERK1/2",1.226E-01,2.386E-01,7,"PI3K cat class IA, PA24A, PKC, PRG2, IL-8, G-protein alpha-i family, ALOX5",
749,Development_Beta adrenergic receptors in brown adipocyte differentiation,36,6.718E-02,1.366E-01,7.525E-02,1.366E-01,5,"FOXC2, PPARGC1 (PGC1-alpha), EGR2 (Krox20), Beta-2 adrenergic receptor, Adenylate cyclase",6.718E-02,1.567E-01,5,"FOXC2, PPARGC1 (PGC1-alpha), EGR2 (Krox20), Beta-2 adrenergic receptor, Adenylate cyclase",
750,"Development_Lipoxin inhibitory action on PDGF, EGF and LTD4 signaling",36,6.718E-02,1.366E-01,7.525E-02,1.366E-01,5,"G-protein alpha-q/11, EGFR, G-protein alpha-i family, Adenylate cyclase, PDGF-R-beta",6.718E-02,1.567E-01,5,"G-protein alpha-q/11, EGFR, G-protein alpha-i family, Adenylate cyclase, PDGF-R-beta",
751,Role of nicotine in pathogenesis of SCLC,57,6.788E-02,1.268E-01,6.788E-02,1.268E-01,7,"PCNA, nAChR alpha-7, FGF2, AKT(PKB), PKC-alpha, HTR1D, ERK1/2",2.714E-01,4.293E-01,5,"nAChR alpha-7, FGF2, AKT(PKB), PKC-alpha, HTR1D",
752,Proinflammatory mediators release and arachidonic acid metabolites production in basophils in asthma,57,6.788E-02,1.268E-01,6.788E-02,1.268E-01,7,"Syk, NGF, PI3K cat class IA, cPLA2, Lyn, G-protein alpha-i family, ERK1/2",1.356E-01,2.587E-01,6,"Syk, NGF, PI3K cat class IA, cPLA2, Lyn, G-protein alpha-i family",
753,Development_Angiopoietin - Tie2 signaling,35,6.819E-02,1.268E-01,6.819E-02,1.268E-01,5,"Angiopoietin 1, STAT3, TIE2, PI3K cat class IA, AKT(PKB)",1.652E-01,2.953E-01,4,"Angiopoietin 1, TIE2, PI3K cat class IA, AKT(PKB)",
754,Immune response_Differentiation of natural regulatory T cells,35,6.819E-02,1.268E-01,6.819E-02,1.268E-01,5,"STAT3, MHC class II, SMAD3, TGF-beta receptor type II, GITRL",3.650E-01,5.317E-01,3,"MHC class II, TGF-beta receptor type II, GITRL",
755,Immune response_Th17 cell differentiation,35,6.819E-02,1.268E-01,6.819E-02,1.268E-01,5,"STAT3, IL-1 beta, IL-6, MHC class II, TGF-beta receptor type II",1.652E-01,2.953E-01,4,"IL-1 beta, IL-6, MHC class II, TGF-beta receptor type II",
756,Neurophysiological process_Ephrin-B receptors in dendritic spine morphogenesis and synaptogenesis,35,6.819E-02,1.268E-01,6.819E-02,1.268E-01,5,"Actin cytoskeletal, Fyn, GABA-A receptor, Ephrin-B receptors, Ephrin-B receptor 2",1.652E-01,2.953E-01,4,"Fyn, GABA-A receptor, Ephrin-B receptors, Ephrin-B receptor 2",
757,Immune response_Naive CD4+ T cell differentiation,46,6.924E-02,1.281E-01,6.924E-02,1.281E-01,6,"STAT3, IL-1 beta, IL-6, MHC class II, RUNX3, STAT4",1.499E-01,2.774E-01,5,"IL-1 beta, IL-6, MHC class II, RUNX3, STAT4",
758,Cytoskeleton remodeling_Regulation of actin cytoskeleton nucleation and polymerization by Rho GTPases,46,6.924E-02,1.281E-01,6.924E-02,1.281E-01,6,"DRF, Actin cytoskeletal, Rac2, Rac1-related, FMNL2, F-Actin cytoskeleton",3.123E-01,4.750E-01,4,"DRF, Rac2, Rac1-related, FMNL2",
759,Development_Endothelin-1/EDNRA transactivation of EGFR,46,6.924E-02,1.281E-01,6.924E-02,1.281E-01,6,"PI3K cat class IA, AKT(PKB), G-protein alpha-q/11, EGFR, EDNRA, ERK1/2",1.499E-01,2.774E-01,5,"PI3K cat class IA, AKT(PKB), G-protein alpha-q/11, EGFR, EDNRA",
760,Development_Positive regulation of WNT/Beta-catenin signaling in the nucleus,69,6.996E-02,1.293E-01,6.996E-02,1.293E-01,8,"Beta-catenin, ERK2 (MAPK1), Tcf(Lef), RUNX, Dsh, WNT, TCF7 (TCF1), Frizzled",4.191E-01,5.836E-01,5,"Tcf(Lef), RUNX, WNT, TCF7 (TCF1), Frizzled",
761,Inhibition of TGF-beta signaling in gastric cancer,25,7.048E-02,1.297E-01,7.048E-02,1.297E-01,4,"TGF-beta 2, SMAD3, RUNX3, TGF-beta receptor type II",1.961E-01,3.359E-01,3,"TGF-beta 2, RUNX3, TGF-beta receptor type II",
762,SLE genetic marker-specific pathways in antigen-presenting cells (APC),84,7.185E-02,1.494E-01,8.447E-02,1.494E-01,9,"IL-1 beta, TLR7, iC3b, Fc gamma RII alpha, ICAM1, STAT4, A20, IFN-beta, TLR4",7.185E-02,1.654E-01,9,"IL-1 beta, TLR7, iC3b, Fc gamma RII alpha, ICAM1, STAT4, A20, IFN-beta, TLR4",
763,Neurophysiological process_Dopamine D2 receptor transactivation of PDGFR in CNS,26,7.198E-02,1.426E-01,7.930E-02,1.426E-01,4,"PKC, PDGF receptor, G-protein alpha-i family, PDGF-R-beta",7.198E-02,1.654E-01,4,"PKC, PDGF receptor, G-protein alpha-i family, PDGF-R-beta",
764,Pioglitazone and Rosiglitazone in treatment of type 2 diabetes and metabolic syndrome X,26,7.198E-02,1.426E-01,7.930E-02,1.426E-01,4,"IL-6, SORBS1, IRS-2, VLDLR",7.198E-02,1.654E-01,4,"IL-6, SORBS1, IRS-2, VLDLR",
765,CD8+ Tc1 cells in allergic contact dermatitis,26,7.198E-02,1.426E-01,7.930E-02,1.426E-01,4,"IL-1 beta, TNF-R2, MHC class II, Caspase-1",7.198E-02,1.654E-01,4,"IL-1 beta, TNF-R2, MHC class II, Caspase-1",
766,Putative role of Estrogen receptor and Androgen receptor signaling in progression of lung cancer,58,7.318E-02,1.341E-01,7.318E-02,1.341E-01,7,"BAD, ERK2 (MAPK1), CYP1A1, Caveolin-1, EGFR, G-protein alpha-i family, ERK1/2",4.808E-01,6.459E-01,4,"CYP1A1, Caveolin-1, EGFR, G-protein alpha-i family",
767,Signal transduction_Leptin signaling in non-neuronal cells,58,7.318E-02,1.341E-01,7.318E-02,1.341E-01,7,"STAT3, IL-6, PI3K cat class IA, TRPC4, AKT(PKB), IRS-2, IL-8",1.439E-01,2.712E-01,6,"IL-6, PI3K cat class IA, TRPC4, AKT(PKB), IRS-2, IL-8",
768,Immune response_Generation of memory CD4+ T cells,37,7.394E-02,1.467E-01,8.268E-02,1.467E-01,5,"IL-15, MHC class II, IL-15RA, IL7RA, CD44",7.394E-02,1.684E-01,5,"IL-15, MHC class II, IL-15RA, IL7RA, CD44",
769,Immune response_IL-4-responsive genes in type 2 immunity,70,7.482E-02,1.366E-01,7.482E-02,1.366E-01,8,"STAT3, COX-2 (PTGS2), ACTA2, AKT(PKB), Eotaxin-2, CCL2, Fibronectin, CCL7",1.370E-01,2.610E-01,7,"COX-2 (PTGS2), ACTA2, AKT(PKB), Eotaxin-2, CCL2, Fibronectin, CCL7",
770,Development_SSTR2 in regulation of cell proliferation,36,7.525E-02,1.366E-01,7.525E-02,1.366E-01,5,"PI3K cat class IA, AKT(PKB), Cyclin E, G-protein alpha-i family, ERK1/2",1.775E-01,3.127E-01,4,"PI3K cat class IA, AKT(PKB), Cyclin E, G-protein alpha-i family",
771,Immune response_IL-12-induced IFN-gamma production,36,7.525E-02,1.366E-01,7.525E-02,1.366E-01,5,"STAT3, IL-18R1, iNOS, STAT4, ERM",1.775E-01,3.127E-01,4,"IL-18R1, iNOS, STAT4, ERM",
772,Immune response_KLRK1 (NKG2D) signaling pathway,47,7.532E-02,1.366E-01,7.532E-02,1.366E-01,6,"Syk, Fyn, PI3K cat class IA, Lck, AKT(PKB), ERK1/2",3.264E-01,4.902E-01,4,"Syk, Fyn, PI3K cat class IA, AKT(PKB)",
773,Canonical Notch signaling pathway in colorectal cancer,47,7.532E-02,1.366E-01,7.532E-02,1.366E-01,6,"Beta-catenin, HES5, AKT(PKB), CD44, Jagged1, WNT",1.599E-01,2.907E-01,5,"HES5, AKT(PKB), CD44, Jagged1, WNT",
774,Chemotaxis_Lipoxin inhibitory action on Formyl-Met-Leu-Phe-induced neutrophil chemotaxis,47,7.532E-02,1.366E-01,7.532E-02,1.366E-01,6,"Actin cytoskeletal, AKT(PKB), ICAM1, Lyn, G-protein alpha-i family, F-Actin cytoskeleton",3.264E-01,4.902E-01,4,"AKT(PKB), ICAM1, Lyn, G-protein alpha-i family",
775,Cytoskeleton remodeling_Substance P mediated membrane blebbing,16,7.694E-02,1.390E-01,7.694E-02,1.390E-01,3,"Myosin II, MLCK, MRLC",2.575E-01,4.146E-01,2,"MLCK, MRLC",
776,Sorafenib-induced inhibition of cell proliferation and angiogenesis in HCC,16,7.694E-02,1.390E-01,7.694E-02,1.390E-01,3,"ERK2 (MAPK1), ERK1/2, PDGF-R-beta",6.375E-01,7.912E-01,1,PDGF-R-beta,
777,c-Myc in multiple myeloma,16,7.694E-02,1.390E-01,7.694E-02,1.390E-01,3,"STAT3, IL-6, YB-1",6.375E-01,7.912E-01,1,IL-6,
778,Oxidative stress_Activation of NADPH oxidase,59,7.872E-02,1.421E-01,7.872E-02,1.421E-01,7,"cPKC (conventional), PI3K cat class IA, Rac2, PKC, AKT(PKB), PKC-alpha, ERK1/2",1.525E-01,2.806E-01,6,"cPKC (conventional), PI3K cat class IA, Rac2, PKC, AKT(PKB), PKC-alpha",
779,Immune response_Fc epsilon RI pathway: signaling through Fyn and PI3K,61,7.896E-02,1.569E-01,9.052E-02,1.569E-01,7,"Syk, SGK1, Fyn, AKT(PKB), LAMP3, Lyn, PI3K cat class IA (p110-delta)",7.896E-02,1.775E-01,7,"Syk, SGK1, Fyn, AKT(PKB), LAMP3, Lyn, PI3K cat class IA (p110-delta)",
780,Blood coagulation_GPCRs in platelet aggregation,71,7.989E-02,1.432E-01,7.989E-02,1.432E-01,8,"Myosin II, Actin cytoskeletal, MELC, PKC-alpha, ITGB3, G-protein alpha-i family, Adenylate cyclase, MRLC",2.696E-01,4.284E-01,6,"MELC, PKC-alpha, ITGB3, G-protein alpha-i family, Adenylate cyclase, MRLC",
781,Signal transduction_Adenosine A2B receptor signaling pathway,71,7.989E-02,1.432E-01,7.989E-02,1.432E-01,8,"IL-6, PI3K cat class IA, PKC, AKT(PKB), Adenosine A2b receptor, G-protein alpha-q/11, Adenylate cyclase, ERK1/2",1.445E-01,2.714E-01,7,"IL-6, PI3K cat class IA, PKC, AKT(PKB), Adenosine A2b receptor, G-protein alpha-q/11, Adenylate cyclase",
782,Notch signaling in oligodendrocyte precursor cell differentiation in multiple sclerosis,27,8.058E-02,1.551E-01,8.864E-02,1.551E-01,4,"SOX10, Myelin basic protein, HES5, Jagged1",8.058E-02,1.792E-01,4,"SOX10, Myelin basic protein, HES5, Jagged1",
783,Regulatory T cells in murine model of contact hypersensitivity,27,8.058E-02,1.551E-01,8.864E-02,1.551E-01,4,"TNF-R2, 5'-NTD, MHC class II, ICAM1",8.058E-02,1.792E-01,4,"TNF-R2, 5'-NTD, MHC class II, ICAM1",
784,Cell adhesion_Cell-matrix glycoconjugates,38,8.105E-02,1.569E-01,9.050E-02,1.569E-01,5,"NCAM1, CD44, Elastin, MMP-9, Versican",8.105E-02,1.792E-01,5,"NCAM1, CD44, Elastin, MMP-9, Versican",
785,Cytoskeleton remodeling_ACM3 and ACM4 in keratinocyte migration,38,8.105E-02,1.569E-01,9.050E-02,1.569E-01,5,"ACM4, iNOS, G-protein alpha-q/11, G-protein alpha-i family, ACM3",8.105E-02,1.792E-01,5,"ACM4, iNOS, G-protein alpha-q/11, G-protein alpha-i family, ACM3",
786,Role of type 2 innate lymphoid cells in asthma,38,8.105E-02,1.569E-01,9.050E-02,1.569E-01,5,"ST2(L), IL7RA, ETS1, IL-33, PI3K cat class IA (p110-delta)",8.105E-02,1.792E-01,5,"ST2(L), IL7RA, ETS1, IL-33, PI3K cat class IA (p110-delta)",
787,Oxidative stress_Role of IL-8 signaling pathway in respiratory burst,48,8.170E-02,1.457E-01,8.170E-02,1.457E-01,6,"Rac2, AKT(PKB), PKC-alpha, IL-8, G-protein alpha-i family, ERK1/2",1.701E-01,3.027E-01,5,"Rac2, AKT(PKB), PKC-alpha, IL-8, G-protein alpha-i family",
788,Development_Adiponectin signaling,48,8.170E-02,1.457E-01,8.170E-02,1.457E-01,6,"STAT3, IL-6, PI3K cat class IA, FGF2, AKT(PKB), ERK1/2",3.406E-01,5.065E-01,4,"IL-6, PI3K cat class IA, FGF2, AKT(PKB)",
789,IL-17-induced mucin expression in CF airways,48,8.170E-02,1.457E-01,8.170E-02,1.457E-01,6,"IL-1 beta, IL-6, MHC class II, TLR4, TLR2, ERK1/2",1.701E-01,3.027E-01,5,"IL-1 beta, IL-6, MHC class II, TLR4, TLR2",
790,GLP-1 in beta cell apoptosis in type 2 diabetes,48,8.170E-02,1.457E-01,8.170E-02,1.457E-01,6,"BAD, IL-1 beta, c-IAP2, IRS-2, p53, ERK1/2",5.724E-01,7.341E-01,3,"IL-1 beta, c-IAP2, IRS-2",
791,Development_Schema: Embryonal cardiomyogenesis,8,8.242E-02,1.543E-01,8.736E-02,1.543E-01,2,"Jagged1, BMP2",8.242E-02,1.819E-01,2,"Jagged1, BMP2",
792,Immune response_Oncostatin M signaling via MAPK,37,8.268E-02,1.467E-01,8.268E-02,1.467E-01,5,"MMP-13, OSMR, ERK2 (MAPK1), CCL2, ERK1/2",3.990E-01,5.626E-01,3,"MMP-13, OSMR, CCL2",
793,Immune response_IL-7 signaling in T lymphocytes,37,8.268E-02,1.467E-01,8.268E-02,1.467E-01,5,"STAT3, Fyn, Lck, AKT(PKB), IRS-2",3.990E-01,5.626E-01,3,"Fyn, AKT(PKB), IRS-2",
794,Immune response_Regulation of T cell function by CTLA-4,37,8.268E-02,1.467E-01,8.268E-02,1.467E-01,5,"Fyn, PI3K cat class IA, Lck, AKT(PKB), Lyn",1.900E-01,3.306E-01,4,"Fyn, PI3K cat class IA, AKT(PKB), Lyn",
795,Neurophysiological process_Regulation of intrinsic membrane properties and excitability of cortical pyramidal neurons,74,8.311E-02,1.660E-01,9.626E-02,1.660E-01,8,"cPKC (conventional), TRPC4, SCN2A, PKC, G-protein alpha-q/11, G-protein alpha-i family, Adenylate cyclase, ACM3",8.311E-02,1.832E-01,8,"cPKC (conventional), TRPC4, SCN2A, PKC, G-protein alpha-q/11, G-protein alpha-i family, Adenylate cyclase, ACM3",
796,Neutrophil resistance to apoptosis in COPD and proresolving impact of lipid mediators,60,8.450E-02,1.494E-01,8.450E-02,1.494E-01,7,"BAD, PI3K cat class IA, SAA1, AKT(PKB), TNF-R2 soluble, Caspase-8, ERK1/2",5.076E-01,6.739E-01,4,"PI3K cat class IA, SAA1, AKT(PKB), TNF-R2 soluble",
797,Oxidative stress_ROS-mediated MAPK activation via canonical pathways,60,8.450E-02,1.494E-01,8.450E-02,1.494E-01,7,"GSTP1, Fyn, ERK2 (MAPK1), SFK, EGFR, ERK1/2, PDGF-R-beta",3.077E-01,4.693E-01,5,"GSTP1, Fyn, SFK, EGFR, PDGF-R-beta",
798,Immune response_TCR alpha/beta signaling pathway,97,8.753E-02,1.544E-01,8.753E-02,1.544E-01,10,"Fyn, MHC class II, Lck, PKC-theta, TRPC3, AKT(PKB), PKC-alpha, Caspase-8, GRAP2, ERK1/2",3.866E-01,5.519E-01,7,"Fyn, MHC class II, PKC-theta, TRPC3, AKT(PKB), PKC-alpha, GRAP2",
799,Breakdown of CD4+ T cell peripheral tolerance in type 1 diabetes mellitus,49,8.837E-02,1.551E-01,8.837E-02,1.551E-01,6,"HLA-DRB1, MHC class II, Lck, PTPN22, STAT4, PD-L1",1.805E-01,3.149E-01,5,"HLA-DRB1, MHC class II, PTPN22, STAT4, PD-L1",
800,Demyelination in multiple sclerosis,49,8.837E-02,1.551E-01,8.837E-02,1.551E-01,6,"Myelin basic protein, iNOS, AKT(PKB), Caspase-8, p53, MMP-9",3.549E-01,5.220E-01,4,"Myelin basic protein, iNOS, AKT(PKB), MMP-9",
801,Nociception_Pro-nociceptive action of Nociceptin in spinal cord at low doses,39,8.852E-02,1.679E-01,9.867E-02,1.679E-01,5,"Histamine H1 receptor, PGE2R4, GABA-A receptor, NR2A, NR2",8.852E-02,1.926E-01,5,"Histamine H1 receptor, PGE2R4, GABA-A receptor, NR2A, NR2",
802,G-protein signaling_G-Protein alpha-i signaling cascades,27,8.864E-02,1.551E-01,8.864E-02,1.551E-01,4,"STAT3, Caveolin-1, G-protein alpha-i family, ERK1/2",5.005E-01,6.664E-01,2,"Caveolin-1, G-protein alpha-i family",
803,Desensitization of Beta-2 adrenergic receptor signaling and reduction of relaxation,27,8.864E-02,1.551E-01,8.864E-02,1.551E-01,4,"IL-1 beta, Beta-2 adrenergic receptor, G-protein alpha-i family, ERK1/2",2.287E-01,3.780E-01,3,"IL-1 beta, Beta-2 adrenergic receptor, G-protein alpha-i family",
804,IL-1 production in melanoma,17,8.919E-02,1.557E-01,8.919E-02,1.557E-01,3,"IL-1 beta, Caspase-1, ERK1/2",2.809E-01,4.392E-01,2,"IL-1 beta, Caspase-1",
805,Involvement of VEGF signaling in the progression of lung cancer,17,8.919E-02,1.557E-01,8.919E-02,1.557E-01,3,"Fyn, AKT(PKB), ERK1/2",2.809E-01,4.392E-01,2,"Fyn, AKT(PKB)",
806,Immune response_IFN-gamma actions on blood cells,28,8.966E-02,1.679E-01,9.848E-02,1.679E-01,4,"IL-15, IL-6, PD-L2, PD-L1",8.966E-02,1.935E-01,4,"IL-15, IL-6, PD-L2, PD-L1",
807,Platelet activation during ADAM-TS13-deficient thrombotic microangiopathy development,28,8.966E-02,1.679E-01,9.848E-02,1.679E-01,4,"Fc gamma RII alpha, Fibronectin, Collagen VI, Collagen III",8.966E-02,1.935E-01,4,"Fc gamma RII alpha, Fibronectin, Collagen VI, Collagen III",
808,Apoptosis and survival_Anti-apoptotic action of membrane-bound ESR1,38,9.050E-02,1.569E-01,9.050E-02,1.569E-01,5,"BAD, PI3K cat class IA, AKT(PKB), PKC-alpha, ERK1/2",4.158E-01,5.821E-01,3,"PI3K cat class IA, AKT(PKB), PKC-alpha",
809,Development_SDF-1 signaling in hematopoietic stem cell homing,38,9.050E-02,1.569E-01,9.050E-02,1.569E-01,5,"PI3K cat class IA, alpha-4/beta-1 integrin, Lyn, MMP-9, ERK1/2",2.029E-01,3.462E-01,4,"PI3K cat class IA, alpha-4/beta-1 integrin, Lyn, MMP-9",
810,Neurophysiological process_GABAergic neurotransmission,51,9.086E-02,1.726E-01,1.026E-01,1.726E-01,6,"ALDR, GABA-A receptor, GAD1, GAT1, G-protein alpha-i family, SLC7A7",9.086E-02,1.937E-01,6,"ALDR, GABA-A receptor, GAD1, GAT1, G-protein alpha-i family, SLC7A7",
811,Development_Beta-adrenergic receptors signaling via Cyclic AMP,51,9.086E-02,1.726E-01,1.026E-01,1.726E-01,6,"PPARGC1 (PGC1-alpha), Beta-2 adrenergic receptor, AKAP6, PDE3A, Troponin C, cardiac, Adenylate cyclase",9.086E-02,1.937E-01,6,"PPARGC1 (PGC1-alpha), Beta-2 adrenergic receptor, AKAP6, PDE3A, Troponin C, cardiac, Adenylate cyclase",
812,Signal transduction_NF-kB activation pathways,51,9.086E-02,1.726E-01,1.026E-01,1.726E-01,6,"IL-1 beta, c-IAP2, Pellino 1, Pellino 2, TLR4, TLR2",9.086E-02,1.937E-01,6,"IL-1 beta, c-IAP2, Pellino 1, Pellino 2, TLR4, TLR2",
813,Neurophysiological process_Corticoliberin signaling via CRHR1 ,50,9.533E-02,1.646E-01,9.533E-02,1.646E-01,6,"POMC, cPKC (conventional), ERK2 (MAPK1), G-protein alpha-q/11, PKC-alpha, Adenylate cyclase",1.912E-01,3.310E-01,5,"POMC, cPKC (conventional), G-protein alpha-q/11, PKC-alpha, Adenylate cyclase",
814,Suppression of p53 signaling in multiple myeloma,50,9.533E-02,1.646E-01,9.533E-02,1.646E-01,6,"IL-6, NOXA, p14ARF, p53 (mitochondrial), Caspase-8, p53",6.004E-01,7.629E-01,3,"IL-6, NOXA, p14ARF",
815,TGF-beta signaling via microRNA in breast cancer,50,9.533E-02,1.646E-01,9.533E-02,1.646E-01,6,"TGF-beta 2, SMAD3, TCF8, ETS1, SLUG, SIP1 (ZFHX1B)",1.912E-01,3.310E-01,5,"TGF-beta 2, TCF8, ETS1, SLUG, SIP1 (ZFHX1B)",
816,Neurophysiological process_Delta-type opioid receptor in the nervous system,40,9.633E-02,1.783E-01,1.072E-01,1.783E-01,5,"PDE1A, PDE1C, Metenkefalin, Leu-enkephalin, G-protein alpha-i family",9.633E-02,2.023E-01,5,"PDE1A, PDE1C, Metenkefalin, Leu-enkephalin, G-protein alpha-i family",
817,Memory CD8+ T cells in allergic contact dermatitis,40,9.633E-02,1.783E-01,1.072E-01,1.783E-01,5,"IL-15, IL-1 beta, IL7RA, alpha-4/beta-1 integrin, ICAM1",9.633E-02,2.023E-01,5,"IL-15, IL-1 beta, IL7RA, alpha-4/beta-1 integrin, ICAM1",
818,Immune response_Th1 and Th2 cell differentiation,40,9.633E-02,1.783E-01,1.072E-01,1.783E-01,5,"MHC class II, CD137 ligand(TNFSF9), RUNX3, CD137(TNFRSF9), STAT4",9.633E-02,2.023E-01,5,"MHC class II, CD137 ligand(TNFSF9), RUNX3, CD137(TNFRSF9), STAT4",
819,Role of IGH translocations in multiple myeloma,40,9.633E-02,1.783E-01,1.072E-01,1.783E-01,5,"N-cadherin, NCAM1, ITGA5, BLIMP1 (PRDI-BF1), CDK6",9.633E-02,2.023E-01,5,"N-cadherin, NCAM1, ITGA5, BLIMP1 (PRDI-BF1), CDK6",
820,Oxidative stress in adipocyte dysfunction in type 2 diabetes and metabolic syndrome X,64,9.638E-02,1.809E-01,1.100E-01,1.809E-01,7,"IL-6, PI3K cat class IA, AKT(PKB), PLA2, IRS-2, CCL2, Xanthine oxidase",9.638E-02,2.023E-01,7,"IL-6, PI3K cat class IA, AKT(PKB), PLA2, IRS-2, CCL2, Xanthine oxidase",
821,Renin-Angiotensin-Aldosterone System,62,9.677E-02,1.664E-01,9.677E-02,1.664E-01,7,"CaMK I, G-protein alpha-q/11, RGS2, PKC-alpha, cPLA2, MDR1, ERK1/2",1.794E-01,3.149E-01,6,"CaMK I, G-protein alpha-q/11, RGS2, PKC-alpha, cPLA2, MDR1",
822,Regulation of microRNAs in colorectal cancer,62,9.677E-02,1.664E-01,9.677E-02,1.664E-01,7,"STAT3, MECOM, AKT(PKB), p53, HGF receptor (Met), LIN-28B, EGFR",3.323E-01,4.947E-01,5,"MECOM, AKT(PKB), HGF receptor (Met), LIN-28B, EGFR",
823,SLE genetic marker-specific pathways in B cells,99,9.712E-02,1.668E-01,9.712E-02,1.668E-01,10,"Syk, TLR7, CalDAG-GEFIII, CD38, ETS1, Lyn, IFN-beta, TLR4, BLIMP1 (PRDI-BF1), ERK1/2",1.538E-01,2.811E-01,9,"Syk, TLR7, CalDAG-GEFIII, CD38, ETS1, Lyn, IFN-beta, TLR4, BLIMP1 (PRDI-BF1)",
824,Immune response_T cell subsets: cell surface markers,52,9.768E-02,1.809E-01,1.101E-01,1.809E-01,6,"ST2(L), CD94, IL-15RA, IL7RA, TCR beta subunit, CD44",9.768E-02,2.037E-01,6,"ST2(L), CD94, IL-15RA, IL7RA, TCR beta subunit, CD44",
825,Cell cycle_Regulation of G1/S transition (part 2),28,9.848E-02,1.679E-01,9.848E-02,1.679E-01,4,"AKT(PKB), Cyclin E, ERK1/2, CDK6",2.454E-01,3.984E-01,3,"AKT(PKB), Cyclin E, CDK6",
826,"Immune response_Th17, Th22 and Th9 cell differentiation ",39,9.867E-02,1.679E-01,9.867E-02,1.679E-01,5,"STAT3, IL-1 beta, IL-6, MHC class II, TGF-beta receptor type II",2.159E-01,3.622E-01,4,"IL-1 beta, IL-6, MHC class II, TGF-beta receptor type II",
827,Role of neurotrophins in activation of p53 in major depressive disorder,39,9.867E-02,1.679E-01,9.867E-02,1.679E-01,5,"NGF, NGFR(TNFRSF16), PI3K cat class IA, p53, PLAT (TPA)",2.159E-01,3.622E-01,4,"NGF, NGFR(TNFRSF16), PI3K cat class IA, PLAT (TPA)",
828,TrkB signaling in Huntington's disease,39,9.867E-02,1.679E-01,9.867E-02,1.679E-01,5,"NGFR(TNFRSF16), PI3K cat class IA, PKC, NR2A, ERK1/2",2.159E-01,3.622E-01,4,"NGFR(TNFRSF16), PI3K cat class IA, PKC, NR2A",
829,Translation _Regulation of EIF2 activity,39,9.867E-02,1.679E-01,9.867E-02,1.679E-01,5,"PI3K cat class IA, AKT(PKB), IRS-2, EGFR, ERK1/2",2.159E-01,3.622E-01,4,"PI3K cat class IA, AKT(PKB), IRS-2, EGFR",
830,Role of IFN-beta in activation of T cell apoptosis in multiple sclerosis,29,9.921E-02,1.803E-01,1.088E-01,1.803E-01,4,"c-IAP2, 5'-NTD, AKT(PKB), IFN-beta",9.921E-02,2.061E-01,4,"c-IAP2, 5'-NTD, AKT(PKB), IFN-beta",
831,Transcription_Assembly of RNA Polymerase II preinitiation complex on TATA-less promoters ,18,1.022E-01,1.726E-01,1.022E-01,1.726E-01,3,"PCNA, p15, MDR1",3.041E-01,4.660E-01,2,"p15, MDR1",
832,Androgen signaling in HCC,18,1.022E-01,1.726E-01,1.022E-01,1.726E-01,3,"HGF, p53, HGF receptor (Met)",3.041E-01,4.660E-01,2,"HGF, HGF receptor (Met)",
833,HIF-1 in gastric cancer,51,1.026E-01,1.726E-01,1.026E-01,1.726E-01,6,"COX-2 (PTGS2), PGE2R2, AKT(PKB), p53, MDR1, ERK1/2",3.833E-01,5.478E-01,4,"COX-2 (PTGS2), PGE2R2, AKT(PKB), MDR1",
834,Signal transduction_PKA signaling,51,1.026E-01,1.726E-01,1.026E-01,1.726E-01,6,"BAD, SMAD3, AKAP12, PDE3A, G-protein alpha-i family, Adenylate cyclase",3.833E-01,5.478E-01,4,"AKAP12, PDE3A, G-protein alpha-i family, Adenylate cyclase",
835,Anti-apoptotic action of ErbB2 in breast cancer,51,1.026E-01,1.726E-01,1.026E-01,1.726E-01,6,"BAD, STAT3, AKT(PKB), ITGA5, EGFR, ERK1/2",6.140E-01,7.700E-01,3,"AKT(PKB), ITGA5, EGFR",
836,Immune response_BAFF-induced signaling,51,1.026E-01,1.726E-01,1.026E-01,1.726E-01,6,"BAD, ERK2 (MAPK1), AKT(PKB), TRIM2, PI3K cat class IA (p110-delta), ERK1/2",6.140E-01,7.700E-01,3,"AKT(PKB), TRIM2, PI3K cat class IA (p110-delta)",
837,Apoptosis and survival_CXCR3-B signaling,63,1.032E-01,1.733E-01,1.032E-01,1.733E-01,7,"STAT3, IDO2, p53, I-TAC, ITGB3, Adenylate cyclase, ERK1/2",5.466E-01,7.111E-01,4,"IDO2, I-TAC, ITGB3, Adenylate cyclase",
838,Neuroprotective action of lithium,63,1.032E-01,1.733E-01,1.032E-01,1.733E-01,7,"Beta-catenin, p53, NR2A, Dsh, WNT, NR2, Frizzled",5.466E-01,7.111E-01,4,"NR2A, WNT, NR2, Frizzled",
839,TLRs-mediated IFN-alpha production by plasmacytoid dendritic cells in SLE,53,1.048E-01,1.919E-01,1.179E-01,1.919E-01,6,"TLR7, AKT(PKB), Fc gamma RII alpha, A20, Pim-1, PI3K cat class IA (p110-delta)",1.048E-01,2.146E-01,6,"TLR7, AKT(PKB), Fc gamma RII alpha, A20, Pim-1, PI3K cat class IA (p110-delta)",
840,Activation of Cortisol production in major depressive disorder,40,1.072E-01,1.783E-01,1.072E-01,1.783E-01,5,"IL-6, ACTH, MDR1, ERK1/2, CYP11A1",2.292E-01,3.780E-01,4,"IL-6, ACTH, MDR1, CYP11A1",
841,Apoptosis and survival_Ceramides signaling pathway,40,1.072E-01,1.783E-01,1.072E-01,1.783E-01,5,"BAD, PI3K cat class IA, AKT(PKB), Caspase-8, ERK1/2",7.139E-01,8.462E-01,2,"PI3K cat class IA, AKT(PKB)",
842,Role of glycosphingolipids in inhibition of Insulin signaling,40,1.072E-01,1.783E-01,1.072E-01,1.783E-01,5,"Actin cytoskeletal, SORBS1, B4G6, AKT(PKB), Caveolin-1",2.292E-01,3.780E-01,4,"SORBS1, B4G6, AKT(PKB), Caveolin-1",
843,Stem cells_Response to hypoxia in glioblastoma stem cells,40,1.072E-01,1.783E-01,1.072E-01,1.783E-01,5,"HES5, p53, Jagged1, BMP4, BMP2",2.292E-01,3.780E-01,4,"HES5, Jagged1, BMP4, BMP2",
844,Protein folding_Membrane trafficking and signal transduction of G-alpha (i) heterotrimeric G-protein,19,1.075E-01,1.896E-01,1.159E-01,1.896E-01,3,"RGS4, G-protein gamma, G-protein alpha-i family",1.075E-01,2.192E-01,3,"RGS4, G-protein gamma, G-protein alpha-i family",
845,Schema: Initiation of T cell recruitment in allergic contact dermatitis,19,1.075E-01,1.896E-01,1.159E-01,1.896E-01,3,"alpha-4/beta-1 integrin, ICAM1, CD1d",1.075E-01,2.192E-01,3,"alpha-4/beta-1 integrin, ICAM1, CD1d",
846,Immune response_ETV3 affect on CSF1-promoted macrophage differentiation,19,1.075E-01,1.896E-01,1.159E-01,1.896E-01,3,"CSF1, MSR1, PLAU (UPA)",1.075E-01,2.192E-01,3,"CSF1, MSR1, PLAU (UPA)",
847,Immune response_Delta-type opioid receptor signaling in T-cells,29,1.088E-01,1.803E-01,1.088E-01,1.803E-01,4,"Metenkefalin, ERK2 (MAPK1), AKT(PKB), G-protein alpha-i family",2.623E-01,4.193E-01,3,"Metenkefalin, AKT(PKB), G-protein alpha-i family",
848,Immune response_CD137 signaling in immune cell,29,1.088E-01,1.803E-01,1.088E-01,1.803E-01,4,"CD137 ligand(TNFSF9), CD137(TNFRSF9), Cyclin E, ERK1/2",2.623E-01,4.193E-01,3,"CD137 ligand(TNFSF9), CD137(TNFRSF9), Cyclin E",
849,Immune response_Reactive oxygen species (ROS) in IL-4 signaling,66,1.091E-01,2.010E-01,1.241E-01,2.010E-01,7,"DUOX2, cPKC (conventional), iNOS, PKC, PDE3A, PKC-alpha, DUOXA1",1.091E-01,2.213E-01,7,"DUOX2, cPKC (conventional), iNOS, PKC, PDE3A, PKC-alpha, DUOXA1",
850,Muscle contraction_S1P2 receptor-mediated smooth muscle contraction,30,1.092E-01,1.940E-01,1.196E-01,1.940E-01,4,"CPI-17, PKC-alpha, MLCK, MRLC",1.092E-01,2.213E-01,4,"CPI-17, PKC-alpha, MLCK, MRLC",
851,Development_TGF-beta receptor signaling,52,1.101E-01,1.809E-01,1.101E-01,1.809E-01,6,"p15, SMAD3, Caveolin-1, ER81, TGF-beta receptor type II, ERK1/2",3.975E-01,5.626E-01,4,"p15, Caveolin-1, ER81, TGF-beta receptor type II",
852,Development_FGF-family signaling,52,1.101E-01,1.809E-01,1.101E-01,1.809E-01,6,"PI3K cat class IA, FGF2, ERK2 (MAPK1), AKT(PKB), PKC-alpha, FGF9",2.133E-01,3.599E-01,5,"PI3K cat class IA, FGF2, AKT(PKB), PKC-alpha, FGF9",
853,G-protein signaling_Proinsulin C-peptide signaling,52,1.101E-01,1.809E-01,1.101E-01,1.809E-01,6,"COX-2 (PTGS2), PI3K cat class IA, AKT(PKB), PKC-alpha, G-protein alpha-i family, ERK1/2",2.133E-01,3.599E-01,5,"COX-2 (PTGS2), PI3K cat class IA, AKT(PKB), PKC-alpha, G-protein alpha-i family",
854,Stem cells_mGluR3 signaling in glioblastoma stem cells,52,1.101E-01,1.809E-01,1.101E-01,1.809E-01,6,"AKT(PKB), G-protein alpha-i family, Adenylate cyclase, GLAST1/EAAT1, SLC7A11, ERK1/2",2.133E-01,3.599E-01,5,"AKT(PKB), G-protein alpha-i family, Adenylate cyclase, GLAST1/EAAT1, SLC7A11",
855,Signal transduction_Adenosine A2A receptor signaling pathway,52,1.101E-01,1.809E-01,1.101E-01,1.809E-01,6,"AKT(PKB), SFK, Adenylate cyclase, G-protein alpha-olf, ERK1/2, Collagen III",2.133E-01,3.599E-01,5,"AKT(PKB), SFK, Adenylate cyclase, G-protein alpha-olf, Collagen III",
856,Blood coagulation_GPVI-dependent platelet activation,54,1.121E-01,2.022E-01,1.259E-01,2.022E-01,6,"Syk, Fyn, PKC-alpha, GRAP2, ITGB3, Lyn",1.121E-01,2.259E-01,6,"Syk, Fyn, PKC-alpha, GRAP2, ITGB3, Lyn",
857,Regulation of AKT(PKB)/ GSK3 beta cascade in bipolar disorder,54,1.121E-01,2.022E-01,1.259E-01,2.022E-01,6,"NGF, G-protein alpha-i1, PI3K cat class IA, FGF2, AKT(PKB), G-protein alpha-i family",1.121E-01,2.259E-01,6,"NGF, G-protein alpha-i1, PI3K cat class IA, FGF2, AKT(PKB), G-protein alpha-i family",
858,Serotonin modulation of dopamine release in nicotine addiction,42,1.129E-01,2.021E-01,1.253E-01,2.021E-01,5,"HTR3, PKC, GABA-A receptor, G-protein alpha-i family, Adenylate cyclase",1.129E-01,2.269E-01,5,"HTR3, PKC, GABA-A receptor, G-protein alpha-i family, Adenylate cyclase",
859,Inhibition of WNT5A-dependent non-canonical pathway in colorectal cancer,19,1.159E-01,1.896E-01,1.159E-01,1.896E-01,3,"Beta-catenin, PKC-alpha, TCF7 (TCF1)",3.273E-01,4.904E-01,2,"PKC-alpha, TCF7 (TCF1)",
860,Immune response_Neurotensin-induced activation of IL-8 in colonocytes,41,1.161E-01,1.896E-01,1.161E-01,1.896E-01,5,"ERK2 (MAPK1), PKC-alpha, IL-8, NT, G-protein alpha-i family",2.427E-01,3.945E-01,4,"PKC-alpha, IL-8, NT, G-protein alpha-i family",
861,Apoptosis and survival_Role of PKR in stress-induced apoptosis,53,1.179E-01,1.919E-01,1.179E-01,1.919E-01,6,"Caspase-8, p53, TLR3, IFN-beta, TLR4, ERK1/2",6.402E-01,7.912E-01,3,"TLR3, IFN-beta, TLR4",
862,"Development_Insulin, IGF-1 and TNF-alpha in brown adipocyte differentiation",53,1.179E-01,1.919E-01,1.179E-01,1.919E-01,6,"FOXC2, PPARGC1 (PGC1-alpha), Beta-2 adrenergic receptor, AKT(PKB), IRS-2, ERK1/2",2.246E-01,3.748E-01,5,"FOXC2, PPARGC1 (PGC1-alpha), Beta-2 adrenergic receptor, AKT(PKB), IRS-2",
863,Development_Osteopontin signaling in osteoclasts,30,1.196E-01,1.940E-01,1.196E-01,1.940E-01,4,"Syk, Actin cytoskeletal, CD44, MSN (moesin)",2.793E-01,4.382E-01,3,"Syk, CD44, MSN (moesin)",
864,T regulatory cells in asthma,30,1.196E-01,1.940E-01,1.196E-01,1.940E-01,4,"STAT3, MHC class II, SMAD3, TGF-beta receptor type II",5.578E-01,7.195E-01,2,"MHC class II, TGF-beta receptor type II",
865,Neurophysiological process_Kappa-type opioid receptor in transmission of nerve impulses,31,1.196E-01,2.078E-01,1.308E-01,2.078E-01,4,"Kir3.4, DREAM, G-protein alpha-i family, Kappa-type opioid receptor",1.196E-01,2.373E-01,4,"Kir3.4, DREAM, G-protein alpha-i family, Kappa-type opioid receptor",
866,CCL2 in Prostate Cancer,20,1.210E-01,2.078E-01,1.303E-01,2.078E-01,3,"AKT(PKB), CCL2, G-protein alpha-i family",1.210E-01,2.379E-01,3,"AKT(PKB), CCL2, G-protein alpha-i family",
867,Role of XBP1 protein in multiple myeloma,20,1.210E-01,2.078E-01,1.303E-01,2.078E-01,3,"IL-6, BOB1, BLIMP1 (PRDI-BF1)",1.210E-01,2.379E-01,3,"IL-6, BOB1, BLIMP1 (PRDI-BF1)",
868,Immune response_Antimicrobial actions of IFN-gamma,43,1.217E-01,2.126E-01,1.349E-01,2.126E-01,5,"IDO1, TLR3, NGAL, Staf-50, MD-2",1.217E-01,2.379E-01,5,"IDO1, TLR3, NGAL, Staf-50, MD-2",
869,Signal transduction_Modulation of calcium and potassium channels by Adenosine A1 receptor,43,1.217E-01,2.126E-01,1.349E-01,2.126E-01,5,"cPKC (conventional), PKC-alpha, cPLA2, G-protein alpha-i family, Adenylate cyclase",1.217E-01,2.379E-01,5,"cPKC (conventional), PKC-alpha, cPLA2, G-protein alpha-i family, Adenylate cyclase",
870,Role of TNF-alpha in type 2 diabetes in skeletal muscle cells,42,1.253E-01,2.021E-01,1.253E-01,2.021E-01,5,"PPARGC1 (PGC1-alpha), HGK(MAP4K4), PKC-theta, ERK2 (MAPK1), PKC-alpha",2.564E-01,4.132E-01,4,"PPARGC1 (PGC1-alpha), HGK(MAP4K4), PKC-theta, PKC-alpha",
871,Apoptosis and survival_BAD phosphorylation,42,1.253E-01,2.021E-01,1.253E-01,2.021E-01,5,"BAD, PI3K cat class IA, AKT(PKB), EGFR, ERK1/2",4.813E-01,6.459E-01,3,"PI3K cat class IA, AKT(PKB), EGFR",
872,Inhibition of GTPase prenylation by statins in asthma and COPD,42,1.253E-01,2.021E-01,1.253E-01,2.021E-01,5,"COX-2 (PTGS2), IL-6, AKT(PKB), IL-8, ERK1/2",2.564E-01,4.132E-01,4,"COX-2 (PTGS2), IL-6, AKT(PKB), IL-8",
873,Immune response_IFN-gamma signaling via JAK/STAT and PLC-gamma,54,1.259E-01,2.022E-01,1.259E-01,2.022E-01,6,"STAT3, NOXA, Fyn, PKC-alpha, XAF1, Aquaporin 1",2.360E-01,3.873E-01,5,"NOXA, Fyn, PKC-alpha, XAF1, Aquaporin 1",
874,Development_Differentiation of white adipocytes ,54,1.259E-01,2.022E-01,1.259E-01,2.022E-01,6,"FOXC2, PPARGC1 (PGC1-alpha), BMP4, PSAT, BMP2, ERK1/2",2.360E-01,3.873E-01,5,"FOXC2, PPARGC1 (PGC1-alpha), BMP4, PSAT, BMP2",
875,Muscle contraction_ACM regulation of smooth muscle contraction,56,1.275E-01,2.236E-01,1.428E-01,2.236E-01,6,"TRPC4, CPI-17, PKC, MLCK, MRLC, ACM3",1.275E-01,2.474E-01,6,"TRPC4, CPI-17, PKC, MLCK, MRLC, ACM3",
876,Neurogenesis_NGF/ TrkA MAPK-mediated signaling,105,1.294E-01,2.075E-01,1.294E-01,2.075E-01,10,"NGF, SHPS-1, PLAUR (uPAR), SGK1, SORBS1, RGS2, Fra-1, Ephrin-A receptor 2, ERK1/2, MEF2C",1.957E-01,3.359E-01,9,"NGF, SHPS-1, PLAUR (uPAR), SGK1, SORBS1, RGS2, Fra-1, Ephrin-A receptor 2, MEF2C",
877,Stem cells_Putative pathways of telomerase regulation in glioblastoma stem cells,20,1.303E-01,2.078E-01,1.303E-01,2.078E-01,3,"PI3K cat class IA, AKT(PKB), p53",3.502E-01,5.162E-01,2,"PI3K cat class IA, AKT(PKB)",
878,wtCFTR and deltaF508-CFTR traffic / Clathrin coated vesicles formation (normal and CF),20,1.303E-01,2.078E-01,1.303E-01,2.078E-01,3,"Actin cytoskeletal, AP180, Actin",3.502E-01,5.162E-01,2,"AP180, Actin",
879,Th2 cytokine-induced alternative activation of alveolar macrophages in asthma,32,1.305E-01,2.235E-01,1.424E-01,2.235E-01,4,"CHI3L1, ST2(L), Eotaxin-2, IL-33",1.305E-01,2.510E-01,4,"CHI3L1, ST2(L), Eotaxin-2, IL-33",
880,Selective Insulin resistance in type 2 diabetes in liver,32,1.305E-01,2.235E-01,1.424E-01,2.235E-01,4,"PPARGC1 (PGC1-alpha), PKC-theta, AKT(PKB), IRS-2",1.305E-01,2.510E-01,4,"PPARGC1 (PGC1-alpha), PKC-theta, AKT(PKB), IRS-2",
881,Development_Activation of ERK by Kappa-type opioid receptor,31,1.308E-01,2.078E-01,1.308E-01,2.078E-01,4,"ERK2 (MAPK1), PKC-alpha, G-protein alpha-i family, Kappa-type opioid receptor",2.964E-01,4.587E-01,3,"PKC-alpha, G-protein alpha-i family, Kappa-type opioid receptor",
882,Development_FGF and BMP signaling in early embryonic hepatogenesis,31,1.308E-01,2.078E-01,1.308E-01,2.078E-01,4,"FGF2, BMP4, BMP2, ERK1/2",2.964E-01,4.587E-01,3,"FGF2, BMP4, BMP2",
883,Immune response_IL-23 signaling pathway,31,1.308E-01,2.078E-01,1.308E-01,2.078E-01,4,"STAT3, PI3K cat class IA, AKT(PKB), STAT4",2.964E-01,4.587E-01,3,"PI3K cat class IA, AKT(PKB), STAT4",
884,Impaired Lipoxin A4 signaling in CF,44,1.308E-01,2.258E-01,1.447E-01,2.258E-01,5,"G-protein alpha-q/11, EGFR, G-protein alpha-i family, Adenylate cyclase, PDGF-R-beta",1.308E-01,2.510E-01,5,"G-protein alpha-q/11, EGFR, G-protein alpha-i family, Adenylate cyclase, PDGF-R-beta",
885,Development_Thrombopoietin signaling via ERK1/2 and PI3K,67,1.314E-01,2.086E-01,1.314E-01,2.086E-01,7,"HOXA9, NF-E2 (45 kDa), PI3K cat class IA, AKT(PKB), IRS-2, BMP4, ERK1/2",2.280E-01,3.780E-01,6,"HOXA9, NF-E2 (45 kDa), PI3K cat class IA, AKT(PKB), IRS-2, BMP4",
886,B cell signaling in hematological malignancies,80,1.342E-01,2.124E-01,1.342E-01,2.124E-01,8,"STAT3, Syk, IL-6, AKT(PKB), CD38, Lyn, CD70(TNFSF7), PI3K cat class IA (p110-delta)",2.197E-01,3.680E-01,7,"Syk, IL-6, AKT(PKB), CD38, Lyn, CD70(TNFSF7), PI3K cat class IA (p110-delta)",
887,Tau pathology in Alzheimer disease,55,1.343E-01,2.124E-01,1.343E-01,2.124E-01,6,"PKC, ERK2 (MAPK1), Caspase-8, NR2, MAP2, ERK1/2",6.651E-01,8.110E-01,3,"PKC, NR2, MAP2",
888,Development_Fetal brown fat cell differentiation,55,1.343E-01,2.124E-01,1.343E-01,2.124E-01,6,"PPARGC1 (PGC1-alpha), PI3K cat class IA, AKT(PKB), IRS-2, Adenylate cyclase, ERK1/2",2.477E-01,4.006E-01,5,"PPARGC1 (PGC1-alpha), PI3K cat class IA, AKT(PKB), IRS-2, Adenylate cyclase",
889,Neurophysiological process_HTR1A receptor signaling in neuronal cells,43,1.349E-01,2.126E-01,1.349E-01,2.126E-01,5,"ERK2 (MAPK1), Kir3.4, G-protein alpha-i family, Adenylate cyclase, MAP2",2.702E-01,4.284E-01,4,"Kir3.4, G-protein alpha-i family, Adenylate cyclase, MAP2",
890,Nicotine signaling (general schema),21,1.351E-01,2.258E-01,1.452E-01,2.258E-01,3,"nAChR alpha-7, HTR3, GABA-A receptor",1.351E-01,2.587E-01,3,"nAChR alpha-7, HTR3, GABA-A receptor",
891,Muscle contraction_Role of kappa-type opioid receptor in heart,33,1.417E-01,2.394E-01,1.545E-01,2.394E-01,4,"Beta-2 adrenergic receptor, G-protein alpha-i family, Adenylate cyclase, Kappa-type opioid receptor",1.417E-01,2.681E-01,4,"Beta-2 adrenergic receptor, G-protein alpha-i family, Adenylate cyclase, Kappa-type opioid receptor",
892,Putative pathways for stimulation of fat cell differentiation by Bisphenol A,32,1.424E-01,2.235E-01,1.424E-01,2.235E-01,4,"Beta-catenin, PPARGC1 (PGC1-alpha), PI3K cat class IA, AKT(PKB)",3.135E-01,4.750E-01,3,"PPARGC1 (PGC1-alpha), PI3K cat class IA, AKT(PKB)",
893,Development_Transcription regulation of granulocyte development,32,1.424E-01,2.235E-01,1.424E-01,2.235E-01,4,"STAT3, c-Fes, PKC, CD13",3.135E-01,4.750E-01,3,"c-Fes, PKC, CD13",
894,Platelet activation as a result of endothelial dysfunction after stenting,56,1.428E-01,2.236E-01,1.428E-01,2.236E-01,6,"Actin cytoskeletal, PKC, PDE3A, PLAT (TPA), G-protein alpha-i family, Adenylate cyclase",2.595E-01,4.157E-01,5,"PKC, PDE3A, PLAT (TPA), G-protein alpha-i family, Adenylate cyclase",
895,Development_Flt3 signaling,44,1.447E-01,2.258E-01,1.447E-01,2.258E-01,5,"BAD, Fyn, PI3K cat class IA, AKT(PKB), ERK1/2",5.127E-01,6.787E-01,3,"Fyn, PI3K cat class IA, AKT(PKB)",
896,Chemotaxis_C5a-induced chemotaxis,44,1.447E-01,2.258E-01,1.447E-01,2.258E-01,5,"Actin cytoskeletal, G-protein alpha-15, G-protein alpha-i family, F-Actin cytoskeleton, ERK1/2",7.620E-01,8.737E-01,2,"G-protein alpha-15, G-protein alpha-i family",
897,Development_Beta-catenin destruction complex signaling,21,1.452E-01,2.258E-01,1.452E-01,2.258E-01,3,"Beta-catenin, Tcf(Lef), TCF7 (TCF1)",3.729E-01,5.379E-01,2,"Tcf(Lef), TCF7 (TCF1)",
898,HCV-dependent transcription regulation leading to HCC,21,1.452E-01,2.258E-01,1.452E-01,2.258E-01,3,"STAT3, p53, Cyclin E",7.361E-01,8.609E-01,1,Cyclin E,
899,Regulation of Adenylate cyclase and IMPA1 by lithium in major depressive disorder,22,1.496E-01,2.469E-01,1.606E-01,2.469E-01,3,"G-protein alpha-i1, G-protein alpha-i family, Adenylate cyclase",1.496E-01,2.774E-01,3,"G-protein alpha-i1, G-protein alpha-i family, Adenylate cyclase",
900,LRRK2 and immune function in Parkinson's disease,22,1.496E-01,2.469E-01,1.606E-01,2.469E-01,3,"MHC class II, CD14, IFN-beta",1.496E-01,2.774E-01,3,"MHC class II, CD14, IFN-beta",
901,G-protein signaling_RhoA regulation pathway,34,1.533E-01,2.541E-01,1.669E-01,2.541E-01,4,"Fyn, BMX, Ephrin-A receptors, G-protein alpha-q/11",1.533E-01,2.806E-01,4,"Fyn, BMX, Ephrin-A receptors, G-protein alpha-q/11",
902,Development_BMP signaling in cardiac myogenesis,34,1.533E-01,2.541E-01,1.669E-01,2.541E-01,4,"BMP6, BMP4, BMP2, MEF2C",1.533E-01,2.806E-01,4,"BMP6, BMP4, BMP2, MEF2C",
903,G-protein signaling_G-Protein alpha-q signaling cascades,34,1.533E-01,2.541E-01,1.669E-01,2.541E-01,4,"PI3K cat class IA, AKT(PKB), G-protein alpha-q/11, RGS2",1.533E-01,2.806E-01,4,"PI3K cat class IA, AKT(PKB), G-protein alpha-q/11, RGS2",
904,Apoptosis and survival_Regulation of Apoptosis by Mitochondrial Proteins,33,1.545E-01,2.394E-01,1.545E-01,2.394E-01,4,"BAD, NOXA, Caspase-8, Bcl-B",6.103E-01,7.696E-01,2,"NOXA, Bcl-B",
905,IL-2 as a growth factor for T cells in multiple sclerosis,33,1.545E-01,2.394E-01,1.545E-01,2.394E-01,4,"PCNA, PI3K cat class IA, AKT(PKB), Cyclin E",3.307E-01,4.939E-01,3,"PI3K cat class IA, AKT(PKB), Cyclin E",
906,Development_Activation of ERK by Alpha-1 adrenergic receptors,45,1.549E-01,2.398E-01,1.549E-01,2.398E-01,5,"G-protein alpha-15, Alpha-1B adrenergic receptor, PKC-alpha, Alpha-1D adrenergic receptor, ERK1/2",2.981E-01,4.604E-01,4,"G-protein alpha-15, Alpha-1B adrenergic receptor, PKC-alpha, Alpha-1D adrenergic receptor",
907,Neurophysiological process_PGE2-induced pain processing,47,1.599E-01,2.654E-01,1.760E-01,2.654E-01,5,"COX-2 (PTGS2), PGE2R2, PGE2R4, cPLA2, Adenylate cyclase",1.599E-01,2.907E-01,5,"COX-2 (PTGS2), PGE2R2, PGE2R4, cPLA2, Adenylate cyclase",
908,Microsatellite instability in gastric cancer,22,1.606E-01,2.469E-01,1.606E-01,2.469E-01,3,"PCNA, p16INK4, TGF-beta receptor type II",3.952E-01,5.612E-01,2,"p16INK4, TGF-beta receptor type II",
909,T regulatory cell migration in asthma,22,1.606E-01,2.469E-01,1.606E-01,2.469E-01,3,"Lck, AKT(PKB), G-protein alpha-i family",3.952E-01,5.612E-01,2,"AKT(PKB), G-protein alpha-i family",
910,Development_Prolactin receptor signaling,58,1.607E-01,2.469E-01,1.607E-01,2.469E-01,6,"STAT3, Fyn, PI3K cat class IA, AKT(PKB), NMI, ERK1/2",4.808E-01,6.459E-01,4,"Fyn, PI3K cat class IA, AKT(PKB), NMI",
911,Immune response_CCR5 signaling in macrophages and T lymphocytes,58,1.607E-01,2.469E-01,1.607E-01,2.469E-01,6,"STAT3, Lck, AKT(PKB), PKC-alpha, G-protein alpha-i family, ERK1/2",7.001E-01,8.364E-01,3,"AKT(PKB), PKC-alpha, G-protein alpha-i family",
912,Effect of H. pylori infection on gastric epithelial cell proliferation,58,1.607E-01,2.469E-01,1.607E-01,2.469E-01,6,"p53, HGF receptor (Met), Lyn, EGFR, TLR4, ERK1/2",4.808E-01,6.459E-01,4,"HGF receptor (Met), Lyn, EGFR, TLR4",
913,Triacylglycerol metabolism p.1,60,1.613E-01,2.677E-01,1.795E-01,2.677E-01,6,"ALDR, AKR1C1, ACSL4, AKR1C4, AK1BA, PLCD",1.613E-01,2.921E-01,6,"ALDR, AKR1C1, ACSL4, AKR1C4, AK1BA, PLCD",
914,Regulation of lipid metabolism_Alpha-1 adrenergic receptors signaling via arachidonic acid,71,1.630E-01,2.502E-01,1.630E-01,2.502E-01,7,"COX-2 (PTGS2), PTGIS, Alpha-1B adrenergic receptor, PKC-alpha, Alpha-1D adrenergic receptor, cPLA2, ERK1/2",2.696E-01,4.284E-01,6,"COX-2 (PTGS2), PTGIS, Alpha-1B adrenergic receptor, PKC-alpha, Alpha-1D adrenergic receptor, cPLA2",
915,Transcription_ChREBP regulation pathway,23,1.647E-01,2.654E-01,1.766E-01,2.654E-01,3,"AMPK gamma subunit, G-protein alpha-i family, Acyl-CoA synthetase",1.647E-01,2.953E-01,3,"AMPK gamma subunit, G-protein alpha-i family, Acyl-CoA synthetase",
916,Development_NODAL signaling in early mesendoderm formation,23,1.647E-01,2.654E-01,1.766E-01,2.654E-01,3,"Mixl1, WNT3, BMP4",1.647E-01,2.953E-01,3,"Mixl1, WNT3, BMP4",
917,G-protein signaling_S1P2 receptor signaling pathway,35,1.652E-01,2.677E-01,1.796E-01,2.677E-01,4,"AKT(PKB), G-protein alpha-i family, Adenylate cyclase, Adenylate cyclase type VII",1.652E-01,2.953E-01,4,"AKT(PKB), G-protein alpha-i family, Adenylate cyclase, Adenylate cyclase type VII",
918,Altered Ca2+ handling in heart failure,35,1.652E-01,2.677E-01,1.796E-01,2.677E-01,4,"Beta-2 adrenergic receptor, NCX1, G-protein alpha-i family, Adenylate cyclase",1.652E-01,2.953E-01,4,"Beta-2 adrenergic receptor, NCX1, G-protein alpha-i family, Adenylate cyclase",
919,TMPRSS2-ERG fusion in Prostate Cancer,46,1.653E-01,2.532E-01,1.653E-01,2.532E-01,5,"YB-1, MxA, Osteonectin, ICAM2, IL-8",3.123E-01,4.750E-01,4,"MxA, Osteonectin, ICAM2, IL-8",
920,Apoptosis and survival_IL-17-induced CIKS-independent signaling pathways,46,1.653E-01,2.532E-01,1.653E-01,2.532E-01,5,"STAT3, PI3K cat class IA, Fra-1, STAT4, ERK1/2",5.431E-01,7.092E-01,3,"PI3K cat class IA, Fra-1, STAT4",
921,Development_CNTF receptor signaling,34,1.669E-01,2.541E-01,1.669E-01,2.541E-01,4,"STAT3, PI3K cat class IA, AKT(PKB), ERK1/2",6.267E-01,7.809E-01,2,"PI3K cat class IA, AKT(PKB)",
922,G-protein signaling_G-Protein beta/gamma signaling cascades,34,1.669E-01,2.541E-01,1.669E-01,2.541E-01,4,"G-protein alpha-15, AKT(PKB), Caveolin-1, ERK1/2",3.479E-01,5.150E-01,3,"G-protein alpha-15, AKT(PKB), Caveolin-1",
923,Regulation of lipid metabolism_G-alpha(q) regulation of lipid metabolism,59,1.700E-01,2.586E-01,1.700E-01,2.586E-01,6,"COX-2 (PTGS2), APOC1, PKC, G-protein alpha-q/11, cPLA2, ERK1/2",2.955E-01,4.587E-01,5,"COX-2 (PTGS2), APOC1, PKC, G-protein alpha-q/11, cPLA2",
924,Protein folding and maturation_Angiotensin system maturation,48,1.701E-01,2.781E-01,1.870E-01,2.781E-01,5,"MC-CPA, MMP-8, Neprilysin, ACE2, CD13",1.701E-01,3.027E-01,5,"MC-CPA, MMP-8, Neprilysin, ACE2, CD13",
925,Aminoglycoside- and cisplatin-induced hair cell death,112,1.735E-01,2.636E-01,1.735E-01,2.636E-01,10,"COX-2 (PTGS2), IL-1 beta, IL-6, Beta-catenin, iNOS, PKC, Caspase-1, Caspase-8, p53, ERK1/2",6.926E-01,8.333E-01,6,"COX-2 (PTGS2), IL-1 beta, IL-6, iNOS, PKC, Caspase-1",
926,Development_Beta-adrenergic receptor-induced regulation of ERK,47,1.760E-01,2.654E-01,1.760E-01,2.654E-01,5,"Beta-2 adrenergic receptor, CD44, G-protein alpha-i family, Adenylate cyclase, ERK1/2",3.264E-01,4.902E-01,4,"Beta-2 adrenergic receptor, CD44, G-protein alpha-i family, Adenylate cyclase",
927,Development_Hedgehog signaling,47,1.760E-01,2.654E-01,1.760E-01,2.654E-01,5,"Beta-catenin, GAS1, GLI-1, PTCH1, GLI-2",3.264E-01,4.902E-01,4,"GAS1, GLI-1, PTCH1, GLI-2",
928,Development_PIP3 signaling in cardiac myocytes,47,1.760E-01,2.654E-01,1.760E-01,2.654E-01,5,"BAD, HGF, PI3K cat class IA, AKT(PKB), HGF receptor (Met)",3.264E-01,4.902E-01,4,"HGF, PI3K cat class IA, AKT(PKB), HGF receptor (Met)",
929,Role of proinflammatory cytokines in activation of p53 in major depressive disorder,47,1.760E-01,2.654E-01,1.760E-01,2.654E-01,5,"3HAO, NOXA, IDO1, TGF-beta, p53",3.264E-01,4.902E-01,4,"3HAO, NOXA, IDO1, TGF-beta",
930,KLF6 and regulation of KLF6 alternative splicing in HCC,23,1.766E-01,2.654E-01,1.766E-01,2.654E-01,3,"PI3K cat class IA, p53, EGFR",4.171E-01,5.821E-01,2,"PI3K cat class IA, EGFR",
931,Development_ERK5 in cell proliferation and neuronal survival,23,1.766E-01,2.654E-01,1.766E-01,2.654E-01,3,"NGF, Lck, MEF2C",4.171E-01,5.821E-01,2,"NGF, MEF2C",
932,Development_Thrombopoietin signaling via JAK-STAT pathway,23,1.766E-01,2.654E-01,1.766E-01,2.654E-01,3,"STAT3, TAP1 (PSF1), Pim-1",4.171E-01,5.821E-01,2,"TAP1 (PSF1), Pim-1",
933,Regulation of CFTR activity (normal and CF),62,1.794E-01,2.927E-01,1.991E-01,2.927E-01,6,"Syk, PGE2R4, Beta-2 adrenergic receptor, Adenosine A2b receptor, G-protein alpha-i family, Adenylate cyclase",1.794E-01,3.149E-01,6,"Syk, PGE2R4, Beta-2 adrenergic receptor, Adenosine A2b receptor, G-protein alpha-i family, Adenylate cyclase",
934,Oxidative stress_Role of Sirtuin1 and PGC1-alpha in activation of antioxidant defense system,60,1.795E-01,2.677E-01,1.795E-01,2.677E-01,6,"GSTP1, AMPK gamma subunit, PPARGC1 (PGC1-alpha), Sestrin 3, p53, SLC7A11",3.077E-01,4.693E-01,5,"GSTP1, AMPK gamma subunit, PPARGC1 (PGC1-alpha), Sestrin 3, SLC7A11",
935,Development_Thyroliberin signaling,60,1.795E-01,2.677E-01,1.795E-01,2.677E-01,6,"RGS4, G-protein alpha-q/11, PKC-alpha, ETS1, Adenylate cyclase, ERK1/2",3.077E-01,4.693E-01,5,"RGS4, G-protein alpha-q/11, PKC-alpha, ETS1, Adenylate cyclase",
936,Stimulation of gastric acid secretion in gastric cancer,60,1.795E-01,2.677E-01,1.795E-01,2.677E-01,6,"G-protein alpha-q/11, PKC-alpha, Kir2.1, Adenylate cyclase, ERK1/2, ACM3",3.077E-01,4.693E-01,5,"G-protein alpha-q/11, PKC-alpha, Kir2.1, Adenylate cyclase, ACM3",
937,TNF-alpha and IL-1 beta induce hyperglycemia in obesity and type 2 diabetes in adipocytes,35,1.796E-01,2.677E-01,1.796E-01,2.677E-01,4,"IL-1 beta, TNF-R2, ERK2 (MAPK1), NGAL",3.650E-01,5.317E-01,3,"IL-1 beta, TNF-R2, NGAL",
938,Cell cycle_ESR1 regulation of G1/S transition,35,1.796E-01,2.677E-01,1.796E-01,2.677E-01,4,"ERK2 (MAPK1), Cyclin E, ERK1/2, CDK6",6.425E-01,7.912E-01,2,"Cyclin E, CDK6",
939,Reproduction_Gonadotropin-releasing hormone (GnRH) signaling,73,1.800E-01,2.679E-01,1.800E-01,2.679E-01,7,"Follistatin, CaMK I, G-protein alpha-q/11, Secretogranin II, PACAP, Adenylate cyclase, ERK1/2",2.911E-01,4.536E-01,6,"Follistatin, CaMK I, G-protein alpha-q/11, Secretogranin II, PACAP, Adenylate cyclase",
940,Development_MicroRNA-dependent regulation of EMT,24,1.802E-01,2.845E-01,1.929E-01,2.845E-01,3,"TGF-beta 2, TCF8, SIP1 (ZFHX1B)",1.802E-01,3.149E-01,3,"TGF-beta 2, TCF8, SIP1 (ZFHX1B)",
941,Regulation of lipid metabolism_Regulation of lipid metabolism by niacin and isoprenaline,49,1.805E-01,2.917E-01,1.982E-01,2.917E-01,5,"Beta-2 adrenergic receptor, PKC, PKC-alpha, G-protein alpha-i family, Adenylate cyclase type VII",1.805E-01,3.149E-01,5,"Beta-2 adrenergic receptor, PKC, PKC-alpha, G-protein alpha-i family, Adenylate cyclase type VII",
942,IgE- and MGF-induced Fyn-mediated activation of lung mast cells in asthma,49,1.805E-01,2.917E-01,1.982E-01,2.917E-01,5,"Syk, S1P1 receptor, Fyn, AKT(PKB), Lyn",1.805E-01,3.149E-01,5,"Syk, S1P1 receptor, Fyn, AKT(PKB), Lyn",
943,Immune response_Inhibitory action of lipoxins on superoxide production induced by IL-8 and Leukotriene B4 in neutrophils,50,1.912E-01,3.034E-01,2.097E-01,3.034E-01,5,"G-protein alpha-15, Rac2, PKC-alpha, IL-8, G-protein alpha-i family",1.912E-01,3.310E-01,5,"G-protein alpha-15, Rac2, PKC-alpha, IL-8, G-protein alpha-i family",
944,Prolactin/ ERK signaling in breast cancer,36,1.926E-01,2.845E-01,1.926E-01,2.845E-01,4,"PI3K cat class IA, AKT(PKB), ERK1/2, MMP-2",3.821E-01,5.472E-01,3,"PI3K cat class IA, AKT(PKB), MMP-2",
945,Endothelial cell apoptosis in COPD,36,1.926E-01,2.845E-01,1.926E-01,2.845E-01,4,"BAD, PI3K cat class IA, AKT(PKB), Neuropilin-1",3.821E-01,5.472E-01,3,"PI3K cat class IA, AKT(PKB), Neuropilin-1",
946,iNKT cell-keratinocyte interactions in allergic contact dermatitis,36,1.926E-01,2.845E-01,1.926E-01,2.845E-01,4,"TCR beta subunit, ICAM1, CD1d, ERK1/2",3.821E-01,5.472E-01,3,"TCR beta subunit, ICAM1, CD1d",
947,Dual role of TGF-beta 1 in HCC ,24,1.929E-01,2.845E-01,1.929E-01,2.845E-01,3,"p15, SMAD3, TGF-beta receptor type II",4.387E-01,6.029E-01,2,"p15, TGF-beta receptor type II",
948,Apoptosis and survival_NO signaling in survival,24,1.929E-01,2.845E-01,1.929E-01,2.845E-01,3,"BAD, AKT(PKB), PI3K cat class IA (p110-delta)",4.387E-01,6.029E-01,2,"AKT(PKB), PI3K cat class IA (p110-delta)",
949,Immune response_IL-27 signaling pathway,24,1.929E-01,2.845E-01,1.929E-01,2.845E-01,3,"STAT3, ICAM1, Pim-1",4.387E-01,6.029E-01,2,"ICAM1, Pim-1",
950,G-protein signaling_M-RAS regulation pathway,24,1.929E-01,2.845E-01,1.929E-01,2.845E-01,3,"Lck, CalDAG-GEFIII, ERK1/2",7.819E-01,8.899E-01,1,CalDAG-GEFIII,
951,Defective macrophage-mediated bacterial phagocytosis in COPD,25,1.961E-01,3.034E-01,2.096E-01,3.034E-01,3,"AKT(PKB), MSR1, MARCO",1.961E-01,3.359E-01,3,"AKT(PKB), MSR1, MARCO",
952,Apoptosis and survival_Role of nuclear PI3K in NGF/ TrkA signaling,25,1.961E-01,3.034E-01,2.096E-01,3.034E-01,3,"NGF, PI3K cat class IA, AKT(PKB)",1.961E-01,3.359E-01,3,"NGF, PI3K cat class IA, AKT(PKB)",
953,Immune response_T cell subsets: secreted signals,25,1.961E-01,3.034E-01,2.096E-01,3.034E-01,3,"IL-6, TGF-beta, CCL20",1.961E-01,3.359E-01,3,"IL-6, TGF-beta, CCL20",
954,Putative pathways of n-3 and n-6 fatty acids in obesity and type 2 diabetes,51,2.022E-01,3.183E-01,2.213E-01,3.183E-01,5,"COX-2 (PTGS2), PTGIS, AKT(PKB), G-protein alpha-q/11, Adenylate cyclase",2.022E-01,3.459E-01,5,"COX-2 (PTGS2), PTGIS, AKT(PKB), G-protein alpha-q/11, Adenylate cyclase",
955,Signal transduction_Cyclic AMP signaling,38,2.029E-01,3.164E-01,2.196E-01,3.164E-01,4,"PKC, PKC-alpha, G-protein alpha-i family, Adenylate cyclase type VII",2.029E-01,3.462E-01,4,"PKC, PKC-alpha, G-protein alpha-i family, Adenylate cyclase type VII",
956,Deregulation of PSD-95-dependent signaling in Huntington's disease,37,2.060E-01,3.025E-01,2.060E-01,3.025E-01,4,"ERK2 (MAPK1), NR2A, NR2, ERK1/2",6.726E-01,8.180E-01,2,"NR2A, NR2",
957,Signal transduction_mTORC2 upstream signaling,65,2.081E-01,3.300E-01,2.299E-01,3.300E-01,6,"Sestrin 3, PI3K cat class IA, AKT(PKB), Protor-2, EGFR, Frizzled",2.081E-01,3.547E-01,6,"Sestrin 3, PI3K cat class IA, AKT(PKB), Protor-2, EGFR, Frizzled",
958,Transcription_PPAR Pathway,63,2.092E-01,3.034E-01,2.092E-01,3.034E-01,6,"COX-2 (PTGS2), PI3K cat class IA, PTGIS, AKT(PKB), PDGF receptor, ERK1/2",3.447E-01,5.120E-01,5,"COX-2 (PTGS2), PI3K cat class IA, PTGIS, AKT(PKB), PDGF receptor",
959,Immune response_IL-2 signaling via JAK/ STAT,25,2.096E-01,3.034E-01,2.096E-01,3.034E-01,3,"STAT3, Syk, STAT4",4.598E-01,6.237E-01,2,"Syk, STAT4",
960,Transcription_Transcription regulation of aminoacid metabolism,25,2.096E-01,3.034E-01,2.096E-01,3.034E-01,3,"NF-E2 (45 kDa), PKC, ERK1/2",4.598E-01,6.237E-01,2,"NF-E2 (45 kDa), PKC",
961,G-protein signaling_K-RAS regulation pathway,25,2.096E-01,3.034E-01,2.096E-01,3.034E-01,3,"Lck, PKC-theta, EGFR",4.598E-01,6.237E-01,2,"PKC-theta, EGFR",
962,G-protein signaling_TC21 regulation pathway,25,2.096E-01,3.034E-01,2.096E-01,3.034E-01,3,"Lck, CalDAG-GEFIII, ERK1/2",7.953E-01,8.982E-01,1,CalDAG-GEFIII,
963,Development_IGF-1 receptor signaling,50,2.097E-01,3.034E-01,2.097E-01,3.034E-01,5,"BAD, PI3K cat class IA, AKT(PKB), IRS-2, ERK1/2",6.004E-01,7.629E-01,3,"PI3K cat class IA, AKT(PKB), IRS-2",
964,Neurophysiological process_Leptin signaling in neurons,50,2.097E-01,3.034E-01,2.097E-01,3.034E-01,5,"NPY, STAT3, POMC, AKT(PKB), IRS-2",3.691E-01,5.360E-01,4,"NPY, POMC, AKT(PKB), IRS-2",
965,Immune response_Function of MEF2 in T lymphocytes,50,2.097E-01,3.034E-01,2.097E-01,3.034E-01,5,"CaMK I, HDAC9, Lck, MEF2, MEF2C",3.691E-01,5.360E-01,4,"CaMK I, HDAC9, MEF2, MEF2C",
966,Development_EDNRB signaling,50,2.097E-01,3.034E-01,2.097E-01,3.034E-01,5,"AKT(PKB), G-protein alpha-q/11, Caveolin-1, G-protein alpha-i family, ERK1/2",3.691E-01,5.360E-01,4,"AKT(PKB), G-protein alpha-q/11, Caveolin-1, G-protein alpha-i family",
967,Apoptosis and survival_HTR1A signaling,50,2.097E-01,3.034E-01,2.097E-01,3.034E-01,5,"STAT3, ERK2 (MAPK1), AKT(PKB), G-protein alpha-i family, Adenylate cyclase",6.004E-01,7.629E-01,3,"AKT(PKB), G-protein alpha-i family, Adenylate cyclase",
968,Nicotine / nAChR alpha-3/nAChR beta-2 signaling in NSCLC,26,2.123E-01,3.256E-01,2.266E-01,3.256E-01,3,"AKT(PKB), PKC-alpha, PI3K cat class IA (p110-delta)",2.123E-01,3.599E-01,3,"AKT(PKB), PKC-alpha, PI3K cat class IA (p110-delta)",
969,Glucagon-induced glucose upregulation in type 2 diabetes in liver ,52,2.133E-01,3.336E-01,2.331E-01,3.336E-01,5,"PPARGC1 (PGC1-alpha), iNOS, G-protein alpha-q/11, G-protein alpha-i family, Adenylate cyclase",2.133E-01,3.599E-01,5,"PPARGC1 (PGC1-alpha), iNOS, G-protein alpha-q/11, G-protein alpha-i family, Adenylate cyclase",
970,Neurophysiological process_Activity-dependent synaptic AMPA receptor removal,64,2.195E-01,3.164E-01,2.195E-01,3.164E-01,6,"Actin cytoskeletal, cPKC (conventional), MAP-1B, PKC, PKC-alpha, NPTX2",3.571E-01,5.241E-01,5,"cPKC (conventional), MAP-1B, PKC, PKC-alpha, NPTX2",
971,Development_Noncanonical WNT signaling in cardiac myogenesis,38,2.196E-01,3.164E-01,2.196E-01,3.164E-01,4,"SMAD3, PKC, FZD7, Dsh",6.869E-01,8.294E-01,2,"PKC, FZD7",
972,"Dysregulation of Adiponectin secretion from adipocytes in obesity, type 2 diabetes and metabolic syndrome X",38,2.196E-01,3.164E-01,2.196E-01,3.164E-01,4,"IL-18R1, AKT(PKB), IL18RAP, ERK1/2",4.158E-01,5.821E-01,3,"IL-18R1, AKT(PKB), IL18RAP",
973,Immune response_IFN-gamma signaling via MAPK,51,2.213E-01,3.183E-01,2.213E-01,3.183E-01,5,"iNOS, ERK2 (MAPK1), IFI16, IFI6, ERK1/2",6.140E-01,7.700E-01,3,"iNOS, IFI16, IFI6",
974,Development_Role of HDAC and calcium/calmodulin-dependent kinase (CaMK) in control of skeletal myogenesis,53,2.246E-01,3.482E-01,2.451E-01,3.482E-01,5,"HDAC9, PI3K cat class IA, MEF2, AKT(PKB), MEF2C",2.246E-01,3.748E-01,5,"HDAC9, PI3K cat class IA, MEF2, AKT(PKB), MEF2C",
975,Development_Generation of pancreatic beta-cells from induced pluripotent stem cells,27,2.287E-01,3.468E-01,2.439E-01,3.468E-01,3,"FGF2, Activin A, Oct-3/4",2.287E-01,3.780E-01,3,"FGF2, Activin A, Oct-3/4",
976,Neurophysiological process_GABA-A receptor life cycle,27,2.287E-01,3.468E-01,2.439E-01,3.468E-01,3,"GABA-A receptor, Dynein 1, cytoplasmic, intermediate chains, PLCL2",2.287E-01,3.780E-01,3,"GABA-A receptor, Dynein 1, cytoplasmic, intermediate chains, PLCL2",
977,Apoptosis and survival_Anti-apoptotic TNFs/NF-kB/IAP pathway,27,2.287E-01,3.468E-01,2.439E-01,3.468E-01,3,"TNF-R2, c-IAP2, CD30(TNFRSF8)",2.287E-01,3.780E-01,3,"TNF-R2, c-IAP2, CD30(TNFRSF8)",
978,Mechanism of gemcitabine action in pancreatic cancer,52,2.331E-01,3.336E-01,2.331E-01,3.336E-01,5,"CDD, CNT3 (SLC28A3), p53, 5'-NT1A, CNT1",3.975E-01,5.626E-01,4,"CDD, CNT3 (SLC28A3), 5'-NT1A, CNT1",
979,Development_PACAP signaling in neural cells,39,2.334E-01,3.336E-01,2.334E-01,3.336E-01,4,"cPKC (conventional), G-protein alpha-q/11, PACAP, ERK1/2",4.325E-01,5.974E-01,3,"cPKC (conventional), G-protein alpha-q/11, PACAP",
980,Transcription_p53 signaling pathway,39,2.334E-01,3.336E-01,2.334E-01,3.336E-01,4,"Beta-catenin, p14ARF, p53, MMP-2",7.007E-01,8.364E-01,2,"p14ARF, MMP-2",
981,Metabolic syndrome X (general schema),15,2.342E-01,3.491E-01,2.460E-01,3.491E-01,2,"IL-1 beta, IL-6",2.342E-01,3.857E-01,2,"IL-1 beta, IL-6",
982,Impaired inhibitory action of lipoxins on ROS production in neutrophils in CF,54,2.360E-01,3.644E-01,2.573E-01,3.644E-01,5,"G-protein alpha-15, Rac2, PKC-alpha, IL-8, G-protein alpha-i family",2.360E-01,3.873E-01,5,"G-protein alpha-15, Rac2, PKC-alpha, IL-8, G-protein alpha-i family",
983,Development_Oxytocin receptor signaling,41,2.427E-01,3.690E-01,2.616E-01,3.690E-01,4,"cPKC (conventional), iNOS, G-protein alpha-q/11, MEF2C",2.427E-01,3.945E-01,4,"cPKC (conventional), iNOS, G-protein alpha-q/11, MEF2C",
984,Apoptosis and survival_Phosphorylation in TNF-alpha-induced NF-kB signaling,41,2.427E-01,3.690E-01,2.616E-01,3.690E-01,4,"PI3K cat class IA, Pim-1, Adenylate cyclase, CDK6",2.427E-01,3.945E-01,4,"PI3K cat class IA, Pim-1, Adenylate cyclase, CDK6",
985,Activation of osteoclast differentiation in bone lesions formation in multiple myeloma,27,2.439E-01,3.468E-01,2.439E-01,3.468E-01,3,"Osteoprotegerin, alpha-4/beta-1 integrin, ERK1/2",5.005E-01,6.664E-01,2,"Osteoprotegerin, alpha-4/beta-1 integrin",
986,Brca1 in ovarian cancer,27,2.439E-01,3.468E-01,2.439E-01,3.468E-01,3,"Maspin, AKT(PKB), p53",5.005E-01,6.664E-01,2,"Maspin, AKT(PKB)",
987,Immune response_PIP3 signaling in B lymphocytes,42,2.564E-01,3.876E-01,2.759E-01,3.876E-01,4,"Syk, PI3K cat class IA, AKT(PKB), Lyn",2.564E-01,4.132E-01,4,"Syk, PI3K cat class IA, AKT(PKB), Lyn",
988,Translation_Regulation of EIF4F activity,54,2.573E-01,3.644E-01,2.573E-01,3.644E-01,5,"PI3K cat class IA, AKT(PKB), TGF-beta receptor type II, EGFR, ERK1/2",4.256E-01,5.916E-01,4,"PI3K cat class IA, AKT(PKB), TGF-beta receptor type II, EGFR",
989,Retinol metabolism,70,2.590E-01,3.980E-01,2.841E-01,3.980E-01,6,"DHA6, LRAT, DHA2, CYP1A1, Xanthine oxidase, AL1A1",2.590E-01,4.157E-01,6,"DHA6, LRAT, DHA2, CYP1A1, Xanthine oxidase, AL1A1",
990,Development_Delta-type opioid receptor signaling via G-protein alpha-14,28,2.613E-01,3.690E-01,2.613E-01,3.690E-01,3,"STAT3, Metenkefalin, PKC-alpha",5.201E-01,6.865E-01,2,"Metenkefalin, PKC-alpha",
991,Signaling Transduction_Role of MIF as an intracellular mediator,41,2.616E-01,3.690E-01,2.616E-01,3.690E-01,4,"IL-1 beta, p53, PRSS11 (HtrA1), Vimentin",4.652E-01,6.305E-01,3,"IL-1 beta, PRSS11 (HtrA1), Vimentin",
992,Regulation of proinflammatory cytokine production by Th2 cells in asthma,43,2.702E-01,4.059E-01,2.904E-01,4.059E-01,4,"IL-15, ST2(L), MHC class II, IL-33",2.702E-01,4.284E-01,4,"IL-15, ST2(L), MHC class II, IL-33",
993,Regulation of intrinsic membrane properties and excitability of striatopallidal medium spiny neurons in Huntington's disease,57,2.714E-01,4.092E-01,2.945E-01,4.092E-01,5,"cPKC (conventional), SCN2A, PKC, G-protein alpha-q/11, G-protein alpha-i family",2.714E-01,4.293E-01,5,"cPKC (conventional), SCN2A, PKC, G-protein alpha-q/11, G-protein alpha-i family",
994,Role of microRNAs in cell proliferation in colorectal cancer,69,2.731E-01,3.848E-01,2.731E-01,3.848E-01,6,"PGE2R4, Beta-catenin, p53, HGF receptor (Met), miR-221-3p, CDK6",6.194E-01,7.754E-01,4,"PGE2R4, HGF receptor (Met), miR-221-3p, CDK6",
995,GLP-1 in inhibition of beta cell proliferation and function in type 2 diabetes,42,2.759E-01,3.876E-01,2.759E-01,3.876E-01,4,"Beta-catenin, IRS-2, EGFR, ERK1/2",7.389E-01,8.609E-01,2,"IRS-2, EGFR",
996,Translation_Insulin regulation of translation,42,2.759E-01,3.876E-01,2.759E-01,3.876E-01,4,"PI3K cat class IA, AKT(PKB), IRS-2, ERK1/2",4.813E-01,6.459E-01,3,"PI3K cat class IA, AKT(PKB), IRS-2",
997,Apoptosis and survival_p53-dependent apoptosis,29,2.789E-01,3.914E-01,2.789E-01,3.914E-01,3,"BAD, p14ARF, p53",8.413E-01,9.240E-01,1,p14ARF,
998,Inhibition of mast cell functions by Siglecs in asthma,30,2.793E-01,4.092E-01,2.966E-01,4.092E-01,3,"Syk, GRAP2, Lyn",2.793E-01,4.382E-01,3,"Syk, GRAP2, Lyn",
999,Role of histone modificators in progression of multiple myeloma,30,2.793E-01,4.092E-01,2.966E-01,4.092E-01,3,"IL-6, Dynein 1, cytoplasmic, intermediate chains, CDK6",2.793E-01,4.382E-01,3,"IL-6, Dynein 1, cytoplasmic, intermediate chains, CDK6",
1000,Inhibition of mast cell functions by Fc gamma RII beta in asthma,30,2.793E-01,4.092E-01,2.966E-01,4.092E-01,3,"Syk, AKT(PKB), Lyn",2.793E-01,4.382E-01,3,"Syk, AKT(PKB), Lyn",
1001,Neurophysiological process_Mu-type opioid receptor-mediated analgesia,30,2.793E-01,4.092E-01,2.966E-01,4.092E-01,3,"beta-Endorphin extracellular region, G-protein alpha-i family, Adenylate cyclase type VII",2.793E-01,4.382E-01,3,"beta-Endorphin extracellular region, G-protein alpha-i family, Adenylate cyclase type VII",
1002,Transcription_Ligand-dependent activation of the ESR1/SP pathway,30,2.793E-01,4.092E-01,2.966E-01,4.092E-01,3,"Cyclin E, EGFR, ADA",2.793E-01,4.382E-01,3,"Cyclin E, EGFR, ADA",
1003,Transcription_Transcription factor Tubby signaling pathways,17,2.809E-01,4.092E-01,2.943E-01,4.092E-01,2,"PKC, G-protein alpha-q/11",2.809E-01,4.392E-01,2,"PKC, G-protein alpha-q/11",
1004,Development_Keratinocyte differentiation,56,2.820E-01,3.954E-01,2.820E-01,3.954E-01,5,"SMAD3, G-protein alpha-q/11, Fra-1, PKC-alpha, ERK1/2",6.771E-01,8.219E-01,3,"G-protein alpha-q/11, Fra-1, PKC-alpha",
1005,Neurophysiological process_Melatonin signaling,44,2.841E-01,4.200E-01,3.050E-01,4.200E-01,4,"G-protein alpha-i family, Adenylate cyclase, Melatonin receptor 1A, ALOX5",2.841E-01,4.432E-01,4,"G-protein alpha-i family, Adenylate cyclase, Melatonin receptor 1A, ALOX5",
1006,Impaired inhibitory action of lipoxins and Resolvin E1 on neutrophil functions in CF,43,2.904E-01,4.059E-01,2.904E-01,4.059E-01,4,"IL-1 beta, IL-8, G-protein alpha-i family, ERK1/2",4.971E-01,6.645E-01,3,"IL-1 beta, IL-8, G-protein alpha-i family",
1007,DNA damage_Role of SUMO in p53 regulation,17,2.943E-01,4.092E-01,2.943E-01,4.092E-01,2,"AKT(PKB), p53",6.598E-01,8.060E-01,1,AKT(PKB),
1008,Cytoskeleton remodeling_FAK signaling,57,2.945E-01,4.092E-01,2.945E-01,4.092E-01,5,"PI3K cat class IA, AKT(PKB), G-protein alpha-q/11, Fibronectin, ERK1/2",4.672E-01,6.319E-01,4,"PI3K cat class IA, AKT(PKB), G-protein alpha-q/11, Fibronectin",
1009,IL-1 beta-dependent CFTR expression,31,2.964E-01,4.308E-01,3.144E-01,4.308E-01,3,"IL-1 beta, Pellino 1, Pellino 2",2.964E-01,4.587E-01,3,"IL-1 beta, Pellino 1, Pellino 2",
1010,Influence of low doses of Arsenite on glucose uptake in adipocytes,31,2.964E-01,4.308E-01,3.144E-01,4.308E-01,3,"PI3K cat class IA, AKT(PKB), IRS-2",2.964E-01,4.587E-01,3,"PI3K cat class IA, AKT(PKB), IRS-2",
1011,Transport_Aldosterone-mediated regulation of ENaC sodium transport,30,2.966E-01,4.092E-01,2.966E-01,4.092E-01,3,"SGK1, ERK2 (MAPK1), AKT(PKB)",5.578E-01,7.195E-01,2,"SGK1, AKT(PKB)",
1012,Putative role of Tregs in COPD,30,2.966E-01,4.092E-01,2.966E-01,4.092E-01,3,"STAT3, IL7RA, ERK1/2",8.510E-01,9.280E-01,1,IL7RA,
1013,Production of arachidonic acid derivatives by mast cells in asthma,30,2.966E-01,4.092E-01,2.966E-01,4.092E-01,3,"COX-2 (PTGS2), cPLA2, ERK1/2",5.578E-01,7.195E-01,2,"COX-2 (PTGS2), cPLA2",
1014,Signal transduction_Additional pathways of NF-kB activation (in the nucleus),30,2.966E-01,4.092E-01,2.966E-01,4.092E-01,3,"Adenylate cyclase, ERK1/2, CDK6",5.578E-01,7.195E-01,2,"Adenylate cyclase, CDK6",
1015,Stem cells_Excitotoxicity of Glutamate in glioblastoma,45,2.981E-01,4.337E-01,3.196E-01,4.337E-01,4,"CDO1, G-protein alpha-i family, GLAST1/EAAT1, SLC7A11",2.981E-01,4.604E-01,4,"CDO1, G-protein alpha-i family, GLAST1/EAAT1, SLC7A11",
1016,"Role of inflammasome in macrophages, adipocytes and pancreatic beta cells in type 2 diabetes",18,3.041E-01,4.337E-01,3.183E-01,4.337E-01,2,"IL-1 beta, Caspase-1",3.041E-01,4.660E-01,2,"IL-1 beta, Caspase-1",
1017,Beta-adrenergic-dependent CFTR expression,18,3.041E-01,4.337E-01,3.183E-01,4.337E-01,2,"Beta-2 adrenergic receptor, Adenylate cyclase",3.041E-01,4.660E-01,2,"Beta-2 adrenergic receptor, Adenylate cyclase",
1018,Multiple myeloma (general schema),18,3.041E-01,4.337E-01,3.183E-01,4.337E-01,2,"IL-6, FGF2",3.041E-01,4.660E-01,2,"IL-6, FGF2",
1019,Stem cells_CD30 signaling in transformed embryonic stem cells,18,3.041E-01,4.337E-01,3.183E-01,4.337E-01,2,"Oct-3/4, CD30(TNFRSF8)",3.041E-01,4.660E-01,2,"Oct-3/4, CD30(TNFRSF8)",
1020,Proliferative action of Gastrin in pancreatic cancer,44,3.050E-01,4.200E-01,3.050E-01,4.200E-01,4,"STAT3, PI3K cat class IA, PKC-alpha, ERK1/2",7.620E-01,8.737E-01,2,"PI3K cat class IA, PKC-alpha",
1021,Angiotensin II Signaling in Cardiac Hypertrophy,72,3.066E-01,4.218E-01,3.066E-01,4.218E-01,6,"TRPC6, TRPC3, G-protein alpha-q/11, PKC-alpha, NCX1, ERK1/2",4.558E-01,6.227E-01,5,"TRPC6, TRPC3, G-protein alpha-q/11, PKC-alpha, NCX1",
1022,Development_Inhibition of angiogenesis by PEDF,31,3.144E-01,4.308E-01,3.144E-01,4.308E-01,3,"PA24A, Caspase-8, p53",8.602E-01,9.335E-01,1,PA24A,
1023,Inhibition of TGF-beta signaling in lung cancer,31,3.144E-01,4.308E-01,3.144E-01,4.308E-01,3,"p15, SMAD3, TGF-beta receptor type II",5.758E-01,7.378E-01,2,"p15, TGF-beta receptor type II",
1024,Development_Schema: Methods of somatic cell reprogramming into induced pluripotent stem cells,6,3.164E-01,4.412E-01,3.254E-01,4.412E-01,1,Oct-3/4,3.164E-01,4.788E-01,1,Oct-3/4,
1025,Nicotine signaling in chromaffin cells,45,3.196E-01,4.337E-01,3.196E-01,4.337E-01,4,"N-cadherin, Beta-catenin, PKC-alpha, ERK1/2",7.729E-01,8.832E-01,2,"N-cadherin, PKC-alpha",
1026,Apo-2L(TNFSF10)-induced apoptosis in melanoma,45,3.196E-01,4.337E-01,3.196E-01,4.337E-01,4,"Caspase-8, IL-8, IFN-beta, XAF1",5.281E-01,6.936E-01,3,"IL-8, IFN-beta, XAF1",
1027,Development_EPO-induced MAPK pathway,45,3.196E-01,4.337E-01,3.196E-01,4.337E-01,4,"Syk, PKC-alpha, Lyn, ERK1/2",5.281E-01,6.936E-01,3,"Syk, PKC-alpha, Lyn",
1028,Development_Membrane-bound ESR1: interaction with growth factors signaling,45,3.196E-01,4.337E-01,3.196E-01,4.337E-01,4,"PI3K cat class IA, AKT(PKB), Caveolin-1, ERK1/2",5.281E-01,6.936E-01,3,"PI3K cat class IA, AKT(PKB), Caveolin-1",
1029,"Role of TNF-alpha, IL-1beta and IL-6 in development of obesity and type 2 diabetes in liver",45,3.196E-01,4.337E-01,3.196E-01,4.337E-01,4,"STAT3, IL-1 beta, IL-6, TNF-R2",5.281E-01,6.936E-01,3,"IL-1 beta, IL-6, TNF-R2",
1030,Transport_Alpha-2 adrenergic receptor regulation of ion channels,47,3.264E-01,4.676E-01,3.490E-01,4.676E-01,4,"G-protein alpha-i1, PKC, AKT(PKB), G-protein alpha-i family",3.264E-01,4.902E-01,4,"G-protein alpha-i1, PKC, AKT(PKB), G-protein alpha-i family",
1031,Development_Alpha-1 adrenergic receptors signaling via Cyclic AMP,19,3.273E-01,4.607E-01,3.421E-01,4.607E-01,2,"Alpha-1B adrenergic receptor, Adenylate cyclase",3.273E-01,4.904E-01,2,"Alpha-1B adrenergic receptor, Adenylate cyclase",
1032,Immune response_IL-6 signaling pathway via MEK/ERK and PI3K/AKT cascades,74,3.293E-01,4.460E-01,3.293E-01,4.460E-01,6,"BAD, STAT3, IL-6, PI3K cat class IA, AKT(PKB), ERK1/2",8.410E-01,9.240E-01,3,"IL-6, PI3K cat class IA, AKT(PKB)",
1033,G-protein signaling_Regulation of CDC42 activity,33,3.307E-01,4.676E-01,3.499E-01,4.676E-01,3,"CDGAP, Fyn, Caspase-1",3.307E-01,4.939E-01,3,"CDGAP, Fyn, Caspase-1",
1034,Development_Activation of astroglial cells proliferation by ACM3,33,3.307E-01,4.676E-01,3.499E-01,4.676E-01,3,"PI3K cat class IA, AKT(PKB), ACM3",3.307E-01,4.939E-01,3,"PI3K cat class IA, AKT(PKB), ACM3",
1035,Signal transduction_ERK1/2 signaling pathway,32,3.321E-01,4.485E-01,3.321E-01,4.485E-01,3,"ERK2 (MAPK1), PKC-alpha, ERK1/2",8.688E-01,9.384E-01,1,PKC-alpha,
1036,Epithelial cell apoptosis in COPD,32,3.321E-01,4.485E-01,3.321E-01,4.485E-01,3,"BAD, AKT(PKB), p53",8.688E-01,9.384E-01,1,AKT(PKB),
1037,DNA damage_ATM/ATR regulation of G1/S checkpoint,32,3.321E-01,4.485E-01,3.321E-01,4.485E-01,3,"PCNA, p53, Cyclin E",8.688E-01,9.384E-01,1,Cyclin E,
1038,Regulation of intrinsic membrane properties and excitability of striatonigral medium spiny neurons in Huntington's disease,62,3.323E-01,4.783E-01,3.583E-01,4.783E-01,5,"cPKC (conventional), SCN2A, PKC, G-protein alpha-q/11, G-protein alpha-olf",3.323E-01,4.947E-01,5,"cPKC (conventional), SCN2A, PKC, G-protein alpha-q/11, G-protein alpha-olf",
1039,Transport_ACM3 signaling in lacrimal glands,75,3.408E-01,4.598E-01,3.408E-01,4.598E-01,6,"CD14, G-protein alpha-q/11, PKC-alpha, Mucin 7, ERK1/2, ACM3",4.919E-01,6.594E-01,5,"CD14, G-protein alpha-q/11, PKC-alpha, Mucin 7, ACM3",
1040,Cannabinoid receptor signaling in nicotine addiction,34,3.479E-01,4.861E-01,3.676E-01,4.861E-01,3,"nAChR alpha-7, G-protein alpha-i1, G-protein alpha-i family",3.479E-01,5.150E-01,3,"nAChR alpha-7, G-protein alpha-i1, G-protein alpha-i family",
1041,Regulation of lipid metabolism_Insulin signaling: generic cascades,47,3.490E-01,4.676E-01,3.490E-01,4.676E-01,4,"PI3K cat class IA, AKT(PKB), IRS-2, ERK1/2",5.579E-01,7.195E-01,3,"PI3K cat class IA, AKT(PKB), IRS-2",
1042,Development_WNT5A signaling,47,3.490E-01,4.676E-01,3.490E-01,4.676E-01,4,"Beta-catenin, PKC-alpha, Tcf(Lef), Dsh",7.934E-01,8.982E-01,2,"PKC-alpha, Tcf(Lef)",
1043,G-protein signaling_N-RAS regulation pathway,33,3.499E-01,4.676E-01,3.499E-01,4.676E-01,3,"MHC class II, Lck, EGFR",6.103E-01,7.696E-01,2,"MHC class II, EGFR",
1044,Development_EGFR signaling via small GTPases,33,3.499E-01,4.676E-01,3.499E-01,4.676E-01,3,"PI3K cat class IA, EGFR, ERK1/2",6.103E-01,7.696E-01,2,"PI3K cat class IA, EGFR",
1045,Resistance of pancreatic cancer cells to death receptor signaling,33,3.499E-01,4.676E-01,3.499E-01,4.676E-01,3,"TRUNDD(TNFRSF10D), c-IAP2, Caspase-8",6.103E-01,7.696E-01,2,"TRUNDD(TNFRSF10D), c-IAP2",
1046,Neurophysiological process_Olfactory transduction,20,3.502E-01,4.861E-01,3.657E-01,4.861E-01,2,"Olfactory receptor, G-protein alpha-olf",3.502E-01,5.162E-01,2,"Olfactory receptor, G-protein alpha-olf",
1047,PR action in breast cancer: stimulation of metastasis,20,3.502E-01,4.861E-01,3.657E-01,4.861E-01,2,"Tissue factor, IRS-2",3.502E-01,5.162E-01,2,"Tissue factor, IRS-2",
1048,Axonal degeneration in multiple sclerosis,49,3.549E-01,4.995E-01,3.785E-01,4.995E-01,4,"SCN2A, iNOS, GluR6, NCX1",3.549E-01,5.220E-01,4,"SCN2A, iNOS, GluR6, NCX1",
1049,Regulatory T cells in human allergic contact dermatitis,7,3.584E-01,4.865E-01,3.683E-01,4.865E-01,1,MHC class II,3.584E-01,5.255E-01,1,MHC class II,
1050,Immune response_NF-AT signaling and leukocyte interactions,48,3.638E-01,4.851E-01,3.638E-01,4.851E-01,4,"COX-2 (PTGS2), MHC class II, Lck, cPLA2",5.724E-01,7.341E-01,3,"COX-2 (PTGS2), MHC class II, cPLA2",
1051,Development_Regulation of telomere length and cellular immortalization,35,3.650E-01,5.046E-01,3.852E-01,5.046E-01,3,"PI3K cat class IA, AKT(PKB), PKC-alpha",3.650E-01,5.317E-01,3,"PI3K cat class IA, AKT(PKB), PKC-alpha",
1052,Neurophysiological process_Thyroliberin in cell hyperpolarization and excitability,35,3.650E-01,5.046E-01,3.852E-01,5.046E-01,3,"cPKC (conventional), PKC-alpha, Kir3.4",3.650E-01,5.317E-01,3,"cPKC (conventional), PKC-alpha, Kir3.4",
1053,Oxidative stress_NOX and DUOX families of NADPH oxidases ,35,3.650E-01,5.046E-01,3.852E-01,5.046E-01,3,"DUOX2, Rac2, DUOXA1",3.650E-01,5.317E-01,3,"DUOX2, Rac2, DUOXA1",
1054,Action of lithium on synaptic transmission and autophagy,35,3.650E-01,5.046E-01,3.852E-01,5.046E-01,3,"PKC-alpha, Adenylate cyclase, Adenylate cyclase type VII",3.650E-01,5.317E-01,3,"PKC-alpha, Adenylate cyclase, Adenylate cyclase type VII",
1055,Apoptosis and survival_Caspase cascade,34,3.676E-01,4.861E-01,3.676E-01,4.861E-01,3,"Caspase-10, AKT(PKB), Caspase-8",6.267E-01,7.809E-01,2,"Caspase-10, AKT(PKB)",
1056,Immune response_IL-11 signaling via JAK/STAT,34,3.676E-01,4.861E-01,3.676E-01,4.861E-01,3,"STAT3, A2M, Pim-1",6.267E-01,7.809E-01,2,"A2M, Pim-1",
1057,Development_Histone acetylation in embryonic stem cells,34,3.676E-01,4.861E-01,3.676E-01,4.861E-01,3,"SNAIL1, Oct-3/4, p53",8.845E-01,9.500E-01,1,Oct-3/4,
1058,Oxidative stress_ROS-mediated activation of MAPK via inhibition of phosphatases,34,3.676E-01,4.861E-01,3.676E-01,4.861E-01,3,"EGFR, ERK1/2, PDGF-R-beta",6.267E-01,7.809E-01,2,"EGFR, PDGF-R-beta",
1059,"Apoptosis and survival_Cytoplasmic/mitochondrial transport of proapoptotic proteins Bid, Bmf and Bim",34,3.676E-01,4.861E-01,3.676E-01,4.861E-01,3,"HGK(MAP4K4), Caspase-10, Caspase-8",6.267E-01,7.809E-01,2,"HGK(MAP4K4), Caspase-10",
1060,Muscle contraction_Regulation of eNOS activity in endothelial cells,65,3.695E-01,5.169E-01,3.968E-01,5.169E-01,5,"PI3K cat class IA, AKT(PKB), Caveolin-1, ETS1, G-protein alpha-i family",3.695E-01,5.360E-01,5,"PI3K cat class IA, AKT(PKB), Caveolin-1, ETS1, G-protein alpha-i family",
1061,Possible regulation of HSF-1/ chaperone pathway in Huntington's disease,21,3.729E-01,5.075E-01,3.889E-01,5.075E-01,2,"PLA2, PKC-alpha",3.729E-01,5.379E-01,2,"PLA2, PKC-alpha",
1062,Cell cycle_Cell cycle (generic schema),21,3.729E-01,5.075E-01,3.889E-01,5.075E-01,2,"Cyclin E, CDK6",3.729E-01,5.379E-01,2,"Cyclin E, CDK6",
1063,Development_Generation of pancreatic beta-cells from embryonic stem cells (early stages),21,3.729E-01,5.075E-01,3.889E-01,5.075E-01,2,"Activin A, Oct-3/4",3.729E-01,5.379E-01,2,"Activin A, Oct-3/4",
1064,Gamma-secretase regulation of mammary cell development,21,3.729E-01,5.075E-01,3.889E-01,5.075E-01,2,"NOTCH4 (ICD4), NOTCH4",3.729E-01,5.379E-01,2,"NOTCH4 (ICD4), NOTCH4",
1065,Immune response_T regulatory cell-mediated modulation of antigen-presenting cell functions,66,3.819E-01,5.298E-01,4.096E-01,5.298E-01,5,"3HAO, IDO1, 5'-NTD, MHC class II, ICAM1",3.819E-01,5.472E-01,5,"3HAO, IDO1, 5'-NTD, MHC class II, ICAM1",
1066,Higher ESR1 / ESR2 ratio in breast cancer,36,3.821E-01,5.236E-01,4.028E-01,5.236E-01,3,"ITGA1, AKT(PKB), Cyclin E",3.821E-01,5.472E-01,3,"ITGA1, AKT(PKB), Cyclin E",
1067,Th2-cytokines induced expression of Mucin 5AC and maintenance of mucous cell phenotype in normal airway epithelium,35,3.852E-01,5.046E-01,3.852E-01,5.046E-01,3,"TGF-beta 2, TGF-beta receptor type II, ERK1/2",6.425E-01,7.912E-01,2,"TGF-beta 2, TGF-beta receptor type II",
1068,Anti-apoptotic action of Gastrin in gastric cancer,35,3.852E-01,5.046E-01,3.852E-01,5.046E-01,3,"BAD, PKC-alpha, ERK1/2",8.916E-01,9.509E-01,1,PKC-alpha,
1069,Immune response_Lipoxins and Resolvin E1 inhibitory action on neutrophil functions,35,3.852E-01,5.046E-01,3.852E-01,5.046E-01,3,"IL-8, G-protein alpha-i family, ERK1/2",6.425E-01,7.912E-01,2,"IL-8, G-protein alpha-i family",
1070,Anti-apoptotic action of Gastrin in pancreatic cancer,35,3.852E-01,5.046E-01,3.852E-01,5.046E-01,3,"BAD, PI3K cat class IA, AKT(PKB)",6.425E-01,7.912E-01,2,"PI3K cat class IA, AKT(PKB)",
1071,Immune response_IL-13 signaling via PI3K-ERK pathway,50,3.932E-01,5.126E-01,3.932E-01,5.126E-01,4,"AKT(PKB), IRS-2, PI3K cat class IA (p110-delta), ERK1/2",6.004E-01,7.629E-01,3,"AKT(PKB), IRS-2, PI3K cat class IA (p110-delta)",
1072,Differences between Langerhans cells and dermal dendritic cells in allergic contact dermatitis,22,3.952E-01,5.298E-01,4.117E-01,5.298E-01,2,"MHC class II, PD-L1",3.952E-01,5.612E-01,2,"MHC class II, PD-L1",
1073,Amitraz-induced inhibition of Insulin secretion,22,3.952E-01,5.298E-01,4.117E-01,5.298E-01,2,"G-protein alpha-i1, G-protein alpha-i family",3.952E-01,5.612E-01,2,"G-protein alpha-i1, G-protein alpha-i family",
1074,Role of Huntingtin in regulation of BDNF in Huntington's disease,22,3.952E-01,5.298E-01,4.117E-01,5.298E-01,2,"PI3K cat class IA, AKT(PKB)",3.952E-01,5.612E-01,2,"PI3K cat class IA, AKT(PKB)",
1075,Immune responses in asthma (schema),8,3.978E-01,5.298E-01,4.084E-01,5.298E-01,1,IL-1 beta,3.978E-01,5.626E-01,1,IL-1 beta,
1076,G-protein signaling_Regulation of p38 and JNK signaling mediated by G-proteins,37,3.990E-01,5.397E-01,4.201E-01,5.397E-01,3,"G-protein alpha-q/11, G-protein alpha-i family, MEF2C",3.990E-01,5.626E-01,3,"G-protein alpha-q/11, G-protein alpha-i family, MEF2C",
1077,G-protein signaling_G-Protein alpha-s signaling cascades,36,4.028E-01,5.236E-01,4.028E-01,5.236E-01,3,"RGS2, AK5, ERK1/2",6.578E-01,8.050E-01,2,"RGS2, AK5",
1078,microRNA in Prostate Cancer,51,4.078E-01,5.297E-01,4.078E-01,5.297E-01,4,"CD44, p53, microRNA 221, CDK6",6.140E-01,7.700E-01,3,"CD44, microRNA 221, CDK6",
1079,Dysregulation of direct glucose-induced inhibition of Glucagon secretion from alpha-cells in type 2 diabetes  ,53,4.116E-01,5.576E-01,4.368E-01,5.576E-01,4,"Kv2.2, iNOS, CDX2, PAX6",4.116E-01,5.797E-01,4,"Kv2.2, iNOS, CDX2, PAX6",
1080,Development_S1P4 receptor signaling pathway,22,4.117E-01,5.298E-01,4.117E-01,5.298E-01,2,"G-protein alpha-i family, ERK1/2",7.524E-01,8.655E-01,1,G-protein alpha-i family,
1081,Inhibition of GSK3 beta by lithium in major depressive disorder,22,4.117E-01,5.298E-01,4.117E-01,5.298E-01,2,"SMAD3, AKT(PKB)",7.524E-01,8.655E-01,1,AKT(PKB),
1082,Translation_Role of Retinoic acid signaling in the initiation of translation,22,4.117E-01,5.298E-01,4.117E-01,5.298E-01,2,"MAP2, ERK1/2",7.524E-01,8.655E-01,1,MAP2,
1083,Development_Dopamine-induced expression of CNTF in adult neurogenesis,22,4.117E-01,5.298E-01,4.117E-01,5.298E-01,2,"STAT3, G-protein alpha-i family",7.524E-01,8.655E-01,1,G-protein alpha-i family,
1084,Cell cycle_Role of 14-3-3 proteins in cell cycle regulation,22,4.117E-01,5.298E-01,4.117E-01,5.298E-01,2,"AKT(PKB), p53",7.524E-01,8.655E-01,1,AKT(PKB),
1085,Development_Mu-type opioid receptor signaling,38,4.158E-01,5.576E-01,4.373E-01,5.576E-01,3,"beta-Endorphin extracellular region, AKT(PKB), G-protein alpha-i family",4.158E-01,5.821E-01,3,"beta-Endorphin extracellular region, AKT(PKB), G-protein alpha-i family",
1086,Defective efferocytosis in COPD,38,4.158E-01,5.576E-01,4.373E-01,5.576E-01,3,"MFGE8, CD14, Protein S",4.158E-01,5.821E-01,3,"MFGE8, CD14, Protein S",
1087,G-protein signaling_Cross-talk between Ras-family GTPases,23,4.171E-01,5.561E-01,4.341E-01,5.561E-01,2,"PI3K cat class IA, AKT(PKB)",4.171E-01,5.821E-01,2,"PI3K cat class IA, AKT(PKB)",
1088,Transcription_CoREST complex-mediated epigenetic gene silencing,37,4.201E-01,5.397E-01,4.201E-01,5.397E-01,3,"SCN2A, SNAIL1, GFI-1",6.726E-01,8.180E-01,2,"SCN2A, GFI-1",
1089,Neurophysiological process_NMDA-dependent postsynaptic long-term potentiation in CA1 hippocampal neurons,82,4.215E-01,5.409E-01,4.215E-01,5.409E-01,6,"ERK2 (MAPK1), AKT(PKB), PKC-alpha, NR2A, NR2, ERK1/2",7.499E-01,8.655E-01,4,"AKT(PKB), PKC-alpha, NR2A, NR2",
1090,Dysregulation of indirect glucose-induced inhibition of Glucagon secretion from alpha-cells in type 2 diabetes ,54,4.256E-01,5.732E-01,4.512E-01,5.732E-01,4,"PI3K cat class IA, GABA-A receptor, IRS-2, PAX6",4.256E-01,5.916E-01,4,"PI3K cat class IA, GABA-A receptor, IRS-2, PAX6",
1091,NRSF-dependent transcription deregulation in Huntington's Disease,39,4.325E-01,5.741E-01,4.543E-01,5.741E-01,3,"ACM4, ITGB1, Enkephalin A",4.325E-01,5.974E-01,3,"ACM4, ITGB1, Enkephalin A",
1092,Regulation of degradation of deltaF508-CFTR in CF,39,4.325E-01,5.741E-01,4.543E-01,5.741E-01,3,"BAG-2, Dynein 1, cytoplasmic, intermediate chains, UCHL1",4.325E-01,5.974E-01,3,"BAG-2, Dynein 1, cytoplasmic, intermediate chains, UCHL1",
1093,Role of iNKT and B cells in T cell recruitment in allergic contact dermatitis,39,4.325E-01,5.741E-01,4.543E-01,5.741E-01,3,"alpha-4/beta-1 integrin, ICAM1, CD1d",4.325E-01,5.974E-01,3,"alpha-4/beta-1 integrin, ICAM1, CD1d",
1094,"VLDL, LDL dyslipidemia in type 2 diabetes and metabolic syndrome X",39,4.325E-01,5.741E-01,4.543E-01,5.741E-01,3,"Biglycan proteoglycan, Versican proteoglycan, MSR1",4.325E-01,5.974E-01,3,"Biglycan proteoglycan, Versican proteoglycan, MSR1",
1095,Nicotine signaling in GABAergic neurons,39,4.325E-01,5.741E-01,4.543E-01,5.741E-01,3,"GABA-A receptor, GAT1, G-protein alpha-i family",4.325E-01,5.974E-01,3,"GABA-A receptor, GAT1, G-protein alpha-i family",
1096,Neurophysiological process_Long-term depression in cerebellum,53,4.368E-01,5.576E-01,4.368E-01,5.576E-01,4,"PA24A, PKC-alpha, cPLA2, ERK1/2",6.402E-01,7.912E-01,3,"PA24A, PKC-alpha, cPLA2",
1097,IgE-dependent production of pro-inflammatory mediators by neutrophils in asthma,38,4.373E-01,5.576E-01,4.373E-01,5.576E-01,3,"COX-2 (PTGS2), IL-8, ERK1/2",6.869E-01,8.294E-01,2,"COX-2 (PTGS2), IL-8",
1098,Huntingtin-depended transcription deregulation in Huntington's Disease,24,4.387E-01,5.752E-01,4.560E-01,5.752E-01,2,"NGFR(TNFRSF16), Enkephalin A",4.387E-01,6.029E-01,2,"NGFR(TNFRSF16), Enkephalin A",
1099,Transcription_Negative regulation of HIF1A function,69,4.478E-01,5.700E-01,4.478E-01,5.700E-01,5,"FHL3, p14ARF, FHL1 (SLIM1), RUNX3, p53",6.194E-01,7.754E-01,4,"FHL3, p14ARF, FHL1 (SLIM1), RUNX3",
1100,Transcription_Role of heterochromatin protein 1 (HP1) family in transcriptional silencing,40,4.490E-01,5.904E-01,4.711E-01,5.904E-01,3,"HDAC9, MEF2, Cyclin E",4.490E-01,6.139E-01,3,"HDAC9, MEF2, Cyclin E",
1101,Role of Ghrelin in activation eating behavior in obesity,40,4.490E-01,5.904E-01,4.711E-01,5.904E-01,3,"NPY, G-protein alpha-q/11, Adenylate cyclase type VII",4.490E-01,6.139E-01,3,"NPY, G-protein alpha-q/11, Adenylate cyclase type VII",
1102,Neurophysiological process_ACM1 and ACM2 in neuronal membrane polarization,40,4.490E-01,5.904E-01,4.711E-01,5.904E-01,3,"G-protein alpha-i1, PKC-alpha, Kir2.1",4.490E-01,6.139E-01,3,"G-protein alpha-i1, PKC-alpha, Kir2.1",
1103,Androstenedione and testosterone biosynthesis and metabolism p.3,40,4.490E-01,5.904E-01,4.711E-01,5.904E-01,3,"AKR1C3, AKR1C4, AKR1C2",4.490E-01,6.139E-01,3,"AKR1C3, AKR1C4, AKR1C2",
1104,Development_FGFR signaling pathway,54,4.512E-01,5.732E-01,4.512E-01,5.732E-01,4,"PI3K cat class IA, FGF2, AKT(PKB), ERK1/2",6.528E-01,8.012E-01,3,"PI3K cat class IA, FGF2, AKT(PKB)",
1105,Deregulation of Ca2+-dependent neuronal cell survival in Huntington's disease,39,4.543E-01,5.741E-01,4.543E-01,5.741E-01,3,"Beta-catenin, PI3K cat class IA, AKT(PKB)",7.007E-01,8.364E-01,2,"PI3K cat class IA, AKT(PKB)",
1106,Development_Signaling of Beta-adrenergic receptors via Beta-arrestins,24,4.560E-01,5.752E-01,4.560E-01,5.752E-01,2,"Beta-2 adrenergic receptor, ERK1/2",7.819E-01,8.899E-01,1,Beta-2 adrenergic receptor,
1107,Putative pathways of activation of monoclonal protein secretion in multiple myeloma,25,4.598E-01,5.963E-01,4.774E-01,5.963E-01,2,"BOB1, BLIMP1 (PRDI-BF1)",4.598E-01,6.237E-01,2,"BOB1, BLIMP1 (PRDI-BF1)",
1108,Gamma-secretase regulation of gastrointestinal epithelial cell development,25,4.598E-01,5.963E-01,4.774E-01,5.963E-01,2,"Jagged1, PAX6",4.598E-01,6.237E-01,2,"Jagged1, PAX6",
1109,Putative pathways of hormone action in neurofibromatosis type 1,25,4.598E-01,5.963E-01,4.774E-01,5.963E-01,2,"EGR2 (Krox20), PI3K cat class IA",4.598E-01,6.237E-01,2,"EGR2 (Krox20), PI3K cat class IA",
1110,Th2-cytokine-induced airway epithelium mucous metaplasia in COPD,70,4.604E-01,5.801E-01,4.604E-01,5.801E-01,5,"Actin cytoskeletal, iNOS, Adenosine A2b receptor, G-protein alpha-q/11, ERK1/2",8.125E-01,9.100E-01,3,"iNOS, Adenosine A2b receptor, G-protein alpha-q/11",
1111,Sitagliptin in treatment of type 2 diabetes and metabolic syndrome X,10,4.696E-01,6.005E-01,4.812E-01,6.005E-01,1,DPP4,4.696E-01,6.345E-01,1,DPP4,
1112,Reproduction_Progesterone-mediated oocyte maturation,40,4.711E-01,5.904E-01,4.711E-01,5.904E-01,3,"ERK2 (MAPK1), G-protein alpha-i family, Adenylate cyclase",7.139E-01,8.462E-01,2,"G-protein alpha-i family, Adenylate cyclase",
1113,Th2-cytokines-induced mucous metaplasia in asthma,40,4.711E-01,5.904E-01,4.711E-01,5.904E-01,3,"PI3K cat class IA, IRS-2, ERK1/2",7.139E-01,8.462E-01,2,"PI3K cat class IA, IRS-2",
1114,Development_Glucocorticoid receptor signaling,25,4.774E-01,5.963E-01,4.774E-01,5.963E-01,2,"MMP-13, SMAD3",7.953E-01,8.982E-01,1,MMP-13,
1115,Neurophysiological process_GABA-B receptor signaling at postsynaptic sides of synapses,26,4.804E-01,6.174E-01,4.983E-01,6.174E-01,2,"Kir3.4, G-protein alpha-i family",4.804E-01,6.459E-01,2,"Kir3.4, G-protein alpha-i family",
1116,Apoptosis and survival_Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway,42,4.813E-01,6.232E-01,5.039E-01,6.232E-01,3,"NGF, TNF-R2, NGFR(TNFRSF16)",4.813E-01,6.459E-01,3,"NGF, TNF-R2, NGFR(TNFRSF16)",
1117,Regulation of lipid metabolism_Stimulation of Arachidonic acid production by ACM receptors,72,4.853E-01,6.044E-01,4.853E-01,6.044E-01,5,"PKC, PKC-alpha, cPLA2, ERK1/2, ACM3",6.530E-01,8.012E-01,4,"PKC, PKC-alpha, cPLA2, ACM3",
1118,Role of epigenetic alterations in proliferation and differentiation of SCLC cells,72,4.853E-01,6.044E-01,4.853E-01,6.044E-01,5,"Beta-catenin, Caveolin-1, p53, DMRTA2, CDK6",8.272E-01,9.185E-01,3,"Caveolin-1, DMRTA2, CDK6",
1119,Development_Growth hormone-releasing hormone (GH-RH) signaling,41,4.876E-01,6.057E-01,4.876E-01,6.057E-01,3,"cPKC (conventional), Adenylate cyclase, ERK1/2",7.267E-01,8.532E-01,2,"cPKC (conventional), Adenylate cyclase",
1120,Possible pathway of TGF-beta 1-dependent inhibition of CFTR expression,41,4.876E-01,6.057E-01,4.876E-01,6.057E-01,3,"Beta-2 adrenergic receptor, SMAD3, TGF-beta receptor type II",7.267E-01,8.532E-01,2,"Beta-2 adrenergic receptor, TGF-beta receptor type II",
1121,Apoptosis and survival_Phosphorylation and acetylation in TNF-alpha-induced NF-kB signaling,41,4.876E-01,6.057E-01,4.876E-01,6.057E-01,3,"PI3K cat class IA, PKC-alpha, ERK1/2",7.267E-01,8.532E-01,2,"PI3K cat class IA, PKC-alpha",
1122,Development_Non-genomic action of Retinoic acid in cell differentiation,57,4.935E-01,6.119E-01,4.935E-01,6.119E-01,4,"COX-2 (PTGS2), AKT(PKB), PKC-alpha, ERK1/2",6.888E-01,8.294E-01,3,"COX-2 (PTGS2), AKT(PKB), PKC-alpha",
1123,Regulation of lipid metabolism_Insulin regulation of glycogen metabolism ,57,4.935E-01,6.119E-01,4.935E-01,6.119E-01,4,"PI3K cat class IA, AKT(PKB), IRS-2, ERK1/2",6.888E-01,8.294E-01,3,"PI3K cat class IA, AKT(PKB), IRS-2",
1124,Renal secretion of inorganic electrolytes,59,4.943E-01,6.414E-01,5.209E-01,6.414E-01,4,"SLC4A4, NCX1, Aquaporin 1, CALB1",4.943E-01,6.620E-01,4,"SLC4A4, NCX1, Aquaporin 1, CALB1",
1125,Development_Growth hormone signaling via PI3K/AKT and MAPK cascades,42,5.039E-01,6.232E-01,5.039E-01,6.232E-01,3,"ERK2 (MAPK1), AKT(PKB), IRS-2",7.389E-01,8.609E-01,2,"AKT(PKB), IRS-2",
1126,Vitamin B3 and NAD+ metabolism,125,5.048E-01,6.630E-01,5.432E-01,6.630E-01,8,"PAM, ALPL, 5'-NTD, ALPP, MCT1 (SLC16A1), CD38, Xanthine oxidase, NNMT",5.048E-01,6.714E-01,8,"PAM, ALPL, 5'-NTD, ALPP, MCT1 (SLC16A1), CD38, Xanthine oxidase, NNMT",
1127,NMDA-independent presynaptic long-term potentiation in Huntington's disease,58,5.073E-01,6.268E-01,5.073E-01,6.268E-01,4,"Actin cytoskeletal, GABA-A receptor, PKC-alpha, GluR6",7.001E-01,8.364E-01,3,"GABA-A receptor, PKC-alpha, GluR6",
1128,Chondroitin sulfate and dermatan sulfate metabolism,60,5.076E-01,6.550E-01,5.344E-01,6.550E-01,4,"CGAT1, CHST3, SART2, CHSTD",5.076E-01,6.739E-01,4,"CGAT1, CHST3, SART2, CHSTD",
1129,Immune response_Distinct metabolic pathways in naive and effector CD8+ T cells,74,5.098E-01,6.293E-01,5.098E-01,6.293E-01,5,"Fyn, PI3K cat class IA, Lck, AKT(PKB), ERK1/2",8.410E-01,9.240E-01,3,"Fyn, PI3K cat class IA, AKT(PKB)",
1130,Ganglioside Metabolism p2,44,5.127E-01,6.560E-01,5.356E-01,6.560E-01,3,"SIA7C, SIAT8A, SIA7E",5.127E-01,6.787E-01,3,"SIA7C, SIAT8A, SIA7E",
1131,Apoptosis and survival_TNFR1 signaling pathway,43,5.199E-01,6.413E-01,5.199E-01,6.413E-01,3,"c-IAP2, Caspase-10, Caspase-8",7.507E-01,8.655E-01,2,"c-IAP2, Caspase-10",
1132,Muscle contraction_nNOS signaling in skeletal muscle ,28,5.201E-01,6.578E-01,5.385E-01,6.578E-01,2,"Dystrophin, Actin",5.201E-01,6.865E-01,2,"Dystrophin, Actin",
1133,Pro-oncogenic action of Androgen receptor in ovarian cancer,28,5.201E-01,6.578E-01,5.385E-01,6.578E-01,2,"GSTP1, TGF-beta receptor type II",5.201E-01,6.865E-01,2,"GSTP1, TGF-beta receptor type II",
1134,Neolacto-series GSL Metabolism p.2,61,5.208E-01,6.660E-01,5.476E-01,6.660E-01,4,"B3GNT5, SIA10, CHST4, SIA7E",5.208E-01,6.867E-01,4,"B3GNT5, SIA10, CHST4, SIA7E",
1135,Neurophysiological process_Constitutive and activity-dependent synaptic AMPA receptor delivery,59,5.209E-01,6.414E-01,5.209E-01,6.414E-01,4,"Actin cytoskeletal, PKC, PKC-alpha, NEEP21",7.111E-01,8.462E-01,3,"PKC, PKC-alpha, NEEP21",
1136,"Development_NCAM1-mediated neurite outgrowth, synapse assembly and neuronal survival",75,5.219E-01,6.420E-01,5.219E-01,6.420E-01,5,"Fyn, NCAM1, PKC, AKT(PKB), ERK1/2",6.844E-01,8.294E-01,4,"Fyn, NCAM1, PKC, AKT(PKB)",
1137,"Development_The role of GDNF ligand family/ RET receptor in cell survival, growth and proliferation",92,5.336E-01,6.550E-01,5.336E-01,6.550E-01,6,"STAT3, ITGB1, PI3K cat class IA, AKT(PKB), F-Actin cytoskeleton, ERK1/2",9.276E-01,9.681E-01,3,"ITGB1, PI3K cat class IA, AKT(PKB)",
1138,A shift from oxidative to glycolytic muscle fiber phenotype in quadriceps muscles in COPD,60,5.344E-01,6.550E-01,5.344E-01,6.550E-01,4,"PPARGC1 (PGC1-alpha), MEF2, ERK2 (MAPK1), Troponin C, cardiac",7.218E-01,8.497E-01,3,"PPARGC1 (PGC1-alpha), MEF2, Troponin C, cardiac",
1139,Signal transduction_mTORC1 downstream signaling,60,5.344E-01,6.550E-01,5.344E-01,6.550E-01,4,"BAD, STAT3, SGK1, p53",9.779E-01,9.959E-01,1,SGK1,
1140,Development_Regulation of CDK5 in CNS,28,5.385E-01,6.578E-01,5.385E-01,6.578E-01,2,"NGF, ERK1/2",8.308E-01,9.185E-01,1,NGF,
1141,Cholesterol and Sphingolipid transport / Recycling to plasma membrane in lung (normal and CF),29,5.392E-01,6.754E-01,5.577E-01,6.754E-01,2,"PA24A, Caveolin-1",5.392E-01,7.055E-01,2,"PA24A, Caveolin-1",
1142,Cholesterol and Sphingolipid transport / Influx to the early endosome in lung (normal and CF),29,5.392E-01,6.754E-01,5.577E-01,6.754E-01,2,"Caveolin-1, Caveolin-2",5.392E-01,7.055E-01,2,"Caveolin-1, Caveolin-2",
1143,Vitamin D2 (ergocalciferol) metabolism,29,5.392E-01,6.754E-01,5.577E-01,6.754E-01,2,"CYP27A1, CYP24A1",5.392E-01,7.055E-01,2,"CYP27A1, CYP24A1",
1144,Serotonin - melatonin biosynthesis and metabolism,46,5.431E-01,6.838E-01,5.662E-01,6.838E-01,3,"ALDR, IDO1, CYP1A1",5.431E-01,7.092E-01,3,"ALDR, IDO1, CYP1A1",
1145,Transcription_Sirtuin6 regulation and functions ,63,5.466E-01,6.915E-01,5.735E-01,6.915E-01,4,"AMPK gamma subunit, PPARGC1 (PGC1-alpha), c-IAP2, ICAM1",5.466E-01,7.111E-01,4,"AMPK gamma subunit, PPARGC1 (PGC1-alpha), c-IAP2, ICAM1",
1146,Lacto-series GSL Metabolism,63,5.466E-01,6.915E-01,5.735E-01,6.915E-01,4,"B3GNT5, B3GT2, ABO system transferase, SIA7E",5.466E-01,7.111E-01,4,"B3GNT5, B3GT2, ABO system transferase, SIA7E",
1147,Induction of mucin secretion in  airway goblet cells by purinergic receptors,61,5.476E-01,6.660E-01,5.476E-01,6.660E-01,4,"Actin cytoskeletal, iNOS, G-protein alpha-q/11, PKC-alpha",7.322E-01,8.584E-01,3,"iNOS, G-protein alpha-q/11, PKC-alpha",
1148,Cell cycle_Role of SCF complex in cell cycle regulation,29,5.577E-01,6.754E-01,5.577E-01,6.754E-01,2,"SMAD3, Cyclin E",8.413E-01,9.240E-01,1,Cyclin E,
1149,Histone deacetylases in Prostate Cancer,29,5.577E-01,6.754E-01,5.577E-01,6.754E-01,2,"HDAC9, p53",8.413E-01,9.240E-01,1,HDAC9,
1150,Mechanisms of deltaF508 CFTR activation by S-nitrosoglutathione,47,5.579E-01,6.957E-01,5.810E-01,6.957E-01,3,"Ceruloplasmin, iNOS, IL-8",5.579E-01,7.195E-01,3,"Ceruloplasmin, iNOS, IL-8",
1151,"Development_TNF-alpha, IL-1 alpha and WNT5A-dependent regulation of osteogenesis and adipogenesis in mesenchymal stem cells",47,5.579E-01,6.957E-01,5.810E-01,6.957E-01,3,"ALPL, TAZ, RUNX2",5.579E-01,7.195E-01,3,"ALPL, TAZ, RUNX2",
1152,Neurophysiological process_Dopamine D2 receptor signaling in CNS,47,5.579E-01,6.957E-01,5.810E-01,6.957E-01,3,"Kir3.4, G-protein alpha-i family, Adenylate cyclase type VII",5.579E-01,7.195E-01,3,"Kir3.4, G-protein alpha-i family, Adenylate cyclase type VII",
1153,wtCFTR and deltaF508 traffic / Membrane expression (normal and CF),47,5.579E-01,6.957E-01,5.810E-01,6.957E-01,3,"HGF, Beta-2 adrenergic receptor, HGF receptor (Met)",5.579E-01,7.195E-01,3,"HGF, Beta-2 adrenergic receptor, HGF receptor (Met)",
1154,Development_G-protein-mediated regulation of MAPK-ERK signaling,46,5.662E-01,6.838E-01,5.662E-01,6.838E-01,3,"ERK2 (MAPK1), G-protein alpha-q/11, G-protein alpha-i family",7.834E-01,8.899E-01,2,"G-protein alpha-q/11, G-protein alpha-i family",
1155,Role of GIP in pathogenesis of type 2 diabetes,46,5.662E-01,6.838E-01,5.662E-01,6.838E-01,3,"BAD, AKT(PKB), ERK1/2",9.461E-01,9.733E-01,1,AKT(PKB),
1156,Tinnitus-associated changes in auditory pathway ,82,5.722E-01,7.157E-01,6.024E-01,7.157E-01,5,"GRID1, GABA-A receptor, GAD1, NR2A, GluR6",5.722E-01,7.341E-01,5,"GRID1, GABA-A receptor, GAD1, NR2A, GluR6",
1157,Androgen biosynthetic pathways,82,5.722E-01,7.157E-01,6.024E-01,7.157E-01,5,"AKR1C1, AKR1C3, AKR1C4, AKR1C2, CYP11A1",5.722E-01,7.341E-01,5,"AKR1C1, AKR1C3, AKR1C4, AKR1C2, CYP11A1",
1158,"Nicotine signaling in dopaminergic neurons, Pt. 1 - cell body",48,5.724E-01,7.112E-01,5.955E-01,7.112E-01,3,"nAChR alpha-7, GABA-A receptor, G-protein alpha-i family",5.724E-01,7.341E-01,3,"nAChR alpha-7, GABA-A receptor, G-protein alpha-i family",
1159,Globo-(isoglobo) series GSL Metabolism,48,5.724E-01,7.112E-01,5.955E-01,7.112E-01,3,"ABO system transferase, SIA7E, G3ST1",5.724E-01,7.341E-01,3,"ABO system transferase, SIA7E, G3ST1",
1160,Retinoic acid maintains mucocilliary differentiation and mucins expression in normal and asthmatic airway epithelium,30,5.764E-01,6.925E-01,5.764E-01,6.925E-01,2,"PKC-alpha, ERK1/2",8.510E-01,9.280E-01,1,PKC-alpha,
1161,Asthma-specific pathways of airway smooth muscle cell proliferation,14,5.885E-01,7.154E-01,6.011E-01,7.154E-01,1,PPARGC1 (PGC1-alpha),5.885E-01,7.519E-01,1,PPARGC1 (PGC1-alpha),
1162,Immune response  _Sialic-acid receptors (Siglecs) signaling,14,5.885E-01,7.154E-01,6.011E-01,7.154E-01,1,Lyn,5.885E-01,7.519E-01,1,Lyn,
1163,Cell cycle_Nucleocytoplasmic transport of CDK/Cyclins,14,5.885E-01,7.154E-01,6.011E-01,7.154E-01,1,Cyclin E,5.885E-01,7.519E-01,1,Cyclin E,
1164,Neurophysiological process_Glucose-excited neurons of ventromedial nucleus (rodent model),32,5.933E-01,7.259E-01,6.119E-01,7.259E-01,2,"SLC5A1, GABA-A receptor",5.933E-01,7.567E-01,2,"SLC5A1, GABA-A receptor",
1165,Cell cycle_Role of Nek in cell cycle regulation,32,5.933E-01,7.259E-01,6.119E-01,7.259E-01,2,"Tubulin beta, PI3K cat class IA",5.933E-01,7.567E-01,2,"Tubulin beta, PI3K cat class IA",
1166,Apoptosis and survival_Role of IAP-proteins in apoptosis,31,5.944E-01,7.112E-01,5.944E-01,7.112E-01,2,"c-IAP2, Caspase-8",8.602E-01,9.335E-01,1,c-IAP2,
1167,Phospholipid metabolism p.3,33,6.103E-01,7.428E-01,6.288E-01,7.428E-01,2,"LRAT, PA24A",6.103E-01,7.696E-01,2,"LRAT, PA24A",
1168,Nicotine signaling in glutamatergic neurons,33,6.103E-01,7.428E-01,6.288E-01,7.428E-01,2,"PKC-alpha, G-protein alpha-i family",6.103E-01,7.696E-01,2,"PKC-alpha, G-protein alpha-i family",
1169,Cytoskeleton remodeling_Thyroliberin in cytoskeleton remodeling,33,6.103E-01,7.428E-01,6.288E-01,7.428E-01,2,"PKC-alpha, Adenylate cyclase",6.103E-01,7.696E-01,2,"PKC-alpha, Adenylate cyclase",
1170,Heme metabolism,103,6.124E-01,7.606E-01,6.450E-01,7.606E-01,6,"Ceruloplasmin, Apotransferrin, UGT1A1, Neuroglobin, Holotransferrin, UGT1A6",6.124E-01,7.700E-01,6,"Ceruloplasmin, Apotransferrin, UGT1A1, Neuroglobin, Holotransferrin, UGT1A6",
1171,Cortisone biosynthesis and metabolism,51,6.140E-01,7.517E-01,6.369E-01,7.517E-01,3,"AKR1C3, AKR1C4, AKR1C2",6.140E-01,7.700E-01,3,"AKR1C3, AKR1C4, AKR1C2",
1172,Apoptosis and survival_Granzyme B signaling,33,6.288E-01,7.428E-01,6.288E-01,7.428E-01,2,"Caspase-10, Caspase-8",8.769E-01,9.449E-01,1,Caspase-10,
1173,"Mechanism of Pioglitazone/ Metformin and Rosiglitazone/ Metformin  cooperative action in Diabetes mellitus, Type 2",16,6.375E-01,7.648E-01,6.502E-01,7.648E-01,1,AMPK gamma subunit,6.375E-01,7.912E-01,1,AMPK gamma subunit,
1174,Intercellular relations in asthma (general schema),16,6.375E-01,7.648E-01,6.502E-01,7.648E-01,1,ICAM1,6.375E-01,7.912E-01,1,ICAM1,
1175,NF-kB pathway in multiple myeloma,35,6.425E-01,7.748E-01,6.609E-01,7.748E-01,2,"IL-6, c-IAP2",6.425E-01,7.912E-01,2,"IL-6, c-IAP2",
1176,Keratan sulfate metabolism p.1,35,6.425E-01,7.748E-01,6.609E-01,7.748E-01,2,"CHST3, CHST6",6.425E-01,7.912E-01,2,"CHST3, CHST6",
1177,Beta-alanine metabolism,35,6.425E-01,7.748E-01,6.609E-01,7.748E-01,2,"GAD1, DPYD",6.425E-01,7.912E-01,2,"GAD1, DPYD",
1178,ATP metabolism,107,6.495E-01,7.927E-01,6.813E-01,7.927E-01,6,"PDE7B, PDE1C, PDE3A, AK5, CD38, Adenylate cyclase type VII",6.495E-01,7.991E-01,6,"PDE7B, PDE1C, PDE3A, AK5, CD38, Adenylate cyclase type VII",
1179,Nicotine signaling in cholinergic neurons,52,6.501E-01,7.648E-01,6.501E-01,7.648E-01,3,"NGF, PI3K cat class IA, ERK2 (MAPK1)",8.376E-01,9.240E-01,2,"NGF, PI3K cat class IA",
1180,GTP metabolism,54,6.528E-01,7.873E-01,6.753E-01,7.873E-01,3,"PDE1A, PDE1C, PDE3A",6.528E-01,8.012E-01,3,"PDE1A, PDE1C, PDE3A",
1181,G-protein signaling_Rac2 regulation pathway,36,6.578E-01,7.873E-01,6.761E-01,7.873E-01,2,"Rac2, iNOS",6.578E-01,8.050E-01,2,"Rac2, iNOS",
1182,Statin action on the PI3K/ Akt pathway in COPD,36,6.578E-01,7.873E-01,6.761E-01,7.873E-01,2,"PI3K cat class IA, AKT(PKB)",6.578E-01,8.050E-01,2,"PI3K cat class IA, AKT(PKB)",
1183,G-protein signaling_Rap2A regulation pathway,17,6.598E-01,7.850E-01,6.724E-01,7.850E-01,1,G-protein alpha-i family,6.598E-01,8.060E-01,1,G-protein alpha-i family,
1184,Development_Growth hormone signaling via STATs and PLC/IP3,35,6.609E-01,7.748E-01,6.609E-01,7.748E-01,2,"STAT3, Fyn",8.916E-01,9.509E-01,1,Fyn,
1185,Translation_Translation regulation by Alpha-1 adrenergic receptors,53,6.629E-01,7.764E-01,6.629E-01,7.764E-01,3,"ERK2 (MAPK1), Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor",8.453E-01,9.277E-01,2,"Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor",
1186,Interconnectivity between Folic acid and Fluorouracil pathways in gastric cancer,91,6.648E-01,8.042E-01,6.935E-01,8.042E-01,5,"CES1, CDD, UDP, Aquaporin 9, DPYD",6.648E-01,8.110E-01,5,"CES1, CDD, UDP, Aquaporin 9, DPYD",
1187,Cholesterol and Sphingolipid transport / Transport from Golgi and ER to the apical membrane (normal and CF),37,6.726E-01,8.023E-01,6.907E-01,8.023E-01,2,"CES1, Caveolin-1",6.726E-01,8.180E-01,2,"CES1, Caveolin-1",
1188,Muscle contraction_Regulation of eNOS activity in cardiomyocytes,56,6.771E-01,8.101E-01,6.992E-01,8.101E-01,3,"AKAP6, PDE3A, G-protein alpha-i family",6.771E-01,8.219E-01,3,"AKAP6, PDE3A, G-protein alpha-i family",
1189,Regulation of lipid metabolism_Regulation of acetyl-CoA carboxylase 1 activity,18,6.808E-01,8.042E-01,6.932E-01,8.042E-01,1,AMPK gamma subunit,6.808E-01,8.256E-01,1,AMPK gamma subunit,
1190,"Regulation of lipid metabolism_Regulation of lipid metabolism via LXR, NF-Y and SREBP",38,6.869E-01,8.146E-01,7.048E-01,8.146E-01,2,"AMPK gamma subunit, Caveolin-1",6.869E-01,8.294E-01,2,"AMPK gamma subunit, Caveolin-1",
1191,HDL dyslipidemia in type 2 diabetes and metabolic syndrome X,38,6.869E-01,8.146E-01,7.048E-01,8.146E-01,2,"S1P1 receptor, LIPE",6.869E-01,8.294E-01,2,"S1P1 receptor, LIPE",
1192,Prostaglandin 1 biosynthesis and metabolism,57,6.888E-01,8.206E-01,7.106E-01,8.206E-01,3,"COX-2 (PTGS2), PTGIS, Acyl-CoA synthetase",6.888E-01,8.294E-01,3,"COX-2 (PTGS2), PTGIS, Acyl-CoA synthetase",
1193,Regulation of lipid metabolism_Regulation of acetyl-CoA carboxylase 2 activity in muscle,19,7.004E-01,8.217E-01,7.128E-01,8.217E-01,1,AMPK gamma subunit,7.004E-01,8.364E-01,1,AMPK gamma subunit,
1194,Ethanol/Acetaldehyde-dependent stimulation of MMP-9 expression in HCC,19,7.004E-01,8.217E-01,7.128E-01,8.217E-01,1,MMP-9,7.004E-01,8.364E-01,1,MMP-9,
1195,Keratan sulfate metabolism p.2,39,7.007E-01,8.254E-01,7.183E-01,8.254E-01,2,"CHST3, CHST4",7.007E-01,8.364E-01,2,"CHST3, CHST4",
1196,HIV-1 signaling via CCR5 in macrophages and T lymphocytes,39,7.007E-01,8.254E-01,7.183E-01,8.254E-01,2,"CCL2, PKC-alpha",7.007E-01,8.364E-01,2,"CCL2, PKC-alpha",
1197,G-protein signaling_G-Protein alpha-12 signaling pathway,38,7.048E-01,8.146E-01,7.048E-01,8.146E-01,2,"PI3K cat class IA, ERK1/2",9.104E-01,9.616E-01,1,PI3K cat class IA,
1198,L-Methionine metabolism,59,7.111E-01,8.348E-01,7.325E-01,8.348E-01,3,"BHMT, BHMT2, SLC7A7",7.111E-01,8.462E-01,3,"BHMT, BHMT2, SLC7A7",
1199,Neurophysiological process_Glucose-excited neurons of arcuate nucleus (rodent model),40,7.139E-01,8.342E-01,7.314E-01,8.342E-01,2,"POMC, SLC5A1",7.139E-01,8.462E-01,2,"POMC, SLC5A1",
1200,G-protein signaling_Rap1A regulation pathway,40,7.139E-01,8.342E-01,7.314E-01,8.342E-01,2,"CalDAG-GEFIII, G-protein alpha-i family",7.139E-01,8.462E-01,2,"CalDAG-GEFIII, G-protein alpha-i family",
1201,Recurrent gene fusions in Prostate Cancer,40,7.139E-01,8.342E-01,7.314E-01,8.342E-01,2,"ER81, ERM",7.139E-01,8.462E-01,2,"ER81, ERM",
1202,Atorvastatin in treatment of type 2 diabetes and metabolic syndrome X,39,7.183E-01,8.254E-01,7.183E-01,8.254E-01,2,"ERK2 (MAPK1), OATP-B",9.159E-01,9.626E-01,1,OATP-B,
1203,Autocrine Somatotropin signaling in breast cancer,39,7.183E-01,8.254E-01,7.183E-01,8.254E-01,2,"HOXA1, ERK1/2",9.159E-01,9.626E-01,1,HOXA1,
1204,Development_Direct reprogramming of cardiac fibroblasts into cardiomyocytes,20,7.188E-01,8.342E-01,7.310E-01,8.342E-01,1,MEF2C,7.188E-01,8.477E-01,1,MEF2C,
1205,Regulation of degradation of wtCFTR,20,7.188E-01,8.342E-01,7.310E-01,8.342E-01,1,BAG-2,7.188E-01,8.477E-01,1,BAG-2,
1206,Mechanisms of hapten presentation to T cells in allergic contact dermatitis,20,7.188E-01,8.342E-01,7.310E-01,8.342E-01,1,MHC class II,7.188E-01,8.477E-01,1,MHC class II,
1207,Development_TGF-beta-induction of EMT via ROS,20,7.188E-01,8.342E-01,7.310E-01,8.342E-01,1,TGF-beta receptor type II,7.188E-01,8.477E-01,1,TGF-beta receptor type II,
1208,Regulation of caspase activity in Huntington's disease,20,7.188E-01,8.342E-01,7.310E-01,8.342E-01,1,Caspase-1,7.188E-01,8.477E-01,1,Caspase-1,
1209,Protein folding and maturation_Insulin processing,20,7.188E-01,8.342E-01,7.310E-01,8.342E-01,1,PC1,7.188E-01,8.477E-01,1,PC1,
1210,Immune response_ICOS signaling pathway in T-helper cell,60,7.218E-01,8.453E-01,7.429E-01,8.453E-01,3,"MHC class II, PI3K cat class IA, AKT(PKB)",7.218E-01,8.497E-01,3,"MHC class II, PI3K cat class IA, AKT(PKB)",
1211,L-Tryptophan metabolism (part 1),80,7.323E-01,8.555E-01,7.562E-01,8.555E-01,4,"ALDR, IDO1, IDO2, AL1A1",7.323E-01,8.584E-01,4,"ALDR, IDO1, IDO2, AL1A1",
1212,Role of prenatal nicotine exposure in inhibition of pancreatic beta cells differentiation and function,21,7.361E-01,8.499E-01,7.481E-01,8.499E-01,1,PAX6,7.361E-01,8.609E-01,1,PAX6,
1213,Tumor metabolic pathways promoting development of Treg cells,96,7.375E-01,8.399E-01,7.375E-01,8.399E-01,5,"STAT3, 5'-NTD, MHC class II, TGF-beta receptor type II, PD-L1",8.489E-01,9.280E-01,4,"5'-NTD, MHC class II, TGF-beta receptor type II, PD-L1",
1214,Transport_HDL-mediated reverse cholesterol transport,42,7.389E-01,8.555E-01,7.559E-01,8.555E-01,2,"CES1, LIPE",7.389E-01,8.609E-01,2,"CES1, LIPE",
1215,Estradiol metabolism,42,7.389E-01,8.555E-01,7.559E-01,8.555E-01,2,"UGT1A1, CYP1A1",7.389E-01,8.609E-01,2,"UGT1A1, CYP1A1",
1216,Apoptosis and survival_Lymphotoxin-beta receptor signaling,42,7.389E-01,8.555E-01,7.559E-01,8.555E-01,2,"LIGHT(TNFSF14), IL-8",7.389E-01,8.609E-01,2,"LIGHT(TNFSF14), IL-8",
1217,Heparan sulfate/heparin metabolism,62,7.423E-01,8.604E-01,7.628E-01,8.604E-01,3,"3-OST-3A, Exostosin-1, 3-OST1",7.423E-01,8.641E-01,3,"3-OST-3A, Exostosin-1, 3-OST1",
1218,"Nicotine signaling in dopaminergic neurons, Pt. 2 - axon terminal",43,7.507E-01,8.619E-01,7.674E-01,8.619E-01,2,"PLAT (TPA), G-protein alpha-i family",7.507E-01,8.655E-01,2,"PLAT (TPA), G-protein alpha-i family",
1219,Vitamin D3 metabolic C-23 and C-24 pathways,43,7.507E-01,8.619E-01,7.674E-01,8.619E-01,2,"CYP27A1, CYP24A1",7.507E-01,8.655E-01,2,"CYP27A1, CYP24A1",
1220,Transcription_CREM signaling in testis,22,7.524E-01,8.604E-01,7.642E-01,8.604E-01,1,KIF17,7.524E-01,8.655E-01,1,KIF17,
1221,PXR signaling via cross-talk / Rodent version,22,7.524E-01,8.604E-01,7.642E-01,8.604E-01,1,PPARGC1 (PGC1-alpha),7.524E-01,8.655E-01,1,PPARGC1 (PGC1-alpha),
1222,Taurine and hypotaurine metabolism,22,7.524E-01,8.604E-01,7.642E-01,8.604E-01,1,CDO1,7.524E-01,8.655E-01,1,CDO1,
1223,PXR signaling via cross-talk / Human Version,22,7.524E-01,8.604E-01,7.642E-01,8.604E-01,1,PPARGC1 (PGC1-alpha),7.524E-01,8.655E-01,1,PPARGC1 (PGC1-alpha),
1224,CFTR-dependent regulation of ion channels in CF,42,7.559E-01,8.555E-01,7.559E-01,8.555E-01,2,"Actin cytoskeletal, G-protein alpha-q/11",9.305E-01,9.682E-01,1,G-protein alpha-q/11,
1225,Transport_Intracellular cholesterol transport,83,7.583E-01,8.716E-01,7.812E-01,8.725E-01,4,"CES1, Caveolin-1, Caveolin-2, VLDLR",7.583E-01,8.716E-01,4,"CES1, Caveolin-1, Caveolin-2, VLDLR",
1226,Regulation of metabolism_Triiodothyronine and Thyroxine signaling,44,7.620E-01,8.709E-01,7.784E-01,8.709E-01,2,"Beta-2 adrenergic receptor, Calcipressin 2",7.620E-01,8.737E-01,2,"Beta-2 adrenergic receptor, Calcipressin 2",
1227,Apoptosis and survival_TNF-alpha-induced Caspase-8 signaling,43,7.674E-01,8.619E-01,7.674E-01,8.619E-01,2,"AKT(PKB), Caspase-8",9.348E-01,9.682E-01,1,AKT(PKB),
1228,Proteolysis_Putative ubiquitin pathway,23,7.676E-01,8.709E-01,7.792E-01,8.709E-01,1,Synphilin 1,7.676E-01,8.778E-01,1,Synphilin 1,
1229,Ascorbate metabolism,23,7.676E-01,8.709E-01,7.792E-01,8.709E-01,1,PAM,7.676E-01,8.778E-01,1,PAM,
1230,Apoptosis and survival_NO signaling in apoptosis,23,7.676E-01,8.709E-01,7.792E-01,8.709E-01,1,iNOS,7.676E-01,8.778E-01,1,iNOS,
1231,Apoptosis and survival_FAS signaling cascades,44,7.784E-01,8.709E-01,7.784E-01,8.709E-01,2,"Caspase-10, Caspase-8",9.388E-01,9.694E-01,1,Caspase-10,
1232,Role of mevalonate pathway in multiple myeloma,44,7.784E-01,8.709E-01,7.784E-01,8.709E-01,2,"PI3K cat class IA, ERK1/2",9.388E-01,9.694E-01,1,PI3K cat class IA,
1233,"Triacylglycerol biosynthesis in obesity and diabetes mellitus, type II",24,7.819E-01,8.838E-01,7.932E-01,8.838E-01,1,PLCD,7.819E-01,8.899E-01,1,PLCD,
1234,"Mechanism of action of DGAT1 inhibitors in obesity and diabetes mellitus, type II (Variant 1)",24,7.819E-01,8.838E-01,7.932E-01,8.838E-01,1,PLCD,7.819E-01,8.899E-01,1,PLCD,
1235,Niacin-HDL metabolism,46,7.834E-01,8.890E-01,7.991E-01,8.890E-01,2,"PAM, NNMT",7.834E-01,8.899E-01,2,"PAM, NNMT",
1236,Anandamide biosynthesis and metabolism,46,7.834E-01,8.890E-01,7.991E-01,8.890E-01,2,"PA24A, PTPN22",7.834E-01,8.899E-01,2,"PA24A, PTPN22",
1237,Renal secretion of drugs / Rodent version ,47,7.934E-01,8.955E-01,8.088E-01,8.955E-01,2,"SLC22A3, MDR1",7.934E-01,8.982E-01,2,"SLC22A3, MDR1",
1238,Transport_GPR40 signaling pathway in beta cells,47,7.934E-01,8.955E-01,8.088E-01,8.955E-01,2,"Kv2.2, G-protein alpha-q/11",7.934E-01,8.982E-01,2,"Kv2.2, G-protein alpha-q/11",
1239,Transport_RAB5A regulation pathway,25,7.953E-01,8.955E-01,8.064E-01,8.955E-01,1,EGFR,7.953E-01,8.982E-01,1,EGFR,
1240,Fenofibrate in treatment of type 2 diabetes and metabolic syndrome X,25,7.953E-01,8.955E-01,8.064E-01,8.955E-01,1,Acyl-CoA synthetase,7.953E-01,8.982E-01,1,Acyl-CoA synthetase,
1241,Neolacto-series GSL Metabolism p.3,68,7.966E-01,8.989E-01,8.150E-01,9.000E-01,3,"B3GNT5, SIA10, ABO system transferase",7.966E-01,8.989E-01,3,"B3GNT5, SIA10, ABO system transferase",
1242,Immune response_OX40L/ OX40 signaling pathway,69,8.047E-01,9.037E-01,8.227E-01,9.037E-01,3,"PI3K cat class IA, PKC-theta, AKT(PKB)",8.047E-01,9.057E-01,3,"PI3K cat class IA, PKC-theta, AKT(PKB)",
1243,CREB1-dependent transcription deregulation in Huntington's Disease,26,8.079E-01,9.000E-01,8.187E-01,9.000E-01,1,PPARGC1 (PGC1-alpha),8.079E-01,9.057E-01,1,PPARGC1 (PGC1-alpha),
1244,Cell cycle_Initiation of mitosis,26,8.079E-01,9.000E-01,8.187E-01,9.000E-01,1,AKT(PKB),8.079E-01,9.057E-01,1,AKT(PKB),
1245,Glyoxylate metabolism,26,8.079E-01,9.000E-01,8.187E-01,9.000E-01,1,MCT1 (SLC16A1),8.079E-01,9.057E-01,1,MCT1 (SLC16A1),
1246,CAR signaling via cross-talk / Human Version,26,8.079E-01,9.000E-01,8.187E-01,9.000E-01,1,PPARGC1 (PGC1-alpha),8.079E-01,9.057E-01,1,PPARGC1 (PGC1-alpha),
1247,Development_NOTCH1-mediated pathway for NF-KB activity modulation,26,8.079E-01,9.000E-01,8.187E-01,9.000E-01,1,Jagged1,8.079E-01,9.057E-01,1,Jagged1,
1248,"SREBP1 cross-talk with PXR, CAR and LXR",26,8.079E-01,9.000E-01,8.187E-01,9.000E-01,1,PPARGC1 (PGC1-alpha),8.079E-01,9.057E-01,1,PPARGC1 (PGC1-alpha),
1249,Signal transduction_JNK pathway,47,8.088E-01,8.955E-01,8.088E-01,8.955E-01,2,"HGK(MAP4K4), p53",9.495E-01,9.745E-01,1,HGK(MAP4K4),
1250,Neurophysiological process_Circadian rhythm,47,8.088E-01,8.955E-01,8.088E-01,8.955E-01,2,"PACAP, ERK1/2",9.495E-01,9.745E-01,1,PACAP,
1251,CAR signaling via cross-talk / Rodent version,27,8.197E-01,9.069E-01,8.302E-01,9.069E-01,1,PPARGC1 (PGC1-alpha),8.197E-01,9.136E-01,1,PPARGC1 (PGC1-alpha),
1252,Glomerular filtration and renal reabsorption of bile acids / Rodent version,27,8.197E-01,9.069E-01,8.302E-01,9.069E-01,1,AKR1C1,8.197E-01,9.136E-01,1,AKR1C1,
1253,Neurophysiological process_GABA-B receptor-mediated regulation of glutamate signaling in Purkinje cells,27,8.197E-01,9.069E-01,8.302E-01,9.069E-01,1,G-protein alpha-i family,8.197E-01,9.136E-01,1,G-protein alpha-i family,
1254,Insulin-dependent stimulation of SREBP-1 in type 2 diabetes in liver,27,8.197E-01,9.069E-01,8.302E-01,9.069E-01,1,IRS-2,8.197E-01,9.136E-01,1,IRS-2,
1255,Triacylglycerol metabolism p.2,27,8.197E-01,9.069E-01,8.302E-01,9.069E-01,1,LIPE,8.197E-01,9.136E-01,1,LIPE,
1256,Glutathione metabolism,71,8.200E-01,9.123E-01,8.373E-01,9.123E-01,3,"GSTP1, GPX7, CD13",8.200E-01,9.136E-01,3,"GSTP1, GPX7, CD13",
1257,Immune response_Production and main functions of biologically active leukotrienes and Lipoxin A4,50,8.210E-01,9.119E-01,8.354E-01,9.119E-01,2,"cPLA2, ALOX5",8.210E-01,9.136E-01,2,"cPLA2, ALOX5",
1258,Regulation of lipid metabolism_Insulin regulation of fatty acid metabolism,89,8.250E-01,9.055E-01,8.250E-01,9.055E-01,4,"PI3K cat class IA, AKT(PKB), IRS-2, ERK1/2",9.171E-01,9.630E-01,3,"PI3K cat class IA, AKT(PKB), IRS-2",
1259,Neolacto-series GSL Metabolism p.1,72,8.272E-01,9.150E-01,8.442E-01,9.150E-01,3,"B3GNT5, SIA10, ABO system transferase",8.272E-01,9.185E-01,3,"B3GNT5, SIA10, ABO system transferase",
1260,Neurophysiological process_GABA-B receptor signaling in presynaptic nerve terminals,28,8.308E-01,9.123E-01,8.410E-01,9.123E-01,1,G-protein alpha-i family,8.308E-01,9.185E-01,1,G-protein alpha-i family,
1261,Role of Diethylhexyl Phthalate and Tributyltin in fat cell differentiation ,28,8.308E-01,9.123E-01,8.410E-01,9.123E-01,1,PPARGC1 (PGC1-alpha),8.308E-01,9.185E-01,1,PPARGC1 (PGC1-alpha),
1262,Mitogenic action of Estradiol / ESR1 (nuclear) in breast cancer,28,8.308E-01,9.123E-01,8.410E-01,9.123E-01,1,Cyclin E,8.308E-01,9.185E-01,1,Cyclin E,
1263,Neurophysiological process_Role of CDK5 in presynaptic signaling,28,8.308E-01,9.123E-01,8.410E-01,9.123E-01,1,Endophilin A1,8.308E-01,9.185E-01,1,Endophilin A1,
1264,GLP-1 in inhibition of insulin secretion in type 2 diabetes,28,8.308E-01,9.123E-01,8.410E-01,9.123E-01,1,EGFR,8.308E-01,9.185E-01,1,EGFR,
1265,Transport_Clathrin-coated vesicle cycle,71,8.373E-01,9.123E-01,8.373E-01,9.123E-01,3,"Actin cytoskeletal, AP180, Actin",9.378E-01,9.694E-01,2,"AP180, Actin",
1266,CoA biosynthesis,52,8.376E-01,9.198E-01,8.513E-01,9.198E-01,2,"VNN1, ACSL4",8.376E-01,9.240E-01,2,"VNN1, ACSL4",
1267,Adiponectin in pathogenesis of type 2 diabetes,29,8.413E-01,9.198E-01,8.511E-01,9.198E-01,1,PPARGC1 (PGC1-alpha),8.413E-01,9.240E-01,1,PPARGC1 (PGC1-alpha),
1268,"Regulation of lipid metabolism_RXR-dependent regulation of lipid metabolism via PPAR, RAR and VDR",30,8.510E-01,9.249E-01,8.606E-01,9.249E-01,1,CYP24A1,8.510E-01,9.280E-01,1,CYP24A1,
1269,Stem cells_Neovascularization of glioblastoma in response to hypoxia,30,8.510E-01,9.249E-01,8.606E-01,9.249E-01,1,PKC-alpha,8.510E-01,9.280E-01,1,PKC-alpha,
1270,Role of prenatal nicotine exposure in apoptosis and proliferation of pancreatic beta cells,30,8.510E-01,9.249E-01,8.606E-01,9.249E-01,1,nAChR alpha-7,8.510E-01,9.280E-01,1,nAChR alpha-7,
1271,Neurophysiological process_nNOS signaling in neuronal synapses,30,8.510E-01,9.249E-01,8.606E-01,9.249E-01,1,NR2,8.510E-01,9.280E-01,1,NR2,
1272,Putative pathways of Oleic acid sensing in ventromedial hypothalamus in obesity (rodent model),30,8.510E-01,9.249E-01,8.606E-01,9.249E-01,1,ACSL4,8.510E-01,9.280E-01,1,ACSL4,
1273,Role of ER stress in obesity and type 2 diabetes,54,8.527E-01,9.291E-01,8.657E-01,9.297E-01,2,"PI3K cat class IA, IRS-2",8.527E-01,9.291E-01,2,"PI3K cat class IA, IRS-2",
1274,Linoleic acid metabolism,31,8.602E-01,9.316E-01,8.695E-01,9.316E-01,1,PA24A,8.602E-01,9.335E-01,1,PA24A,
1275,"SREBP1 cross-talk with PXR, CAR and LXR/ Rodent version",31,8.602E-01,9.316E-01,8.695E-01,9.316E-01,1,PPARGC1 (PGC1-alpha),8.602E-01,9.335E-01,1,PPARGC1 (PGC1-alpha),
1276,Role of IL-2 in the enhancement of NK cell cytotoxicity in multiple sclerosis,31,8.602E-01,9.316E-01,8.695E-01,9.316E-01,1,PI3K cat class IA,8.602E-01,9.335E-01,1,PI3K cat class IA,
1277,Acetylcholine biosynthesis and metabolism,32,8.688E-01,9.369E-01,8.778E-01,9.369E-01,1,PA24A,8.688E-01,9.384E-01,1,PA24A,
1278,Immune response_BAFF-induced non-canonical NF-kB signaling,32,8.688E-01,9.369E-01,8.778E-01,9.369E-01,1,c-IAP2,8.688E-01,9.384E-01,1,c-IAP2,
1279,Cell cycle_Start of DNA replication in early S phase,32,8.688E-01,9.369E-01,8.778E-01,9.369E-01,1,Cyclin E,8.688E-01,9.384E-01,1,Cyclin E,
1280,L-Arginine metabolism,79,8.714E-01,9.404E-01,8.856E-01,9.431E-01,3,"iNOS, ADC, AL1A1",8.714E-01,9.404E-01,3,"iNOS, ADC, AL1A1",
1281,Cell cycle_Spindle assembly and chromosome separation,33,8.769E-01,9.431E-01,8.856E-01,9.431E-01,1,"Dynein 1, cytoplasmic, intermediate chains",8.769E-01,9.449E-01,1,"Dynein 1, cytoplasmic, intermediate chains",
1282,ATP/ITP metabolism,123,8.810E-01,9.486E-01,8.979E-01,9.521E-01,5,"5'-NTD, ALPP, AK5, 5'-NT1A, ADA",8.810E-01,9.486E-01,5,"5'-NTD, ALPP, AK5, 5'-NT1A, ADA",
1283,Regulation of CFTR gating (normal and CF),34,8.845E-01,9.493E-01,8.929E-01,9.493E-01,1,Adenylate cyclase,8.845E-01,9.500E-01,1,Adenylate cyclase,
1284,Vitamin B6 metabolism,34,8.845E-01,9.493E-01,8.929E-01,9.493E-01,1,ALPL,8.845E-01,9.500E-01,1,ALPL,
1285,HETE and HPETE biosynthesis and metabolism,82,8.870E-01,9.509E-01,9.002E-01,9.521E-01,3,"COX-2 (PTGS2), PTGIS, ALOX5",8.870E-01,9.509E-01,3,"COX-2 (PTGS2), PTGIS, ALOX5",
1286,Aminosugar metabolism,60,8.907E-01,9.509E-01,9.016E-01,9.521E-01,2,"GFPT2, UDP-GlcNAc- 2-epimerase",8.907E-01,9.509E-01,2,"GFPT2, UDP-GlcNAc- 2-epimerase",
1287,Aberrant lipid trafficking and metabolism in age-related macular degeneration pathogenesis,60,8.907E-01,9.509E-01,9.016E-01,9.521E-01,2,"CYP27A1, TLR2",8.907E-01,9.509E-01,2,"CYP27A1, TLR2",
1288,Apoptosis and survival_TNF-alpha-induced ROS-dependent Caspase-3 signaling,60,8.907E-01,9.509E-01,9.016E-01,9.521E-01,2,"Rac2, PI3K cat class IA (p110-delta)",8.907E-01,9.509E-01,2,"Rac2, PI3K cat class IA (p110-delta)",
1289,Antioxidant effects of statins in COPD,60,8.907E-01,9.509E-01,9.016E-01,9.521E-01,2,"Rac2, Caveolin-1",8.907E-01,9.509E-01,2,"Rac2, Caveolin-1",
1290,Transcription_Role of the non-genomic action of Retinoic acid and phosphorylation of Retinoic acid receptors in the initiation of transcription,35,8.916E-01,9.509E-01,8.997E-01,9.521E-01,1,STRA6,8.916E-01,9.509E-01,1,STRA6,
1291,Glucose-excited neurons of arcuate nucleus in obesity (rodent model),35,8.916E-01,9.509E-01,8.997E-01,9.521E-01,1,POMC,8.916E-01,9.509E-01,1,POMC,
1292,Urea cycle,36,8.983E-01,9.539E-01,9.061E-01,9.539E-01,1,Aquaporin 9,8.983E-01,9.558E-01,1,Aquaporin 9,
1293,Nitrogen metabolism,36,8.983E-01,9.539E-01,9.061E-01,9.539E-01,1,Carbonic anhydrase IX,8.983E-01,9.558E-01,1,Carbonic anhydrase IX,
1294,G-protein signaling_Regulation of RAC1 activity,36,8.983E-01,9.539E-01,9.061E-01,9.539E-01,1,Caspase-1,8.983E-01,9.558E-01,1,Caspase-1,
1295,CTP/UTP metabolism,107,9.014E-01,9.584E-01,9.149E-01,9.603E-01,4,"CDD, UDP, DPYD, AK5",9.014E-01,9.584E-01,4,"CDD, UDP, DPYD, AK5",
1296,Cholehepatic circulation of bile acids / Rodent version,37,9.045E-01,9.588E-01,9.121E-01,9.588E-01,1,AKR1C1,9.045E-01,9.609E-01,1,AKR1C1,
1297,Prostaglandin 2 biosynthesis and metabolism,86,9.052E-01,9.603E-01,9.169E-01,9.603E-01,3,"COX-2 (PTGS2), PTGIS, AKR1C3",9.052E-01,9.609E-01,3,"COX-2 (PTGS2), PTGIS, AKR1C3",
1298,O-glycan biosynthesis,63,9.061E-01,9.603E-01,9.160E-01,9.603E-01,2,"B3GT2, GALNTL2",9.061E-01,9.612E-01,2,"B3GT2, GALNTL2",
1299,Cholesterol metabolism,87,9.093E-01,9.608E-01,9.207E-01,9.608E-01,3,"CYP27A1, AKR1C4, CYP7B1",9.093E-01,9.616E-01,3,"CYP27A1, AKR1C4, CYP7B1",
1300,Cortisol biosynthesis from Cholesterol,38,9.104E-01,9.603E-01,9.177E-01,9.603E-01,1,CYP11A1,9.104E-01,9.616E-01,1,CYP11A1,
1301,Aldosterone biosynthesis and metabolism,38,9.104E-01,9.603E-01,9.177E-01,9.603E-01,1,AKR1C4,9.104E-01,9.616E-01,1,AKR1C4,
1302,Plasmalogen biosynthesis,64,9.108E-01,9.608E-01,9.204E-01,9.608E-01,2,"PLA2, PLCD",9.108E-01,9.616E-01,2,"PLA2, PLCD",
1303,Polyamine metabolism,64,9.108E-01,9.608E-01,9.204E-01,9.608E-01,2,"ADC, Spermine oxidase",9.108E-01,9.616E-01,2,"ADC, Spermine oxidase",
1304,Transport_Regulation of ATP-binding transporters by Retinoic acid and orphan nuclear receptor PXR,39,9.159E-01,9.608E-01,9.229E-01,9.608E-01,1,MDR1,9.159E-01,9.626E-01,1,MDR1,
1305,Butanoic acid metabolism,39,9.159E-01,9.608E-01,9.229E-01,9.608E-01,1,MCT1 (SLC16A1),9.159E-01,9.626E-01,1,MCT1 (SLC16A1),
1306,Apoptosis and survival_APRIL and BAFF signaling,39,9.159E-01,9.608E-01,9.229E-01,9.608E-01,1,COX-2 (PTGS2),9.159E-01,9.626E-01,1,COX-2 (PTGS2),
1307,Apoptosis and survival_Ubiquitination and phosphorylation in TNF-alpha-induced NF-kB signaling,39,9.159E-01,9.608E-01,9.229E-01,9.608E-01,1,c-IAP2,9.159E-01,9.626E-01,1,c-IAP2,
1308,HCV-mediated liver damage and predisposition to HCC via cell stress,63,9.160E-01,9.603E-01,9.160E-01,9.603E-01,2,"STAT3, IL-6",9.818E-01,9.959E-01,1,IL-6,
1309,GTP-XTP metabolism,90,9.207E-01,9.643E-01,9.311E-01,9.664E-01,3,"5'-NTD, Xanthine oxidase, Guanine deaminase",9.207E-01,9.643E-01,3,"5'-NTD, Xanthine oxidase, Guanine deaminase",
1310,Neurophysiological process_Netrin-1 in regulation of axon guidance,40,9.211E-01,9.637E-01,9.278E-01,9.637E-01,1,Fyn,9.211E-01,9.643E-01,1,Fyn,
1311,Leukotriene 4 biosynthesis and metabolism,40,9.211E-01,9.637E-01,9.278E-01,9.637E-01,1,ALOX5,9.211E-01,9.643E-01,1,ALOX5,
1312,Enterohepatic circulation of bile acids / Rodent version,40,9.211E-01,9.637E-01,9.278E-01,9.637E-01,1,AKR1C1,9.211E-01,9.643E-01,1,AKR1C1,
1313,Neurophysiological process_Glucose-inhibited neurons of ventromedial and arcuate nuclei (rodent model),41,9.260E-01,9.664E-01,9.324E-01,9.664E-01,1,NPY,9.260E-01,9.679E-01,1,NPY,
1314,Regulation of metabolism_Bile acids regulation of glucose and lipid metabolism via FXR,41,9.260E-01,9.664E-01,9.324E-01,9.664E-01,1,AKT(PKB),9.260E-01,9.679E-01,1,AKT(PKB),
1315,TTP metabolism,68,9.274E-01,9.679E-01,9.357E-01,9.679E-01,2,"UDP, DPYD",9.274E-01,9.681E-01,2,"UDP, DPYD",
1316,Sulfur metabolism,42,9.305E-01,9.679E-01,9.367E-01,9.679E-01,1,CDO1,9.305E-01,9.682E-01,1,CDO1,
1317,Disruption of methionine metabolism in induction and progression of HCC,42,9.305E-01,9.679E-01,9.367E-01,9.679E-01,1,BHMT,9.305E-01,9.682E-01,1,BHMT,
1318,Transcription_FXR-regulated cholesterol and bile acids cellular transport,42,9.305E-01,9.679E-01,9.367E-01,9.679E-01,1,MDR1,9.305E-01,9.682E-01,1,MDR1,
1319,dATP/dITP metabolism,94,9.339E-01,9.682E-01,9.430E-01,9.709E-01,3,"5'-NTD, AK5, ADA",9.339E-01,9.682E-01,3,"5'-NTD, AK5, ADA",
1320,Regulation of metabolism_Role of Adiponectin in regulation of metabolism,43,9.348E-01,9.682E-01,9.408E-01,9.692E-01,1,PPARGC1 (PGC1-alpha),9.348E-01,9.682E-01,1,PPARGC1 (PGC1-alpha),
1321,N-Glycan biosynthesis p2,43,9.348E-01,9.682E-01,9.408E-01,9.692E-01,1,GNT-III,9.348E-01,9.682E-01,1,GNT-III,
1322,"Leucine, isoleucine and valine metabolism",43,9.348E-01,9.682E-01,9.408E-01,9.692E-01,1,BCAT1,9.348E-01,9.682E-01,1,BCAT1,
1323,Development_Notch Signaling Pathway,43,9.348E-01,9.682E-01,9.408E-01,9.692E-01,1,Jagged1,9.348E-01,9.682E-01,1,Jagged1,
1324,Transport_cAMP/ Ca(2+)-dependent Insulin secretion,44,9.388E-01,9.694E-01,9.445E-01,9.717E-01,1,PKC-alpha,9.388E-01,9.694E-01,1,PKC-alpha,
1325,"Metabolism of L-cysteine, D-cysteine and L-cystine",119,9.397E-01,9.695E-01,9.492E-01,9.751E-01,4,"CDO1, Ceruloplasmin, GLAST1/EAAT1, SLC7A11",9.397E-01,9.695E-01,4,"CDO1, Ceruloplasmin, GLAST1/EAAT1, SLC7A11",
1326,Mitochondrial unsaturated fatty acid beta-oxidation,45,9.426E-01,9.719E-01,9.481E-01,9.746E-01,1,ACSL4,9.426E-01,9.719E-01,1,ACSL4,
1327,L-Alanine and L-cysteine metabolism,46,9.461E-01,9.733E-01,9.514E-01,9.766E-01,1,CDO1,9.461E-01,9.733E-01,1,CDO1,
1328,dCTP/dUTP metabolism,74,9.469E-01,9.733E-01,9.536E-01,9.774E-01,2,"CDD, AK5",9.469E-01,9.733E-01,2,"CDD, AK5",
1329,Arachidonic acid production,74,9.469E-01,9.733E-01,9.536E-01,9.774E-01,2,"PA24A, ACSL4",9.469E-01,9.733E-01,2,"PA24A, ACSL4",
1330,Gamma-aminobutyrate (GABA) biosynthesis and metabolism,52,9.632E-01,9.865E-01,9.672E-01,9.900E-01,1,GAD1,9.632E-01,9.865E-01,1,GAD1,
1331,Impaired NO signaling in CF airways,52,9.632E-01,9.865E-01,9.672E-01,9.900E-01,1,iNOS,9.632E-01,9.865E-01,1,iNOS,
1332,Fructose metabolism,81,9.633E-01,9.865E-01,9.684E-01,9.904E-01,2,"ALDR, AK1BA",9.633E-01,9.865E-01,2,"ALDR, AK1BA",
1333,Androstenedione and testosterone biosynthesis and metabolism p.1,54,9.676E-01,9.887E-01,9.713E-01,9.912E-01,1,CYP1A1,9.676E-01,9.887E-01,1,CYP1A1,
1334,Ganglioside Metabolism p1,54,9.676E-01,9.887E-01,9.713E-01,9.912E-01,1,SIAT8A,9.676E-01,9.887E-01,1,SIAT8A,
1335,Arsenite metabolism and transport,54,9.676E-01,9.887E-01,9.713E-01,9.912E-01,1,Aquaporin 9,9.676E-01,9.887E-01,1,Aquaporin 9,
1336,Nicotine metabolism in liver,56,9.715E-01,9.919E-01,9.748E-01,9.941E-01,1,FMO3,9.715E-01,9.919E-01,1,FMO3,
1337,Transcription_Epigenetic regulation of gene expression,57,9.733E-01,9.929E-01,9.764E-01,9.950E-01,1,HDAC9,9.733E-01,9.929E-01,1,HDAC9,
1338,n-6 Polyunsaturated fatty acid biosynthesis,61,9.793E-01,9.959E-01,9.819E-01,9.972E-01,1,ACSL4,9.793E-01,9.959E-01,1,ACSL4,
1339,Immune response_The effect of IDO1 on T cell metabolism,89,9.798E-01,9.972E-01,9.798E-01,9.972E-01,2,"IDO1, p53",9.965E-01,9.980E-01,1,IDO1,
1340,Galactose metabolism,63,9.818E-01,9.959E-01,9.841E-01,9.972E-01,1,ALD2,9.818E-01,9.959E-01,1,ALD2,
1341,n-3 Polyunsaturated fatty acid biosynthesis,63,9.818E-01,9.959E-01,9.841E-01,9.972E-01,1,ACSL4,9.818E-01,9.959E-01,1,ACSL4,
1342,Bile Acid Biosynthesis,94,9.818E-01,9.959E-01,9.848E-01,9.972E-01,2,"CYP27A1, AKR1C4",9.818E-01,9.959E-01,2,"CYP27A1, AKR1C4",
1343,Histidine-glutamate-glutamine metabolism,95,9.828E-01,9.959E-01,9.856E-01,9.972E-01,2,"GAD1, GFPT2",9.828E-01,9.959E-01,2,"GAD1, GFPT2",
1344,Folic acid metabolism,64,9.829E-01,9.959E-01,9.852E-01,9.972E-01,1,ALDH1L2,9.829E-01,9.959E-01,1,ALDH1L2,
1345,Unsaturated fatty acid biosynthesis,65,9.839E-01,9.959E-01,9.861E-01,9.972E-01,1,ACSL4,9.839E-01,9.959E-01,1,ACSL4,
1346,L-Tryptophan metabolism (part 2),97,9.846E-01,9.959E-01,9.872E-01,9.972E-01,2,"3HAO, SULT1B1",9.846E-01,9.959E-01,2,"3HAO, SULT1B1",
1347,Pyruvate metabolism,66,9.849E-01,9.959E-01,9.870E-01,9.972E-01,1,MCT1 (SLC16A1),9.849E-01,9.959E-01,1,MCT1 (SLC16A1),
1348,Metabolism in pancreatic cancer cells,66,9.849E-01,9.959E-01,9.870E-01,9.972E-01,1,SLC7A11,9.849E-01,9.959E-01,1,SLC7A11,
1349,Lipoprotein metabolism,68,9.867E-01,9.970E-01,9.886E-01,9.978E-01,1,VLDLR,9.867E-01,9.970E-01,1,VLDLR,
1350,Tyrosine metabolism p.1 (dopamine) ,70,9.883E-01,9.974E-01,9.900E-01,9.978E-01,1,AL1A1,9.883E-01,9.974E-01,1,AL1A1,
1351,Aspartate and asparagine metabolism,73,9.904E-01,9.974E-01,9.918E-01,9.978E-01,1,GAD1,9.904E-01,9.974E-01,1,GAD1,
1352,L-Phenylalanine metabolism,74,9.910E-01,9.974E-01,9.923E-01,9.978E-01,1,AL1A1,9.910E-01,9.974E-01,1,AL1A1,
1353,Peroxysomal straight-chain fatty acid beta-oxidation,74,9.910E-01,9.974E-01,9.923E-01,9.978E-01,1,ACSL4,9.910E-01,9.974E-01,1,ACSL4,
1354,Sphingolipid metabolism,107,9.911E-01,9.974E-01,9.928E-01,9.978E-01,2,"B4G6, G3ST1",9.911E-01,9.974E-01,2,"B4G6, G3ST1",
1355,Catecholamine metabolism,75,9.915E-01,9.974E-01,9.928E-01,9.978E-01,1,AL1A1,9.915E-01,9.974E-01,1,AL1A1,
1356,Vitamin E (alfa-tocopherol) metabolism,81,9.942E-01,9.980E-01,9.952E-01,9.984E-01,1,ACSL4,9.942E-01,9.980E-01,1,ACSL4,
1357,Tyrosine metabolism p.2 (melanin),83,9.949E-01,9.980E-01,9.958E-01,9.984E-01,1,Xanthine oxidase,9.949E-01,9.980E-01,1,Xanthine oxidase,
1358,Peroxisomal branched chain fatty acid oxidation,84,9.952E-01,9.980E-01,9.960E-01,9.984E-01,1,ACADL,9.952E-01,9.980E-01,1,ACADL,
1359,Phosphatidylinositol metabolism,85,9.955E-01,9.980E-01,9.963E-01,9.984E-01,1,INPP,9.955E-01,9.980E-01,1,INPP,
1360,Mitochondrial beta-oxidation of long-chain saturated fatty acids,125,9.968E-01,9.980E-01,9.975E-01,9.984E-01,2,"ACSL4, ACADL",9.968E-01,9.980E-01,2,"ACSL4, ACADL",
1361,L-Lysine metabolism,93,9.973E-01,9.980E-01,9.978E-01,9.984E-01,1,SLC7A7,9.973E-01,9.980E-01,1,SLC7A7,
1362,Glycine and L-Serine metabolism,133,9.980E-01,9.980E-01,9.984E-01,9.984E-01,2,"BHMT, PSAT",9.980E-01,9.980E-01,2,"BHMT, PSAT",
,,,,,,,,,,,,,
